What To Expect After Your Doctor Finds a Lung Nodule 2026-09-02 · mlpr-prnewswire-wire · Healthcare https://www.prnewswire.com/news-releases/what-to-expect-after-your-doctor-finds-a-lung-nodule-302866957.html American Lung Association's campaign, in partnership with Olympus, offers roadmap to help patients gain control over their health with nodule management and early detection CHICAGO, Sept. 2, 2026 /PRNewswire/ -- One of the greatest opportunities to improve lung cancer outcomes is the... ———————————————————————————————————————————————————————————— Norroy Bioscience Initiates Pivotal Phase III Clinical Trial of 177Lu-NYM032, a PSMA-Targeted Radioligand Therapy for mCRPC 2026-09-02 · mlpr-prnewswire-wire · Healthcare https://www.prnewswire.com/news-releases/norroy-bioscience-initiates-pivotal-phase-iii-clinical-trial-of-177lu-nym032-a-psma-targeted-radioligand-therapy-for-mcrpc-302867430.html WUXI, China, Sept. 2, 2026 /PRNewswire/ -- NORROY BIOSCIENCE (NORROY), a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals, announced that it has received regulatory clearance from China's National Medical Products Administration (NMPA) to initiate a... ———————————————————————————————————————————————————————————— Ensayo clínico de un innovador sistema de mapeo y ablación por campo pulsado 2026-09-02 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/ensayo-clinico-de-un-innovador-sistema-de-mapeo-y-ablacion-por-campo-pulsado-302867410.html -Texas Cardiac Arrhythmia Institute en St. David's Medical Center primeros en EE.UU. en participar en un ensayo clínico de un innovador sistema de mapeo y ablación por campo pulsado AUSTIN, Texas, 2 de septiembre de 2026 /PRNewswire/ -- El Texas Cardiac Arrhythmia Institute (TCAI) en St.... ———————————————————————————————————————————————————————————— Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S. to participate in trial for innovative mapping and pulsed field ablation system 2026-09-02 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/texas-cardiac-arrhythmia-institute-at-st-davids-medical-center-first-in-us-to-participate-in-trial-for-innovative-mapping-and-pulsed-field-ablation-system-302866616.html AUSTIN, Texas, Sept. 2, 2026 /PRNewswire/ -- The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first facility in the nation to participate in a clinical trial to evaluate the safety and effectiveness of a next-generation mapping and pulsed... ———————————————————————————————————————————————————————————— Resetting Lives Inc. Expands Global Mission With Executive Health & Life Audit(TM) for High-Achieving Leaders 2026-09-02 · mlpr-newsfile · Healthcare https://www.newsfilecorp.com/release/312027/Resetting-Lives-Inc.-Expands-Global-Mission-With-Executive-Health-Life-AuditTM-for-HighAchieving-Leaders Edmonton, Alberta--(Newsfile Corp. - September 2, 2026) - Resetting Lives Inc., founded by Nigerian-born, Canada-based transformation strategist Coach Ayomide Adeyina, is expanding its work around personal development and whole-person wellbeing with the development of the Executive Health & Life Audit™, a proprietary self-awareness framework designed for high-achieving executives and leaders to examine the broader factors influencing how they live, lead and make decisions.The initiative reflects... ———————————————————————————————————————————————————————————— Dr. Daniel Amen Brings Brain Health to Faith Communities With New WHOLE-4 Program 2026-09-02 · PR Newswire · SaaS, Healthcare, Education https://www.prnewswire.com/news-releases/dr-daniel-amen-brings-brain-health-to-faith-communities-with-new-whole-4-program-302867386.html New program combines brain science, mental health and spiritual principles to help churches build healthier communities COSTA MESA, Calif., Sept. 2, 2026 /PRNewswire/ -- Amen University, the online brain health education platform founded by double board-certified psychiatrist and 20-time... ———————————————————————————————————————————————————————————— New York Cancer & Blood Specialists Welcomes Medical Oncologist-Hematologist Dr. Rebecca Zweifler 2026-09-02 · PR.com · Healthcare https://www.pr.com/press-release/978101 New York Cancer & Blood Specialists (NYCBS), one of the Nation’s leading oncology practices, proudly announces the addition of hematologist-oncologist, Dr. Rebecca Zweifler. Beginning September 1, 2026, Dr. Zweifler will be practicing at NYCBS’s office located at 500 W 181st Street, 9th Floor, New York, NY 10033. “We are excited to welcome Dr. Zweifler to New York Cancer & Blood [PR.com] ———————————————————————————————————————————————————————————— Vara Receives World-First CE Certification for Autonomous AI in Breast Cancer Screening 2026-09-02 · mlpr-businesswire · AI, Healthcare https://finance.yahoo.com/healthcare/articles/vara-receives-world-first-ce-060000026.html BERLIN, Germany, September 02, 2026--Vara has received CE certification under the EU Medical Device Regulation (Class IIb) for autonomous triage in organised breast cancer screening – the first breast AI certified anywhere to report screening examinations as normal without radiologist review. ———————————————————————————————————————————————————————————— Nicox annonce l’extension de son horizon de trésorerie 2026-09-02 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/09/02/3354826/0/fr/nicox-annonce-l-extension-de-son-horizon-de-tr%C3%A9sorerie.html 1 Estimation non auditée préparée par la Direction sur la base des informations disponibles à la date du présent communiqué de presse. La prochaine publication financière de la Société portera sur les comptes du premier semestre 2026 et interviendra en octobre 2026. 2 La date PDUFA correspond à la date cible à laquelle la Food and Drug Administration (FDA) américaine prévoit d’achever la revue d’une demande d’autorisation de mise sur le marché (NDA) et de rendre sa décision, conformément au Prescription Durg User Fee Act (PDUFA). ———————————————————————————————————————————————————————————— IBA joins PFAROS European initiative to advance PFAS destruction for healthcare and pharmaceutical applications 2026-09-02 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/09/02/3354822/0/en/iba-joins-pfaros-european-initiative-to-advance-pfas-destruction-for-healthcare-and-pharmaceutical-applications.html Louvain-la-Neuve, Belgium, 2 September 2026, 7 a.m. – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announces its participation in PFAROS, a new European research and innovation initiative launched to address environmental emissions and exposure concerns related to per- and polyfluoroalkyl substances (PFAS) in the pharmaceutical and medical sectors. As part of the project, IBA will co-lead the work on end-of-life and waste-management technologies, bringing its electron beam and Rhodotron ® expertise to the assessment of PFAS destruction solutions. ———————————————————————————————————————————————————————————— Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference 2026-09-02 · mlpr-businesswire · Finance, Healthcare https://finance.yahoo.com/healthcare/articles/innate-pharma-participate-h-c-050000038.html MARSEILLE, France, September 02, 2026--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in a fireside chat and one-on-one investor meetings at the following conference: ———————————————————————————————————————————————————————————— Sunshine Insurance Delivers Strong Digital-Intelligence Transformation Results, as Technology Empowerment Steps into a Greater Level 2026-09-02 · mlpr-acnnewswire · AI, SaaS, Healthcare, Real Estate, Automotive, Education https://www.acnnewswire.com/press-release/english/109717/ HONG KONG, Sept 2, 2026 - (ACN Newswire) - The competitive logic of the insurance industry has shifted from scale expansion to value cultivation. Against this backdrop, the role of technology has also been elevated from efficiency-enhancing tools to a strategic foundation for navigating economic cycles. As a leading privately owned insurance group in China, Sunshine Insurance (6963.HK) has released its interim results, which not only demonstrate solid financial performance but also clearly outline a digital-intelligence transformation path driven by the dual engines of “robot engineering” and “data engineering”. As of June 30, 2026, Sunshine Insurance recorded gross written premiums (“GWPs”) of RMB90.91 billion, up 12.5% year-on-year, with net profit attributable to equity owners of the parent rising 38.5% to RMB4.69 billion. The value of new business in life insurance business increased by 16.4%, while the property and casualty insurance business optimized the underwriting combined ratio to 98.7%. Behind these numbers, a deep-seated technological transformation spanning sales, services and management is unlocking sustained momentum. Sales Revolution: From “Human-Only” to “Human-Machine Collaboration” The traditional insurance industry has been heavily reliant on human resources, where the capability ceiling of the sales force often defines the upper limit of business growth. Sunshine Insurance is now breaking this constraint through AI agent technology. On the life insurance side, sales robots have been deeply embedded across the entire customer engagement lifecycle. According to the Company, the robot is powered by 13 AI agent platforms and nearly 100 vertical AI agents, covering 7 major categories and 60 to 70 sub-scenarios in life insurance sales. The system leverages big data to precisely generate customer profiles, automatically produce personalized marketing plans and communication strategies, and identify customer conversion intent in real time during interactions. As of the end of the Reporting Period, the robot has completed 263,000 instances of assisted customer management, achieving cumulative converted standard premiums exceeding RMB30 million. On the agency-team side, monthly customer outreach and face-to-face visits by marketers rose by more than 20%, the policy addition rate for existing clients climbed by 12%, and the new-agent policy-writing rate more than doubled. This means frontline agents have gained a reliable “digital advisor”, enabling systematic improvements in their operational efficiency and specialization. Practices in the property and casualty insurance segment have achieved greater scale deployment. Leveraging predictive models, the telesales assistant robot covers approximately 200,000 customer leads daily and steadily supports the daily operations of more than 2,000 agents, delivering a shift from a “scatter-gun approach” to “precision targeting”. Furthermore, the renewal prediction model, based on 75 factors, enables high-precision prediction of the renewal probability for each auto insurance customer. It supports automated quotation and differentiated operation, transforming in-depth cultivation of existing clients from experience-driven to algorithm-driven operations. “Autopilot” Moment for the Claims Value Chain Claims handling constitutes the most critical touchpoint of insurance service experience and a core link in operating costs. Sunshine Insurance’s “claims service robot” is driving automation across this sophisticated workflow. At present, the robot has expanded its service scope from auto insurance to third-party claims, bodily injury, and non-auto health and accident insurance. In the first half of the year, it served 1.09 million customers, provided over 400,000 intelligent assisted responses, and achieved a customer satisfaction rate of 98%. Notably, with the robot proactively tracking vehicle repairs and injury recovery status, the average claim settlement cycle for served customers has been shortened by 10 days. In non-auto insurance lines, such as the student safety insurance and supplementary medical insurance, pilot programs for end-to-end automated processing were launched through multi-agent collaboration.  On the loss-adjustment side, pilot programs have been launched for intelligent assessment of minor vehicle damage claims. Robots can autonomously guide customers through the document upload process. The full behavioral trajectory from claim reporting to settlement can be traced via the operations monitoring platform, laying a data foundation for continuous optimization of claims service. This represents more than efficiency gains; it signifies a redefinition of service standards. Management Empowerment: Dual Leaps from Actuarial Pricing to Frontline Execution Beyond optimizing “the last mile” customer experience, intelligent transformation on Sunshine Insurance’s management side is reshaping the underlying operational capabilities and frontline execution of the insurance business. Risk pricing sits at the core of insurance operations. Built on its “data engineering” foundation, Sunshine Insurance is revamping this core competency. The auto insurance risk pricing robot has completed the construction of a dataset covering the entire process of quoting, underwriting, and claims settlement, reducing data preparation time from 5 days to 1 day and shortening time required to detect anomalies cycle from 8 hours to 1 hour. A closed-loop capability of “automated anomaly inspection + model simulation verification + dynamic solution output” was preliminarily established, enabling actuarial pricing to leap from quarterly-level responses to nearly real-time dynamic adjustments. Meanwhile, the Group has established an integrated plan covering data collection, database construction and data application, and deeply integrated 20 strategic data engineering projects into key business areas. Such foundational investments are transforming data from static resources into fluid, insight-generating strategic assets. In addition, Sunshine Insurance has extended its management reach to the front-line grassroots level. The four-tiered branch management robot empowers grassroots through intelligent agents such as “AI Little Tabulator, AI Little Advisor, and AI Little Designer”. Managers can complete the entire process of tabulation, data querying, and attribution through natural language processing. To date, this system has been deployed across 820 four-tiered branches nationwide, with a cumulative total of 621,000 pushes in the first half of the year. It has standardized and automated management processes that previously relied on manual experience, allowing grassroots managers to conduct routine management analysis at lower cost and greater speed. Conclusion From human-machine collaboration at the sales frontline, to the automated restructuring of the reimbursement cycle, and further to the systematic upgrade of  actuarial pricing and grassroots management, Sunshine Insurance’s technology deployment has moved beyond the initial phase of process digitalization and entered a phase of deep, coordinated advancement characterized by a multi-intelligent agent architecture and dynamic closed-loop data. As China’s insurance industry enters a critical period of high-quality development, Sunshine Insurance’s practice offers a valuable reference case: the barriers to technology adoption are diminishing, and the true differentiator lies in the depth of integration between technology and core business scenarios, as well as the efficiency with which it transforms the operating value chain. An insurance group with total assets of over RMB700 billion has begun recalibrating its strategic direction through data and algorithms, and its next-phase growth trajectory warrants re-evaluation from multiple dimensions. Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com ———————————————————————————————————————————————————————————— HardRx Review 2026: Could One Sildenafil + Tadalafil Tablet Be the Simpler ED Option Men Have Been Looking For? 2026-09-02 · Newswire.com · Healthcare https://www.newswire.com/news/hardrx-review-2026-could-one-sildenafil-tadalafil-tablet-be-the-simpler-ed For men comparing online ED treatment in 2026, HardRx puts sildenafil and tadalafil into one compounded sublingual prescription-creating a convenience-driven option worth a closer look while keeping the final decision where it belongs: with a licensed clinician reviewing the patient's health history, medications, and treatment needs. ———————————————————————————————————————————————————————————— Nutex Health Data Breach: Edelson Lechtzin LLP Investigates Theft of Patient and Employee Data 2026-09-02 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/nutex-health-data-breach-edelson-lechtzin-llp-investigates-theft-of-patient-and-employee-data-302867007.html Free case evaluations for individuals affected by the Nutex Health cyberattack claimed by The Gentlemen ransomware group HOUSTON, Sept. 1, 2026 /PRNewswire/ -- Edelson Lechtzin LLP, a national class action law firm, is investigating data privacy claims arising from a cyberattack on Nutex... ———————————————————————————————————————————————————————————— Ono Pharma Enters into a Drug Discovery Partnership with Aitia in Neurological Diseases 2026-09-02 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/ono-pharma-enters-drug-discovery-010000933.html OSAKA, Japan & CAMBRIDGE, Mass., September 02, 2026--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono") today announced that it has entered into a drug discovery partnership agreement with Aitia, Inc. (Headquarters: Cambridge, Massachusetts, USA; CEO: Colin Hill; "Aitia"). ———————————————————————————————————————————————————————————— Zepp Health Corporation Reports Second Quarter of 2026 Unaudited Financial Results 2026-09-02 · PR Newswire · Finance, Healthcare https://www.prnewswire.com/news-releases/zepp-health-corporation-reports-second-quarter-of-2026-unaudited-financial-results-302866933.html MILPITAS, Calif., Sept. 1, 2026 /PRNewswire/ -- Zepp Health Corporation (NYSE: ZEPP) ("Zepp", the "Company" or "we") today announced its unaudited financial results for the second quarter of 2026. Second Quarter of 2026 Financial and Operating Highlights: Revenue reached US$63.5 million,... ———————————————————————————————————————————————————————————— World No.1 with 56% Profit Surge: Saint Bella Redefines Family Care Economics 2026-09-02 · mlpr-acnnewswire · Finance, AI, SaaS, Healthcare, Retail https://www.acnnewswire.com/press-release/english/109696/ HONG KONG, Sep 2, 2026 - (ACN Newswire) - Postpartum care has historically presented a challenging unit economic profile: low purchase frequency, high labor intensity, and significant execution friction across regions. Constrained by these structural headwinds, most industry operators operate near break-even levels. Saint Bella Group (2508.HK), the world’s largest postpartum care provider by market share, has delivered a set of interim financial results that defies these broader sector dynamics. During the first half, profit growth significantly outpaced top-line expansion—demonstrating strong operational leverage. Five core financial metrics outline the mechanics driving this margin expansion: Revenue and Adjusted Profit Growth: H1 revenue grew 36.0% year-on-year (YoY) to RMB 611 million. Adjusted net profit surged 56.2% YoY to RMB 60.58 million, driving adjusted net margin up to 9.9%. Profit growth outstripped top-line gains as fixed-cost absorption improved. Core Brand Expansion (ASP up 15.9% to RMB 171,000): Across its brand portfolio—Saint Bella, Bella Isla, and Baby Bella (spanning ultra-luxury to upper-mid tiers)—group-wide average selling price (ASP) rose 15.9% YoY to RMB 171,000. Pricing power across core brands expanded despite broader macroeconomic discounting pressures in consumer services. Lifecycle Diversification: Postpartum care revenue grew 31.4% YoY to RMB 508 million. Non-postpartum, full-lifecycle services and products increased their revenue share to 31.5%, led by a 59.1% YoY surge in family care services and a 44.4% YoY gain in women’s health nutrition. Customer Lifetime Value (LTV) & Retention Metrics: The repeat-purchase conversion rate across non-postpartum offerings reached a record 96.3%. Conversion from core postpartum care to STB postpartum recovery services reached 94%. Average contract duration for family care extended to 169 days with a 57% renewal rate, indicating a transition from transactional engagements to multi-period recurring revenue. Global Footprint, Consolidation & AI Monetization: Operating centers in New York, Bangkok, and Singapore expanded operations, driving overseas revenue up 244% YoY. The acquisition of Wuhan-based Freya closed during the period. Proprietary AI agents generated RMB 6.9 million in revenue, marking initial financial validation for the group's technology stack. These operational data points signal a fundamental strategic shift: Saint Bella is transitioning from single-event postpartum care delivery to managing long-term customer lifetime value (LTV) across multiple brands and environments. While traditional peers remain focused on local bed-capacity competition, the industry leader is restructuring its growth flywheel. Core Operations: ASP Expansion, Penetration, and M&A Postpartum care remains Saint Bella’s foundational anchor and primary customer acquisition channel, generating RMB 508 million in H1 revenue (+31.4% YoY). Across its tiered multi-brand structure—Saint Bella, Bella Isla, and Baby Bella—group ASP increased 15.9% YoY to RMB 171,000. Delivering simultaneous volume and price growth sets the group apart in a consumer sector currently marked by price-cutting. Top-line performance is backed by deep service attach rates and high retention. During the reporting period, 94% of postpartum care clients cross-purchased STB postpartum recovery services. With overall repeat-purchase conversion reaching 96.3%, brand equity continues to reinforce customer retention. Saint Bella is executing a dual organic and inorganic growth strategy. The strategic acquisition of Freya—a premium maternal and infant care operator in Wuhan—added three standalone centers, 160 beds, and approximately 10,000 high-net-worth members, resolving a strategic coverage gap in central China. By integrating its standardized operational workflows and higher-margin recovery services into Freya’s network, Saint Bella expects near-term scale efficiencies. As of H1, Saint Bella’s global footprint stood at 148 operating centers. Strategic Pivot: Capturing Full-Lifecycle Customer Value While postpartum care acts as an efficient acquisition vector, full-lifecycle services drive long-term monetization. The Group's monetization sequence follows a structured funnel: Initial Acquisition & Trust: High-net-worth clients enter the funnel through premium postpartum care, establishing foundational brand trust. Postpartum Recovery Cross-Sell: STB services extend engagement beyond the standard 28-day stay, capturing spend across the full physiological recovery cycle. Family Care Retainers: Yujia’s age-tiered early childhood development framework (ages 0–3) extends average contract duration to 169 days, achieving a 57% renewal rate. Health & Nutrition Recurrence: Women’s health nutrition transitions the engagement model into high-frequency, mid-ticket daily wellness spending. This multi-stage model is driving tangible financial shift. Outpacing the core postpartum segment, family care revenue rose 59.1% YoY while health nutrition grew 44.4% YoY, driving non-postpartum revenue to 31.5% of total revenue. Furthermore, the addition of Freya’s ~10,000 member base provides an immediate addressable pool for cross-selling. Scalable Infrastructure: Global Network, Specialized Talent, and AI Execution Executing this expanded service coverage across geographies relies on three key operational pillars: skilled labor supply, international distribution, and standardized quality controls. Talent Development: The group’s certified family care specialist pool reached 11,495 headcount, adding 1,995 newly certified specialists in H1 (+42% vs. H2 of the prior year). In a labor-intensive sector, maintaining a deep talent bench is essential for cross-regional scaling and quality assurance. Global Footprint & Strategic Partnerships: Operating 148 centers worldwide, international sites in New York, Bangkok, and Singapore are progressively scaling operations. Complementing center-based models, an overseas in-home care program drove a 244% YoY increase in international revenue. To accelerate global expansion, Saint Bella entered into a strategic partnership with L Catterton, the consumer-focused private equity firm backed by LVMH. The partnership drives co-developing international market opportunities, introducing global brands, acquiring cross-border talent, and sourcing target M&A candidates. Proprietary AI Deployment: "Dr. Bella," the group's proprietary domain-specific large language model, is deployed across 60+ affiliated brands and 207 postpartum centers. The system automates clinical consultations, dynamic care plan generation, and customer management. AI-driven operations generated RMB 6.9 million in revenue during H1, validating initial technology commercialization. Over the longer term, codifying human service expertise into scalable software protocols enhances cross-center operational consistency and lowers asset-light expansion costs. Outlook Market leadership in the family care sector is shifting away from pure center footprint expansion. Future enterprise value will accrue to platforms capable of establishing early client trust, extending service lifecycles, and standardizing service delivery through digital technology and trained talent pools. According to Frost & Sullivan, Saint Bella ranked first globally by revenue in 2025, capturing a 0.5% market share—leading the second-largest operator by over 47%. While legacy operators remain focused on single-center economics, Saint Bella is leveraging high-end postpartum care as a customer acquisition bridge—building a full-lifecycle, omni-channel family care platform with defensible competitive moats. Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com ———————————————————————————————————————————————————————————— Care Can’t Wait! Long-Term Care workers hold province wide day of action calling out delays in contract negotiations with Extendicare 2026-09-01 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/care-t-wait-long-term-222800346.html Markham, ON, September 01, 2026--For months, 8 CUPE locals representing over 1100 long term care workers across Ontario have been kept waiting for a fair contract. Where other workers would have been able to go on strike to force the employer back to the table, these workers are denied that right under the Hospital Labour Disputes Arbitration Act (HLDAA), forcing them into a long and drawn-out process to get a fair contract. ———————————————————————————————————————————————————————————— Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway 2026-09-01 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/09/01/3354739/0/en/telix-completes-enrollment-in-phase-3-bipass-study-aligns-with-fda-on-nda-pathway.html MELBOURNE, Australia and INDIANAPOLIS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced completion of patient enrollment in the Phase 3 BiPASS™ study of its commercial PSMA-PET 1 imaging agents, Illuccix® (kit for the preparation of gallium Ga68 gozetotide injection) and Gozellix® (kit for the preparation of gallium Ga68 gozetotide injection) for prostate cancer imaging in the pre-biopsy setting. Telix has also aligned with the United States (U.S.) Food and Drug Administration (FDA) on a New Drug Application (NDA) pathway for BiPASS that, if approved, would support reimbursement as a new product and broaden patient access. ———————————————————————————————————————————————————————————— AHF Webinar Panel Discussion—Freedom from Debt: A Global Dialogue on Fiscal Space, Health, and Development 2026-09-01 · mlpr-businesswire · Healthcare, Education https://finance.yahoo.com/economy/policy/articles/ahf-webinar-panel-discussion-freedom-220800508.html MIAMI, September 01, 2026--AIDS Healthcare Foundation (AHF), in collaboration with the University of Miami Public Health Policy Lab, will co-host a webinar, "Freedom from Debt: A Global Dialogue on Fiscal Space, Health, and Development," on Thursday, September 3, 2026, at 10:00 AM EDT, virtually via Zoom. Register here. ———————————————————————————————————————————————————————————— Pennant Group to Participate in the 2026 Jefferies Healthcare Services Conference 2026-09-01 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/09/01/3354734/0/en/pennant-group-to-participate-in-the-2026-jefferies-healthcare-services-conference.html EAGLE, Idaho, Sept. 01, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, announced today that it will participate in the upcoming 2026 Jefferies Healthcare Services Conference on September 15, 2026. ———————————————————————————————————————————————————————————— Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Colombia 2026-09-01 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/09/01/3354730/0/en/knight-therapeutics-announces-regulatory-approval-of-tavalisse-in-colombia.html MONTREAL, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has received regulatory approval from INVIMA, the Colombian health regulatory agency, for TAVALISSE ® (fostamatinib disodium hexahydrate) for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response, loss of response, or intolerance to prior treatment with corticosteroids and intravenous immunoglobulin. 1 ———————————————————————————————————————————————————————————— Feinstein Institutes’ researchers find jumping genes at the center of blood immune networks disrupted in schizophrenia 2026-09-01 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/feinstein-institutes-researchers-jumping-genes-212800550.html MANHASSET, N.Y., September 01, 2026--Unlocking a crucial piece of schizophrenia’s molecular puzzle, scientists at Northwell Health’s Feinstein Institutes for Medical Research have found that jumping genes, also known as transposable elements, are linked to a communication breakdown in the blood gene expression networks of people living with schizophrenia. Jumping genes are DNA sequences from ancient viruses and other elements that could once move around the human genome – and in rare cases still ———————————————————————————————————————————————————————————— New National Survey From MedStar Health Finds Many Men Over 55 Are Missing Prostate Cancer Screening 2026-09-01 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/new-national-survey-from-medstar-health-finds-many-men-over-55-are-missing-prostate-cancer-screening-302866874.html COLUMBIA, Md., Sept. 1, 2026 /PRNewswire/ -- A new national survey from MedStar Health suggests millions of men age 55 and older may be missing chances to get screened for prostate cancer, even though it is one of the most common cancers in men. Of surveyed men age 55 and older, 30% have... ———————————————————————————————————————————————————————————— MindMaze Therapeutics to Present at Upcoming Investor and Industry Conferences 2026-09-01 · NewMediaWire · Healthcare https://www.newmediawire.com/news/mindmaze-therapeutics-to-present-at-upcoming-investor-and-industry-conferences-7089137 GENEVA, SWITZERLAND - September 1, 2026 ( NEWMEDIAWIRE ) - MindMaze Therapeutics Holding SA (SIX: MMTX ) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics, today announced its participation in several upcoming investor and industry conferences in the United States and Europe. Investor Conferences Conference: Baader Investment Conference Location: Munich, Germany Presentation: September 21, 2026 at 5:40 p.m. CET Conference: Global Markets Forum Location: New York, NY Presentation: October 7, 2026 Management will be available for one-on-one meetings. Investors interested in meeting with the Company are invited to contact ir@mindmazetherapeutics.com. Industry Conferences Conference: American Medical Rehabilitation Providers Association (AMRPA) Edu ———————————————————————————————————————————————————————————— Paubox Opens HIPAA Compliant Forms to AI Agents 2026-09-01 · mlpr-businesswire · AI, SaaS, Healthcare https://finance.yahoo.com/healthcare/articles/paubox-opens-hipaa-compliant-forms-211600835.html SAN FRANCISCO, September 01, 2026--Paubox has made its HIPAA compliant forms callable by AI agents. An agent can pull a form's questions, collect a patient's answers in conversation, and submit the completed response into Paubox. The record lands under the same business associate agreement (BAA) that covers the rest of the platform. ———————————————————————————————————————————————————————————— Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 2026-09-01 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/09/01/3354678/0/en/zentalis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on September 1, 2026, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 269,000 shares of the Company’s common stock to four (4) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual’s entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5 ———————————————————————————————————————————————————————————— NeuroPace to Participate in 2026 Cantor Global Healthcare Conference 2026-09-01 · mlpr-businesswire · Finance, Healthcare https://finance.yahoo.com/healthcare/articles/neuropace-participate-2026-cantor-global-210100686.html MOUNTAIN VIEW, Calif., September 01, 2026--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate in the upcoming 2026 Cantor Global Healthcare Conference. ———————————————————————————————————————————————————————————— Glidewell Holds First Course at New East Coast Clinical Education Center ... 2026-09-01 · PR-Inside · Healthcare, Education https://pr-inside.com/glidewell-holds-first-course-at-new-east-coast-clinical-education-center-r5218383.htm (PR-inside.com) Sixty-four dentists complete inaugural two-day implant course with Dr. Timothy Kosinski to earn 12 hours of CE IRVINE, CA / ACCESS Newswire / September 1, 2026 / Glidewell, America's leading dental laboratory and developer of innovative technologies, held its first live course at its Glidewell Clinical Education Center in Raleigh, North Carolina over the weekend, marking the official opening of its new East Coast facility. The inaugural program, Surgical Placement of Dental Implants: A Restorative-Driven Approach, was taught August 28-29 by esteemed educator Timothy F. Kosinski, DDS, and drew 64 attendees, each of whom earned 12 hours of continuing education. Over two days, .. ———————————————————————————————————————————————————————————— CMS Approves New Technology Add-on Payment for Reflow Medical’s Spur® Peripheral Retrievable Stent System 2026-09-01 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/cms-approves-technology-add-payment-210000045.html SAN CLEMENTE, Calif., September 01, 2026--Reflow Medical, Inc. announced that the Centers for Medicare & Medicaid Services (CMS) has granted the Spur Peripheral Retrievable Stent System a New Technology Add-on Payment (NTAP), providing additional reimbursement for eligible Fee-for-Service Medicare inpatient cases beginning October 1, 2026. ———————————————————————————————————————————————————————————— Glidewell Holds First Course at New East Coast Clinical Education Center in Raleigh, North Carolina 2026-09-01 · Newswire.com · Healthcare, Education https://www.newswire.com/news/glidewell-holds-first-course-at-new-east-coast-clinical-education-center-in Sixty-four dentists complete inaugural two-day implant course with Dr. Timothy Kosinski to earn 12 hours of CE ———————————————————————————————————————————————————————————— Father-to-daughter bone marrow transplant gives daughter a second chance at life 2026-09-01 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/father-to-daughter-bone-marrow-transplant-gives-daughter-a-second-chance-at-life-302866842.html First case of its kind at Nicklaus Children's Hospital and among only a few in the U.S. MIAMI, Sept. 1, 2026 /PRNewswire/ -- Nicklaus Children's Hospital Helen & Jacob Shaham Cancer & Blood Disorders Institute has successfully accomplished a bone marrow transplant on a 2-year-old girl... ———————————————————————————————————————————————————————————— Duncan Ferguson Joins Neovii Pharmaceuticals AG to Lead Global Commercial Expansion as Chief Commercial Officer 2026-09-01 · NewMediaWire · Healthcare https://www.newmediawire.com/news/duncan-ferguson-joins-neovii-pharmaceuticals-ag-to-lead-global-commercial-expansion-as-chief-commercial-officer-7089130 RAPPERSWIL, SWITZERLAND - September 1, 2026 ( NEWMEDIAWIRE ) - Neovii Pharmaceuticals AG today announced the appointment of Duncan Ferguson as Chief Commercial Officer (CCO) , effective 1 September 2026. Ferguson joins the company at a pivotal stage as Neovii accelerates the global expansion of its transplantation franchise and advances its strategic growth initiatives in immune-mediated diseases. Duncan brings nearly three decades of global commercial leadership experience spanning specialty pharmaceuticals, rare diseases, immunology, oncology and neuroscience. Throughout his career, he has built and scaled international commercial organizations, led successful market expansion strategies, and supported the launch and growth of innovative therapies across multiple regions. Most recently, ———————————————————————————————————————————————————————————— Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September 2026-09-01 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/09/01/3354648/0/en/relay-therapeutics-to-participate-in-two-upcoming-investor-conferences-in-september.html CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in September: ———————————————————————————————————————————————————————————— Styx Biotechnologies Announces Strategic Agreement with ZoeNCure Therapeutics to Accelerate Next-Generation ADC Pipeline to Clinic 2026-09-01 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/styx-biotechnologies-announces-strategic-agreement-204500467.html SAN DIEGO, September 01, 2026--Styx Biotechnologies, Inc., a San Diego-based biotechnology company developing next-generation antibody-drug conjugates (ADCs) for solid tumors, today announced a strategic agreement with ZoeNCure Therapeutics Pvt. Ltd. to accelerate selected Styx ADC programs toward first-in-human clinical studies. ———————————————————————————————————————————————————————————— aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis 2026-09-01 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/09/01/3354637/0/en/atyr-pharma-provides-update-on-timing-of-regulatory-response-for-planned-phase-3-study-of-efzofitimod-in-pulmonary-sarcoidosis.html aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis ———————————————————————————————————————————————————————————— Braveheart Bio to Participate in Cantor Global Healthcare Conference 2026-09-01 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/09/01/3354630/0/en/braveheart-bio-to-participate-in-cantor-global-healthcare-conference.html SAN FRANCISCO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced that it will participate in the Cantor Global Healthcare Conference, being held September 9-11 in New York, NY. Management will participate in a fireside chat on Thursday, September 10, 2026 at 3:20 p.m. EDT. ———————————————————————————————————————————————————————————— Cellectis Announces Participation in Upcoming Investor Conferences 2026-09-01 · GlobeNewswire · Finance, SaaS, Healthcare https://www.globenewswire.com/news-release/2026/09/01/3354624/0/en/cellectis-announces-participation-in-upcoming-investor-conferences.html NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that it will participate in the upcoming investor conferences: ———————————————————————————————————————————————————————————— iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference 2026-09-01 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/09/01/3354626/0/en/ibio-to-participate-in-the-2026-wells-fargo-annual-healthcare-conference.html SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced that it will participate in the Wells Fargo 21st Annual Healthcare Conference, taking place September 8-10, 2026, in Boston. ———————————————————————————————————————————————————————————— Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 2026-09-01 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/09/01/3354619/0/en/aura-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that inducement equity awards (collectively, “Inducement Awards”) were granted to Erica Kratz, Ph.D., Aura’s new Chief Regulatory and Quality Officer, Susan Abu-Absi, Ph.D., Aura’s new Chief Operating Officer, and Julie Person, Aura’s new Chief People Officer, each on September 1, 2026 (the “Grant Date”). The Inducement Awards were approved by the Compensation Committee of the Board of Directors of the Company in accordance with Nasdaq Listing Rule 5635(c)(4). ———————————————————————————————————————————————————————————— HelloNation Article Featuring Dental Expert Dr. Christopher Glenn Miller Explains Full Mouth Tooth Replacement Options From Dentures to Implants 2026-09-01 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/hellonation-article-featuring-dental-expert-dr-christopher-glenn-miller-explains-full-mouth-tooth-replacement-options-from-dentures-to-implants-302864943.html The article reviews how dentures and implant-based restorations support comfort, stability, and long-term jawbone health for patients missing teeth. ROCHESTER, N.Y., Sept. 1, 2026 /PRNewswire/ -- What options are available today for patients who need a full mouth replacement? According to... ———————————————————————————————————————————————————————————— Bringing Meals, Health and Support to the Streets of Downtown Phoenix 2026-09-01 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/bringing-meals-health-and-support-to-the-streets-of-downtown-phoenix-302866748.html AZ Blue Health Choice, AZ Langar on Wheels and Zeihan ProHealth partner to provide essential resources directly to people in need. PHOENIX, Sept. 1, 2026 /PRNewswire/ -- Thousands of hot meals, health screenings and essential supplies are reaching people experiencing homelessness in... ———————————————————————————————————————————————————————————— FROM TRANSPLANTATION TO DONATION: NEW CORE CEO DEBORAH MAURER LOOKS TO EXPAND WHAT'S POSSIBLE 2026-09-01 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/from-transplantation-to-donation-new-core-ceo-deborah-maurer-looks-to-expand-whats-possible-302866740.html Marking exactly one month into her tenure, longtime transplant director looks to build on CORE's nearly 50 years of life-saving impact through clinical innovation, stronger healthcare partnerships and investment in the future. PITTSBURGH, Sept. 1, 2026 /PRNewswire/ -- Deborah Maurer, RN,... ———————————————————————————————————————————————————————————— Select Health Recognizes 30 Organizations Addressing Community Health Needs in Idaho, Nevada, Utah 2026-09-01 · PRUnderground · Healthcare https://prunderground.com/select-health-recognizes-30-organizations-addressing-community-health-needs-in-i/cmtisu9ee00000bkvakxxi97a Intermountain Health's Select Health awards $150,000 to 30 organizations addressing community health needs across Idaho, Nevada, and Utah The post Select Health Recognizes 30 Organizations Addressing Community Health Needs in Idaho, Nevada, Utah first appeared on ———————————————————————————————————————————————————————————— Levi & Korsinsky Notifies Fractyl Health, Inc. (GUTS) Investors - Lead ... 2026-09-01 · PR-Inside · Finance, Healthcare https://pr-inside.com/levi-korsinsky-notifies-fractyl-health-inc-guts-investors-lead-r5218375.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / September 1, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Fractyl Health, Inc. (NASDAQ:GUTS) securities. If you suffered a loss on your Fractyl Health, Inc. investment and would like to explore a potential recovery under the federal securities laws, Learn about Fractyl Health, Inc. Class Action or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit was filed .. ———————————————————————————————————————————————————————————— HRC Fertility Appoints Dr. Robert Boostanfar as Chief Medical Officer 2026-09-01 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/hrc-fertility-appoints-dr-robert-boostanfar-as-chief-medical-officer-302866649.html LOS ANGELES, Sept. 1, 2026 /PRNewswire/ -- HRC Fertility, one of the nation's leading fertility networks, announced the appointment of Robert Boostanfar, M.D., as Chief Medical Officer (CMO). A longtime HRC physician, legacy partner and nationally recognized reproductive endocrinologist,... ———————————————————————————————————————————————————————————— Trends for Health Insurer Profitability as Assessed by Mark Farrah Associates 2026-09-01 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/trends-health-insurer-profitability-assessed-174700231.html PITTSBURGH, September 01, 2026--MFA compared 2025 and 2024, PMPM health premiums and expenses for the Individual, Employer-Group, Medicare, and Medicaid segments. ———————————————————————————————————————————————————————————— Helogen Announces October Missions to Advance Commercial Manufacturing in Orbit and Establish First Regulatory Pathway 2026-09-01 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/helogen-announces-october-missions-advance-140000025.html LOS ANGELES, September 01, 2026--Helogen, the ​​company building autonomous factories in space for advanced material production, today announced two missions scheduled for October 2026. The missions will support the manufacturing of biomaterials for artificial retinas and orthopedic applications, while advancing the company’s work toward GMP-compliant production and FDA review. ———————————————————————————————————————————————————————————— SBC Medical to Participate in Several Upcoming Investor Conferences in September 2026 2026-09-01 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/sbc-medical-participate-several-upcoming-173500034.html IRVINE, Calif., September 01, 2026--SBC Medical will be conducting a Non-Deal Roadshow (NDR) and participating in several investor conferences throughout September 2026. ———————————————————————————————————————————————————————————— RETRANSMISSION: Six Million Marijuana Patients - or a Medical Myth? ... 2026-09-01 · PR-Inside · Healthcare https://pr-inside.com/retransmission-six-million-marijuana-patients-or-a-medical-myth-r5218346.htm (PR-inside.com) "The marijuana physician participation is below 4% in major states - with three doctors generating more than one quarter of the recommendations in Colorado - ALJ testitomy undercuts claims of broad national medical acceptance by the fake marijuana news", said Duane Boise CEO MMJ International Holdings. WASHINGTON, D.C. / ACCESS Newswire / September 1, 2026 / Sworn testimony in the federal marijuana-rescheduling hearing challenges widely repeated media claims that six million registered medical marijuana patients demonstrate broad acceptance of marijuana within the American medical profession. The six million figure counts registrations in state authorized programs. It does not establish six million physician .. ———————————————————————————————————————————————————————————— Seven dozen medical students disperse across the Mid-South for clinical rotations 2026-09-01 · PR Newswire · Healthcare, Education https://www.prnewswire.com/news-releases/seven-dozen-medical-students-disperse-across-the-mid-south-for-clinical-rotations-302866627.html Marking significant milestone for first class of Baptist University College of Osteopathic Medicine students MEMPHIS, Tenn., Sept. 1, 2026 /PRNewswire/ -- The first-ever third-year class of students of Baptist Health Sciences University College of Osteopathic Medicine began their clinical... ———————————————————————————————————————————————————————————— IdentityIQ Expands Access to Identity Protection and Financial Wellness Tools with New Spanish-Language Experience 2026-09-01 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/identityiq-expands-access-to-identity-protection-and-financial-wellness-tools-with-new-spanish-language-experience-302866626.html New Spanish-language version brings identity protection, credit monitoring and financial health resources to more than 41 million Spanish-dominant speakers in the U.S. TEMECULA, Calif., Sept. 1, 2026 /PRNewswire/ -- IdentityIQ, a leading provider of identity theft protection, credit... ———————————————————————————————————————————————————————————— RiverBend Counseling Adds Kenzi Gray, LPC-Associate, to New Braunfels, TX Clinical Team 2026-09-01 · PRUnderground · Healthcare https://prunderground.com/riverbend-counseling-adds-kenzi-gray-lpc-associate-to-new-braunfels-tx-clinical-/cmtirbgdc000704kzei5b4vmt RiverBend Counseling has added Kenzi Gray, LPC-Associate, in New Braunfels, TX. She works with teens, young adults, and adults on anxiety, identity, and life transitions. The post RiverBend Counseling Adds Kenzi Gray, LPC-Associate, to New Braunfels, TX Clinical Team first appeared on ———————————————————————————————————————————————————————————— GUTS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces ... 2026-09-01 · PR-Inside · Finance, Healthcare https://pr-inside.com/guts-investor-alert-bronstein-gewirtz-and-grossman-llc-announces-r5218325.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / September 1, 2026 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Fractyl Health, Inc. (NASDAQ:GUTS) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Fractyl securities between January 13, 2025 and January 29, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/cases/fractyl-health-inc-guts-class_action_lawsuit. Fractyl Case .. ———————————————————————————————————————————————————————————— Securities Lawsuit Alert: Fractyl Health, Inc. (GUTS) - Contact Levi ... 2026-09-01 · PR-Inside · Finance, Healthcare https://pr-inside.com/securities-lawsuit-alert-fractyl-health-inc-guts-contact-levi-r5218284.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / September 1, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Fractyl Health, Inc. (NASDAQ:GUTS) securities. If you suffered a loss on your Fractyl Health, Inc. investment and would like to explore a potential recovery under the federal securities laws, Learn about Fractyl Health, Inc. Class Action or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit was filed .. ———————————————————————————————————————————————————————————— Six Million Marijuana Patients - or a Medical Myth? Sworn DEA Testimony ... 2026-09-01 · PR-Inside · Healthcare https://pr-inside.com/six-million-marijuana-patients-or-a-medical-myth-sworn-dea-testimony-r5218280.htm (PR-inside.com) "The marijuana physician participation is below 4% in major states - with three doctors generating more than one quarter of the recommendations in Colorado - ALJ testitomy undercuts claims of broad national medical acceptance by the fake marijuana news", said Duane Boise CEO MMJ International Holdings. WASHINGTON, D.C. / ACCESS Newswire / September 1, 2026 / Sworn testimony in the federal marijuana-rescheduling hearing challenges widely repeated media claims that six million registered medical marijuana patients demonstrate broad acceptance of marijuana within the American medical profession. The six million figure counts registrations in state authorized programs. It does not establish six million physician .. ———————————————————————————————————————————————————————————— Six Million Marijuana Patients - or a Medical Myth? Sworn DEA Testimony Exposes What the Headlines Left Out 2026-09-01 · Newswire.com · Healthcare https://www.newswire.com/news/six-million-marijuana-patients-or-a-medical-myth-sworn-dea-testimony-3374864 "The marijuana physician participation is below 4% in major states - with three doctors generating more than one quarter of the recommendations in Colorado - ALJ testitomy undercuts claims of broad national medical acceptance by the fake marijuana news", said Duane Boise CEO MMJ International Holdings. ———————————————————————————————————————————————————————————— Bronstein, Gewirtz & Grossman LLC Urges Fractyl Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm 2026-09-01 · mlpr-newsfile · Finance, Healthcare https://www.newsfilecorp.com/release/311067/Bronstein-Gewirtz-Grossman-LLC-Urges-Fractyl-Health-Inc.-Investors-to-Act-Class-Action-Filed-Alleging-Investor-Harm New York, New York--(Newsfile Corp. - September 1, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Fractyl Health, Inc. (NASDAQ: GUTS) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Fractyl securities between January 13, 2025... ———————————————————————————————————————————————————————————— The Benefit Doctor Responds as Healthcare Costs Hit 20-Year High 2026-09-01 · PRUnderground · Healthcare https://prunderground.com/the-benefit-doctor-responds-as-healthcare-costs-hit-20-year-high/cmtitszxz000w04jsmo7jl2hv Phoenix-based employee benefits brokerage calls on employers to act as 2027 healthcare cost projections reach their steepest growth rate in over two decades. The post The Benefit Doctor Responds as Healthcare Costs Hit 20-Year High first appeared on ———————————————————————————————————————————————————————————— In HelloNation, Dental Expert Dr. Landon B. Rockwell Explains the Safety of Dental X-Rays 2026-09-01 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/in-hellonation-dental-expert-dr-landon-b-rockwell-explains-the-safety-of-dental-x-rays-302745654.html The Article Examines Radiation Levels, Preventive Benefits, and How Modern Imaging Supports Long-Term Oral Health TOOELE, Utah, Sept. 1, 2026 /PRNewswire/ -- Are dental X-rays safe, and should patients be concerned about radiation exposure during routine dental checkups? According to a... ———————————————————————————————————————————————————————————— A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture 2026-09-01 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/a-wave-of-weight-loss-drugs-is-quietly-creating-a-multi-billion-dollar-opportunity-that-aesthetic-medicine-is-racing-to-capture-302866509.html NEW YORK, Sept. 1, 2026 /PRNewswire/ -- Equity Insider News Commentary - The global medical aesthetics market has quietly become one of the most durable growth stories in healthcare. Multiple market-research firms size it at roughly US$22 billion to US$23 billion in 2026, with projections... ———————————————————————————————————————————————————————————— Pacific Mobile Structures Expands Healthcare Solutions with Custom Modular Diagnostic Imaging Centers 2026-09-01 · PRWeb · Healthcare https://www.prweb.com/releases/pacific-mobile-structures-expands-healthcare-solutions-with-custom-modular-diagnostic-imaging-centers-302858058.html Pacific Mobile Structures is helping healthcare providers expand diagnostic imaging capacity faster with custom modular facilities designed for MRI, CT, X-ray, mammography, PET, and outpatient imaging services. By combining off-site construction with specialized medical-grade engineering,... ———————————————————————————————————————————————————————————— ALKU Acquires rockITdata to Expand AI Capabilities and Healthcare IT Solutions 2026-09-01 · mlpr-prnewswire-wire · Finance, AI, Healthcare https://www.prnewswire.com/news-releases/alku-acquires-rockitdata-to-expand-ai-capabilities-and-healthcare-it-solutions-302866278.html ALKU Pairs Staffing Model with rockITdata's Solutions Expertise to Deliver Complete Project Ownership and Fuel Rapid Growth Across AI, Healthcare IT and Federal Health ANDOVER, Mass., Sept. 1, 2026 /PRNewswire/ -- ALKU, a leading specialized staffing firm, today announced the acquisition... ———————————————————————————————————————————————————————————— LeanTaaS Acquires Aidin to Orchestrate Patient Flow from Admission Through Transition 2026-09-01 · mlpr-prnewswire-wire · Healthcare https://www.prnewswire.com/news-releases/leantaas-acquires-aidin-to-orchestrate-patient-flow-from-admission-through-transition-302866223.html Combination connects inpatient flow intelligence with care transition coordination to help health systems reduce avoidable days, unlock capacity, and improve timely patient access. SANTA CLARA, Calif., Sept. 1, 2026 /PRNewswire/ -- LeanTaaS, the market leader in capacity management,... ———————————————————————————————————————————————————————————— Lighteum Medical Appoints Gaurav Agarwal as Chief Executive Officer 2026-09-01 · mlpr-prnewswire-wire · Healthcare https://www.prnewswire.com/news-releases/lighteum-medical-appoints-gaurav-agarwal-as-chief-executive-officer-302866022.html Experienced MedTech Executive to Lead with a Focus on Customers, Speed and Execution SAN DIEGO, Sept. 1, 2026 /PRNewswire/ -- Lighteum Medical, a global provider of precision medical components, today announced the appointment of Gaurav Agarwal as Chief Executive Officer (CEO), effective... ———————————————————————————————————————————————————————————— /C O R R E C T I O N -- VirtuAlly/ 2026-09-01 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/virtually-expands-virtual-triage-nursing-service-through-collaboration-with-musc-health-302866388.html In the news release, VirtuAlly Expands Virtual Triage Nursing Service Through Collaboration With MUSC Health, issued 01-Sep-2026 by VirtuAlly over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at... ———————————————————————————————————————————————————————————— Haier Biomedical Highlights Automated Biostorage and Connected Pharma Solutions at ISPE Singapore 2026 2026-09-01 · PR Newswire · SaaS, Healthcare https://www.prnewswire.com/news-releases/haier-biomedical-highlights-automated-biostorage-and-connected-pharma-solutions-at-ispe-singapore-2026-302866427.html Haier Biomedical Accelerates Its Transformation into an Intelligent Biopharmaceutical Infrastructure Platform at ISPE Singapore 2026 SINGAPORE, Sept. 1, 2026 /PRNewswire/ -- Haier Biomedical (SHA: 688139) showcased a portfolio of automated and digital solutions spanning key pharmaceutical... ———————————————————————————————————————————————————————————— Ready Computing Selected by Alabama Medicaid Agency to Modernize One ... 2026-09-01 · PR-Inside · SaaS, Healthcare https://pr-inside.com/ready-computing-selected-by-alabama-medicaid-agency-to-modernize-one-r5218267.htm (PR-inside.com) Statewide initiative expands Ready Computing's leadership in healthcare interoperability while advancing Alabama's next-generation health information exchange. NEW YORK, NY / ACCESS Newswire / September 1, 2026 / Ready Computing today announced that it has been selected by the Alabama Medicaid Agency to modernize and operate One Health Record (OHR), Alabama's statewide Health Information Exchange (HIE). The award marks another significant milestone in Ready Computing's continued expansion as a trusted partner for statewide healthcare interoperability initiatives. As part of the initiative, Ready Computing will migrate One Health Record to Microsoft Azure, establishing a modern, scalable cloud foundation designed to strengthen the security, reliability, .. ———————————————————————————————————————————————————————————— Ready Computing Selected by Alabama Medicaid Agency to Modernize One Health Record, the State's Health Information Exchange 2026-09-01 · Newswire.com · Healthcare https://www.newswire.com/news/ready-computing-selected-by-alabama-medicaid-agency-to-modernize-one-22831931 Statewide initiative expands Ready Computing's leadership in healthcare interoperability while advancing Alabama's next-generation health information exchange. ———————————————————————————————————————————————————————————— LambdaVision Advances Space-Based Manufacturing With Its First Mission Beyond the ISS 2026-09-01 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/lambdavision-advances-space-based-manufacturing-141100715.html WOODBRIDGE, Conn., September 01, 2026--LambdaVision, a pre-clinical-stage biotech advancing on-Earth and microgravity bioprocesses, today announced an upcoming mission with Helogen Corporation to deepen its knowledge of the space-based properties of the protein used in LambdaVision’s artificial retina. Scheduled to launch in October 2026, the mission will mark LambdaVision’s first flight beyond the International Space Station (ISS) and an essential next step in the company’s strategy to expand i ———————————————————————————————————————————————————————————— MiSalud Health Launches Whole-Woman Health Care for Bilingual Front-Line Workers 2026-09-01 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/misalud-health-launches-whole-woman-140700225.html SAN FRANCISCO, September 01, 2026--MiSalud Health launches bilingual Spanish/English Women's Health Program for blue-collar workers, including overlooked part-time employees ———————————————————————————————————————————————————————————— Did You Lose Money on Fractyl Health, Inc. (GUTS)? Levi & Korsinsky ... 2026-09-01 · PR-Inside · Finance, Healthcare https://pr-inside.com/did-you-lose-money-on-fractyl-health-inc-guts-levi-korsinsky-r5218254.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / September 1, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Fractyl Health, Inc. (NASDAQ:GUTS) securities. If you suffered a loss on your Fractyl Health, Inc. investment and would like to explore a potential recovery under the federal securities laws, Learn about Fractyl Health, Inc. Class Action or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit was filed .. ———————————————————————————————————————————————————————————— Black Book Report Warns Hospital AI Adoption Is Outpacing Cybersecurity ... 2026-09-01 · PR-Inside · AI, Healthcare https://pr-inside.com/black-book-report-warns-hospital-ai-adoption-is-outpacing-cybersecurity-r5218251.htm (PR-inside.com) New hospital action framework identifies shadow AI, agent privileges, third-party exposure and clinical downtime as urgent threats through 2027 CHICAGO, IL / ACCESS Newswire / September 1, 2026 / Hospitals are deploying artificial intelligence faster than many are adapting their identity controls, data-loss prevention, asset inventories, vendor oversight and incident-response plans, according to a new industry AI/cybersecurity report from Black Book Research. The report, "Hospital AI Cybersecurity Readiness: What Hospitals Must Do Now Before AI Pilots, Data Loading, Agents and Third Parties Create the Next Breach Surface," warns that AI is expanding healthcare's attack surface while simultaneously making phishing, vulnerability exploitation, credential .. ———————————————————————————————————————————————————————————— BigHat Biosciences Announces First Patient Dosed in Phase 1 Trial Evaluating BHB810, a Novel CDH17-Directed Antibody-Drug Conjugate, for the Treatment of Gastric Cancer and other Advanced Gastrointestinal Tumors 2026-09-01 · mlpr-businesswire · AI, SaaS, Healthcare https://finance.yahoo.com/healthcare/articles/bighat-biosciences-announces-first-patient-140000418.html SAN MATEO, Calif., September 01, 2026--BigHat Biosciences, a clinical-stage, AI-driven protein therapeutics platform company, today announced that the first patient has been dosed in its Phase 1 clinical trial evaluating BHB810, a novel, potentially best-in-class Cadherin-17 (CDH17)-directed VHH-Fc antibody-drug conjugate (ADC) for the treatment of gastric cancer and other advanced gastrointestinal (GI) malignancies. BHB810 was engineered using BigHat’s AI-powered antibody design platform to com ———————————————————————————————————————————————————————————— Black Book Report Warns Hospital AI Adoption Is Outpacing Cybersecurity Controls 2026-09-01 · Newswire.com · AI, Healthcare https://www.newswire.com/news/black-book-report-warns-hospital-ai-adoption-is-outpacing-cybersecurity-controls New hospital action framework identifies shadow AI, agent privileges, third-party exposure and clinical downtime as urgent threats through 2027 ———————————————————————————————————————————————————————————— DepoIQ Is Now InFactIQ: Evidence Intelligence for Claims and Litigation 2026-09-01 · PRWeb · SaaS, Healthcare, Media https://www.prweb.com/releases/depoiq-is-now-infactiq-evidence-intelligence-for-claims-and-litigation-302864665.html DepoIQ is now InFactIQ, an evidence intelligence platform that reads the complete case file - testimony, medical records, bills, claim files, and video - to check a witness' story against the evidence. The platform fact-checks live testimony in real time and cites every finding to its... ———————————————————————————————————————————————————————————— ODG by MCG Expert Joins Workers' Comp Experts for Panel Discussion on Claims Consistency at National Comp 2026 2026-09-01 · PR Newswire · AI, Healthcare https://www.prnewswire.com/news-releases/odg-by-mcg-expert-joins-workers-comp-experts-for-panel-discussion-on-claims-consistency-at-national-comp-2026-302860114.html Workers' compensation industry experts to explore how evidence-based guidelines, technology, and AI can support more consistent claims decisions SEATTLE, Sept. 1, 2026 /PRNewswire/ -- ODG by MCG, an MCG Health company and part of the Hearst Health network, announces its Director of... ———————————————————————————————————————————————————————————— SpendMend Names Rob Proctor Chief Commercial Officer 2026-09-01 · PR-Inside · Healthcare https://pr-inside.com/spendmend-names-rob-proctor-chief-commercial-officer-r5218246.htm (PR-inside.com) GRAND RAPIDS, MI / ACCESS Newswire / September 1, 2026 / SpendMend, the leading provider of cost cycle management solutions to the healthcare industry, today announced the appointment of Rob Proctor as Chief Commercial Officer. Proctor will lead all go-to-market activities for the company. Proctor brings more than 20 years of healthcare leadership and commercial experience spanning healthcare technology, health systems, consulting, and medical supply distribution. Throughout his career, he has built and led high-performing teams, developed scalable commercial systems, and partnered with healthcare executives to improve financial and operational performance. Most recently, Proctor served as Vice President of Enterprise Sales at .. ———————————————————————————————————————————————————————————— Medical Care Technologies Inc. (OTCID:MDCE) Centers StrainScan Pro ... 2026-09-01 · PR-Inside · AI, SaaS, Healthcare https://pr-inside.com/medical-care-technologies-inc-otcid-mdce-centers-strainscan-pro-r5218241.htm (PR-inside.com) Proprietary AI Vision Platform Now Positioned as a Quality-Control Tool for Farming Operations and High-Volume Foodservice Environments MESA, AZ / ACCESS Newswire / September 1, 2026 / Medical Care Technologies Inc. (OTCID:MDCE) today reinforced that StrainScan Pro is being advanced as an artificial intelligence vision platform built for the agriculture and foodservice industries - two of the largest economic sectors in the world. StrainScan Pro is proprietary AI vision software designed to support visual quality analysis, consistency checks, and early identification of quality issues. The Company is focusing the platform on practical enterprise use across farming, post-harvest handling, and foodservice operations, including .. ———————————————————————————————————————————————————————————— Medical Care Technologies Inc. (OTCID:MDCE) Centers StrainScan Pro on Multi-Trillion-Dollar Agriculture and Foodservice Markets 2026-09-01 · Newswire.com · AI, SaaS, Healthcare https://www.newswire.com/news/medical-care-technologies-inc-otcid-mdce-centers-strainscan-pro-on-multi Proprietary AI Vision Platform Now Positioned as a Quality-Control Tool for Farming Operations and High-Volume Foodservice Environments ———————————————————————————————————————————————————————————— 1upHealth Launches 1up Clinical Connect to Help Payers Strengthen HEDIS ... 2026-09-01 · PR-Inside · Healthcare https://pr-inside.com/uphealth-launches-1up-clinical-connect-to-help-payers-strengthen-hedis-r5218238.htm (PR-inside.com) Interoperability Leader Announces Capital Health Plan as Inaugural User of New Solution BOSTON, MA / ACCESS Newswire / September 1, 2026 / 1upHealth, a leader in health data interoperability, today announced it has launched 1up Clinical Connect, a solution that allows health plans to automatically acquire clinical data from provider EHRs and unify it with claims data into a single longitudinal member record. Longstanding 1upHealth customer Capital Health Plan is the first to implement the new solution, using it to close care gaps, sharpen risk adjustment accuracy, and improve outcomes. Health plans need clinical data to run critical programs like HEDIS, Star .. ———————————————————————————————————————————————————————————— CNS Pharmaceuticals Details Business Development Strategy Driving Its ... 2026-09-01 · PR-Inside · Finance, Healthcare https://pr-inside.com/cns-pharmaceuticals-details-business-development-strategy-driving-its-r5218237.htm (PR-inside.com) Chief Business Officer, Dylan Wenke, Participates in Virtual Investor "What This Means" Segment Access the segment here HOUSTON, TX / ACCESS Newswire / September 1, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in a Virtual Investor "What This Means" Segment. Dylan Wenke, Chief Business Officer of CNS Pharmaceuticals, provided an update on its business development strategy as part of its broader transformation as the Company works to establish a pipeline focused on oncology or neurology with best in class .. ———————————————————————————————————————————————————————————— Salesforce Named a Leader in the 2026 Gartner® Magic Quadrant™ for Healthcare Provider Industry Cloud Platforms 2026-09-01 · mlpr-salesforce · AI, SaaS, Healthcare https://www.salesforce.com/news/stories/gartner-magic-quadrant-healthcare-provider-industry-cloud-platforms-2026/ Agentforce Health helps health systems unify patient data and deploy autonomous AI agents to deliver faster, more personalized care. ———————————————————————————————————————————————————————————— Vituity Launches MVMNT to Move Longevity Medicine From Conversation to Clinical Practice 2026-09-01 · Newswire.com · Healthcare https://www.newswire.com/news/vituity-launches-mvmnt-to-move-longevity-medicine-from-conversation-to-22854812 Inaugural summit brings clinicians and innovators together with evidence-based frameworks for integrating longevity medicine into practice today ———————————————————————————————————————————————————————————— Syra Health, Wake County Public Health Expand Wellness Partnership 2026-09-01 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/syra-health-wake-county-public-health-expand-wellness-partnership-302864492.html CARMEL, Ind., Sept. 1, 2026 /PRNewswire/ -- Syra Health Corp. (OTCQB: SYRA) ("Syra Health" or the "Company"), an integrated healthcare solutions company powering better health outcomes through prevention-focused, accessible, and affordable solutions, announced today the expansion of its... ———————————————————————————————————————————————————————————— Cornerstone Robotics Announces Strategic Partnership with Medtronic to Expand Global Access to Robotic-assisted Surgery 2026-09-01 · mlpr-acnnewswire · Finance, SaaS, Healthcare, Energy https://www.acnnewswire.com/press-release/english/109692/ HONG KONG, Sep 1, 2026 - (ACN Newswire) - Cornerstone Robotics, an innovative surgical robotics company founded and headquartered in Hong Kong, today announced a strategic partnership with Medtronic (NYSE: MDT), a global leader in healthcare technology. As part of the partnership, Medtronic will make an approximately US$700 million strategic investment in Cornerstone Robotics and have rights to distribute Cornerstone Robotics’ SentireTM surgical system in select markets outside the U.S. where the system is market approved. A Shared Vision: Bridging the Global Access Gap in Minimally Invasive Care With robotic-assisted surgery adoption still in single digits globally, the opportunity to make advanced surgical care accessible to more patients, physicians, and health systems around the world is significant. Addressing this market requires both continuous technical innovation and strong market scaling capabilities. By aligning Cornerstone Robotics’ technology with Medtronic’s comprehensive global presence, the two companies aim to make high-quality robotic-assisted surgery accessible to more patients worldwide. A Strategic Alignment: Scaling Technology Solutions to Reach More Patients Cornerstone Robotics has established a strong strategic foundation through its full-stack in-house R&D and vertically integrated paradigm. By independently developing its core hardware, control software, advanced algorithms, and proprietary imaging and energy platforms, Cornerstone Robotics maintains substantial control over product integration, quality, and supply chain resilience. This underpins the exceptional stability and high-fidelity performance of the Sentire surgical system in demanding clinical environments. In 2024, Cornerstone Robotics’ Sentire surgical system received National Medical Products Administration approval in China. In May 2026, Sentire surgical system received CE Mark in the European Union and approval from Singapore Health Sciences Authority, both covering minimally invasive general, gynecologic, thoracic, and urologic surgical procedures. “This partnership marks an important step in advancing access to robotic-assisted surgery around the world,” said Professor Kwok Wai Samuel AU, Founder and CEO of Cornerstone Robotics. “There remains a significant gap between the growing demand for minimally invasive surgery and the availability of robotic-assisted surgical technologies. At Cornerstone Robotics, we have built a strong foundation through full-stack in-house R&D and vertical integration, enabling us to continuously advance the core technologies of surgical robotics. Our partnership with Medtronic positions us to further accelerate and scale our work to bring the benefits of robotic-assisted surgery to more surgeons and patients around the world.” “This investment and distribution agreement strengthens Medtronic’s ability to further expand access to minimally invasive surgery to more patients around the world. We’re excited to bring more choice in robotics, and Sentire is a strong complement to our Hugo platform," said Matt Anderson, Senior Vice President and President, Surgical at Medtronic. The partnership marks a significant milestone for both companies to collaboratively advance their shared mission of making robotic-assisted surgery more accessible worldwide. Advisors Kirkland & Ellis and Global Law Office are acting as legal counsel to Cornerstone Robotics. Morgan Stanley & Co. LLC is serving as exclusive financial advisor to Medtronic, and Cleary Gottlieb Steen & Hamilton LLP is serving as lead legal counsel. About Cornerstone Robotics Founded and headquartered in Hong Kong, Cornerstone Robotics is an innovative surgical robotics company driven by the vision of leading medical innovations for a healthier world. We advance surgical care with cutting-edge robotic systems that make high-quality healthcare more accessible and efficient globally. With three global R&D hubs and six business centres worldwide, Cornerstone Robotics has established a 30,000-square-meter manufacturing facility in China. Developed entirely in-house, our SentireTM surgical system has completed multi-specialty clinical trials and received market approval across China, the European Union and Singapore, advancing high-quality surgical care worldwide. To find out more information, please visit https://en.csrbtx.com/ and follow us on LinkedIn. About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow on LinkedIn. Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com ———————————————————————————————————————————————————————————— Intelligent Bio Solutions Achieves Above 98% Accuracy in Method Comparison Study, Supporting Planned 2026 FDA 510(k) Submission 2026-09-01 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/09/01/3354170/0/en/intelligent-bio-solutions-achieves-above-98-accuracy-in-method-comparison-study-supporting-planned-2026-fda-510-k-submission.html Multi-site clinical study delivers strong performance data for Intelligent Fingerprinting Drug Screening System Multi-site clinical study delivers strong performance data for Intelligent Fingerprinting Drug Screening System ———————————————————————————————————————————————————————————— CytoDyn Closes $16.5 Million Financing to Fund Continued Development of Leronlimab 2026-09-01 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/09/01/3354141/19782/en/cytodyn-closes-16-5-million-financing-to-fund-continued-development-of-leronlimab.html VANCOUVER, Washington, Sept. 01, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC), today announced that it has closed on a financing of $16.5 million in gross proceeds, with Paulson Investment Company acting as placement agent. ———————————————————————————————————————————————————————————— Intelligent Bio Solutions Announces Private Placement of up to $15 Million to a Single Existing Institutional Investor Priced At-the-Market Under Nasdaq Rules 2026-09-01 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/09/01/3354145/0/en/intelligent-bio-solutions-announces-private-placement-of-up-to-15-million-to-a-single-existing-institutional-investor-priced-at-the-market-under-nasdaq-rules.html $5 Million Upfront at Closing and $5 Million Tranche Warrant Callable by the Company Following FDA 510(k) Clearance of Intelligent Fingerprinting Drug Screening System $5 Million Upfront at Closing and $5 Million Tranche Warrant Callable by the Company Following FDA 510(k) Clearance of Intelligent Fingerprinting Drug Screening System ———————————————————————————————————————————————————————————— SCYNEXIS to Participate in Upcoming Investor Conferences 2026-09-01 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/09/01/3354140/0/en/scynexis-to-participate-in-upcoming-investor-conferences.html JERSEY CITY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with significant unmet medical need, today announced that the company will participate in the following investor conferences: ———————————————————————————————————————————————————————————— Yoga India Foundation – One of the Best Yoga Schools for Yoga Teacher Training in India 2026-09-01 · PressReleaseNews · Healthcare, Education https://pressreleasenews.org/pressroom/yoga-india-foundation-one-of-the-best-yoga-schools-for-yoga-teacher-training-in-india Yoga India Foundation is a leading yoga teacher training school in Rishikesh, India, offering Yoga Alliance-certified programs. With over 5,000 students trained from 90+ countries, the school provides authentic, traditional yoga education in a peaceful ashram setting. Programs include 100, 200, 300, and 500-hour courses, ———————————————————————————————————————————————————————————— Ayrmid Appoints Ideogen for Omisirge(R) in EMEA 2026-09-01 · PR-Inside · Healthcare https://pr-inside.com/ayrmid-appoints-ideogen-for-omisirge-r-in-emea-r5218214.htm (PR-inside.com) Ayrmid Appoints Ideogen as Exclusive Partner for Omisirge® across Multiple Regions in Europe, MENA and CIS Ideogen granted exclusive rights to launch a managed access program for Omisirge across 55 markets, covering both FDA-approved Omisirge indications DUBLIN, IE / ACCESS Newswire / September 1, 2026 / Ayrmid Ltd. ("Ayrmid" or the "Company"), parent company of Gamida Cell Inc., today announced the appointment of Ideogen Group GmbH ("Ideogen") as its exclusive distributor for Omisirge® (omidubicel-onlv). Under the agreement, Ideogen is granted exclusive rights to launch a managed access program for Omisirge across 55 markets in Europe (excluding Greece and Cyprus), the Middle East .. ———————————————————————————————————————————————————————————— "Beyond Quick Fixes": Moving Toward Meaningful Change 2026-09-01 · mlpr-newsfile · Healthcare https://www.newsfilecorp.com/release/311977/Beyond-Quick-Fixes-Moving-Toward-Meaningful-Change Austin, Texas--(Newsfile Corp. - September 1, 2026) - As the weight of stress, emotional overwhelm, and pervasive uncertainty continue to impact everyday life, Dr. Celeste Birkhofer's Beyond Quick Fixes: Essential Ingredients for Better Mental Health and a Fulfilling Life (Greenleaf Book Group Press, Sept 1, 2026, $23.95) provides a timely, research-informed guide to help move beyond reactive, superficial remedies to cultivate meaningful transformation and resilience. This book serves as a... ———————————————————————————————————————————————————————————— Apptly and Koning Announce Strategic Partnership to Expand Patient Access to Non-Compression 3D Breast Imaging 2026-09-01 · mlpr-newsfile · Healthcare https://www.newsfilecorp.com/release/312371/Apptly-and-Koning-Announce-Strategic-Partnership-to-Expand-Patient-Access-to-NonCompression-3D-Breast-Imaging Vancouver, British Columbia--(Newsfile Corp. - September 1, 2026) - Apptly Health Technologies Corp. (CSE: APPT) (FSE: 4KL) (the "Company" or "Apptly"), operator of the UberDoc direct-pay healthcare marketplace, today announced a strategic partnership with Koning Corporation ("Koning"), manufacturer of the FDA-approved Koning Vera Breast CT.Highlights:FDA-Approved Breast CT: The Koning Vera Breast CT is the only breast CT system with FDA premarket approval for diagnostic imaging of the breast.... ———————————————————————————————————————————————————————————— Healthcare organizations can now connect EHR and additional industry data to ChatGPT 2026-09-01 · mlpr-openai · AI, Healthcare https://openai.com/index/chatgpt-connects-health-records-and-healthcare-sources ChatGPT can now connect to trusted healthcare data, helping clinicians securely access patient context, medical research, and more. ———————————————————————————————————————————————————————————— Loamara Co. Announces Strategic Partnership With myRocky to Launch Loamara Wellness 2026-09-01 · NewMediaWire · SaaS, Healthcare, Retail https://www.newmediawire.com/news/loamara-co-announces-strategic-partnership-with-myrocky-to-launch-loamara-wellness-7089100 Ten-year Partnership Combines Loamara’s Product Development Expertise With myRocky’s Clinical Platform and Experience Supporting More Than 400,000 Patients TORONTO, ONTARIO - September 1, 2026 ( NEWMEDIAWIRE ) - Loamara Co. , the wellness company behind Green Monke, today announced a ten-year strategic partnership with Rocky Health Inc. (“myRocky”), a leading Health Canada approved digital health platform, to launch Loamara Wellness, a new product line focused on longevity, nutrition and proactive health. The first products will focus on supporting people using GLP 1 medications, alongside protein rich powders designed to support broader nutrition and wellness needs. Additional capsule, powder and gummy formats are expected to follow. The companies are targeting a commercial launch through ———————————————————————————————————————————————————————————— SmartConnect and Benepicks Unite to Eliminate the ICHRA "Medicare Cliff" 2026-09-01 · mlpr-prnewswire-wire · SaaS, Healthcare https://www.prnewswire.com/news-releases/smartconnect-and-benepicks-unite-to-eliminate-the-ichra-medicare-cliff-302862887.html Bridging the gap between ICHRA and Medicare: Two industry leaders combine tax-free health allowances and zero-cost advocacy to combat rising healthcare costs for the aging workforce. The Problem: Standard ICHRA platforms lack Medicare integration, leaving aging workers to navigate complex... ———————————————————————————————————————————————————————————— Vivos Therapeutics to Present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference 2026-09-01 · mlpr-newsfile · Finance, Healthcare https://www.newsfilecorp.com/release/312338/Vivos-Therapeutics-to-Present-at-the-2026-Moody-Capital-Solutions-Disruptive-Growth-Life-Sciences-Conference Littleton, Colorado--(Newsfile Corp. - September 1, 2026) - Vivos Therapeutics, Inc. (NASDAQ: VVOS) ("Vivos" or the "Company"), a leading medical technology and healthcare services company focused on the diagnosis and treatment of obstructive sleep apnea (OSA) and related breathing and sleep disorders, today announced that Founder and Chief Executive Officer R. Kirk Huntsman will present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference, taking place September 9... ———————————————————————————————————————————————————————————— Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) 2026-09-01 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/09/01/3354039/33240/en/emergent-biosolutions-awarded-contract-modification-valued-at-approximately-24-million-for-cyfendus-anthrax-vaccine-adsorbed-adjuvanted.html GAITHERSBURG, Md., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification valued at approximately $24 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to supply CYFENDUS ® (Anthrax Vaccine Adsorbed, Adjuvanted) for anthrax preparedness efforts. Anthrax remains a significant global biological threat due to its potential use in a bioterrorism event and its implications for public health and national security. ———————————————————————————————————————————————————————————— Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program 2026-09-01 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/09/01/3354030/0/en/kala-bio-and-virotek-announce-letter-of-intent-to-establish-an-exclusive-u-s-distribution-partnership-for-ophthalmology-genetic-testing-program.html ARLINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kala Bio, Inc. (Nasdaq: KALA) ("Kala") and Virotek Inc. ("Virotek"), a CLIA-registered precision health and clinical genomics company, today announced that they have entered into a letter of intent (the "LOI") outlining the principal terms under which the companies intend to negotiate a definitive agreement appointing Kala as the exclusive distributor and reseller in the United States of Virotek's genetic testing and screening program for ophthalmological indications. ———————————————————————————————————————————————————————————— Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled 2026-09-01 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/09/01/3354028/0/en/clearmind-reaches-key-milestone-cmnd-100-phase-iia-now-underway-for-alcohol-use-disorder-trial-one-third-of-part-c-enrolled.html Vancouver, Canada, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), announced today the initiation of Phase lla, the next stage of its double-blind, placebo-controlled Phase I/IIa clinical trial evaluating CMND-100 for the treatment of AUD, with six patients enrolled to date. Three participants have been enrolled at Tel Aviv Sourasky Medical Center (TASMC) and three at Hadassah Medical Center in Jerusalem, initiating the first multiple-dose treatment phase of Part C (“phase IIa”) following the successful completion of the tria ———————————————————————————————————————————————————————————— DocGo Announces Upcoming Participation at Morgan Stanley 24th Annual Global Healthcare Conference 2026-09-01 · mlpr-businesswire · Finance, Healthcare https://finance.yahoo.com/healthcare/articles/docgo-announces-upcoming-participation-morgan-113500846.html NEW YORK, September 01, 2026--DocGo Inc. (Nasdaq: DCGO) ("DocGo"), a leading provider of technology-enabled mobile health and medical transportation services, announced today that Lee Bienstock, Chief Executive Officer, will participate in 1x1 meetings at the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday September 16th, and will deliver a fireside presentation at 12:20 PM ET on that day. A webcast of the event will be available on the investor relations section of DocGo’s ———————————————————————————————————————————————————————————— Ardelyx to Participate in Upcoming Investor Conferences 2026-09-01 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/09/01/3354015/0/en/ardelyx-to-participate-in-upcoming-investor-conferences.html WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in the following investor conferences: ———————————————————————————————————————————————————————————— BridgeBio to Participate in September Investor Conferences 2026-09-01 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/09/01/3354014/0/en/bridgebio-to-participate-in-september-investor-conferences.html PALO ALTO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate in fireside chats at the following healthcare investor conferences: ———————————————————————————————————————————————————————————— Faeth Therapeutics to Participate in Upcoming September Investor Conferences 2026-09-01 · mlpr-businesswire · Finance, Healthcare https://finance.yahoo.com/healthcare/articles/faeth-therapeutics-participate-upcoming-september-113000001.html AUSTIN, Texas, September 01, 2026--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that management will participate in the following upcoming investor conferences: ———————————————————————————————————————————————————————————— Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy 2026-09-01 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/kazia-therapeutics-reports-preclinical-data-showing-paxalisib-reprograms-immunotherapy-resistant-msspmmr-colorectal-cancer-and-enhances-response-to-immunotherapy-302865533.html Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further Reduction Paxalisib Was Well Tolerated as Monotherapy and in Combination with Checkpoint Inhibition Kazia is Preparing to... ———————————————————————————————————————————————————————————— Keenova Marks the 2nd Annual National Hand Health Month with New Dupuytren's Contracture Mixed Reality Experience and Awareness Initiatives 2026-09-01 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/keenova-marks-the-2nd-annual-national-hand-health-month-with-new-dupuytrens-contracture-mixed-reality-experience-and-awareness-initiatives-302865227.html Monthlong campaign in September aims to elevate awareness of hand health, encourage early detection of Dupuytren's contracture, and connect patients with appropriate care DUBLIN, Sept. 1, 2026 /PRNewswire/ -- Keenova Therapeutics plc today announced plans for the 2nd Annual National Hand... ———————————————————————————————————————————————————————————— Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) 2026-09-01 · mlpr-businesswire · Finance, Healthcare https://finance.yahoo.com/healthcare/articles/stoke-therapeutics-biogen-announce-presentations-113000584.html BEDFORD, Mass. & CAMBRIDGE, Mass., September 01, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. ———————————————————————————————————————————————————————————— Functional Medicine IS Longevity Medicine(TM) Masterclass Returns to Redefine the Future of Healthspan 2026-09-01 · Newswire.com · Healthcare https://www.newswire.com/news/functional-medicine-is-longevity-medicine-tm-masterclass-returns-to-22854965 Free 2-day online event brings together leading experts to unite functional and longevity medicine with cutting-edge science and clinical tools ———————————————————————————————————————————————————————————— Calluna Pharma Announces Participation in Upcoming Scientific and Investor Conferences 2026-09-01 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/calluna-pharma-announces-participation-upcoming-110200416.html OSLO, Norway & BOSTON, September 01, 2026--Calluna Pharma Announces Participation in Upcoming Conferences to highlight Phase 2 AURORA study of CAL101 in IPF ahead of planned Q1 2027 readout ———————————————————————————————————————————————————————————— ZEO ScientifiX Announces Multidisciplinary Expert Faculty Lineup for ... 2026-09-01 · PR-Inside · Healthcare, Education https://pr-inside.com/zeo-scientifix-announces-multidisciplinary-expert-faculty-lineup-for-r5218187.htm (PR-inside.com) Leading physicians, scientists, regulatory experts, and healthcare innovators will convene October 23-25 at Fort Lauderdale's Pier Sixty-Six Resort + Marina for three days of regenerative medicine education, hands-on clinical training, and interdisciplinary collaboration FORT LAUDERDALE, FL / ACCESS Newswire / September 1, 2026 / ZEO ScientifiX, Inc. (OTCQB:ZEOX) ("ZEO ScientifiX" or the "Company") today announced the multidisciplinary faculty and guest speaker lineup for the inaugural ZEO Xperience, a three-day immersive regenerative medicine event for healthcare professionals taking place October 23-25, 2026, at Pier Sixty-Six Resort + Marina in Fort Lauderdale, Florida. Bringing together physicians, scientists, regulatory professionals, clinical educators, and healthcare ———————————————————————————————————————————————————————————— AI/ML Innovations subsidiary NeuralCloud Appoints Former FDA Reviewer ... 2026-09-01 · PR-Inside · AI, Healthcare https://pr-inside.com/aiml-innovations-subsidiary-neuralcloud-appoints-former-fda-reviewer-r5218182.htm (PR-inside.com) Regulatory Executive Brings More Than 15 Years of FDA, Medical Device, SaMD, and Digital Health Experience to Support AIML's Medical Device Strategy TORONTO, ON / ACCESS Newswire / September 1, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a company advancing artificial intelligence and neural-network-based technologies for digital health, is pleased to announce that its wholly owned subsidiary, NeuralCloud Solutions Inc. ("NeuralCloud"), has appointed Dr. Mehmet A. Kosoglu, Ph.D., as Head of Regulatory. Dr. Kosoglu is a former U.S. Food and Drug Administration ("FDA") lead reviewer and scientist with more than 15 years of experience spanning medical device development, biotechnology, .. ———————————————————————————————————————————————————————————— What is the Best Online PRP Course? 2026-09-01 · PR-Inside · Healthcare, Education https://pr-inside.com/what-is-the-best-online-prp-course-r5218181.htm (PR-inside.com) The Best Online PRP Course is the AACM PRP & PRF Certification Program SEATTLE, WA / ACCESS Newswire / September 1, 2026 / Among the online training options available, the American Academy of Cosmetic Medicine (AACM) is the best choice for medical professionals seeking structured, self-paced education in platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) therapies for only $299, and it is accredited for 3 hours of continuing medical education credits. The course is accredited by the Accreditation Council for Continuing Medical Education (ACCME) , the Accreditation Council for Pharmacy Education (ACPE) , and the American Nurses Credentialing Center (ANCC) , and .. ———————————————————————————————————————————————————————————— Insurance Coverage for Transgender Surgery 2026-09-01 · PR-Inside · Healthcare https://pr-inside.com/insurance-coverage-for-transgender-surgery-r5218180.htm (PR-inside.com) Insurance coverage for gender affirming surgeries is accepted by Dr. Sajan SEATTLE, WA / ACCESS Newswire / September 1, 2026 / For transgender and nonbinary patients considering gender affirming surgery, insurance can be an important factor when choosing a surgeon. Dr. Javad Sajan of Allure Esthetic Plastic Surgery accepts private insurance for transgender and gender affirming surgeries and is in-network with most private insurance carriers. His practice offers a range of gender affirming procedures, including FTM top surgery , MTF breast augmentation , body contouring , tracheal shave procedures , and other surgical options based on each patient's goals. Insurance coverage for .. ———————————————————————————————————————————————————————————— RMTG's Cellgenic Commences Commercial Activity in Peru, Extending Its ... 2026-09-01 · PR-Inside · Healthcare https://pr-inside.com/rmtg-s-cellgenic-commences-commercial-activity-in-peru-extending-its-r5218178.htm (PR-inside.com) Peru becomes the newest addition to Cellgenic's Latin American commercial network - one of three coordinated market initiatives across the region, subject to applicable local regulatory requirements. MIAMI, FL / ACCESS Newswire / September 1, 2026 / Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, today announced the commencement of Cellgenic commercial activity in Peru through the establishment of local commercial arrangements, including exclusive representation arrangements in permitted channels. The Peru announcement extends Cellgenic's Latin American commercial network, which the Company has been building through market .. ———————————————————————————————————————————————————————————— Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update 2026-09-01 · mlpr-businesswire · Finance, Healthcare, Automotive https://finance.yahoo.com/healthcare/articles/adicet-bio-announces-completion-last-110000302.html REDWOOD CITY, Calif., September 01, 2026--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced completion of the last patient visit for the planned Phase 1 safety and efficacy analysis of prulacabtagene leucel (prula-cel) in patients with systemic lupus erythematosus (SLE) with or without lupus nephritis (L ———————————————————————————————————————————————————————————— Bionic Bloom Integrated Health Welcomes Sarah Jameson Albrecht, MS, as New Provider 2026-09-01 · Newswire.com · Healthcare https://www.newswire.com/news/bionic-bloom-integrated-health-welcomes-sarah-jameson-albrecht-ms-as-new Certified Nature Based Counselor brings trauma-informed, neurodivergent-affirming and creativity-centered support to adults and adolescents ———————————————————————————————————————————————————————————— Enanta Pharmaceuticals to Participate in September Investor Conferences 2026-09-01 · mlpr-businesswire · Finance, Healthcare https://finance.yahoo.com/healthcare/articles/enanta-pharmaceuticals-participate-september-investor-110000580.html WATERTOWN, Mass., September 01, 2026--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in two investor conferences in September: ———————————————————————————————————————————————————————————— ZEO ScientifiX Announces Multidisciplinary Expert Faculty Lineup for the ZEO Xperience 2026-09-01 · Newswire.com · Healthcare, Education https://www.newswire.com/news/zeo-scientifix-announces-multidisciplinary-expert-faculty-lineup-for-the-zeo Leading physicians, scientists, regulatory experts, and healthcare innovators will convene October 23-25 at Fort Lauderdale's Pier Sixty-Six Resort + Marina for three days of regenerative medicine education, hands-on clinical training, and interdisciplinary collaboration ———————————————————————————————————————————————————————————— Q32 Bio to Participate in Upcoming September Investor Conferences 2026-09-01 · PR Newswire · Finance, Healthcare https://www.prnewswire.com/news-releases/q32-bio-to-participate-in-upcoming-september-investor-conferences-302865342.html WALTHAM, Mass., Sept. 1, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced that management will... ———————————————————————————————————————————————————————————— MiniMed Delivers Strong Start to Fiscal Year 2027 with U.S. Growth Acceleration 2026-09-01 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/minimed-delivers-strong-start-to-fiscal-year-2027-with-us-growth-acceleration-302865523.html Strong start to fiscal year with net sales of $843 million growing 17% as reported and 16% organic U.S. net sales growth accelerated to 13%; continued robust international net sales growth of 18% as reported, 17% organic Advanced global pipeline ahead of schedule with FDA submission for... ———————————————————————————————————————————————————————————— Medtronic Announces Strategic Partnership with Cornerstone Robotics to Further Expand Global Access to Robotic-Assisted Surgery 2026-09-01 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/medtronic-announces-strategic-partnership-with-cornerstone-robotics-to-further-expand-global-access-to-robotic-assisted-surgery-302865504.html Partnership expands Medtronic's robotic-assisted surgery portfolio to expand access globally and gives surgeons and health systems more choice and flexibility $700 million investment includes rights to distribute Cornerstone Robotics' Sentire™ surgical system in select markets outside the... ———————————————————————————————————————————————————————————— Enovis Invests in Innovation with Binding Offer to Acquire eCential Robotics, a Leading Developer of Enabling Technologies and Surgical Robotics 2026-09-01 · GlobeNewswire · Finance, SaaS, Healthcare https://www.globenewswire.com/news-release/2026/09/01/3353906/0/en/enovis-invests-in-innovation-with-binding-offer-to-acquire-ecential-robotics-a-leading-developer-of-enabling-technologies-and-surgical-robotics.html Dallas, TX, Sept. 01, 2026 (GLOBE NEWSWIRE) -- – Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology company, announced today that it has entered into a binding offer to acquire eCential Robotics, a leading developer of enabling technologies and surgical robotics. The acquisition expands the ASTRA™ enabling technology platform with robotic automation capabilities, creating a more comprehensive ecosystem designed to improve surgical precision, streamline workflows, and enhance patient outcomes. ———————————————————————————————————————————————————————————— HealthTab™ Programme Expands Nationally Across England 2026-09-01 · GlobeNewswire · SaaS, Healthcare https://www.globenewswire.com/news-release/2026/09/01/3353905/0/en/healthtab-programme-expands-nationally-across-england.html VANCOUVER, British Columbia, Sept. 01, 2026 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) is pleased to announce that NHS England has confirmed the national expansion of the Barts Health pharmacy cholesterol testing programme powered by Avricore’s HealthTab™ platform. ———————————————————————————————————————————————————————————— 45th Watch & Clock Fair and 14th Salon de TIME open today 2026-09-01 · mlpr-acnnewswire · AI, SaaS, Healthcare, Energy, Retail, Automotive, Education https://www.acnnewswire.com/press-release/english/109684/ HONG KONG, Sep 1, 2026 - (ACN Newswire) - The 45th Hong Kong Watch & Clock Fair and the 14th Salon de TIME, jointly organised by the Hong Kong Trade Development Council (HKTDC), Hong Kong Watch Manufacturers Association Limited and The Federation of Hong Kong Watch Trades & Industries Limited, open today under the theme “Sparkling Moments Through Time”. The twin fairs have attracted more than 630 exhibitors from 16 countries and regions, creating the world's largest one-stop watch and clock marketplace.  The 45th HKTDC Hong Kong Watch & Clock Fair and the 14th Salon de TIME opened today. Guests at the opening ceremony included Algernon Yau (centre), Secretary for Commerce and Economic Development of the Hong Kong SAR Government; Sophia Chong (fourth from the right), HKTDC Executive Director; SK Chong (first from the right) and Frankie Lam (first from the left), Co-Chairmen of HKTDC Hong Kong Watch & Clock Fair 2026 Organising Committee; and various industry representatives The physical fairs are taking place at the Hong Kong Convention and Exhibition Centre (HKCEC) for five consecutive days from 1 to 5 September. Meanwhile, the Click2Match AI-powered business matching platform will remain open until 12 September, allowing exhibitors and buyers worldwide to continue their business discussions online. The Hong Kong Watch & Clock Fair showcases a wide variety of exquisitely crafted timepieces, accessories and components, offering a one-stop sourcing and trading platform for global buyers Salon de TIME will once again open to both industry professionals and the public for free. Selected brands will offer on-site retail sales, allowing visitors to purchase their favourite timepieces during the fair. A “Time Tunnel” has been specially created to celebrate the 45th edition of the Hong Kong Watch & Clock Fair, allowing visitors to revisit three key stages in the fair’s development since its inception in 1982 The fairs officially opened today with an opening ceremony officiated by Algernon Yau, Secretary for Commerce and Economic Development of the Hong Kong SAR Government. Joining him were Sophia Chong, Executive Director of the HKTDC, and SK Chong and Frankie Lam, Co-Chairmen of the HKTDC Hong Kong Watch & Clock Fair Organising Committee 2026. Speaking at the ceremony, SK Chong said: “This year marks the 45th edition of the Hong Kong Watch & Clock Fair, a remarkable milestone for both the fair and Hong Kong’s watch and clock industry. The fair boasts a truly international line-up featuring strong global participation, including group pavilions from Francéclat, the Swiss Independent Watchmakers Pavilion, Guangzhou and Taiwan, as well as a first-time pavilion from Hengyang, Hunan province. In addition, we are pleased to welcome new exhibitors from Norway, Singapore and the US, further reinforcing Hong Kong’s position as a premier international trading hub for the global watch industry.” HKTDC Executive Director Sophia Chong said: “Amid the ongoing reconfiguration of global supply chains and changing market demand, the Hong Kong Watch & Clock Fair and Salon de TIME continue to provide the industry with an efficient business platform. By leveraging Hong Kong’s unique strengths as a superconnector and super value-adder, we help enterprises explore new markets and seize emerging opportunities. The fairs also support the watch and clock industry in moving up the value chain and strengthening brand development, further reinforcing Hong Kong’s leading position as an international hub for watch and clock trade.” “Time Tunnel” celebrates 45th edition-Salon de TIME reaches a new high The Hong Kong Watch & Clock Fair features multiple thematic zones covering every segment of the watchmaking value chain. Among them, Pageant of Eternity showcases premium finished watches from original equipment manufacturers (OEMs) and original design manufacturers (ODMs). One exhibitor, Time Grand Ltd, a Hong Kong company with more than 20 years of industry experience, provides product development, engineering design and manufacturing services for watch brands worldwide. The company also collaborates with Swiss watchmaking enterprises to offer one-stop watch production solutions, highlighting Hong Kong's strengths in connecting local expertise with international markets. Other exhibition zones cover a comprehensive range of products and services, including Complete Watches, Clocks, Machinery & Equipment, Packaging & Display, Parts, Components & Accessories, offering buyers a convenient one-stop sourcing platform. A “Time Tunnel” has been specially created to celebrate the 45th edition of the Hong Kong Watch & Clock Fair, allowing visitors to revisit three key stages in the fair’s development since its inception in 1982: - 1980s to 1990s: The fair became a premier global sourcing platform for the watch and clock industry. - 2000s to 2020s: As Hong Kong’s watch industry evolved from OEM manufacturing to brand development, the fair became a professional platform for promotion, networking and industry exchange. - From 2020 onwards: The fair has further integrated manufacturing, sourcing and brand promotion, while expanding through cross-sector collaboration into a multifaceted platform that brings together craftsmanship, design, technology, lifestyle, culture and consumer engagement. Salon de TIME has reached a new record this year, attracting more than 150 watch brands from around the world. The event features six thematic zones, including Microbrands, where both the number of participating countries and regions and the number of brands have more than doubled compared with last year. A longstanding highlight of the fair, the World Brand Piazza returns for its 16th consecutive year, in collaboration with Prince Jewellery & Watch, showcasing luxury creations from six internationally renowned watch brands: Baume & Mercier, Corum, DeWitt, Franck Muller, Montblanc and Sarcar. Other themed zones include Chic & Trendy, Craft Treasure, Renaissance Moment and Wearable Tech. This year's exhibitors are introducing distinctive new timepieces that reflect the latest market trends, leveraging the fair to gain exposure and capture new orders. Featured innovative watches include: Sports and outdoor trends drive demand for professional timepieces To capitalise on the growing popularity of sports and outdoor lifestyles, exhibitors are showcasing professional sports watches that blend practicality with style. - EDOX presents the “The Water Champion” Delfin 1973 Automatic, featuring a double O-ring crown and pusher system that enhances water resistance to 200 metres. (Booth: 3F-H20) - Making its debut at the fair, Norwegian brand Micromilspec showcases the MILGRAPH, a timepiece developed for special operations forces. Its offset crown design helps reduce the risk of wrist injuries, while the QuadGrip bezel ensures easy operation even when wearing full tactical gear. (Booth: 3F-F22) - A variety of brands are also introducing sports and outdoor performance watches, including ALBA and LORUS by Seiko (Booth: 3G-E18), CAUGHT (Booth: 3F-D05), Quantum (Booth: 3G-C03), SPINNAKER (Booth: 3G-D02) and Slazenger (Booth: 3G-C03). Sustainability trend drives growth in eco-friendly timepieces As environmental protection and corporate social responsibility (ESG) continue to gain importance, the fair once again highlights exhibitors offering sustainable watch products through its Green Solutions Suppliers label, making it easier for buyers to identify environmentally conscious suppliers. - Local microbrand Sunrex showcases the Sunrex 611, powered by the brand’s proprietary VILUMINUS™ solar movement. Equipped solely with a solar-powered battery, the watch harnesses light as its energy source and continues to operate even in the absence of light. (Booth: 3F-F17) - Microbrand Robotfigs presents the Cubot watch, crafted from upcycled materials such as metal wires, copper and acrylic. Transforming everyday surplus materials into imaginative robot-inspired creations, each watch comes with a dedicated robot display stand and three exclusive designer toy accessories: a baseball bat, skateboard and dumbbell, redefining the concept of a “time companion”. (Booth: 3F-H24) - Several exhibitors are also showcasing environmentally friendly watches and accessories, including Hip Shing Leather Watch Straps Mfy Ltd (Booth: 1B-C35) and Gordon C & Co Ltd. (Booth: 1E-C09). Cross-sector collaborations and limited editions appeal to niche consumer segments Many brands are enhancing the value and artistic appeal of their timepieces through cross-industry collaborations and limited-edition releases. - LINK2CARE has partnered with Swiss watch brand MARVIN to launch a luxury smartwatch featuring a fishing-inspired relief dial and a bi-directional mechanical gear system that showcases MARVIN’s exquisite watchmaking craftsmanship. The watch features LINK2CARE’s patented leather strap, which incorporates medical-grade vital signs sensors, enabling wearers to monitor their health. (Booth: 3G-A07) - Memorigin presents the “Verdant Resonance Tourbillon Watch”, featuring a luminous carbon-fibre case designed to evoke the glow of fireflies under the night sky. A three-dimensional guzheng-inspired small-seconds display at the 9 o’clock position, complemented by green luminous incense-burner motifs, recreates the elegant atmosphere of traditional Chinese scholars’ gatherings. (Booth: 3F-C05) - The Swiss Independent Watchmakers Pavilion showcases the “Corleone Mini Collection” by Pilo & Co Genève, created to celebrate the brand’s 25th anniversary. Reinterpreting the classic Corleone design as a ladies’ watch, each colour variant is limited to just 10 pieces, making it highly collectible. (Booth: 3F-H07). Microbrands win over younger consumers with creative designs In recent years, microbrands have emerged as a new force in the watch industry, attracting younger consumers with their distinctive designs and competitive pricing. - Making its debut at the fair, US brand BREDA is showcasing the “Pulse Locket” Gold and Metal Bracelet Watch. Featuring a unique locket-style design, the watch dial remains concealed when closed and is revealed only when the wearer chooses to open it. (Booth: 3F-D16) - Other participating microbrands include CIMIER (Booth: 3F-H26), Fayy (Booth: 3F-G19), Leger A. Fah (Booth: 3F-H20), No Identity (Booth: 3F-H25), AISION (Booth: 3F-H20), INANLOU (Booth: 3F-F15), as well as the strap-focused microbrand Monves (Booth: 3F-F16). Exciting activities open to the public Salon de TIME will present a wide range of signature activities and watch showcases open to the public. On 4 September, renowned watch artist and collector Labeg will host a workshop on crafting watch models from corrugated cardboard. A special “Time Arena” zone has also been introduced this year, blending sports and fine timepieces to offer visitors a fresh, interactive experience. One highlight, “Watch2Care Smart x Lifestyle Experience Days”, will take place from 4 to 5 September and feature a variety of hands-on activities, including yoga and mobility training sessions. Visitors can try their hand at pickleball, one of the fastest-growing sports in recent years. Other highlights include a series of watch parades and new product launch events. Memorigin will welcome several celebrity guests, including celebrity Vic Teo, Hong Kong basketball star Alfred Wong Lut Yiu, and renowned face-changing performer Hathor Wai. A lucky draw will be held daily throughout the fair, offering visitors the chance to win premium watches. Industry leaders share insights on market trends This year’s Hong Kong Watch & Clock Fair features more than 40 events, including forums, seminars and networking sessions designed to foster industry exchange and knowledge sharing. The Hong Kong International Watch Forum, held today, brought together leaders of watch associations from the Chinese Mainland, Germany, France, Switzerland, Japan and Korea to share the latest trade statistics and industry developments in their respective markets. Discussions also explored new opportunities arising from integrating traditional watchmaking craftsmanship with emerging technologies. The Asian Watch Conference, to be held tomorrow (2 September), will be themed “Hong Kong as the hub of International Watch Trades”. The conference will feature a senior analyst from international research firm Euromonitor International (Hong Kong), who will provide insights into the latest developments in the global watch market. Representatives from online watch resale platform Chrono24 will discuss how to connect with demand across global markets, while a representative from Lazada Hong Kong will share strategies for leveraging e-commerce platforms to accelerate market expansion. On 3 September, FIYTA will hold an aeronautics launch event for a watch specially designed in honour of Lai Ka-ying, Hong Kong’s first female payload specialist. The company’s Chief Designer, Sun Lei, will also share the inspiration and design concepts behind the timepiece. Also taking place that day is the Tick-Tock Showtime: The Media Spotlight Pitch, jointly organised by Watch CataVlog. The event will feature presentations by 10 microbrands, with a judging panel comprising media representatives from Indonesia, the Middle East and Hong Kong, each selecting their favourite brand. On 4 September, the seminar “Off the Beaten Path: Indie Watchmakers vs. Independent Brands – Trends & Trajectories” will explore the distinctions, evolution and future trends of independent watchmaking and independent brands. Speakers include Noel Wong, Founder of Watch The World, Watch Collector & Discerning Commentator; Benjamin Hui, Watch Collector & Founder of Independent Watcher; and Lu Jinzhi, Chairman of ZBIOLAND. Throughout the fair, watch brands including Watch2Care, SAGA, Peacock, Sea-Gull, Shanghai Watch, Franck Muller, Quantum and INANLOU will host a series of new product launch events, unveiling their latest timepieces to an international audience. The 43rd Hong Kong Watch & Clock Design Competition, jointly organised by the HKTDC, the Hong Kong Watch Manufacturers Association Ltd and the Federation of Hong Kong Watch Trades & Industries Ltd, aims to promote watch design exchange and nurture local talent. This year, the themes for the Open Group and Student Group are “Transcending Time” and “Contours of the Breeze” respectively. The competition will continue to feature The Made-to-Sell Award, recognising student entries with outstanding commercial potential. The award presentation ceremony will be held on 5 September at the fair’s event stage, with celebrity Joey Thye attending as a guest. In addition, CENTRESTAGE, another flagship event organised by the HKTDC, will be held at the Hong Kong Convention and Exhibition Centre from 2 to 5 September. Bringing together fashion brands and designer collections from around the world, the event will create strong synergies with the watch fairs and offer visitors a one-stop destination to source prestigious timepieces and stylish fashion apparel from across the globe. Photo download: https://bit.ly/3UOXqBY The 45th HKTDC Hong Kong Watch & Clock Fair and the 14th Salon de TIME opened today. Guests at the opening ceremony included Algernon Yau (centre), Secretary for Commerce and Economic Development of the Hong Kong SAR Government; Sophia Chong (fourth from the right), HKTDC Executive Director; SK Chong (first from the right) and Frankie Lam (first from the left), Co-Chairmen of HKTDC Hong Kong Watch & Clock Fair 2026 Organising Committee; and various industry representatives The Hong Kong Watch & Clock Fair showcases a wide variety of exquisitely crafted timepieces, accessories and components, offering a one-stop sourcing and trading platform for global buyers A “Time Tunnel” has been specially created to celebrate the 45th edition of the Hong Kong Watch & Clock Fair, allowing visitors to revisit three key stages in the fair’s development since its inception in 1982 Salon de TIME features over 150 international brands and comprises six major themed zones, all of which are open to the public Sponsored for the 16th consecutive year by Prince Jewellery & Watch, the World Brand Piazza showcases six world-class watch brands This year’s Salon de TIME features a strong lineup of Guochao-inspired brands and Chinese watchmakers, showcasing their craftsmanship and creativity. Among them is Zbioland, which presents the Barcelona ZBL1009 timepiece. The watch is powered by the brand’s first in-house developed Calibre 961 movement and draws inspiration from the works of renowned Spanish architect Antoni Gaudí, reflecting distinctive architectural aesthetics in its design This year's exhibition features an impressive collection of award-winning timepieces. Among them is CIGA Design's AVENTUR·Blue Planet, which features a three-dimensional rotating globe on the dial. The watch was honoured with the “Challenge Watch Prize” at the 2021 Grand Prix d'Horlogerie de Genève (GPHG), widely regarded as the "Oscars" of the watchmaking industry During the fair period, a series of watch launch events and watch parades are being held, featuring models showcasing exquisite timepieces and bringing these remarkable creations to life on the runway The winning and shortlisted entries of the 43rd Hong Kong Watch and Clock Design Competition are currently on display in the foyer of Hall 1, showcasing local creative talent Media enquiriesPlease contact the HKTDC’s Communications & Public Affairs Department: Johnny Tsui Tel: (852) 2584 4395 Email: johnny.cy.tsui@hktdc.org Websites Hong Kong Watch & Clock Fair: https://www.hktdc.com/event/hkwatchfair/en Salon de TIME: https://www.hktdc.com/event/te/en HKTDC Media Room: mediaroom.hktdc.com About HKTDC The Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.  Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com ———————————————————————————————————————————————————————————— UNLOCKD Expands Ancient Extracts Into Nine Mushroom World Locations as Companies Explore Next-Generation Functional Wellness Retail Concept 2026-09-01 · NewMediaWire · Retail, Healthcare https://www.newmediawire.com/news/unlockd-expands-ancient-extracts-into-nine-mushroom-world-locations-as-companies-explore-next-generation-functional-wellness-retail-concept-7089092 Ancient Extracts Selected as a Premium Functional Wellness Brand as Mushroom World Expands Beyond the Traditional CBD Retail Model and Toward Functional Mushrooms, Specialty Beverages and Next-generation Wellness LANCASTER, PA - September 1, 2026 ( NEWMEDIAWIRE ) - BitFrontier Capital Holdings, Inc. (OTCID: BFCH), doing business as UNLOCKD Inc. (“UNLOCKD” or the “Company”), today announced the expansion of its Ancient Extracts brand into all nine Mushroom World retail locations, establishing a specialty retail footprint for the Company’s growing portfolio of functional mushroom coffee, matcha, functional lattes and wellness products. The relationship represents more than an additional retail placement for Ancient Extracts. Management believes Mushroom World provides an early example of a b ———————————————————————————————————————————————————————————— REE Medical's "Operation Onward" Branded Entertainment Series Reach Exceeds 715,000 in Under 30 Days 2026-09-01 · PR Newswire · SaaS, Healthcare, Media https://www.prnewswire.com/news-releases/ree-medicals-operation-onward-branded-entertainment-series-reach-exceeds-715-000-in-under-30-days-302865588.html Influencer-led content strategy from REE Medical, Refuel Agency, and SPIRRA exceeded its first-episode reach goal by 60%, building a new platform for veteran stories and support. PRINCETON, N.J., Sept. 1, 2026 /PRNewswire/ -- Refuel Agency today announced early results from Operation... ———————————————————————————————————————————————————————————— Form 8.5 (EPT/RI)-Advanced Medical Solutions Group plc 2026-09-01 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/09/01/3353883/0/en/form-8-5-ept-ri-advanced-medical-solutions-group-plc.html FORM 8.5 (EPT/RI) ———————————————————————————————————————————————————————————— Exonate Becomes Foventa Therapeutics 2026-09-01 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/exonate-becomes-foventa-therapeutics-302865302.html The new name, which takes inspiration from the fovea, marks the company's transition to focus on clinical development in non-proliferative diabetic retinopathy. In earlier clinical trials, FOV407 exhibited remarkable ability to suppress harmful vascular leakage in patients' eyes.... ———————————————————————————————————————————————————————————— ProCARE Portal Introduces Industry-First Tiered Money-Back Satisfaction Guarantee for Enterprise Healthcare Provider Compensation Software 2026-09-01 · PRWeb · SaaS, Healthcare https://www.prweb.com/releases/procare-portal-introduces-industry-first-tiered-money-back-satisfaction-guarantee-for-enterprise-healthcare-provider-compensation-software-302864687.html Aligning vendor accountability with health system operational goals, ProCARE, a leading provider compensation platform, offers a risk-free framework to eliminate manual administrative burdens and restore compensation integrity. CHANDLER, Arizona, Sept. 1, 2026 /PRNewswire-PRWeb/ --... ———————————————————————————————————————————————————————————— New UK supplement brand launches today for over three million people who work while Britain sleeps 2026-09-01 · Pressat · Healthcare, Retail https://pressat.co.uk/releases/new-uk-supplement-brand-launches-today-for-over-three-million-people-who-work-while-britain-sleeps-00ad9de7d27227848f761a1f3efdb05a/ Tuesday 1 September, 2026 LONDON, 1 September 2026. Over three million people in the UK work through the night. Nurses, care workers, drivers, security officers, warehouse staff, bakers, emergency call handlers. They keep the country running at 3am, and almost nothing on the supplement shelf is built for them. Noctiva Health launches today to change that. Its debut product, Noctiva Reset, is a UK made once daily food supplement formulated for night shift workers, from a company that has made honesty its founding rule: every active ingredient disclosed to the milligram, no proprietary blends, and no claims the evidence does not support. "Nobody owns night workers," said Adi Jani, founder of Noctiva Health, who spent sixteen years presenting live overnight television. "The supplement industr ———————————————————————————————————————————————————————————— Surface Disinfectant Products Market Trends: From Hospitals to Households 2026-09-01 · Express Press Release · Healthcare https://express-press-release.net/news/2026/09/01/1769982 Hygiene has moved from an afterthought to a boardroom priority, and nowhere is that more visible than in the surface disinfectant products industry. From hospital [read full press release...] ———————————————————————————————————————————————————————————— GLOBAL POWER SOLUTIONS PROVIDES UPDATE ON POTENTIAL REACTIVATION OF PERU HOSPITAL PROJECT 2026-09-01 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/09/01/3353833/0/en/global-power-solutions-provides-update-on-potential-reactivation-of-peru-hospital-project.html Vancouver, British Columbia, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Global Power Solutions Corp. (TSXV: PWER) (FSE: NJA) (“Global Power” or the “Company”) is pleased to provide an update regarding the potential reactivation of a previously announced hospital development project in Peru involving EsSalud, Peru’s Social Health Insurance authority. The Company’s predecessor, Minaean SP Construction Corp., previously entered into a Memorandum of Understanding (“MOU”) with EsSalud in connection with the proposed development and construction of a 224-bed hospital in Chiclayo, Lambayeque Province, Peru. The project did not advance during the period of political and administrative change in Peru, and the previous MOU has since expired. Representatives of the current EsSalud administration have recentl ———————————————————————————————————————————————————————————— New York Cancer & Blood Specialists Welcomes Medical Oncologist-Hematologist Dr. Jacob Levenson 2026-09-01 · PR.com · Healthcare https://www.pr.com/press-release/977992 New York Cancer & Blood Specialists (NYCBS), one of the Nation’s leading oncology practices, proudly announces the addition of hematologist-oncologist, Dr. Jacob Levenson. Beginning August 31, 2026, Dr. Levenson will be practicing at NYCBS’s office located at 2330 Eastchester Road, Bronx, NY 10469. “We are pleased to welcome Dr. Levenson to New York Cancer & Blood Specialists,” said Dr. [PR.com] ———————————————————————————————————————————————————————————— Why Healthcare Business Banking Solutions & Services Are Evolving Faster Than Ever 2026-09-01 · Express Press Release · Healthcare https://express-press-release.net/news/2026/09/01/1769971 Healthcare organizations are navigating one of the most financially complex periods in the industry’s history. Rising costs, shifting reimbursement models, cyber threats, and evolving patient [read full press release...] ———————————————————————————————————————————————————————————— Avicenna International Hospital Publishes Face and Neck Lift Patient Pathway for UK Patients 2026-09-01 · mlpr-newsfile · Healthcare https://www.newsfilecorp.com/release/311618/Avicenna-International-Hospital-Publishes-Face-and-Neck-Lift-Patient-Pathway-for-UK-Patients Istanbul, Turkey--(Newsfile Corp. - September 1, 2026) - Avicenna International Hospital has published its Face and Neck Lift Patient Pathway for UK Patients, setting out how its existing clinical process is applied to patients travelling from the UK to its Ataşehir, Istanbul hospital. The pathway documents clinical assessment before travel, individual surgical planning, hospital admission, early post-operative review and follow-up after the patient returns home. Dr Caner Kaya, Specialist in... ———————————————————————————————————————————————————————————— Hong Kong's Belt and Road Summit explores new cross-regional opportunities this September 2026-09-01 · mlpr-acnnewswire · AI, SaaS, Healthcare, Energy, Media, Education https://www.acnnewswire.com/press-release/english/109676/ HONG KONG, Sep 1, 2026 - (ACN Newswire) - The 11th Belt and Road Summit, co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC), will be held from 9 to 10 September (Wednesday to Thursday) at the Hong Kong Convention and Exhibition Centre in Wan Chai. For over a decade, Hong Kong has brought together government and business leaders from Belt and Road countries and regions to deepen local, regional economic and trade ties through this signature event. With the theme of Advancing High-quality Development - Embarking on a New Journey, this year’s Belt and Road Summit will explore fresh potential arising from new patterns of regional cooperation in trade, investment and development among Belt and Road and other markets, particularly ASEAN, Central Asia and the Middle East.  Presenting insights from nearly 100 distinguished policymakers and business leaders, new multifaceted thematic showcases and business matching activities, this year’s Summit offers a wealth of knowledge, extensive networks and quality investment and business opportunities, facilitated through Hong Kong, the global business platform that connects the Chinese Mainland and the world. The 11th Belt and Road Summit will be held from 9 to 10 September (Wednesday to Thursday) at the Hong Kong Convention and Exhibition Centre in Wan Chai. In 2025 (shown in photo), the event’s 10th edition attracted 6,200 participants from 70+ countries and regions. The picture shows the Belt and Road Summit in 2025. Anna Cheung, Associate Executive Director of the HKTDC, said: "Amid the reconfiguration of the global economic landscape, Hong Kong has been both an important platform for Mainland enterprises to go global and a preferred gateway for international enterprises to enter the Mainland and Asian markets.  As a core member of the GoGlobal Task Force which was established by the HKSAR Government to facilitate enterprises to go global, the HKTDC has been leveraging Hong Kong’s strengths as an international business and investment platform to facilitate cooperation. To further support Mainland enterprises in tapping opportunities in the Belt and Road and other emerging markets, this year’s Belt and Road Summit will introduce a dedicated Go Global Chapter, featuring thematic breakout sessions focusing on go global opportunities and Hong Kong’s professional services strengths, the newly established GoGlobal Connect Zone for service providers, roundtable discussions and the GoGlobal Business Study Mission to Nansha, Guangzhou. These initiatives will further strengthen Hong Kong’s role as a ‘superconnector’ and ‘super value-adder’, promoting high-quality cooperation in Belt and Road and other markets. The HKTDC has also been actively advancing cross-regional economic and trade cooperation. This year, we have organised a business delegation to visit Belt and Road countries and regions and hosted the flagship overseas promotion event ‘Think Business, Think Hong Kong’ in Malaysia, continuing to develop new markets, connect with new partners and explore new opportunities, further leveraging Hong Kong’s strengths in connecting the Chinese Mainland and the world, while deepening Hong Kong’s links with global markets." This year’s Belt and Road Summit will feature a new GoGlobal Connect Zone, showcasing professional services solutions across different sectors in Hong Kong and providing consultation and practical support for enterprises going global. The picture shows the Asia Summit on Global Health held in May 2026, featuring the “GoGlobal Connect” and the Business of Healthcare Advisory Zone. New directions in global economic development from the policy perspective The first day of the Summit will open with exchanges between government and corporate leaders. The Opening Session will feature heavyweights such as John Lee, Chief Executive of the HKSAR, Carolina Cosse, Vice President of Uruguay, Saleumxay Kommasith, Deputy Prime Minister of Laos, and Professor Frederick Ma, Chairman of the HKTDC, sharing their perspectives on global economic and trade development from the policy and international cooperation perspectives. The highly anticipated Policy Dialogue session, with the theme of Building Resilient Trade and Investment Frameworks in a Diverse Global Landscape, will be chaired by Algernon Yau, Secretary for Commerce and Economic Development of the HKSAR. He will exchange views with such government officials as Khandakar Abdul Muktadir, Minister for Commerce, Industries, Textiles and Jute of Bangladesh, Wasantha Samarasinghe, Minister of Trade, Commerce, Food Security and Co-operative Development of Sri Lanka, and Dr Kirida Bhaopichitr, Vice Minister for Commerce of Thailand, to discuss strengthening cross-border trade and investment cooperation and enhancing economic resilience, as well as sharing experiences in promoting trade facilitation and investment cooperation. The Business Plenary I: Harnessing Business Opportunities for Sustainable Growth and Shared Prosperity session, with a market focus on ASEAN and Central Asia, will explore how enterprises can promote sustainable development and achieve more inclusive economic growth while expanding business opportunities and advancing investment cooperation. The session will be chaired by Dr Victor K Fung, Chairman of Fung Investments, and feature Dr Jonathan Choi, Chairman of Sunwah Group, Shinta Widjaja Kamdani, CEO of Sintesa Group and Chairman of the Indonesian Employer Association, Vikrom Kromadit, CEO of Amata Corporation PCL, Farkhad Rashidovich Okhonov, Member of the Board of Directors and Chairman of the Management Board of Halyk Finance, Somboun Phongsavanh, Chairman of Shareholder Committee, Phongsavanh Group. They will share practical experiences from different markets and industries and explore ways to seize cross-border cooperation opportunities and foster mutual benefit and win-win cooperation. The Keynote Luncheon will feature welcome remarks by Paul Chan, Financial Secretary of the HKSAR, opening remarks by Wang Shuguang, Vice Chairman of the Board, President and Member of the Management Committee of China International Capital Corporation Limited, and a keynote address by Dr Kao Kim Hourn, Secretary-General of ASEAN. Exploring cooperation with Central Asia and the Middle East to support enterprises in going global through Hong Kong Continuing to focus on expanding international markets, deepening cross-regional cooperation and advancing high-quality development, this year’s Summit will introduce new thematic chapters, namely, the Go Global Chapter, Central Asia Chapter and Middle East Chapter. The new Go Global Chapter will provide a one-stop platform for Mainland enterprises to exchange ideas and connect with potential partners as they expand overseas. On the first day, the Thematic Breakout Session Hong Kong: Super Connector - World-class Springboard – Professional Services Empowering Global Expansion will explore how Hong Kong’s professional services can support enterprises in expanding into Belt and Road markets. On the second day, the Thematic Breakout Session Chinese Mainland Enterprises Going Global:  Driving Mutual Growth Across Belt and Road Economies will further share practical experiences of enterprises expanding into overseas markets. In addition, the Summit will feature a new GoGlobal Connect Zone, showcasing professional services solutions across different sectors in Hong Kong and providing consultation and practical support for enterprises going global. The Summit will also arrange one-on-one meetings between Mainland enterprises seeking to expand overseas and potential partners and service providers, as well as hold roundtable discussions on going global, providing more comprehensive and enhanced support for Mainland enterprises expanding overseas. The Summit will also organise the GoGlobal Business Study Mission to Nansha, Guangzhou, enabling participants to gain first-hand understanding of development and investment opportunities in the Greater Bay Area. Central Asia and Middle East Chapters showcase investment opportunities Following the successful delegations led by John Lee, Chief Executive of the HKSAR, and organised by the HKTDC over the past two years, Hong Kong, Central Asia and the Middle East have strengthened ties with reciprocal exchanges.  The Summit will further enhance these ties by inviting government officials and business leaders from these regions to share their latest development opportunities and investment prospects, and will feature a dedicated Central Asia Chapter and a Middle East Chapter, featuring consulates, business organisations and companies showcasing investment projects and commercial opportunities across the regions. The two-day Project Investment Sessions held during the Summit will also explore investment, infrastructure, smart city and professional services opportunities arising from major development projects in Central Asia and the Middle East. The Cocktail Reception will be officiated by Paul Lam, Secretary for Justice of the HKSAR, who will deliver welcoming remarks. The reception will also feature ethnic music performances, allowing participants to gain a deeper understanding of Central Asia and Middle East from another perspective and promoting cultural exchanges. Global expert insights on finance, technology, green development and youth The second day of the Summit will open with a special address session, featuring Professor Teresa Cheng, Secretary-General of the International Organization for Mediation and other distinguished guests. Making its debut this year, a Dialogue for Future session themed Think Tank Dialogue: The Belt and Road Initiative and Asia-Pacific Cooperation in a Changing Global Landscape will feature a conversation between Professor Li Cheng, Director of Centre on Contemporary China and the World and Professor of School of Governance and Policy, The University of Hong Kong and Gim Huay Neo, Managing Director of Member of the Managing Board, World Economic Forum. A Business plenary on the same day, themed Unlocking New Market Opportunities along and beyond the Belt and Road, will focus on the Middle East and African markets. Chaired by Professor KC Chan, Chairman of WeLab Bank, the panel of speakers will include Mansoor Rashid Al-Khater, Chief Executive Officer of Qatar Financial Centre, Muneer Ali Al Muneeri, Deputy President for Operations of Oman Investment Authority, Dr Mteto Nyati, Chairman of Eskom, Cliff Zhang, CEO & Founding Partner of Templewater Hong Kong Limited and Samaila Zubairu, President and Chief Executive Officer of Africa Finance Corporation. The session will examine the immense potential of emerging markets within and beyond the Belt and Road countries and regions amid evolving global business landscapes, as well as how Hong Kong can support global enterprises in capturing new market opportunities. Alongside themes of Finance, Green Development, Youth and Technology, this year’s summit will introduce brand-new thematic breakout sessions including going global and the low-altitude economy. From corporate global expansion and emerging-industry advancement to talent nurturing, these sessions will explore fresh opportunities for high-quality development. Among them, the Thematic Breakout Session: Dialogue with Youth Business Leaders - Hong Kong as an International Hub for High-Calibre Talent will discuss how Hong Kong can leverage its strengths in local education, research, innovation and technology to attract top talent worldwide and inject new momentum into Hong Kong and regional growth. Project investment enhanced with signature projects and extended deal making The Summit will once again host Project Investment Session, Belt and Road Summit Deal Making and Exhibition zone, featuring more than 300 investment projects, with a combined investment value exceeding US$3.7 billion, and over 800 one-on-one project matching meetings to help enterprises connect with potential partners. The Project Investment Session will provide a platform for project owners from different countries to present their projects, giving investors and service intermediaries a comprehensive understanding of the investment opportunities in different sectors. Pitching sessions will focus on five main areas: (1) energy, natural resources and public utilities, (2) urban development, (3) New Market Focus: The Middle East, Africa and Latin America, (4) transport and logistics infrastructure, and (5) innovation and technology. The Signature Projects Session will highlight the massive infrastructure and investment potential of Alatau City and Data Centre Valley in Kazakhstan, as well as the Ankara-Istanbul High-Speed Rail in Türkiye. The Belt and Road Summit Deal Making session will create vital negotiation opportunities for participants. Running in parallel with the Summit and extended online from 14 to 15 September, it pools global resources and facilitates long-term collaboration and resource integration through one-on-one meetings. The exhibition zones bring together over 120 exhibitors. Alongside the Hong Kong Zone and Global Investment Zone, three new zones have been introduced this year. The University Zone assembles local universities to showcase research outputs, innovative technologies and talent-related strengths. The GreenTech Zone features artificial intelligence, green technologies and smart-city solutions, building bridges between technology enterprises and investors. The GoGlobal Connect Zone displays services and resources supporting enterprises’ overseas expansion, connecting businesses to global commercial networks and empowering them to tap into international markets. There are also regional-themed zones, including the returning Chinese Mainland Zone and the ASEAN Zone, which showcase promising investment projects and business opportunities from Belt and Road markets. The 11th Belt and Road Summit is supported by a wide range of partners, including China International Capital Corporation Limited as Strategic Partner, and Bank of China (Hong Kong) Limited as the Banking Partner. Other supporters include Standard Chartered Bank (Hong Kong) Limited as Cross-border Business Partner, The Hongkong and Shanghai Banking Corporation Limited as the Global Connectivity Partner, Huatai International Financial Holdings Company Limited as Innovative Finance Partner, International Financial Centre of Oman as Diamond Sponsor, as well as CCB International (Holdings) Limited and China Mobile International Limited as Platinum Sponsors. New ASEAN Market Day to be held alongside Belt and Road Week The Belt and Road Summit is one of the key flagship events of Belt and Road Week, a themed week featuring events related to the Belt and Road Initiative held around Hong Kong. With representatives of ASEAN member states coming to Hong Kong to participate in the Summit, the HKTDC will introduce a new flagship event, ASEAN Market Day, which will be held on the afternoon of 10 September. The event, the first in a series of market days, will bring together business leaders and experts to share practical experience, helping Hong Kong businesses, particularly SMEs, gain a deeper understanding of the latest development trends and business opportunities in different ASEAN markets before taking steps to expand. Following the session, participants can visit the ASEAN Zone at the Summit for consultation sessions with representatives from the HKTDC’s offices in ASEAN and various ASEAN Consulates General and associations to exchange views and connect with potential partners. Looking ahead, the HKTDC will continue with the series of market days focusing on different regions with high business potential, such as Africa and the Middle East, and closer to home, the Guangdong-Hong Kong-Macau Greater Bay Area in the Chinese Mainland. Held alongside the Summit is the Belt and Road Global Forum Annual Roundtable, a closed-door roundtable held on the morning of 11 September, which brings together Hong Kong, Mainland and international organisations and business associations to share information, interact and explore multilateral cooperation.   The 11th Belt and Road Summit Date 9 to 10 September 2026 Venue Hall 5B-E, Hong Kong Convention and Exhibition Centre Remarks Video and audio recordings at the Summit should be used only in the context of media reporting Media Registration Please contact lsong@yuantung.com.hk or tleung@yuantung.com.hk for media registration Websites Belt and Road Summit: https://www.beltandroadsummit.com/conference/bnr/en Programme: https://www.beltandroadsummit.com/conference/bnr/en/programme Speaker list: https://www.beltandroadsummit.com/conference/bnr/en/speaker Media representatives who would like to conduct interviews with the speakers, please submit interview requests to lsong@yuantung.com.hk or tleung@yuantung.com.hk by 4 September 2026. Photo download: https://bit.ly/45WBpUo The 11th Belt and Road Summit will be held from 9 to 10 September (Wednesday to Thursday) at the Hong Kong Convention and Exhibition Centre in Wan Chai. In 2025 (shown in photo), the event’s 10th edition attracted 6,200 participants from 70+ countries and regions. The picture shows the Belt and Road Summit in 2025. This year’s Belt and Road Summit will feature a new GoGlobal Connect Zone, showcasing professional services solutions across different sectors in Hong Kong and providing consultation and practical support for enterprises going global. The picture shows the Asia Summit on Global Health held in May 2026, featuring the “GoGlobal Connect” and the Business of Healthcare Advisory Zone. Media Enquiries Yuan Tung Financial Relations: Louise Song Tel: (852) 3428 5691 Email: lsong@yuantung.com.hk Tiffany Leung Tel: (852) 3428 2361 Email: tleung@yuantung.com.hk Fung Wong Tel: (852) 3428 3122 Email: hfwong@yuantung.com.hk HKTDC’s Communications & Public Affairs Department Navin Law Tel: (852) 2584 4525 Email: navin.cm.law@hktdc.org Serena Cheung Tel: (852) 2584 4572 Email: serena.hm.cheung@hktdc.org Winnie Kan Tel: (852) 2584 4055 Email: winnie.wy.kan@hktdc.org HKTDC Media Room: https://mediaroom.hktdc.com/en About HKTDC The Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via trade publications, research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.  Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com ———————————————————————————————————————————————————————————— Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays 2026-09-01 · mlpr-businesswire · SaaS, Healthcare https://finance.yahoo.com/healthcare/articles/fujirebio-expands-access-canada-blood-050000721.html GHENT, Belgium & TOKYO, September 01, 2026--H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. ———————————————————————————————————————————————————————————— Dr. Andrea Joy Smith Launches New Website for Dental Education, Clinical ... 2026-09-01 · PR-Inside · Healthcare, Education https://pr-inside.com/dr-andrea-joy-smith-launches-new-website-for-dental-education-clinical-r5218132.htm (PR-inside.com) SACRAMENTO, CA / ACCESS Newswire / September 1, 2026 / Dentist, mentor and educator Dr. Andrea Joy Smith, DDS, DICOI, DIAMDI, has launched a new professional website, DrAndreaJoySmith.com, bringing together her dental education programs, clinical insights, industry news, professional accomplishments and resources for dentists in one online destination. With more than 30 years of experience in dentistry, Dr. Smith has expanded her work beyond patient care to include dental education, mentorship and professional training. The new website reflects those areas of her career while creating a growing educational resource for dental professionals. A major component of the site is Dr. Smith's dental .. ———————————————————————————————————————————————————————————— Herbal Dispatch Reports 2026 Second Quarter Financial Results 2026-09-01 · mlpr-newsfile · SaaS, Healthcare https://www.newsfilecorp.com/release/312364/Herbal-Dispatch-Reports-2026-Second-Quarter-Financial-Results Vancouver, British Columbia--(Newsfile Corp. - September 1, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a cannabis commerce and international distribution platform, today reported financial results for the three and six months ended June 30, 2026, highlighted by strong growth in its medical and international businesses, a 74% increase in quarterly gross profit, and an expansion in gross margin to 28.8%.The results reflect the continued... ———————————————————————————————————————————————————————————— North Carolina Approves Reimbursement of VR Therapy for Neurodivergent Residents Under NC Innovations Waiver 2026-09-01 · PR Newswire · SaaS, Healthcare https://www.prnewswire.com/news-releases/north-carolina-approves-reimbursement-of-vr-therapy-for-neurodivergent-residents-under-nc-innovations-waiver-302865547.html Under the state's NC Innovations Waiver, eligible families in Alliance Health's seven-county region can now request Floreo's virtual reality therapy platform through their care manager. CHEVY CHASE, Md., Sept. 1, 2026 /PRNewswire/ -- North Carolina has approved Medicaid Waiver... ———————————————————————————————————————————————————————————— PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities 2026-09-01 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/09/01/3353773/0/en/pmv-pharma-announces-pricing-of-oversubscribed-50-million-public-offering-of-securities.html PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, announced today the pricing of an underwritten public offering consisting of (i) 22,055,000 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase an aggregate of up to 19,900,000 shares of its common stock, and (ii) accompanying warrants to purchase an aggregate of 41,955,000 shares of common stock. The common stock and pre-funded warrants are being sold in combination with an accompanying warrant to purchase one share of common stock for each share of common stock or pre-funded warrant sold. The accom ———————————————————————————————————————————————————————————— VALOR Network Selects RADIN™ Health to Power Federal Teleradiology Services, with Total Medical Imaging Providing Nationwide Physician Coverage 2026-09-01 · PR Newswire · SaaS, Healthcare https://www.prnewswire.com/news-releases/valor-network-selects-radin-health-to-power-federal-teleradiology-services-with-total-medical-imaging-providing-nationwide-physician-coverage-302865521.html VALOR Network expands its federal healthcare imaging capabilities through RADIN's secure cloud-based radiology platform and Total Medical Imaging's national network of radiologists supporting diagnostic imaging services for the Department of Veterans Affairs and Department of War.... ———————————————————————————————————————————————————————————— PNR INVESTORS: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Pentair plc and Announces Opportunity for Investors with Substantial Losses to Lead Class Action Lawsuit Before October 2, 2026 Deadline 2026-09-01 · mlpr-newsfile · Finance, Healthcare https://www.newsfilecorp.com/release/311963/PNR-INVESTORS-Robbins-Geller-Rudman-Dowd-LLP-Files-Class-Action-Lawsuit-Against-Pentair-plc-and-Announces-Opportunity-for-Investors-with-Substantial-Losses-to-Lead-Class-Action-Lawsuit-Before-October-2-2026-Deadline San Diego, California--(Newsfile Corp. - August 31, 2026) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Pentair plc (NYSE: PNR) ordinary shares between March 11, 2025 and July 14, 2026, both dates inclusive (the "Class Period"), have until October 2, 2026 to seek appointment as lead plaintiff of the Pentair class action lawsuit. Captioned City of Warren General Retirement Health, Life and Disability Benefits Plan and Trust v. Pentair plc, No. 26-cv-03597 (D.... ———————————————————————————————————————————————————————————— Coastal Vision Medical Group Leads Orange County in Experience with ... 2026-08-31 · PR-Inside · Healthcare https://pr-inside.com/coastal-vision-medical-group-leads-orange-county-in-experience-with-r5218071.htm (PR-inside.com) Dr. Dan B. Tran and Coastal Vision Recognized as Orange County Leaders in Advanced Cataract Lens Technology ORANGE, CA / ACCESS Newswire / August 31, 2026 / Coastal Vision Medical Group proudly announces that Dan B. Tran, MD, Founder and Medical Director, has performed the most TECNIS PureSee™ IOL procedures of any surgeon in Orange County, with Coastal Vision Medical Group also ranking as the highest volume PureSee practice in the county. The distinction reflects Coastal Vision Medical Group's extensive experience with the technology and its continued commitment to providing advanced, personalized cataract and refractive lens surgery options based on each patient's .. ———————————————————————————————————————————————————————————— Coastal Vision Medical Group Leads Orange County in Experience with TECNIS PureSee(TM) IOL 2026-08-31 · Newswire.com · Healthcare https://www.newswire.com/news/coastal-vision-medical-group-leads-orange-county-in-experience-with-tecnis Dr. Dan B. Tran and Coastal Vision Recognized as Orange County Leaders in Advanced Cataract Lens Technology ———————————————————————————————————————————————————————————— Lobe Sciences Ltd. Announces Closing of Upsize to Non-Brokered Private ... 2026-08-31 · PR-Inside · Healthcare https://pr-inside.com/lobe-sciences-ltd-announces-closing-of-upsize-to-non-brokered-private-r5218055.htm (PR-inside.com) NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / August 31, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company advancing therapeutic development programs through focused subsidiary companies, is pleased to announce closing of the second tranche of its previously announced non-brokered private placement offering of common shares in the capital of the Company ("Common Shares") at a price of $0.085 per Common Share (the "Private Placement"). The Company closed the first tranche of the Private Placement on August 19, 2026 (the "First Tranche") through the .. ———————————————————————————————————————————————————————————— Let the DEA Marijuana Games Begin 2026-08-31 · PR-Inside · Healthcare https://pr-inside.com/let-the-dea-marijuana-games-begin-r5218051.htm (PR-inside.com) "DEA's New Questionnaire Exposes a Federal Marijuana System Built on State Rules, Special Exceptions and Questions No One Can Answer Cleanly", stated Duane Boise CEO MMJ International Holdings. WASHINGTON, D.C. / ACCESS Newswire / August 31, 2026 / The marijuana industry celebrated Schedule III as federal recognition. Now federal recognition has arrived carrying a clipboard. BE CAREFUL WHAT YOU WISH FOR A 26-question Drug Enforcement Administration follow-up form obtained by Marijuana Moment asks state marijuana operators to identify their suppliers, laboratories, employees, inventory systems, interstate plans, security controls, patient-verification procedures and methods for destroying moldy, insect-infested or expired marijuana. This is where the political .. ———————————————————————————————————————————————————————————— Altrova Health Reports Third Quarter Fiscal 2026 Financial Results 2026-08-31 · mlpr-newsfile · Healthcare https://www.newsfilecorp.com/release/312309/Altrova-Health-Reports-Third-Quarter-Fiscal-2026-Financial-Results Toronto, Ontario--(Newsfile Corp. - August 31, 2026) - Altrova Health Inc. (CSE: ROVA) (OTCQB: ATVHF) (FSE: WF8) ("Altrova Health" or the "Company") today announced its financial results for the three and nine-month periods ended June 30, 2026 ("Q3 Fiscal 2026"). The Company's condensed interim consolidated financial statements and related management's discussion and analysis for the period (collectively, the "Interim Filings") have been filed under the Company's profile on SEDAR+ at... ———————————————————————————————————————————————————————————— Class Action Lawsuit Filed Against Fractyl Health, Inc. (GUTS) - Recover ... 2026-08-31 · PR-Inside · Finance, Healthcare https://pr-inside.com/class-action-lawsuit-filed-against-fractyl-health-inc-guts-recover-r5218049.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 31, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Fractyl Health, Inc. (NASDAQ:GUTS) securities. If you suffered a loss on your Fractyl Health, Inc. investment and would like to explore a potential recovery under the federal securities laws, Learn about Fractyl Health, Inc. Class Action or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit was filed .. ———————————————————————————————————————————————————————————— Konstantin vision eyewear center outlines measurement standards behind designer frames 2026-08-31 · PressReleaseNews · Healthcare https://pressreleasenews.org/pressroom/konstantin-vision-eyewear-center-outlines-measurement-standards-behind-designer-frames Konstantin Vision & Eyewear Center in New York details its in-house fitting process for designer frames, covering measurements, alignment and on-site adjustments. ———————————————————————————————————————————————————————————— Dual Restoration positions itself as a 24/7 biohazard cleanup company for medical centers in Brooklyn 2026-08-31 · PressReleaseNews · Healthcare https://pressreleasenews.org/pressroom/dual-restoration-positions-itself-as-a-24-7-biohazard-cleanup-company-for-medical-centers-in-brooklyn Dual Restoration, a Brooklyn-based restoration firm, has launched a dedicated 24/7 biohazard cleanup company service for healthcare facilities managing infection and contamination risks. ———————————————————————————————————————————————————————————— Ultra Violette Becomes First Brand in the US to Launch a Sunscreen Containing Newly FDA-Approved Filter Bemotrizinol 2026-08-31 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/ultra-violette-becomes-first-brand-in-the-us-to-launch-a-sunscreen-containing-newly-fda-approved-filter-bemotrizinol-302865398.html Cult Australian suncare brand debuts Unblock Screen™ SPF 50, the first US sunscreen formulated with Bemotrizinol (BEMT), approved by the FDA in June 2026 NEW YORK, Aug. 31, 2026 /PRNewswire/ -- Ultra Violette, the cult Australian suncare brand known for pairing high-performance SPF with... ———————————————————————————————————————————————————————————— Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting 2026-08-31 · PR Newswire · Finance, Healthcare https://www.prnewswire.com/news-releases/enliven-therapeutics-announces-oral-and-poster-presentations-at-the-society-of-hematologic-oncology-soho-2026-annual-meeting-302865282.html BURLINGAME, Calif., Aug. 31, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that the Company will present data from... ———————————————————————————————————————————————————————————— Pomerantz LLP Brings Class Action Lawsuit Against Fractyl Health, Inc. ... 2026-08-31 · PR-Inside · Finance, Healthcare https://pr-inside.com/pomerantz-llp-brings-class-action-lawsuit-against-fractyl-health-inc-r5218031.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 31, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Fractyl Health, Inc. ("Fractyl" or the "Company") (NASDAQ:GUTS) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 26-cv-07167, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fractyl securities between January 13, 2025 and January 29, 2026, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations .. ———————————————————————————————————————————————————————————— AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting 2026-08-31 · mlpr-businesswire · Finance, SaaS, Healthcare https://finance.yahoo.com/healthcare/articles/an2-therapeutics-presents-clinical-translational-220000738.html MENLO PARK, Calif., August 31, 2026--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that four abstracts highlighting clinical and nonclinical data supporting the development of epetraborole, a novel boron-containing oral candidate for the treatment of polycythemia vera (PV), will be presented at the Society of Hematologic Onco ———————————————————————————————————————————————————————————— Astellas enters voluntary agreement with U.S. government supporting affordable access to medicines 2026-08-31 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/astellas-enters-voluntary-agreement-with-us-government-supporting-affordable-access-to-medicines-302865379.html – Agreement supports commitment to patient access, affordability and innovation – TOKYO, Aug. 31, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it has reached an agreement with the U.S. government that reflects our... ———————————————————————————————————————————————————————————— Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting 2026-08-31 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/31/3353741/0/en/disc-medicine-announces-multiple-presentations-across-portfolio-at-the-society-of-hematologic-oncology-soho-2026-annual-meeting.html WATERTOWN, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it will present data from multiple clinical programs, including an oral presentation of initial data from the RESTORE-PV trial of DISC-3405 in patients with polycythemia vera (PV), at the SOHO Annual Meeting, which will be held in Houston, Texas on September 9-12, 2026. ———————————————————————————————————————————————————————————— ActivatedYou's Essential Skin Food Wins Collagen Product of the Year at the 2026 Mindful Awards 2026-08-31 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/activatedyous-essential-skin-food-wins-collagen-product-of-the-year-at-the-2026-mindful-awards-302865386.html Plant-Based Collagen Support Supplement Recognized for Its Clean, Science-Backed Approach to Skin Health LOS ANGELES, Aug. 31, 2026 /PRNewswire/ -- ActivatedYou®, the wellness brand known for its holistic approach to health, announced today that its Essential Skin Food™ supplement has... ———————————————————————————————————————————————————————————— Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) 2026-08-31 · mlpr-businesswire · Finance, Healthcare, Automotive https://finance.yahoo.com/healthcare/articles/adicet-bio-reports-inducement-grant-213900981.html REDWOOD CITY, Calif., August 31, 2026--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced it granted an inducement award on August 31, 2026. ———————————————————————————————————————————————————————————— Investing in the Future by Upholding Traditional Values 2026-08-31 · PR Newswire · Finance, Healthcare https://www.prnewswire.com/news-releases/investing-in-the-future-by-upholding-traditional-values-302865368.html Sealaska, the Alaska Native regional corporation for Southeast Alaska, is building a future rooted in Indigenous values. By growing businesses that improve ocean health around the world, Sealaska generates sustainable revenue that is reinvested in shareholders, communities, culture and... ———————————————————————————————————————————————————————————— Greenway Reports First Quarter Fiscal 2027 Financial Results 2026-08-31 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/greenway-reports-first-quarter-fiscal-2027-financial-results-302865287.html KINGSVILLE, ON, Aug. 31, 2026 /PRNewswire/ -- Greenway Greenhouse Cannabis Corporation (CSE: GWAY) (OTCQB: GWAYF) ("Greenway" or the "Company"), a cultivator of high-quality greenhouse cannabis for the Canadian and international medical cannabis markets, today announced its unaudited... ———————————————————————————————————————————————————————————— Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions 2026-08-31 · mlpr-businesswire · Finance, Healthcare, Energy https://finance.yahoo.com/markets/stocks/articles/certain-blackrock-closed-end-funds-203000551.html NEW YORK, August 31, 2026--Today, BlackRock Resources & Commodities Strategy Trust (NYSE: BCX), BlackRock Enhanced Equity Dividend Trust (NYSE: BDJ), BlackRock Energy and Resources Trust (NYSE: BGR), BlackRock Enhanced International Dividend Trust (NYSE: BGY), BlackRock Health Sciences Trust (NYSE: BME), BlackRock Health Sciences Term Trust (NYSE: BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE: BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE: BUI), BlackRock En ———————————————————————————————————————————————————————————— Olema Oncology to Participate in Upcoming Investor Conferences 2026-08-31 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/31/3353709/0/en/olema-oncology-to-participate-in-upcoming-investor-conferences.html SAN FRANCISCO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences: ———————————————————————————————————————————————————————————— Zura Bio to Participate in the Cantor Global Healthcare Conference 2026-08-31 · mlpr-businesswire · Finance, Healthcare https://finance.yahoo.com/healthcare/articles/zura-bio-participate-cantor-global-203000316.html HENDERSON, Nev., August 31, 2026--Zura Bio Limited (Nasdaq: ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that members of its management team will participate in the following upcoming investor conference: ———————————————————————————————————————————————————————————— SEC and FDA Announce MOU to Bolster Cooperation and Ensure Market Integrity 2026-08-31 · mlpr-newsfile · Healthcare https://www.newsfilecorp.com/release/312271/SEC-and-FDA-Announce-MOU-to-Bolster-Cooperation-and-Ensure-Market-Integrity Washington, D.C.--(Newsfile Corp. - August 31, 2026) - The Securities and Exchange Commission and the Food and Drug Administration today announced that they have entered into a Memorandum of Understanding (MOU) designed to assist the agencies in carrying out their respective missions of ensuring the integrity of the financial markets and protecting public health. The MOU establishes a framework for the agencies to enhance cooperation in their regulatory and enforcement... ———————————————————————————————————————————————————————————— Enovis to Participate in the 2026 Wells Fargo Healthcare Conference 2026-08-31 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/31/3353695/0/en/enovis-to-participate-in-the-2026-wells-fargo-healthcare-conference.html Dallas, TX, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that it will participate in the 2026 Wells Fargo HealthCare conference on Tuesday, September 8, 2026 at the Encore Boston Harbor. ———————————————————————————————————————————————————————————— SI-BONE To Present at Morgan Stanley 24th Global Healthcare Conference on September 14, 2026 2026-08-31 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/31/3353689/0/en/si-bone-to-present-at-morgan-stanley-24th-global-healthcare-conference-on-september-14-2026.html SANTA CLARA, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming 2026 Morgan Stanley 24 th Annual Global Healthcare Conference in New York, NY. Management will be hosting a fireside chat on Monday, September 14, 2026, at 8:30 a.m. Pacific Time/ 11:30 a.m. Eastern Time. ———————————————————————————————————————————————————————————— NeuroThera Labs Achieves Significant Enrollment Momentum in SCI210 Autism Clinical Trial 2026-08-31 · NewMediaWire · Healthcare, Retail https://www.newmediawire.com/news/neurothera-labs-achieves-significant-enrollment-momentum-in-sci210-autism-clinical-trial-7089069 TORONTO, ONTARIO - August 31, 2026 ( NEWMEDIAWIRE ) - NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage pharmaceutical company and a subsidiary of SciSparc Ltd., today announced continued advancement in participant enrollment for its clinical trial assessing its innovative SCI-210 treatment for symptoms associated with autism spectrum disorder (“ ASD ”). The clinical trial, conducted at Soroka Medical Center in Israel, is a double-blind, randomized, placebo-controlled study evaluating the safety and efficacy of SCI-210 in children diagnosed with ASD. To date, 26 children have been enrolled, marking strong progress toward the planned total of 60 children between the ages of five and 18, each of whom will receive treatment over a 20-week period. SCI-210 ———————————————————————————————————————————————————————————— Manhattan Womens Health Expands Leading Upper East Side Providers with Kelly Lu, NP 2026-08-31 · PRWeb · Healthcare https://www.prweb.com/releases/manhattan-womens-health-expands-leading-upper-east-side-providers-with-kelly-lu-np-302864831.html Manhattan Womens Health, a premier OB/GYN practice located on New York City's Upper East Side, is pleased to welcome Kelly Lu, NP, to its distinguished clinical team. With this addition, the practice further reinforces its commitment to delivering exceptional obstetrical and gynecological... ———————————————————————————————————————————————————————————— PPMW LAUNCHES TELEHEALTH HERPES TREATMENT THROUGH PLANNED PARENTHOOD DIRECT, MEETING RISING DEMAND FOR STI CARE 2026-08-31 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/ppmw-launches-telehealth-herpes-treatment-through-planned-parenthood-direct-meeting-rising-demand-for-sti-care-302865288.html As provider shortages and health center closures strain care access nationwide—especially in rural areas, Planned Parenthood of Metropolitan Washington, DC removes barriers to care with its new, convenient, and discreet telehealth HSV treatment. WASHINGTON, Aug. 31, 2026 /PRNewswire/ --... ———————————————————————————————————————————————————————————— /C O R R E C T I O N -- WallachBeth Capital LLC/ 2026-08-31 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/wallachbeth-capital-announces-closing-of-tenon-medical-302865124.html In the news release, WallachBeth Capital Announces Closing of Tenon Medical, issued 31-Aug-2026 by WallachBeth Capital LLC over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end: WallachBeth... ———————————————————————————————————————————————————————————— Cohen & Jaffe: Reagan & Jax Memorial Golf Tournament Returns to Support Children's Charities 2026-08-31 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/cohen--jaffe-reagan--jax-memorial-golf-tournament-returns-to-support-childrens-charities-302865262.html EAST NORWICH, N.Y., Aug. 31, 2026 /PRNewswire/ -- Honoring the memory of Reagan and Jaxson Cohen while supporting charities dedicated to children's health and well-being, the annual Reagan & Jax Memorial Golf Tournament will take place on September 24, 2026. The rain date is October 15,... ———————————————————————————————————————————————————————————— Colorado Urology Names Megan Rood Chief Executive Officer 2026-08-31 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/colorado-urology-names-megan-rood-chief-executive-officer-302865249.html Experienced Colorado healthcare leader brings more than 20 years of physician practice and ASC leadership experience to support continued growth and patient-centered care DENVER, Aug. 31, 2026 /PRNewswire/ -- Colorado Urology, Denver's leading independent urology practice, has named Megan... ———————————————————————————————————————————————————————————— Boehringer Ingelheim Celebrates Grand Opening of New U.S. Animal Health Headquarters in Johns Creek, Georgia 2026-08-31 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/boehringer-ingelheim-celebrates-grand-opening-of-new-us-animal-health-headquarters-in-johns-creek-georgia-302865243.html NexGard® Plus donation to Johns Creek Police Department K-9 officers marks the company's commitment to the community. JOHNS CREEK, Ga., Aug. 31, 2026 /PRNewswire/ -- Boehringer Ingelheim today celebrated the grand opening of its new U.S. Animal Health headquarters in Johns Creek, Georgia,... ———————————————————————————————————————————————————————————— Dr. Timothy Francis Scholarship Launches National Application Cycle for Future Medical Leaders and Integrative Healthcare Innovators 2026-08-31 · mlpr-newsfile · Healthcare https://www.newsfilecorp.com/release/312132/Dr.-Timothy-Francis-Scholarship-Launches-National-Application-Cycle-for-Future-Medical-Leaders-and-Integrative-Healthcare-Innovators Las Vegas, Nevada--(Newsfile Corp. - August 31, 2026) - The Dr. Timothy Francis Scholarship for Medical Students officially announces the opening of its national application cycle, inviting undergraduate and professional students across the United States to apply for this prestigious merit-based opportunity. Established by Dr. Timothy Francis, a distinguished authority in chiropractic, applied kinesiology, and homeopathy with over four decades of clinical and teaching experience, the scholarship... ———————————————————————————————————————————————————————————— Respiratory Protection Day: Safeguarding Puerto Rico's Workforce from Airborne Hazards 2026-08-31 · WebWire · Healthcare https://www.webwire.com/ViewPressRel.asp?aId=359764 For many workers across Puerto Rico, the air they breathe on the job can present an invisible occupational health risk. Construction workers, healthcare professionals, manufacturers, emergency responders, and others may encounter dust, fumes, chemicals, biological contaminants, and other airborne hazards as part of their work. Ahead of Respiratory Protection Day on September 1, Zimmetry Environmental is highlighting the importance of effective respiratory protection programs in identifying... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=359764 ———————————————————————————————————————————————————————————— RADIN™ Health Announces Northern Oklahoma Radiology Physicians' Adoption of RADIN PACS + Dictation AI to Expand Remote Radiology Services Across Oklahoma 2026-08-31 · PR Newswire · AI, Healthcare https://www.prnewswire.com/news-releases/radin-health-announces-northern-oklahoma-radiology-physicians-adoption-of-radin-pacs--dictation-ai-to-expand-remote-radiology-services-across-oklahoma-302865177.html NORP delivers statewide radiology coverage through a unified workflow while hospitals and imaging centers maintain their existing PACS and RIS environments SHERIDAN, Wyo., Aug. 31, 2026 /PRNewswire/ -- RADIN Health today announced that Northern Oklahoma Radiology Physicians (NORP) has... ———————————————————————————————————————————————————————————— Recover Investment Losses: Class Action Initiated Against Fractyl Health, ... 2026-08-31 · PR-Inside · Finance, Healthcare https://pr-inside.com/recover-investment-losses-class-action-initiated-against-fractyl-health-r5217946.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 31, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Fractyl Health, Inc. (NASDAQ:GUTS) securities. If you suffered a loss on your Fractyl Health, Inc. investment and would like to explore a potential recovery under the federal securities laws, Learn about Fractyl Health, Inc. Class Action or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit was filed .. ———————————————————————————————————————————————————————————— GUTS SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces ... 2026-08-31 · PR-Inside · Finance, Healthcare https://pr-inside.com/guts-shareholder-alert-bronstein-gewirtz-and-grossman-llc-announces-r5217935.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 31, 2026 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Fractyl Health, Inc. (NASDAQ:GUTS) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Fractyl securities between January 13, 2025 and January 29, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/cases/fractyl-health-inc-guts-class_action_lawsuit. Fractyl Case .. ———————————————————————————————————————————————————————————— Aesthetics Hawaii Launches Physician-Guided Hyperbaric Oxygen Therapy in Honolulu, Bringing Hospital-Grade Chamber Technology to a Private Practice Setting 2026-08-31 · PRWeb · Healthcare https://www.prweb.com/releases/aesthetics-hawaii-launches-physician-guided-hyperbaric-oxygen-therapy-in-honolulu-bringing-hospital-grade-chamber-technology-to-a-private-practice-setting-302864805.html Under the direction of Dr. David Yew, MD, the Honolulu practice introduces State of the Art Hard-Shell, 2.0 ATA hyperbaric chamber therapy under Direct Physician Oversight HONOLULU, Aug. 31, 2026 /PRNewswire-PRWeb/ -- Aesthetics Hawaii, a Honolulu-based aesthetic and longevity wellness... ———————————————————————————————————————————————————————————— Caregility Expands Careforce Ecosystem with DataSource Technology to Scale Customer Support 2026-08-31 · PRWeb · AI, Healthcare https://www.prweb.com/releases/caregility-expands-careforce-ecosystem-with-datasource-technology-to-scale-customer-support-302865098.html Partnership extends Caregility's onsite preventive maintenance support capacity as health systems embrace inpatient virtual care and AI across complex, multi-site environments WALL, N.J., Aug. 31, 2026 /PRNewswire-PRWeb/ -- Caregility, a global leader in enterprise connected care and AI... ———————————————————————————————————————————————————————————— Paralyzed Veterans of America Takes 2026 Healthcare Summit + Expo to Vegas to Advance Care for Spinal Cord Injury, MS, and ALS 2026-08-31 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/paralyzed-veterans-of-america-takes-2026-healthcare-summit--expo-to-vegas-to-advance-care-for-spinal-cord-injury-ms-and-als-302865133.html VA Secretary Doug Collins plus 400+ clinicians across U.S. unite to discuss emerging research, evaluate new tech, share breakthroughs, and strengthen medical care LAS VEGAS, Aug. 31, 2026 /PRNewswire/ -- Paralyzed Veterans of America today officially commenced its 2026 Healthcare Summit +... ———————————————————————————————————————————————————————————— MEMSCAP: H1 2026 RESULTS 2026-08-31 · mlpr-businesswire · Finance, Healthcare https://finance.yahoo.com/markets/stocks/articles/memscap-h1-2026-results-163000037.html GRENOBLE, France, August 31, 2026--Regulatory News: MEMSCAP (Euronext Paris: MEMS), leading provider of high-accuracy, high-stability pressure sensor solutions for the aerospace and medical markets using MEMS technology (Micro Electro Mechanical Systems), today announced its revenue and results for the first half of 2026 ended June 30, 2026. ———————————————————————————————————————————————————————————— WallachBeth Capital Announces Closing of Tenon Medical 2026-08-31 · PR Newswire · Finance, Healthcare https://www.prnewswire.com/news-releases/wallachbeth-capital-announces-closing-of-tenon-medical-302865124.html $3M Private Placement Offering JERSEY CITY, N.J., Aug. 31, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that Tenon Medical, Inc. (NASDAQ: TNON) ("Tenon" or the "Company"), a medical device company... ———————————————————————————————————————————————————————————— BostonGene to Showcase Novel Genomic Classifier and Immunotherapy Selection Framework at SOHO 2026 2026-08-31 · mlpr-businesswire · AI, Healthcare https://finance.yahoo.com/healthcare/articles/bostongene-showcase-novel-genomic-classifier-160300784.html WALTHAM, Mass., August 31, 2026--BostonGene, developer of the leading AI model for tumor and immune biology, today announced that two abstracts have been accepted for poster presentation at Society of Hematologic Oncology (SOHO) 2026 Annual Meeting, taking place September 9 - 12 in Houston, Texas. The 14th Annual Meeting will bring together thousands of global experts to showcase practice-changing breakthroughs and practical clinical applications in blood cancer treatment. ———————————————————————————————————————————————————————————— Tenon Medical Announces Closing of $3M Private Placement Offering 2026-08-31 · PR-Inside · Finance, Healthcare https://pr-inside.com/tenon-medical-announces-closing-of-3m-private-placement-offering-r5217893.htm (PR-inside.com) LOS GATOS, CA / ACCESS Newswire / August 31, 2026 / Tenon Medical, Inc. (Nasdaq:TNON), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, has closed its previously announced private placement pursuant to securities purchase agreement with an institutional investor to sell 597,610 shares of common stock (or pre-funded warrants in lieu thereof), together with a warrant to purchase up to an aggregate 1,058,517 shares of common stock, in a private placement offering. The combined effective offering price for each share of common stock and accompanying warrants to be issued is $5.02. The combined effective .. ———————————————————————————————————————————————————————————— The Partner Companies Appoints Angelo Randerson as Director, Environmental, Health & Safety 2026-08-31 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/the-partner-companies-appoints-angelo-randerson-as-director-environmental-health--safety-302865097.html Randerson will lead TPC's enterprise-wide EHS strategy across its manufacturing operations, strengthening safety culture, regulatory compliance and risk management. CHICAGO, Aug. 31, 2026 /PRNewswire/ -- The Partner Companies (TPC) has announced Angelo Randerson as Director, Environmental... ———————————————————————————————————————————————————————————— Dr. Tobias Janowitz joins Feinstein Institutes as new Institute of Cancer Research director 2026-08-31 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/dr-tobias-janowitz-joins-feinstein-151200692.html MANHASSET, N.Y., August 31, 2026--At the Feinstein Institutes for Medical Research, clinicians and scientists produce knowledge to cure disease, conducting clinical trials and basic and translational science to improve cancer treatment. To help propel the Feinstein Institutes’ cancer research, Tobias Janowitz, MD, PhD, has been appointed director of its Institute of Cancer Research. In addition, he will take on the roles of Robert and Janet Perro Professor in Cancer Research and director of Tran ———————————————————————————————————————————————————————————— ECLAT Health Solutions to Showcase Unified Risk and Quality Review at RISE West 2026 2026-08-31 · mlpr-businesswire · SaaS, Healthcare https://finance.yahoo.com/healthcare/articles/eclat-health-solutions-showcase-unified-150100159.html HERNDON, Va., August 31, 2026--ECLAT Health Solutions will showcase unified risk and quality review functionality within its evaire platform at RISE West in San Diego, Sept. 2-4. ———————————————————————————————————————————————————————————— Pennsylvania Trial Attorneys David P. Thiruselvam and Keith Thomas ... 2026-08-31 · PR-Inside · Healthcare https://pr-inside.com/pennsylvania-trial-attorneys-david-p-thiruselvam-and-keith-thomas-r5217884.htm (PR-inside.com) The Victims' Recovery Law Center pursues civil claims against residential care facilities in Philadelphia, Pittsburgh, and across Pennsylvania whose negligent supervision and safety protocol failures cause catastrophic injury or wrongful death to patients in their care. PHILADELPHIA, PA / ACCESS Newswire / August 31, 2026 / When a residential care facility, a psychiatric hospital, a rehabilitation center, a group home, or a long-term care facility fails to implement adequate supervision protocols, places patients with known violent histories in unsafe conditions, or ignores documented warning signs of imminent harm, the consequences can be catastrophic and irreversible. The Victims' Recovery Law Center, a .. ———————————————————————————————————————————————————————————— BIOTECanada Announces 2026 Gold Leaf Award Winners, Recognizing Excellence Across Canada’s Biotechnology Ecosystem 2026-08-31 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/biotecanada-announces-2026-gold-leaf-144900548.html OTTAWA, Ontario, August 31, 2026--BIOTECanada, the national industry association representing Canada’s biotechnology sector, is pleased to announce the winners of the 2026 Gold Leaf Awards, recognizing outstanding leadership, innovation and impact across Canadian biotech. ———————————————————————————————————————————————————————————— Scan.com Raises $220 Million to Build the Largest Medical Imaging Network in the US 2026-08-31 · mlpr-businesswire · Finance, Healthcare https://finance.yahoo.com/healthcare/articles/scan-com-raises-220-million-143000683.html ATLANTA, August 31, 2026--Scan.com raises $220M in funding to build the largest US medical imaging network, with revenue doubling YoY, surpassing a $165M annualized run rate. ———————————————————————————————————————————————————————————— Vadzo Imaging announces the combination of HDR and VCM Autofocus with the Falcon-830CRH Onsemi HyperLux AR0830 8MP Color Rolling Shutter USB Camera 2026-08-31 · Newswire.com · Healthcare, Retail https://www.newswire.com/news/vadzo-imaging-announces-the-combination-of-hdr-and-vcm-autofocus-with-22853045 The Falcon-830CRH is an 8MP 4K HDR USB Camera built on the Onsemi AR0830 HyperLux LP sensor that combines Line Interleaved HDR and enhanced Dynamic Range with software-controlled VCM autofocus inside a single UVC-compliant USB 3.2 Gen 1 module. It is engineered for retail analytics, access control, medical imaging, kiosk, and smart city programs where scene contrast and subject distance both change faster than a fixed exposure and fixed focus design can follow. It delivers 3840 x 2160 color output with in-sensor dynamic range extension and no host-side HDR compositing overhead. ———————————————————————————————————————————————————————————— WellBeam, Kettering Health and Alternate Solutions Health Network Partner to Modernize Home Health Collaboration Through EMR-Integrated Workflows 2026-08-31 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/wellbeam-kettering-health-alternate-solutions-141500104.html REDWOOD CITY, Calif., August 31, 2026--WellBeam, a healthcare technology company focused on improving longitudinal care management through seamless EMR and clinical workflow interoperability, today announced a strategic partnership with Kettering Health, a regional integrated health system, and Alternate Solutions Health Network (ASHN), a leading provider of home health services. Together, the organizations are modernizing how physicians and home health clinicians collaborate to more effectively ———————————————————————————————————————————————————————————— Brentwood Residents Can Now Access Specialized Therapy With Continuous Digital Support 2026-08-31 · PRWeb · Healthcare https://www.prweb.com/releases/brentwood-residents-can-now-access-specialized-therapy-with-continuous-digital-support-302862590.html Anchored Counseling Co., a therapy practice in Brentwood, Tennessee, is integrating its sister brand, Becoming Anchored Co., to offer clients continued guidance between in-person sessions. Residents can now pair clinical sessions with ongoing digital support, including guided podcasts,... ———————————————————————————————————————————————————————————— Galaxis Technology Announces 2026 Interim Results, Revenue Surges 45.1% YoY and Overseas Business Expansion Accelerates 2026-08-31 · mlpr-acnnewswire · Finance, Healthcare, Real Estate https://www.acnnewswire.com/press-release/english/109646/ HONG KONG, August 31, 2026 - (ACN Newswire) - The integrated intelligent intralogistics robotics provider - Zhejiang Galaxis Technology Group Co., Ltd. (“Galaxis Technology” or the “Company”, stock code: 2729.HK) is pleased to announce its interim results for the six-month period ended 30 June 2026 (the “Reporting Period”). During the Reporting Period, the Company recorded revenue of approximately RMB504.9 million, representing a YoY increase of 45.1%. The revenue growth was mainly attributable to the increase in the number of large-scale multi-function comprehensive system and AMR deployment projects delivered in PRC. The gross profit was approximately RMB88.2 million, representing a YoY increase of 42.7% and a gross profit margin of 17.5%. The loss for the period decreased to approximately RMB73.3 million, narrowing by 14.7% YoY. As at 30 June 2026, the Company achieved an aggregate backlog value of robots and systems of approximately RMB2.2 billion, which the Company expects to fulfill within the next three years, out of which 56 were ongoing overseas projects with an aggregate backlog value of RMB710 million. During the Reporting Period, the Company has been carrying out its globalization strategy systematically in overseas markets, setting up local teams in North America, Southeast Asia, South America, Europe and other overseas markets. The total number of its overseas partners reached 22, and its business has expanded to 31 countries and regions. Business opportunities sourced from overseas markets increased substantially by 61.5%. The Company made multiple key progress in overseas markets. It entered into the Australian market with very-narrow-aisle fork-type robots (VFRs) and secured project orders for VFR from a health supplement manufacturing company; officially entered the global shuttle system supplier directory of a globally renowned Swedish home goods retailer; secured new VFR projects in Japan with a leading global electronics manufacturer and a domestic furniture retailer, which marked its market presence in Japan; secured a new pallet shuttle project with a Brazilian food processing company, making progress in the development of South American markets. In terms of domestic market development, during the Reporting Period, the Company successfully completed a core exemplary project in the Chinese Mainland. The project deployed 120 MSRs, 98 VFRs and a 15-kilometer-long automated conveyor track, with a daily outbound processing capacity of 320,000 order lines, a daily throughput of 60,000 items, and a shipping accuracy and timely delivery rate above 99.9%, which fully illustrates its strengths in technology implementation and systematic delivery in large-scale and complex projects. The Company adheres to the R&D philosophy of “scenario-oriented, technology-based”, continuously strengthening its integrated hardware and software technical edges and enriching its robot portfolio to meet the diverse needs of intralogistics scenarios. Its R&D expenses during the Reporting Period amounted to RMB38.7 million, representing a YoY increase of 27.3%. As at 30 June 2026, the Company has 965 employees in total, among whom 286 are R&D personnel, accounting for 29.6% of the total headcount. The consistent investment in R&D and talent accumulation is being translated into a core driving force for product iteration and scenario-based deployment, laying a deep and solid foundation for the Company’s long-term competitive advantages. Looking ahead, Dr. GU Chunguang, Chairman of the Board, Executive Director and Chief Executive Officer of Galaxis Technology, stated: “In the first half of 2026, we achieved substantial revenue growth, secured benchmark projects in domestic and overseas markets and narrowed loss, which reflects positive operating momentum. Going forward, we will continue to follow the long-term development path of ‘based in China, best in global’ by maintaining product innovation leadership through continued investment in R&D; strengthening localized execution in overseas markets; expanding into new industries and application scenarios; reinforcing industrial-chain collaboration; and improving management and operating efficiency, and achieve sustainable growth in both domestic and international markets. Thus, we can further strengthen our core competitive strengths.” About Zhejiang Galaxis Technology Group Co., Ltd. Galaxis Technology (Stock Code: 2729.HK)  is an intelligent intralogistics robotics provider focused on advancing automation in modern warehouse operations. The Company provides robotics products centred on three core product lines: multi-directional shuttle robots (MSRs), autonomous mobile robots (AMRs), and conveying and sorting robots (CSRs). These products possess core functions of storage, sorting and transport and cover the full scope of intralogistics business operations. Through sustained investment in R&D, the Company has established a comprehensive intellectual property portfolio, including invention patents, utility models, and design patents. Over the years, it built extensive experience in delivering integrated intralogistics solutions across multiple industries. This press release is issued on behalf of Zhejiang Galaxis Technology Group Co., Ltd. by Porda Havas International Finance Communications Group. Should you have any enquiries, please contact: Porda Havas International Finance Communications Group Email: ProjectGalaxy.hk@pordahavas.com Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com ———————————————————————————————————————————————————————————— AdvoCare® Launches Clear Protein 2026-08-31 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/advocare-launches-clear-protein-135900563.html RICHARDSON, Texas, August 31, 2026--AdvoCare International, LLC, a leading health and wellness company, is pleased to announce the launch of Clear Protein, a refreshing new take on protein supplementation that delivers 20g of high‑quality protein, 0g sugar, and crisp fruit flavors — all in a light, juice‑like drink. ———————————————————————————————————————————————————————————— Herbalife Reaffirms Third Quarter and Full Year 2026 Guidance 2026-08-31 · mlpr-businesswire · Finance, SaaS, Healthcare https://finance.yahoo.com/healthcare/articles/herbalife-reaffirms-third-quarter-full-135400744.html LOS ANGELES, August 31, 2026--Herbalife Ltd. (NYSE: HLF), a premier health and wellness company, community and platform, today reaffirmed the third quarter and full-year 2026 financial guidance it provided on August 5, 2026 in connection with its second quarter 2026 earnings release. ———————————————————————————————————————————————————————————— DentScribe White Paper Reveals Why Diagnosed Treatment Goes Unscheduled 2026-08-31 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/dentscribe-white-paper-reveals-why-diagnosed-treatment-goes-unscheduled-302865010.html New white paper shows Treatment Coordinator Notes can reveal why diagnosed care goes unscheduled and how practices can recover it. SUNNYVALE, Calif., Aug. 31, 2026 /PRNewswire/ -- The dentist diagnosed the treatment. The patient understood the need. The fee was discussed. Then nothing got... ———————————————————————————————————————————————————————————— In HelloNation, Medical Weight Loss Expert Susan Stivalo Explains Who Is a Good Candidate for Medical Weight Loss Programs 2026-08-31 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/in-hellonation-medical-weight-loss-expert-susan-stivalo-explains-who-is-a-good-candidate-for-medical-weight-loss-programs-302832983.html The Article Reviews Eligibility Factors, Health Considerations, and the Role of Personalized Medical Support in Weight Management. WHITE PLAINS, N.Y., Aug. 31, 2026 /PRNewswire/ -- Who is a good candidate for medical weight loss programs? HelloNation has published an article that answers... ———————————————————————————————————————————————————————————— Emmaus Life Sciences Announces Agreement for Evaluation of L-glutamine for Pancreatic Cancer 2026-08-31 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/emmaus-life-sciences-announces-agreement-133000413.html TORRANCE, Calif., August 31, 2026--Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into an exclusive option agreement with Cedars-Sinai to continue investigating the clinical utility of L-glutamine oral powder in combination with chemotherapy, as a potential treatment for Pancreatic Ductal Adenocarcinoma (PDAC). ———————————————————————————————————————————————————————————— Gench Education Announces 2026 Interim Results, High-Quality Education Delivers Steady Business Growth 2026-08-31 · mlpr-acnnewswire · Finance, AI, SaaS, Healthcare, Media, Education https://www.acnnewswire.com/press-release/english/109644/ HONG KONG, August 31, 2026 - (ACN Newswire) - Shanghai Gench Education Group Limited (“Gench Education” or the “Company”, together with its subsidiaries, the “Group”, Stock Code:1525.HK) -- the leading higher vocational education group in East China and the largest higher vocational education group in Shanghai, delightedly announced the unaudited consolidated interim results for the six months ended 30 June, 2026 (the “Reporting Period”). During the Reporting Period, the Group recorded revenue of approximately RMB569 million, representing an increase of 6.6% year-on-year (“YoY”). Gross profit was RMB354 million, up 11.7% YoY; Profit for the year was RMB179 million, a YoY rise of 10.2%. Basic and diluted earnings per share attributable to ordinary equity holders of the parent were RMB0.45, compared to RMB0.41 in the same period last year. The growth in performance was primarily attributable to the rise in average tuition fees, boarding fees per student, and revenue from education-related services during the Reporting Period. The Board has resolved the payment of an interim dividend of HKD$0.04 per ordinary share for the six months ended 30 June 2026, maintaining a stable dividend policy. Policy Dividends Continued to Be Released, Lingang’s Location Advantages Solidified Growth Foundation As the largest private university in Shanghai, Shanghai Jian Qiao University (the “University”) has fully benefited from dual support from national vocational education policy and Lingang special area policy. In February 2025, the Management Committee of Lingang New Area issued “the Action Plan for High-Quality Development of Industry-Education Integration in Lingang New Area of China (Shanghai) Pilot Free Trade Zone (2025-2027)”, explicitly supporting the University in building itself into an industry-education integration university. In December 2025, “Shanghai Lingang Science and Technology Innovation City Construction Plan” was launched, encouraging universities to participate in regional innovation development and bringing the Group opportunities in terms of policy support and resources. At the national level, in February 2026, the Ministry of Education issued the “Opinions of the Ministry of Education on Deepening the Reform of Key Elements in Vocational Education and Teaching”, which focuses on the key links of industry-education integration. In June 2026, the State Council issued the “Education Development Plan for the Fifteenth Five-Year Plan Period” (the “Plan”), which proposes launching the “Dual Excellence” construction of high-level application-oriented undergraduate universities, and leading and driving universities to focus on cultivating distinctive disciplinary specialty clusters around key industrial chains. Driven by these multiple policies, the University has leveraged its location in Lingang’s emerging industry agglomeration to transform its geographical advantages into institutional competitiveness. As of 31 August 2025, 77.5% of the University’s 2025 graduates were employed in the Yangtze River Delta region and 59.2% in Shanghai, which fully demonstrated the University’s effective integration into the regional development ecosystem through its educational outcomes. Teaching Quality Has Been Steadily Enhanced, While Digital and Intelligent Transformation Has Been Vigorously Advanced The University remains committed to teaching quality as its core priority, with ongoing efforts to strengthen faculty capacity building, curriculum development and smart campus construction. In terms of faculty, as of 30 September 2025, among the full-time teachers, the master degree or higher accounted for 86.4%, the doctoral degree accounted for 28.8%, the senior title accounted for 38.6%, and the double-position accounted for 47.8%. Grounded in its positioning as an application-oriented technological university, the University vigorously promotes professional teachers to practice in enterprises, organizes thematic workshops on industry education integration, and enhances teachers’ awareness and competence in industry-education integration. In terms of program and curriculum development, in the 2026/27 school year, the University has introduced two undergraduate majors, namely the Artificial Intelligence and the Electronic Packaging Technology, closely aligning with the demands of key industries such as integrated circuits and artificial intelligence. The University focuses on courses connotative construction, constructs “school level – city level – national level” 3-level courses building system, and enhances practical teaching and quality teaching. In 2025, 12 courses were selected as Shanghai first class undergraduate courses - the number of approved courses showed a YoY increase of 50%, reaching a historic new high. Besides, 26 courses were approved as Shanghai higher education municipal level key courses - the number of approved courses ranked the 7th place among higher education institutions in Shanghai, and thus became the only private university in the top 10. The courses cover various types including “AI+courses” and “industry-education integration courses”. In 2025, the “Fundamentals of Gemstone Geology and Crystallography” course of the College of Jewelry was selected as a “Online/Offline Hybrid First-Class Course”, achieving a breakthrough for the University in the construction of national first-class courses. In May 2026, the “Fundamentals of Intelligent Manufacturing Equipment” course of the College of Mechanical and Electronic Engineering was included in the national case collection of “Excellent Intelligent Manufacturing Courses”. The Group continues to deepen the upgrading and renovation of teaching and research instruments and equipment as well as teaching laboratories. The University has deployed smart classrooms integrated with high-definition cameras, intelligent audio devices and high-speed networks, and has built a smart teaching system covering the entire process of talent cultivation, curriculum teaching and quality monitoring. Furthermore, the Group has actively explored the deep integration of AI and education, embedded technologies such as AI, 5G, and VR into the teaching process, and initiated the construction of a DeepSeek-based large model for vertical-domain educational applications, thereby creating three intelligent agents for services, management, and teaching. Industry-Education Integration Has Been Further Deepened, While the Diversified Education Ecosystem Has Been Continuously Improved The Group is fully committed to building an industry-education integrated university. It implements a tripartite operational model integrating “academic schools + industrial colleges + corporate entities”, striving to achieve the synergistic development of “industry, academia, research, and innovation” as an integrated whole. As of 30 June 2026, the University has successively launched seven key industry-education integration projects covering the College of Mechanical and Electronic Engineering, the College of Journalism and Communications, the Business College, the College of Art Design and the College of Jewelry. It has established Medical Engineering Industrial College, the Live Streaming Economy Industrial College, and Big Data Industrial College, is actively preparing for the establishment of the Integrated Circuit Industrial College and the Intelligent Manufacturing Industrial College, and endeavors to create a distinctive educational framework featuring multi-track industry and college collaboration and comprehensive industry-education integration. International cooperation has made steady progress, while external exchanges have continued to expand. The University works with Vaughn College of Aeronautics and Technology, The Kyoto College of Graduate Studies for Informatics, Teesside University, among others, in junior college to master’s program, undergraduate to master’s program, dual bachelor’s program and other programs. In 2025, the University contracted with 11 overseas famous universities/colleges in Germany, United Kingdom, New Zealand, Thailand and other countries, to expand teachers and students’ overseas exchange channels. As the first private university in Shanghai that has obtained the qualification to recruit international students, the University also attracts international students from many countries around the world and forms an international student education system that combines long-term and short-term programs. The University has a well-established lifelong education system. With the Shanghai “Dual-system” Pilot Base for Continuing Education of Employees in Higher Education Institutions (Incubation) as a platform, the University has built an integrated, multi-field and cross-age lifelong education system for knowledge updating and ability enhancement, covering adult higher education, vocational skills training, and youth science and innovation education. As of 30 June 2026, the number of in-service students enrolled in the University’s adult continuing education programs amounted to 3,316, and a total of over 400 types of vocational skill certificate training had been provided. Financial Position Remains Sound, While the Asset-Liability Structure Has Been Continuously Optimized During the Reporting Period, finance costs of the Group decreased by 69.0% YoY, which was primarily due to the result of early repayment of most of long-term interest-bearing bank borrowings by the end of 2025. As at 30 June 2026, the scale of interest-bearing borrowings decreased to RMB276.7 million, with the gearing ratio remaining at 0.1. The financial position has become more robust. Looking forward, Mr. Zhao Donghui, Chairman of the Board and Executive Director of Gench Education, stated: “The Group’s performance in the first half of 2026 achieved steady growth, validating the feasibility of its high-quality development strategy. In the future, we will continue to adhere to the educational philosophy of ‘student-oriented, teaching-centred, undergraduate-focused’ and the work ideology of ‘quality as the core, teaching as the centre, students as the base, teachers as the principal’ to promote the high-quality development of our undertakings. We will also fully capitalize on this historic opportunity by proactively aligning with the national strategy of promoting the high-quality development of vocational education and with Lingang’s regional initiative of becoming a ‘Global Hub of Power’, cultivate more high-quality technical and skilled talents, and accelerate the transformation to an industry-education integration university, and strive to build our University into a first-class private university in China with more unique features and international standing and a long-distance runner for the high-quality development of higher education in China.” About Shanghai Gench Education Group Limited Gench Education (Stock Code: 1525.HK) is a higher vocational education group which provides undergraduate education and junior college education, focusing on high-quality schooling for the provision of excellent education for students. The Group operates Shanghai Jian Qiao University, being the domestic leading private university, at Lingang New Area of China (Shanghai) Pilot Free Trade Zone. As measured by the number of full-time students enrolled in the 2025/26 school year, the University is the largest private university in Shanghai and is also a leading private university in the entire Yangtze River Delta. According to CUAA.net , the University ranked third among all category I private universities in China for five consecutive years and first among private universities in the Yangtze River Delta for seven consecutive years. Over 26 years of operation, the schooling quality of the University ranked in the forefront of peer universities, which has accumulated a solid brand reputation. Since 2004, the University has been consecutively awarded “Shanghai Civilized Unit” over 18 years. The University has won numerous honorary titles such as “National Model Unit of Civilization ”, “Shanghai Garden Unit”, “Shanghai Safe and Civilized Campus”, etc. The University has also been granted reputable title of “Lei Feng Spirit College Demonstration Education Base” among the first batch of universities in the PRC in April 2024, and was awarded the “Contribution Award for Promoting Lei Feng Spirit in the New Era ” in September 2024. In February and March 2025, the University was successively recognized as an “Outstanding Unit in Information Disclosure Work among Shanghai Higher Education Institutions for 2023-2024” and an “Outstanding Unit in Petition Work within the Shanghai Education System for 2024”. This press release is issued by Porda Havas International Finance Communications Group on behalf of Shanghai Gench Education Group Limited. For further information, please contact: Porda Havas International Finance Communications Group E-mail: gench.hk@pordahavas.com Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com ———————————————————————————————————————————————————————————— Health Canada Approves Sunshine Biopharma's Atenolol for Treating and ... 2026-08-31 · PR-Inside · Finance, Healthcare https://pr-inside.com/health-canada-approves-sunshine-biopharma-s-atenolol-for-treating-and-r5217858.htm (PR-inside.com) FORT LAUDERDALE, FL / ACCESS Newswire / August 31, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its Atenolol tablets of 25mg, 50mg and 100mg for the Canadian market. Atenolol is the generic equivalent of the brand name, Tenormin®. Atenolol belongs to a class of drugs known as beta-blockers. It works by blocking the action of certain natural chemicals in the body, such as epinephrine, on the heart and blood vessels. This effect lowers the heart rate, blood pressure, and strain on the .. ———————————————————————————————————————————————————————————— Femcare Ltd Acquires Orion Medical Supplies Ltd in the UK 2026-08-31 · PR-Inside · Finance, Healthcare https://pr-inside.com/femcare-ltd-acquires-orion-medical-supplies-ltd-in-the-uk-r5217854.htm (PR-inside.com) SALT LAKE CITY, UT / ACCESS Newswire / August 31, 2026 / Femcare Ltd. ("Femcare"), a wholly-owned subsidiary of Utah Medical Products, Inc. (Nasdaq:UTMD), announces that it has purchased the entire ordinary share capital of Orion Medical Supplies Ltd ("ORION") of the United Kingdom. ORION is a niche assembler and distributor, primarily in the UK and Europe, of Harm Reduction medical devices. Harm Reduction refers to programs and practices that aim to minimize negative health, social and legal impacts associated with drug use, drug policies and drug laws. ORION's kits incorporate devices that are designed to reduce the spread of blood .. ———————————————————————————————————————————————————————————— USDA Deregulates The Darling 54 American Chestnut 2026-08-31 · PR-Inside · Healthcare https://pr-inside.com/usda-deregulates-the-darling-54-american-chestnut-r5217853.htm (PR-inside.com) The Historic Decision Moves America's Iconic Tree Closer To Forest-Scale Restoration MCGRAW, NY / ACCESS Newswire / August 31, 2026 / SilvaBio is proud to announce that the U.S. Department of Agriculture's (USDA) Animal and Plant Health Inspection Service (APHIS) have formally deregulated the Darling 54 American chestnut -a landmark achievement in a decades-long effort to restore this species to its 25-state native range. Photo credit John Carnessali Following a thorough, multi-year review process, the agency has determined that the modified American chestnut developed at the SUNY College of Environmental Science and Forestry (ESF) is "unlikely to pose a greater plant pest .. ———————————————————————————————————————————————————————————— BODYWELLE Expands Erectile Dysfunction Care With Shockwave Therapy ... 2026-08-31 · PR-Inside · Healthcare https://pr-inside.com/bodywelle-expands-erectile-dysfunction-care-with-shockwave-therapy-r5217852.htm (PR-inside.com) The physician-led practice now offers low-intensity shockwave therapy for erectile dysfunction, following a review of health history, symptoms, and hormone and metabolic panels. MIAMI BEACH, FL / ACCESS Newswire / August 31, 2026 / BODYWELLE , a physician-led longevity and functional medicine practice in Miami Beach, has added low-intensity shockwave therapy to the treatments it offers for erectile dysfunction. The therapy is delivered as part of a men's sexual wellness evaluation rather than as a standalone service, an approach consistent with how the practice treats conditions with vascular and hormonal components. Information about the treatment and the factors that contribute to .. ———————————————————————————————————————————————————————————— BODYWELLE Expands Erectile Dysfunction Care With Shockwave Therapy in Miami Beach 2026-08-31 · Newswire.com · Healthcare https://www.newswire.com/news/bodywelle-expands-erectile-dysfunction-care-with-shockwave-therapy-in-22853482 The physician-led practice now offers low-intensity shockwave therapy for erectile dysfunction, following a review of health history, symptoms, and hormone and metabolic panels. ———————————————————————————————————————————————————————————— Ocumetics Completes Manufacturing of Next Generation Solid State Accommodating Intraocular Lenses for Upcoming Group Two First in Human Clinical Surgeries 2026-08-31 · NewMediaWire · Healthcare https://www.newmediawire.com/news/ocumetics-completes-manufacturing-of-next-generation-solid-state-accommodating-intraocular-lenses-for-upcoming-group-two-first-in-human-clinical-surgeries-7089063 CALGARY, ALBERTA - August 31, 2026 ( NEWMEDIAWIRE ) - Ocumetics Technology Corp. (“ Ocumetics ” or the “ Corporation ”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is pleased to announce the successful completion of manufacturing of its next generation solid state accommodating intraocular lenses (“Ocumetics Lens”), which will be used in the Company’s upcoming Group Two first-in-human clinical surgeries in Mexico City. The completion of manufacturing represents another significant milestone in Ocumetics’ clinical development program and follows the Company’s encouraging experience with its first group of human patients. Key Highlights - Next-generation Ocumetics Lenses successfully manufactured and ready for the Company’s upcoming Group Two first-in-human clinical surgeries in Mexico City. - Cl ———————————————————————————————————————————————————————————— Medical Care Technologies Inc. (OTCID:MDCE) Melanoma Scan Beta Seeks ... 2026-08-31 · PR-Inside · AI, SaaS, Healthcare https://pr-inside.com/medical-care-technologies-inc-otcid-mdce-melanoma-scan-beta-seeks-r5217851.htm (PR-inside.com) Company Advances Beyond Public Cancer Imaging Datasets With First Real-World User-Submitted Testing Phase MESA, AZ / ACCESS Newswire / August 31, 2026 / Medical Care Technologies Inc. (OTCID:MDCE) today announced that its MDCE Melanoma Scan Beta platform is seeking its first set of volunteers for human-submitted dataset testing - a significant step beyond the Company's prior work training and evaluating models solely on established public cancer imaging datasets. Until now, development of MDCE Melanoma Scan Beta has centered on structured internal testing and AI model optimization using gold-standard public dermatology resources, including HAM10000, ISIC Archive collections, and TCIA melanoma cohorts. The move .. ———————————————————————————————————————————————————————————— Medical Care Technologies Inc. (OTCID:MDCE) Melanoma Scan Beta Seeks First Volunteer Cohorts for Human-Submitted Image Dataset Testing 2026-08-31 · Newswire.com · Healthcare https://www.newswire.com/news/medical-care-technologies-inc-otcid-mdce-melanoma-scan-beta-seeks-first Company Advances Beyond Public Cancer Imaging Datasets With First Real-World User-Submitted Testing Phase ———————————————————————————————————————————————————————————— Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical ... 2026-08-31 · PR-Inside · Finance, Healthcare https://pr-inside.com/ensysce-biosciences-completes-final-phase-of-pf614-mpar-102-clinical-r5217850.htm (PR-inside.com) ~ ~ The Second Study Fully Enrolled for Breakthrough Therapy-Designated, First-in-Class Opioid Designed to Protect Against Oral Overdose ~ ~ SAN DIEGO, CA / ACCESS Newswire / August 31, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on complex pain, and advancing next-generation pain and central nervous system therapeutics designed to reduce abuse and overdose risk, today announced completion of enrollment in the final stage of the PF614-MPAR-102 clinical study. The study evaluated its novel MPAR® (Multi-Pill Abuse Resistance) overdose-protection technology. Unlike traditional abuse-deterrent technologies, PF614-MPAR .. ———————————————————————————————————————————————————————————— While Measles Cases Continue to Increase in The USA and Globally, NanoViricides ... 2026-08-31 · PR-Inside · Finance, Healthcare https://pr-inside.com/while-measles-cases-continue-to-increase-in-the-usa-and-globally-nanoviricides-r5217848.htm (PR-inside.com) SHELTON, CT / ACCESS Newswire / August 31, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American: NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, provides an update on its Measles Drug Treatment Program. While CDC is reviewing the two recent measles-related fatalities in Pennsylvania, the total number of confirmed measles cases in the USA has reached 2,903 as of August 27, 2026, in comparison to 2,289 confirmed cases in the whole year of 2025, indicating continuing expansion of measles1. Cases of .. ———————————————————————————————————————————————————————————— Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study 2026-08-31 · Newswire.com · Healthcare https://www.newswire.com/news/ensysce-biosciences-completes-final-phase-of-pf614-mpar-102-clinical-study ~ ~ The Second Study Fully Enrolled for Breakthrough Therapy-Designated, First-in-Class Opioid Designed to Protect Against Oral Overdose ~ ~ ———————————————————————————————————————————————————————————— While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles 2026-08-31 · Newswire.com · Healthcare https://www.newswire.com/news/while-measles-cases-continue-to-increase-in-the-usa-and-globally-nanoviricides ———————————————————————————————————————————————————————————— Wholechain and iFoodDS Integrate to Simplify Compliance with FDA's Food Traceability Rule 2026-08-31 · PRWeb · SaaS, Healthcare https://www.prweb.com/releases/wholechain-and-ifoodds-integrate-to-simplify-compliance-with-fdas-food-traceability-rule-302864652.html Wholechain and iFoodDS have completed a software integration enabling seafood suppliers using Wholechain to seamlessly share critical data across the iFoodDS Trace Exchange™ network to streamline compliance with the FDA's FSMA 204 rule. BLOOMFIELD HILLS, Mich. and SEATTLE, Aug. 31, 2026... ———————————————————————————————————————————————————————————— Higgs Boson Health Announces Acquisition by Globus Medical 2026-08-31 · PRWeb · Finance, Healthcare https://www.prweb.com/releases/higgs-boson-health-announces-acquisition-by-globus-medical-302864641.html Higgs Boson Health today announced it has been acquired by Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company. The Higgs Boson Health team joins Globus Medical to extend surgical intelligence beyond the operating room and across the full care pathway. DURHAM, N.... ———————————————————————————————————————————————————————————— BetterLife Pharma Appoints Charles Duncan as Director and Chair of the Audit Committee 2026-08-31 · mlpr-newsfile · Healthcare https://www.newsfilecorp.com/release/311653/BetterLife-Pharma-Appoints-Charles-Duncan-as-Director-and-Chair-of-the-Audit-Committee Vancouver, British Columbia--(Newsfile Corp. - August 31, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotechnology company developing BETR-001 for the treatment of migraine and headache disorders, is pleased to announce the appointment of Charles Duncan, PhD as Director and Chair of the Audit Committee.Dr. Duncan is a biotechnology strategist, board director and former top-ranked Wall Street biotechnology analyst with nearly... ———————————————————————————————————————————————————————————— Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference 2026-08-31 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/31/3353238/0/en/elicio-therapeutics-to-participate-at-the-h-c-wainwright-28th-annual-global-investment-conference.html BOSTON, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that Robert Connelly, Chief Executive Officer and Pete DeMuth, PhD, Chief Scientific Officer, will participate in a fireside chat at the upcoming H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, in New York, New York. ———————————————————————————————————————————————————————————— From Full Sail to Full-Scale: Adia Med Inc. Assembles Intern Social Media Team 2026-08-31 · mlpr-newsfile · Healthcare, Education https://www.newsfilecorp.com/release/311967/From-Full-Sail-to-FullScale-Adia-Med-Inc.-Assembles-Intern-Social-Media-Team Winter Park, Florida--(Newsfile Corp. - August 31, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies, biologics, and advanced clinical services, today announced that its introductory innovation session earlier this month at Full Sail University delivered exactly the spark the Company was looking for — and that Adia Med has already assembled a social media team of interns to convert that momentum into a new era of organic marketing.From Full Sail... ———————————————————————————————————————————————————————————— Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference 2026-08-31 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/31/3353242/0/en/kalaris-to-present-at-morgan-stanley-24th-annual-global-healthcare-conference.html BERKELEY HEIGHTS, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will participate in a Fireside Chat at the upcoming Morgan Stanley 24th Annual Global Healthcare Conference. Kalaris is currently developing TH103, a dual-action anti-VEGF therapeutic, in a Phase 1b/2 multiple ascending dose study for neovascular Age-related Macular Degeneration (nAMD). ———————————————————————————————————————————————————————————— T-MAXIMUM B7-H3-Targeted Allogeneic CAR-T Therapy MT027 Receives FDA Fast Track Designation, Accelerating Global Development for Intracranial Solid Tumors 2026-08-31 · mlpr-prnewswire-wire · Healthcare, Automotive https://www.prnewswire.com/news-releases/t-maximum-b7-h3-targeted-allogeneic-car-t-therapy-mt027-receives-fda-fast-track-designation-accelerating-global-development-for-intracranial-solid-tumors-302862435.html MT027 has previously been granted FDA Orphan Drug Designation and has entered Phase II clinical development in recurrent glioblastoma BEIJING, Aug. 31, 2026 /PRNewswire/ -- T-MAXIMUM PHARMACEUTICAL Inc. ("T-MAXIMUM") today announced that its investigational allogeneic CAR-T cell therapy... ———————————————————————————————————————————————————————————— Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day 2026-08-31 · GlobeNewswire · Finance, Healthcare, Education https://www.globenewswire.com/news-release/2026/08/31/3353232/33240/en/emergent-biosolutions-reinforces-commitment-to-opioid-overdose-education-and-preparedness-on-international-overdose-awareness-day.html GAITHERSBURG, Md., Aug. 31, 2026 (GLOBE NEWSWIRE) -- In recognition of International Overdose Awareness Day (IOAD), Emergent BioSolutions (NYSE: EBS) is reaffirming its commitment to expanding awareness of opioid overdose risks and increasing preparedness to help save lives. According to the World Health Organization, opioids are associated with nearly 80 percent of drug-related deaths worldwide, highlighting the continued need for education, preparedness and access to life-saving interventions. i As opioid overdose remains a significant global public health challenge, Emergent is focused on empowering people with the information and tools needed to act in the event of an opioid overdose emergency. ———————————————————————————————————————————————————————————— Life Sciences Quality Management Software Market: The Push Toward Connected, Scalable Quality Infrastructure 2026-08-31 · Express Press Release · Healthcare https://express-press-release.net/news/2026/08/31/1769908 Quality is not optional in the life sciences industry — it is the foundation on which patient safety, regulatory approval, and business survival are built. [read full press release...] ———————————————————————————————————————————————————————————— Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis 2026-08-31 · PR Newswire · Finance, Healthcare https://www.prnewswire.com/news-releases/karyopharm-submits-supplemental-new-drug-application-to-the-fda-for-xpovio-selinexor-plus-ruxolitinib-for-patients-with-myelofibrosis-302864537.html – sNDA Submitted under the Accelerated Approval Pathway; Priority Review Requested – NEWTON, Mass., Aug. 31, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has submitted... ———————————————————————————————————————————————————————————— Lost Money on Fractyl Health, Inc. (GUTS)? Join Class Action Before ... 2026-08-31 · PR-Inside · Finance, Healthcare https://pr-inside.com/lost-money-on-fractyl-health-inc-guts-join-class-action-before-r5217816.htm (PR-inside.com) NEW YORK, NY / ACCESS Newswire / August 31, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Fractyl Health, Inc. (NASDAQ:GUTS) securities. If you suffered a loss on your Fractyl Health, Inc. investment and would like to explore a potential recovery under the federal securities laws, Learn about Fractyl Health, Inc. Class Action or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit was filed against .. ———————————————————————————————————————————————————————————— Aviva Aesthetics Expands Greater Phoenix and Scottsdale Presence Through Partnership with Perfect Skin Center 2026-08-31 · PRWeb · SaaS, Healthcare https://www.prweb.com/releases/aviva-aesthetics-expands-greater-phoenix-and-scottsdale-presence-through-partnership-with-perfect-skin-center-302864610.html Physician-led practice with a 26-year legacy joins the entrepreneur-owned platform, adding two Phoenix-area locations in Tempe and Scottsdale CHICAGO, Aug. 31, 2026 /PRNewswire-PRWeb/ -- Aviva Aesthetics, the nation's only entrepreneur-owned medical aesthetics platform, today announced a... ———————————————————————————————————————————————————————————— How To Cover Medical Costs That Insurance Doesn't Cover 2026-08-31 · Newswire.com · Healthcare https://www.newswire.com/news/how-to-cover-medical-costs-that-insurance-doesnt-cover ———————————————————————————————————————————————————————————— Pomerantz LLP Announces Securities Class Action Lawsuit Against Fractyl ... 2026-08-31 · PR-Inside · Finance, Healthcare https://pr-inside.com/pomerantz-llp-announces-securities-class-action-lawsuit-against-fractyl-r5217797.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 31, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Fractyl Health, Inc. ("Fractyl" or the "Company") (NASDAQ:GUTS) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 26-cv-07167, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fractyl securities between January 13, 2025 and January 29, 2026, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations .. ———————————————————————————————————————————————————————————— Dr. Philip S. Low Inducted into 2026 ACS Division of Medicinal Chemistry Hall of Fame 2026-08-31 · PRWeb · Healthcare https://www.prweb.com/releases/dr-philip-s-low-inducted-into-2026-acs-division-of-medicinal-chemistry-hall-of-fame-302864612.html Purdue drug discovery pioneer and LIFT founder recognized posthumously for targeted-therapy research that yielded three FDA-approved medicines WEST LAFAYETTE, Ind., Aug. 31, 2026 /PRNewswire-PRWeb/ -- The Low Institute for Therapeutics (LIFT) today announced that its Founder, the late Dr.... ———————————————————————————————————————————————————————————— OMEZA's OCM will be featured in an approved abstract treating a complex chronic burn patient at Fall SAWC Oct.15-18 in Las Vegas 2026-08-31 · PRWeb · Healthcare https://www.prweb.com/releases/omezas-ocm-will-be-featured-in-an-approved-abstract-treating-a-complex-chronic-burn-patient-at-fall-sawc-oct15-18-in-las-vegas-302862585.html Approved Abstract: A Retrospective Observational Evaluation of OCM as Primary Therapy for a Thermal Burn Wound in an Adult Private Practice Wound Setting. The abstract will be presented at the 2026 Fall SAWC Conference, in Las Vegas, NV by Dr. Angelina Ferguson. Dr. Ferguson is the Chief... ———————————————————————————————————————————————————————————— Origin Agritech Establishes R&D Center in Guizhou with Biotech Unit and State-Backed Seed Joint Venture 2026-08-31 · GlobeNewswire · Finance, SaaS, Healthcare https://www.globenewswire.com/news-release/2026/08/31/3353155/0/en/origin-agritech-establishes-r-d-center-in-guizhou-with-biotech-unit-and-state-backed-seed-joint-venture.html Wholly Owned Guizhou Origin and a 25%-Held Joint Venture with a State-Owned Seed Group Form a Full-Chain Research, Production, and Distribution Platform for Southwest China ———————————————————————————————————————————————————————————— Herbalife Announces Planned CEO Transition 2026-08-31 · mlpr-businesswire · Finance, SaaS, Healthcare https://finance.yahoo.com/healthcare/articles/herbalife-announces-planned-ceo-transition-105000856.html LOS ANGELES, August 31, 2026--Herbalife Ltd. (NYSE: HLF) ("the Company"), a premier health and wellness company, community and platform, today announced that Stephan Gratziani will transition from his role as Chief Executive Officer, effective October 31, 2026. Following the transition, Gratziani will continue supporting Herbalife as a consultant focused on strategy and business development. ———————————————————————————————————————————————————————————— Micot Pharma Reports Positive Operating Cash Flow and Advances Late-Stage Pipeline in 1H 2026 2026-08-31 · mlpr-acnnewswire · Healthcare https://www.acnnewswire.com/press-release/english/109638/ HONG KONG, August 31, 2026 - (ACN Newswire) - Operating Cash Flow Turns Positive for the First Time, with a Significantly Strengthened Capital Structure On August 28, 2026, Micot Pharma (02335.HK), the first publicly listed peptide-focused innovative drug company in Hong Kong, announced its interim results for the first half of 2026. During the reporting period, the Company recorded research and development expenses of RMB128 million, representing a significant year-on-year increase of 215.9%, reflecting an acceleration in R&D investment. Meanwhile, net cash generated from operating activities reached RMB109 million, marking a turnaround from net operating cash outflow in the corresponding period of 2025. An important contributor to this shift was the commercialization partnership for MT1013. In February 2026, Micot Pharma entered into an exclusive commercialization licensing agreement with Everest Medicines for MT1013, the Company's Core Product. Under the agreement, Everest Medicines was granted exclusive commercialization rights for MT1013 in Greater China and the Asia-Pacific region excluding Japan for the treatment of secondary hyperparathyroidism (SHPT). Micot Pharma received an upfront payment of RMB200 million and is eligible to receive potential regulatory and commercial milestone payments of up to RMB1.04 billion, as well as tiered royalties based on net product sales. As of the end of June 2026, the Company's cash and financial assets totaled approximately RMB1.227 billion, compared with RMB270 million at the end of 2025. Total equity reached approximately RMB957 million, compared with net liabilities of approximately RMB960 million at the end of 2025. The Company's gearing ratio also declined substantially from 389.6% to 25.2%. For a clinical-stage biotechnology company, the strengthening of liquidity and capital structure provides important financial support for the continued advancement of multiple clinical programs. MT1013 Advances Through Phase III, with a Clearer Path Toward Commercialization Beyond its financial position, the key question for the market remains the progress and clinical potential of Micot Pharma's pipeline. MT1013 remains the Company's most advanced asset and the product closest to commercialization. MT1013 is the world’s first-in-class, new-generation dual-targeting peptide drug being developed for secondary hyperparathyroidism associated with chronic kidney disease (CKD-SHPT).The drug features a pioneering dual mechanism of action—“CaSR agonist + OGP (Osteogenic Growth Peptide) mimetic.” Unlike conventional approaches that primarily focus on suppressing parathyroid hormone (PTH), MT1013 is designed to regulate PTH, calcium and phosphorus metabolism while simultaneously activating osteogenic pathways to promote bone formation and repair. This represents a potential therapeutic shift from indirectly suppressing bone resorption toward actively promoting bone formation. The Phase III clinical study of MT1013 has completed patient enrollment, and the Company expects to submit a New Drug Application (NDA) in early 2027. In a head-to-head clinical study against the calcimimetic etelcalcetide, the composite target attainment rate for serum calcium, phosphorus, and iPTH in the MT1013 groups after 20–27 weeks of treatment was 39.29% and 34.48%, respectively, approximately 2.2–2.5 times that of etelcalcetide (15.63%). In addition, the proportion of patients in the MT1013 groups achieving a reduction of more than 30% in intact parathyroid hormone (iPTH) from baseline reached 83.9%–93.3%. Clinical data from MT1013 have also been accepted as Late-Breaking Science by the American Society of Nephrology (ASN) Kidney Week. Against this backdrop, Micot Pharma's commercialization partnership with Everest Medicines represents an important step in translating the clinical and scientific value of MT1013 into potential commercial value. Positive Phase II Data for MT200605 Further Validate Its Potential as an Innovative Stroke Therapy Shortly before the release of its interim results, Micot Pharma announced on August 26 that it had completed the Phase II clinical trial of MT200605, its internally developed candidate for the treatment of acute ischemic stroke (AIS). The study was a multicenter, randomized, double-blind, placebo-controlled Phase II trial involving 360 patients, who were randomized at a 1:1:1:1 ratio into three MT200605 dose groups and a placebo group. For the primary efficacy endpoint, the proportion of patients achieving a modified Rankin Scale (mRS) score of 0–1 in the high-dose MT200605 group was higher than that in the placebo group, with the odds ratio (OR) for functional recovery improving by more than 100% versus placebo. From a clinical-benefit perspective, the results suggest that approximately one additional patient could achieve functional independence for every six patients treated. The signal is noteworthy in the context of neuroprotection research, a field in which translating biological mechanisms into meaningful improvements in functional outcomes has historically been challenging. For the secondary endpoints, improvement in National Institutes of Health Stroke Scale (NIHSS) scores in the high-dose group began to separate from placebo by Day 7. The direction of improvement was consistent with the mRS results, with a more pronounced difference observed by Day 14, suggesting faster early neurological recovery among patients receiving high-dose MT200605. Another differentiated observation involved acute kidney injury (AKI). MT200605 demonstrated the potential to reduce the incidence of AKI among patients with AIS in a dose-dependent manner. In the high-dose group, the incidence of AKI was more than 80% lower than that in the placebo group, indicating potential renal-protective benefits in addition to its neurological effects. A Differentiated BDNF/TrkB-Based Mechanism Supporting Potential Brain and Kidney Protection Mechanistically, MT200605 is a small molecule compound that acts as a tropomyosin receptor kinase B (TrkB) agonist with brain-derived neurotrophic factor (BDNF)-like effects. By activating TrkB, it modulates downstream signaling pathways to protect the structure and function of brain neural tissues. Additionally, it enhances mitochondrial ATP synthesis and exerts antioxidant effects by scavenging oxygen free radicals. This differentiated mechanism may also contribute to the renal-protective signal observed in the Phase II trial. MT200605 has received recognition from both domestic and international scientific and regulatory communities. The program has been selected for China's National Science and Technology Major Project for Innovative Drug Development. Its preclinical and Phase I clinical findings have also been accepted for oral presentation at the 18th World Stroke Congress. In addition, the U.S. Food and Drug Administration granted Orphan Drug Designation to MT200605 for the treatment of Huntington's disease in March 2026. A Multi-Layered Pipeline Strengthens Micot Pharma's Capacity for Sustained R&D Output Beyond MT1013 and MT200605, Micot Pharma is building a broader pipeline spanning different stages of clinical development. XTL6001, a GLP-1R/GCGR/MasR triple agonist, has completed database lock for its Phase I clinical trial. By incorporating MasR into its mechanism of action, XTL6001 is designed to extend its therapeutic potential beyond weight management and metabolic regulation toward renal protection and anti-inflammatory and anti-fibrotic effects. Research relating to XTL6001 has been accepted for presentation at several major international scientific conferences, including the American Diabetes Association (ADA) Scientific Sessions 2026, the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 and ASN Kidney Week 2026. Meanwhile, MT1002 continues to advance across indications including anticoagulation during hemodialysis and acute ischemic stroke, further expanding Micot Pharma's development footprint in cardiovascular, cerebrovascular and renal diseases. Entering an Accelerated Validation Phase for R&D Outcomes Taken together, the most important takeaway from Micot Pharma's 2026 interim results is not whether a clinical-stage biotechnology company can achieve near-term profitability. Rather, three developments are taking place simultaneously. First, MT1013 has entered the critical late-stage clinical development period ahead of a potential NDA submission, while its commercialization partnership with Everest Medicines has established a clearer pathway toward commercialization. Second, the Phase II results of MT200605 have provided further clinical evidence supporting the therapeutic potential of its differentiated mechanism in acute ischemic stroke. Third, proceeds from the Company's Hong Kong listing, together with the upfront payment received under the MT1013 commercialization agreement, have substantially strengthened Micot Pharma's liquidity and capital structure, providing greater financial flexibility to advance its clinical pipeline. For investors and industry observers, these developments may represent the central theme through which Micot Pharma's first interim results following its Hong Kong listing should be understood: the Company is moving from a stage dominated by R&D investment toward one in which clinical progress, external partnerships and pipeline value are increasingly being validated through tangible milestones. Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com ———————————————————————————————————————————————————————————— Will we "see" you in New York at Moody's Capital 2026 Disruptive Growth ... 2026-08-31 · PR-Inside · Healthcare, Retail, Education https://pr-inside.com/will-we-see-you-in-new-york-at-moody-s-capital-2026-disruptive-growth-r5217759.htm (PR-inside.com) Dr. Roger Wu, CEO of 20Slash20 Inc, to Present The Eye Drink Company Overview at Moody's Capital 2026 Disruptive Growth and Life Sciences Conference September 9-10. NEW YORK, NY / ACCESS Newswire / August 31, 2026 / As an incubated client of Fast Moving Consumer Goods (OTCID:GGII), 20Slash20, Inc., a health and wellness company focused on advancing eye health awareness through innovative consumer products and education, announced today that Dr. Roger Wu, Founder and CEO of 20Slash20, will present the company's vision, growth strategy, and market opportunities at the Moody's Capital 2026 Disruptive Growth and Life Sciences Conference September 9-10. Dr. Wu's .. ———————————————————————————————————————————————————————————— Recent Release "Borderline Personality Disorder..." by Carlos A. Rueda, Ph.D. Clarifies Two Conditions Often Confused in Clinical Practice 2026-08-31 · PR.com · Healthcare https://www.pr.com/press-release/977362 Carlos A. Rueda, Ph.D. has completed a new book exploring the intricate relationship between borderline personality disorder and premenstrual dysphoric disorder—conditions that frequently overlap in ways that lead to profound diagnostic challenges. The work examines whether these conditions should be understood as separate entities or recognized as interconnected phenomena, a distinction with significant [PR.com] ———————————————————————————————————————————————————————————— Recent Release, "A Healthy Transformation," from Christian Faith Publishing Author Deodge Hill, Explores How Believers Can Honor God Through Their Bodies and Wellness 2026-08-31 · PR.com · Healthcare https://www.pr.com/press-release/977404 Deodge Hill has completed a new book, "A Healthy Transformation: Fit for His Purpose," a faith-centered guide designed to help readers achieve physical, mental, and spiritual wholeness. By seamlessly blending practical health principles with biblical encouragement, this work equips believers to break free from unhealthy patterns, establish sustainable habits, and discover how their wellness journey connects to [PR.com] ———————————————————————————————————————————————————————————— Recent Release, "Inspired to Influence," from Christian Faith Publishing Author Angel Morgan, Chronicles a Transformative Spiritual Journey Through Challenging Seasons 2026-08-31 · PR.com · Healthcare https://www.pr.com/press-release/977391 Angel Morgan has completed a new book, titled, "Inspired to Influence" that traces her personal expedition through invisibility, loss, and ultimately, profound restoration. When facing medical emergencies, devastating diagnoses, and the untimely death of beloved family members, Morgan found herself emotionally overwhelmed and mentally struggling to process her circumstances. Isolated despite having loving family [PR.com] ———————————————————————————————————————————————————————————— Medical Device Coatings Market Benefits From Antimicrobial Solutions 2026-08-31 · Express Press Release · Healthcare https://express-press-release.net/news/2026/08/31/1769878 The global Medical Device Coatings Market was valued at USD 16.3 billion in 2025 and is projected to reach USD 30.0 billion by 2033, expanding at a 7.9% CAGR from 2026 [read full press release...] ———————————————————————————————————————————————————————————— Nutex Health Hospitals Earn Multiple Community Honors in Second Quarter 2026 2026-08-31 · PR Newswire · Finance, Healthcare https://www.prnewswire.com/news-releases/nutex-health-hospitals-earn-multiple-community-honors-in-second-quarter-2026-302863096.html HOUSTON, Aug. 31, 2026 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 28 state-of-the-art micro hospitals and hospital outpatient departments in 12 states and primary care-centric,... ———————————————————————————————————————————————————————————— Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio® to Subcutaneous Presentations 2026-08-31 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/31/3353086/0/en/alvotech-announces-fda-acceptance-for-review-of-biologics-license-application-for-avt80-expanding-proposed-biosimilar-program-for-entyvio-to-subcutaneous-presentations.html REYKJAVIK, Iceland, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT80, a proposed interchangeable biosimilar to Entyvio® (vedolizumab) prefilled syringe and autoinjector for subcutaneous administration. ———————————————————————————————————————————————————————————— Matvæla- og lyfjastofnun Bandaríkjanna (FDA) tekur til afgreiðslu umsókn Alvotech um markaðsleyfi fyrir fyrirhugaða hliðstæðu við Entyvio í sprautu eða lyfjapenna 2026-08-31 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/31/3353084/0/is/matv%C3%A6la-og-lyfjastofnun-bandar%C3%ADkjanna-fda-tekur-til-afgrei%C3%B0slu-ums%C3%B3kn-alvotech-um-marka%C3%B0sleyfi-fyrir-fyrirhuga%C3%B0a-hli%C3%B0st%C3%A6%C3%B0u-vi%C3%B0-entyvio-%C3%AD-sprautu-e%C3%B0a-lyfjapenna.html REYKJAVÍK (31. ágúst 2026) – Alvotech (NASDAQ: ALVO, ALVO SDB) tilkynnti í dag að Matvæla- og lyfjastofnun Bandaríkjanna (FDA) hefði tekið til afgreiðslu umsókn um markaðsleyfi í Bandaríkjunum fyrir AVT80, fyrirhugaða hliðstæðu með útskiptileika við Entyivo (vedolizumab) í áfylltri sprautu eða lyfjapenna. ———————————————————————————————————————————————————————————— National #VoteLikeHealth Campaign to Put Healthcare at Center of Midterm Elections 2026-08-31 · PRWeb · Healthcare https://www.prweb.com/releases/national-votelikehealth-campaign-to-put-healthcare-at-center-of-midterm-elections-302863277.html Community Catalyst, the nation's leading health advocacy organization, this morning launched its Vote Like Your Health Depends On It campaign (#VoteLikeHealth) ahead of the midterm elections in November. BOSTON, Aug. 31, 2026 /PRNewswire-PRWeb/ -- Community Catalyst, the nation's leading... ———————————————————————————————————————————————————————————— Why the Pharma HUB And Patient Access Support Service Market Is at an Inflection Point 2026-08-31 · Express Press Release · Healthcare https://express-press-release.net/news/2026/08/31/1769824 Patient support hubs have quietly become one of the most strategically important — and most contested — functions in pharmaceutical commercialization. For years, the model [read full press release...] ———————————————————————————————————————————————————————————— BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea 2026-08-31 · mlpr-prnewswire-wire · Finance, Healthcare https://www.prnewswire.com/news-releases/biomarin-announces-global-settlement-with-ascendis-pharma-as-ascendis-will-pay-royalties-to-biomarin-on-yuviwel-sales-in-us-eu-brazil-and-south-korea-302864555.html Agreement Resolves all Pending Patent-Related Proceedings Between BioMarin and Ascendis SAN RAFAEL, Calif., Aug. 30, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that it has entered into binding terms with Ascendis Pharma A/S, resolving the patent and... ———————————————————————————————————————————————————————————— HUAWEI WATCH D3 Makes Early Debut at ESC Congress 2026: A New Era in Wrist-Based Blood Pressure Management 2026-08-31 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/huawei-watch-d3-makes-early-debut-at-esc-congress-2026-a-new-era-in-wrist-based-blood-pressure-management-302864640.html MUNICH, Aug. 31, 2026 /PRNewswire/ -- The European Society of Cardiology Congress (ESC Congress 2026), one of the world's most influential academic gatherings in cardiovascular medicine, officially kicked off today in Munich, Germany. Huawei showcased its latest innovations in health and... ———————————————————————————————————————————————————————————— SpeedyIndex Brings AI Agents to Link Building: Donor Domains to Be Scored by Long-Term Indexing Health 2026-08-31 · PRWeb · AI, Healthcare https://www.prweb.com/releases/speedyindex-brings-ai-agents-to-link-building-donor-domains-to-be-scored-by-long-term-indexing-health-302864590.html An AI Consultant in the SpeedyIndex dashboard handled 57% of support requests in its first week. Next up, in Q4 2026: AI agents that rate donor domains by how Google has indexed them over months, quarters and years VANTAA, Finland and HELSINKI, Aug. 30, 2026 /PRNewswire-PRWeb/ --... ———————————————————————————————————————————————————————————— HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China 2026-08-31 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/31/3353003/0/en/hutchmed-announces-sanovo-trial-demonstrated-significant-progression-free-survival-benefit-of-orpathys-plus-tagrisso-in-treatment-na%C3%AFve-patients-with-met-overexpressing-egfr-mutate.html Findings build on the established success of the global SAFFRON and China SACHI trials, extending the clinical value of the all-oral combination into the first-line setting Findings build on the established success of the global SAFFRON and China SACHI trials, extending the clinical value of the all-oral combination into the first-line setting ———————————————————————————————————————————————————————————— Class Action Lawsuit Filed Against Fractyl Health, Inc. (GUTS) – Recover ... 2026-08-30 · PR-Inside · Finance, Healthcare https://pr-inside.com/class-action-lawsuit-filed-against-fractyl-health-inc-guts-recover-r5217695.htm (PR-inside.com) NEW YORK, NY / ACCESS Newswire / August 30, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Fractyl Health, Inc. (NASDAQ:GUTS) securities. If you suffered a loss on your Fractyl Health, Inc. investment and would like to explore a potential recovery under the federal securities laws, Learn about Fractyl Health, Inc. Class Action or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit was filed against .. ———————————————————————————————————————————————————————————— Pomerantz LLP Brings Class Action Against Fractyl Health, Inc. – GUTS 2026-08-30 · PR-Inside · Finance, Healthcare https://pr-inside.com/pomerantz-llp-brings-class-action-against-fractyl-health-inc-guts-r5217663.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 30, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Fractyl Health, Inc. ("Fractyl" or the "Company") (NASDAQ:GUTS) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 26-cv-07167, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fractyl securities between January 13, 2025 and January 29, 2026, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations .. ———————————————————————————————————————————————————————————— Foodsane. The Compassion led alternative to diet culture. 2026-08-30 · Pressat · Healthcare https://pressat.co.uk/releases/foodsane-the-compassion-led-alternative-to-diet-culture-48564cab8e6c7c2050146b353bb58dfa/ Sunday 30 August, 2026 Chartered Psychologist/Senior Accredited Psychotherapist Launches Foodsane: A Compassion-Led Alternative to Diet Culture Devon, UK. Dr Joanna North, Chartered Researching Psychologist, Fellow of the British Psychological Society, and Senior Accredited Psychotherapist, has launched Foodsane, a psychology-based wellness community offering a "middle way" between diet culture, weight loss medication and disordered eating. (www.foodsane.co.uk). Drawing on more than forty years of clinical practice, Dr North developed the RAFT framework: Right Amount, Right Food, Right Time and the accompanying concept of Time Related Eating (TRE), both grounded in nervous-system regulation, interoception (body awareness), and self-compassion rather than restriction or willpower. The initi ———————————————————————————————————————————————————————————— Hims & Hers Health, Inc. (HIMS) Investigation: Bronstein, Gewirtz & ... 2026-08-30 · PR-Inside · Finance, Healthcare https://pr-inside.com/hims-hers-health-inc-hims-investigation-bronstein-gewirtz-r5217596.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 30, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Hims & Hers Health, Inc. ("Hims" or "the Company") (NYSE:HIMS). Investors who purchased Hims securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/cases/hims-hers-health-inc-hims-class_action_lawsuit. Hims Investigation Details On July 29, 2026, the Federal Trade Commission ("FTC") filed a lawsuit against Hims, accusing it of sharing customers' medical information with third-party advertisers. The FTC's criminal complaint accuses Hims of "deceptive and unlawful privacy practices," including sharing sensitive details about patient .. ———————————————————————————————————————————————————————————— Securities Lawsuit Alert: Fractyl Health, Inc. (GUTS) – Contact Levi ... 2026-08-30 · PR-Inside · Finance, Healthcare https://pr-inside.com/securities-lawsuit-alert-fractyl-health-inc-guts-contact-levi-r5217546.htm (PR-inside.com) NEW YORK, NY / ACCESS Newswire / August 30, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Fractyl Health, Inc. (NASDAQ:GUTS) securities. If you suffered a loss on your Fractyl Health, Inc. investment and would like to explore a potential recovery under the federal securities laws, Learn about Fractyl Health, Inc. Class Action or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit was filed against .. ———————————————————————————————————————————————————————————— Pomerantz LLP Announces Securities Class Action Against Fractyl Health, ... 2026-08-30 · PR-Inside · Finance, Healthcare https://pr-inside.com/pomerantz-llp-announces-securities-class-action-against-fractyl-health-r5217509.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 30, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Fractyl Health, Inc. ("Fractyl" or the "Company") (NASDAQ:GUTS) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 26-cv-07167, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fractyl securities between January 13, 2025 and January 29, 2026, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations .. ———————————————————————————————————————————————————————————— Intermountain Health Experts Explain ACOG Guidelines for Immunizations for Pregnant Women 2026-08-30 · PRUnderground · Healthcare https://prunderground.com/intermountain-health-experts-explain-acog-guidelines-for-immunizations-for-pregn/cmtd3mxku000n04ihl6fy28yh New immunizations guidelines for pregnant women help protect moms and babies from common preventable diseases The post Intermountain Health Experts Explain ACOG Guidelines for Immunizations for Pregnant Women first appeared on ———————————————————————————————————————————————————————————— Faith Rooted Author Releases Seven Book Library Built Around One Conviction: Identity Precedes Everything 2026-08-30 · PR.com · Healthcare https://www.pr.com/press-release/969718 Caleb Colona completes the Dig Deep Foundations Series with works spanning fiction, parable, health, finance, and identity all organized around the RESET, BUILD, RISE framework. [PR.com] ———————————————————————————————————————————————————————————— Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings 2026-08-30 · mlpr-businesswire · Finance, Healthcare https://finance.yahoo.com/healthcare/articles/alnylam-presents-data-esc-congress-122300504.html CAMBRIDGE, Mass., August 30, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. ———————————————————————————————————————————————————————————— Aeitto Launches the EasePress Max6, a Filter-Free Slow Juicer That Rinses Clean Without a Brush 2026-08-30 · PR.com · Healthcare, Retail https://www.pr.com/press-release/972578 Aeitto, a user-centric kitchen appliance brand serving health-focused households across North America, today unveiled its new Max6 Slow Juicer, centered on a revolutionary filter-free design that solves the biggest consumer headache: tedious, brush-dependent cleanup after juicing. [PR.com] ———————————————————————————————————————————————————————————— Bayer Announces Phase III REVEAL Study with Investigational PET Radiotracer Iodine 124 Evuzamitide Presented as Late-Breaker at ESC 2026 2026-08-30 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/bayer-announces-phase-iii-reveal-114500219.html WHIPPANY, N.J., August 30, 2026--Bayer today announced the presentation of first detailed results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital, that evaluated the investigational positron emission tomography (PET) radiotracer iodine 124 evuzamitide (I 124 evuzamitide) for the diagnosis of cardiac amyloidosis.1 The pivotal study met its primary endpoints in the assessment of sensitivity and specificity for the diagnosis of cardiac amyloidosis ba ———————————————————————————————————————————————————————————— Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management 2026-08-30 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/ascletis-announces-first-participant-dosed-in-a-global-phase-iii-clinical-program-of-once-daily-oral-small-molecule-glp-1-receptor-agonist-asc30-for-chronic-weight-management-302864376.html - Expected to enroll approximately 4,600 participants with obesity or overweight across two pivotal trials (AURORA-1 and AURORA-2) in the U.S., Europe, and Canada. - Global Phase III clinical program to investigate efficacy and safety of three maintenance doses (20 mg, 40 mg, and 60 mg)... ———————————————————————————————————————————————————————————— INTCO Medical annonce une croissance de 40,6% de son chiffre d'affaires au premier semestre 2026 et porte à 107 milliards d'unités sa capacité de production de gants jetables, la plus importante au monde 2026-08-30 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/intco-medical-annonce-une-croissance-de-40-6-de-son-chiffre-daffaires-au-premier-semestre-2026-et-porte-a-107-milliards-dunites-sa-capacite-de-production-de-gants-jetables-la-plus-importante-au-monde-302864362.html ZIBO, Chine, 30 août 2026 /PRNewswire/ -- INTCO Medical (la « société », 300677.SZ), l'un des principaux fabricants mondiaux de gants jetables, annonce un chiffre d'affaires de 6,91 milliards RMB (environ 1,03 milliard USD) pour le semestre clos le 30 juin 2026, soit une hausse de 40,61%... ———————————————————————————————————————————————————————————— INTCO Medical meldet für das erste Halbjahr 2026 ein Umsatzwachstum von 40,6 % und baut die weltweit größte Produktionskapazität für Einweghandschuhe auf 107 Milliarden Stück aus 2026-08-30 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/intco-medical-meldet-fur-das-erste-halbjahr-2026-ein-umsatzwachstum-von-40-6--und-baut-die-weltweit-groWte-produktionskapazitat-fur-einweghandschuhe-auf-107-milliarden-stuck-aus-302864357.html ZIBO, China, 30. August 2026 /PRNewswire/ -- INTCO Medical („das Unternehmen", 300677.SZ), ein weltweit führender Hersteller von Einweghandschuhen, meldete für die sechs Monate bis zum 30. Juni 2026 einen Umsatz von 6,91 Mrd. RMB (ca. 1,03 Mrd. US-Dollar), ein Plus von 40,61 % gegenüber... ———————————————————————————————————————————————————————————— INTCO Medical rapporteert omzetgroei van 40,6% in de eerste helft van 2026, breidt de grootste wegwerphandschoenencapaciteit ter wereld uit tot 107 miljard stuks 2026-08-30 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/intco-medical-rapporteert-omzetgroei-van-40-6-in-de-eerste-helft-van-2026--breidt-de-grootste-wegwerphandschoenencapaciteit-ter-wereld-uit-tot-107-miljard-stuks-302864348.html ZIBO, China, 30 augustus 2026 /PRNewswire/ -- INTCO Medical ("het bedrijf", 300677.SZ), een toonaangevende wereldwijde fabrikant van wegwerphandschoenen, rapporteerde een omzet van RMB 6,91 miljard (ongeveer USD 1,03 miljard) voor het semester dat eindigt op 30 juni 2026, een stijging van... ———————————————————————————————————————————————————————————— Pomerantz LLP Announces The Filing of a Class Action Litigation Against ... 2026-08-29 · PR-Inside · Finance, Healthcare https://pr-inside.com/pomerantz-llp-announces-the-filing-of-a-class-action-litigation-against-r5217402.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 29, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Fractyl Health, Inc. ("Fractyl" or the "Company") (NASDAQ:GUTS) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 26-cv-07167, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fractyl securities between January 13, 2025 and January 29, 2026, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations .. ———————————————————————————————————————————————————————————— Cunion Frames Its Wearable Health Ecosystem Around Five Health Benefits 2026-08-29 · mlpr-newsfile · Healthcare https://www.newsfilecorp.com/release/312026/Cunion-Frames-Its-Wearable-Health-Ecosystem-Around-Five-Health-Benefits San Diego, California--(Newsfile Corp. - August 29, 2026) - Most health technology can overwhelm users with constant notifications and dashboards, eventually causing them to disengage. In response to this challenge, Cunion is building an ecosystem around the premise that the healthiest device is the one that stays quiet until it has something worth saying. From this approach, Cunion identifies five practical health benefits across its wearable ecosystem.To view an enhanced version of this... ———————————————————————————————————————————————————————————— Women Leaders Association Adds Lisa Reilly as Boston Coaching Partner, Bringing 23 Years of Biotech Leadership and Her Reclamation Method to High-Achieving Women 2026-08-29 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/women-leaders-association-adds-lisa-reilly-as-boston-coaching-partner-bringing-23-years-of-biotech-leadership-and-her-reclamation-method-to-high-achieving-women-302864321.html The association's Boston Coaching Partners roster grows to three — adding an executive and career coach who helps high-performing women lead with clarity, confidence, and authenticity without sacrificing themselves in the process BOSTON, Aug. 29, 2026 /PRNewswire/ -- The Women Leaders... ———————————————————————————————————————————————————————————— Dr. Anita Narang Recognized Among Victoria's Top Optometrists While Advancing the Future of Eye Care 2026-08-29 · PRUnderground · Healthcare https://prunderground.com/dr-anita-narang-recognized-among-victoria-s-top-optometrists-while-advancing-the/cmtdylx5j00000akck2eie5rb The post Dr. Anita Narang Recognized Among Victoria's Top Optometrists While Advancing the Future of Eye Care first appeared on ———————————————————————————————————————————————————————————— Pomerantz LLP Announces Commencement of Class Action Litigation Against ... 2026-08-29 · PR-Inside · Finance, Healthcare https://pr-inside.com/pomerantz-llp-announces-commencement-of-class-action-litigation-against-r5217355.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 29, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Fractyl Health, Inc. ("Fractyl" or the "Company") (NASDAQ:GUTS) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 26-cv-07167, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fractyl securities between January 13, 2025 and January 29, 2026, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations .. ———————————————————————————————————————————————————————————— Meant Earns LegitScript Certification for Its Online GLP-1 Weight Care Platform 2026-08-29 · PR Newswire · SaaS, Healthcare https://www.prnewswire.com/news-releases/meant-earns-legitscript-certification-for-its-online-glp-1-weight-care-platform-302852709.html MANASSAS, Va., Aug. 29, 2026 /PRNewswire/ -- Meant has earned LegitScript certification for its online GLP-1 weight-care platform, a step that reinforces the transparency behind how the service connects patients with licensed U.S. clinical oversight, private Care Coach support and ongoing... ———————————————————————————————————————————————————————————— Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026 2026-08-29 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/29/3352934/35409/en/cytokinetics-announces-additional-results-from-acacia-hcm-and-maple-hcm-presented-in-late-breaking-clinical-trial-session-at-the-european-society-of-cardiology-esc-congress-2026.html Additional Results from ACACIA-HCM Demonstrate Improvements in Cardiac Structure and Diastolic Function in Patients with Non-Obstructive HCM ———————————————————————————————————————————————————————————— Bionic Bloom Integrated Health Welcomes Kathryn Silver, MA, RMHCI as New Art Therapy Provider 2026-08-29 · Newswire.com · Healthcare https://www.newswire.com/news/bionic-bloom-integrated-health-welcomes-kathryn-silver-ma-rmhci-as-new-art Experienced art therapist expands access to creative, trauma-informed care for adults, adolescents and families ———————————————————————————————————————————————————————————— INTCO Medical Reports 40.6% H1 2026 Revenue Growth, Expands World's Largest Disposable Glove Capacity to 107 Billion Pieces 2026-08-29 · PRWeb · Finance, Healthcare https://www.prweb.com/releases/intco-medical-reports-40-6-h1-2026-revenue-growth-expands-worlds-largest-disposable-glove-capacity-to-107-billion-pieces-302863234.html ZIBO, China, Aug. 29, 2026 /PRNewswire/ -- INTCO Medical ("the Company", 300677.SZ), a leading global manufacturer of disposable gloves, reported revenue of RMB 6.91 billion (approx. US$1.03 billion) for the six months ended June 30, 2026, up 40.61% from a year earlier. Net profit... ———————————————————————————————————————————————————————————— Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera 2026-08-29 · Newswire.com · Healthcare https://www.newswire.com/news/protagonist-therapeutics-announces-u-s-fda-approval-of-hepcidin-mimetic-peptide MIMRYLO ™ is the First and Only Hepcidin Mimetic Peptide Therapy Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera, Offering a Novel Mechanism to Maintain Hematocrit Control, Meaningfully Reduce Phlebotomy Burden, and Improve Fatigue Approval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Response During Weeks 20-32 FDA Approval Triggers $275M in Milestones, 14%-29% Royalties, with Up to an Additional $875M in Potential Future Milestones Investor call to be held Monday, August 31st at 8:30 am ET ———————————————————————————————————————————————————————————— Astellas Becomes Host City Partner for One Young World 2027 Tokyo Summit 2026-08-28 · WebWire · Healthcare https://www.webwire.com/ViewPressRel.asp?aId=359715 Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that it has become the first Host City Partner for the One Young World 2027 Tokyo Summit (“the Summit”), the world's largest gatherings of young leaders. - - The Summit is scheduled to take place at the Tokyo International Forum from September 28 to October 1, 2027, with more than 2,000 young leaders from over 190 countries expected to attend. Delegates will discuss global social, environmental... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=359715 ———————————————————————————————————————————————————————————— Visit to Taiwan Civil Aeronautics Administration (CAA)to Exchange Views on Type Certificationand the Commercial Deployment of eVTOL 2026-08-28 · WebWire · Healthcare, Education https://www.webwire.com/ViewPressRel.asp?aId=359713 SkyDrive held a discussion with the Taiwan Civil Aeronautics Administration (CAA), joined by its Taiwanese business partner, 7A Drones, as well as the Industrial Technology Research Institute (ITRI), a premier research organization in Taiwan. - - Together with ITRI and 7A Drones, SkyDrive is working to establish a public-private partnership framework and introduce an eVTOL emergency medical transport model in Taiwan's Penghu Islands (*1). - - In the course of this visit, discussions were hel... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=359713 ———————————————————————————————————————————————————————————— FedEx Passes Milestone in CEIV Pharma Certifications 2026-08-28 · WebWire · Finance, Healthcare https://www.webwire.com/ViewPressRel.asp?aId=359709 FedEx Corp. (NYSE: FDX) has achieved a major milestone in its healthcare logistics journey, securing 30 IATA CEIV Pharma certifications across its global air hubs and cargo handling facilities. This accomplishment positions FedEx among the top global transportation providers with one of the industry's largest networks recognized for excellence in pharmaceutical handling. This underscores a commitment to precision and quality and is a testament to the capabilities leveraged by FedEx Life S... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=359709 ———————————————————————————————————————————————————————————— Lobe Sciences Ltd. Announces Upsize to Non-Brokered Private Placement 2026-08-28 · PR-Inside · Healthcare https://pr-inside.com/lobe-sciences-ltd-announces-upsize-to-non-brokered-private-placement-r5217288.htm (PR-inside.com) NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / August 28, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE), a clinical-stage biopharmaceutical company advancing therapeutic development programs through focused subsidiary companies, is pleased to announce an upsize to its previously announced non-brokered private placement offering of common shares in the capital of the Company ("CommonShares") at a price of $0.085 per Common Share (the "Private Placement"). The Company closed the first tranche of the Private Placement on August 19, 2026 (the "First Tranche") through the issuance of 24,705,880 for .. ———————————————————————————————————————————————————————————— Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera 2026-08-28 · mlpr-businesswire · Finance, Healthcare https://finance.yahoo.com/healthcare/articles/takeda-receives-u-fda-approval-224000959.html OSAKA, Japan & CAMBRIDGE, Mass., August 28, 2026--Takeda (TSE:4502/NYSE:TAK) announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. ———————————————————————————————————————————————————————————— California lawmakers pass bill to create landmark 'non-ultra-processed' food label 2026-08-28 · WebWire · Healthcare https://www.webwire.com/ViewPressRel.asp?aId=359695 Today the California Legislature took a major step toward protecting public health by passing a first-of-its-kind bill to create a certified “non-ultra-processed” food label intended to make it easier for consumers to choose less-processed foods in the grocery store. - - Assembly Bill 2244, authored by Assemblymember Jesse Gabriel (D-Encino ), would develop a state certification program for products that are not ultra-processed, or UPF. If enacted, it would create a new standardized and go... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=359695 ———————————————————————————————————————————————————————————— Class Action Lawsuit Alert: Levi & Korsinsky Reminds Fractyl Health, ... 2026-08-28 · PR-Inside · Finance, Healthcare https://pr-inside.com/class-action-lawsuit-alert-levi-korsinsky-reminds-fractyl-health-r5217283.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 28, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Fractyl Health, Inc. (NASDAQ:GUTS) securities. If you suffered a loss on your Fractyl Health, Inc. investment and would like to explore a potential recovery under the federal securities laws, Learn about Fractyl Health, Inc. Class Action or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit was filed .. ———————————————————————————————————————————————————————————— Global pharmacy leaders identify priorities for integrating pharmacists into primary health care 2026-08-28 · PR Newswire · Finance, SaaS, Healthcare https://www.prnewswire.com/news-releases/global-pharmacy-leaders-identify-priorities-for-integrating-pharmacists-into-primary-health-care-302863186.html MONTRÉAL, Aug. 28, 2026 /PRNewswire/ -- Pharmacy leaders, invited from around the world, gathered in Montréal today for an international forum on advancing pharmacists' integration into primary health care, where they identified workforce readiness, sustainable funding models, supportive... ———————————————————————————————————————————————————————————— Second meeting of the IHR Emergency Committee on the epidemic of Ebola Bundibugyo virus disease in the Democratic Republic of the Congo – Meeting report 2026-08-28 · WebWire · Healthcare https://www.webwire.com/ViewPressRel.asp?aId=359686 The Director-General (DG) of the World Health Organization (WHO) is hereby transmitting the report of the second meeting of the International Health Regulations (2005) ( IHR ) Emergency Committee (Committee) regarding the epidemic of Ebola disease caused by Bundibugyo virus (BVD) in the Democratic Republic of the Congo (DRC), held on Tuesday, 18 August 2026, from 12:00 to 17:00 CEST. - - The DG welcomes the Statement by the Committee, presented at the beginning of its report, and expresse... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=359686 ———————————————————————————————————————————————————————————— Innolitics and BEACON-Neuro.AI Partner to Bring FDA Breakthrough Device BEACONPredict to Market 2026-08-28 · mlpr-businesswire · AI, Healthcare, Education https://finance.yahoo.com/healthcare/articles/innolitics-beacon-neuro-ai-partner-221700178.html SAN FRANCISCO, August 28, 2026--Innolitics, a medical-device software and FDA regulatory services provider, and BEACON-Neuro.AI Inc., a Washington University in St. Louis startup, today announced the partnership behind BEACONPredict, AI software for predicting malignant cerebral edema risk after acute ischemic stroke. Innolitics brought the regulatory strategy and software engineering; BEACON-Neuro.AI brought the clinical science out of Dr. ———————————————————————————————————————————————————————————— Pomerantz LLP Announces The Filing of a Class Action Lawsuit Against ... 2026-08-28 · PR-Inside · Finance, Healthcare https://pr-inside.com/pomerantz-llp-announces-the-filing-of-a-class-action-lawsuit-against-r5217265.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 28, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Fractyl Health, Inc. ("Fractyl" or the "Company") (NASDAQ:GUTS) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 26-cv-07167, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fractyl securities between January 13, 2025 and January 29, 2026, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations .. ———————————————————————————————————————————————————————————— Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update 2026-08-28 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/28/3352900/8624/en/trinity-biotech-provides-diagnostics-business-transformation-and-corporate-update.html - Continued execution of transformation strategy drives commercial, manufacturing and pipeline progress ———————————————————————————————————————————————————————————— Novanta to Present at Baird Global Healthcare Conference on Tuesday, September 15, 2026 2026-08-28 · mlpr-businesswire · Finance, Healthcare https://finance.yahoo.com/healthcare/articles/novanta-present-baird-global-healthcare-210000225.html BOSTON, August 28, 2026--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, and John Lesica, Chief Operating Officer of Medical Solutions, are scheduled to present at the Baird Global Healthcare Conference on Tuesday, September 15, 2026, in New York, NY. ———————————————————————————————————————————————————————————— Theralase(R) Releases Q2 2026 Financial Statements 2026-08-28 · mlpr-newsfile · Healthcare, Energy https://www.newsfilecorp.com/release/311984/TheralaseR-Releases-Q2-2026-Financial-Statements Toronto, Ontario--(Newsfile Corp. - August 28, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical-stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancers, bacteria and viruses, has released the Company's unaudited interim consolidated financial statements for the six-month period ended June 30th, 2026 ("Financial... ———————————————————————————————————————————————————————————— Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update 2026-08-28 · GlobeNewswire · Finance, SaaS, Healthcare https://www.globenewswire.com/news-release/2026/08/28/3352888/0/en/oragenics-reports-continued-clinical-progress-provides-regulatory-and-nyse-american-listing-update.html SARASOTA, Fla., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company developing brain-targeted therapeutics through its proprietary intranasal delivery platform, today provided an update on its Phase IIa clinical trial, U.S. regulatory pathway, and NYSE American continued listing status. ———————————————————————————————————————————————————————————— Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2026 2026-08-28 · PR Newswire · Finance, Healthcare https://www.prnewswire.com/news-releases/zimmer-biomet-announces-quarterly-dividend-for-third-quarter-of-2026-302863013.html WARSAW, Ind., Aug. 28, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2026. The cash... ———————————————————————————————————————————————————————————— Armor Health Establishes Dedicated Client Relations Executive Providing Leadership to Strengthen Partnerships and Support Continued Expansion 2026-08-28 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/armor-health-establishes-dedicated-client-relations-executive-providing-leadership-to-strengthen-partnerships-and-support-continued-expansion-302863137.html MIAMI, Aug. 28, 2026 /PRNewswire/ -- Armor Health (ArmorHealthcare.com), a national provider of correctional healthcare, has named Tamara Taylor, RN, CCHP the Regional Vice President of Client Relations, a newly created position focused on strengthening the company's partnerships with the... ———————————————————————————————————————————————————————————— Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 2026-08-28 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/28/3352881/33485/en/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html VANCOUVER, BC and BOSTON, MA, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to five new non-officer employees consisting of an aggregate of 13,450 share options and 7,850 restricted share units (RSUs). All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of August 27, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). ———————————————————————————————————————————————————————————— Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons 2026-08-28 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/08/28/3352878/0/en/transactions-in-zealand-pharma-shares-and-or-related-securities-by-persons-discharging-managerial-responsibilities-and-or-their-closely-associated-persons.html Company announcement – No. 43 / 2026 ———————————————————————————————————————————————————————————— ExpressRx Launches Medication Safety Initiative with DisposeRx Singles in All 26 Retail Locations 2026-08-28 · PR Newswire · Healthcare, Retail, Education https://www.prnewswire.com/news-releases/expressrx-launches-medication-safety-initiative-with-disposerx-singles-in-all-26-retail-locations-302863125.html New program combines patient education with affordable, in-home medication disposal to help reduce the risks of unused medications in the home. SOUTHERN PINES, N.C., Aug. 28, 2026 /PRNewswire/ -- DisposeRx®, the leader of in-home medication disposal, today announced a new partnership with... ———————————————————————————————————————————————————————————— SS Innovations International (SSII) Indian Surgical Robotics Growth Points to Broader Market Opportunity 2026-08-28 · NewMediaWire · Finance, Healthcare, Retail https://www.newmediawire.com/news/ss-innovations-international-ssii-indian-surgical-robotics-growth-points-to-broader-market-opportunity-7089037 SS Innovation’s SSi Mantra system was used in more than 50 robotic surgeries in a single day at Mohak Bariatrics and Robotics in Indore, highlighting growing clinical utilization in India. The milestone comes as SS Innovations reports 224 SSi Mantra systems installed across 12 countries, providing a growing installed base for future procedure and instrument revenue. Second-quarter 2026 installations reached 30 systems, above the 25 systems modeled by the analyst cited in the supplied report. Quarterly revenue reached $13.9 million, up 39% year over year, while system sales increased 41% to $12.4 million. FDA review of the SSi Mantra 510(k) application is now expected by the end of the first quarter of 2027, while European CE marking remains targeted for the end of 2026. The company’s progr ———————————————————————————————————————————————————————————— U.S. Food and Drug Administration Authorizes Juul Labs' Next Generation JUUL2 System 2026-08-28 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/us-food-and-drug-administration-authorizes-juul-labs-next-generation-juul2-system-302863088.html FDA determines JUUL2 System meets statutory standard of being "appropriate for the protection of public health" JUUL2 System incorporates a suite of innovative technology to better serve adults who smoke WASHINGTON, Aug. 28, 2026 /PRNewswire/ -- Yesterday, the U.S. Food and Drug... ———————————————————————————————————————————————————————————— U.S. FDA Leadership from Three Centers and OII Headline the Center Office Updates Session of the 2026 PDA/FDA Joint Regulatory Conference 2026-08-28 · PRWeb · Healthcare https://www.prweb.com/releases/us-fda-leadership-from-three-centers-and-oii-headline-the-center-office-updates-session-of-the-2026-pdafda-joint-regulatory-conference-302862992.html PDA announced today that senior leaders from the FDA's centers for drugs, biologics and veterinary medicine as well as the Office of Inspections and Investigations will participate in the plenary on Monday, Sept. 14, as part of the 2026 PDA/FDA Joint Regulatory Conference in Washington, D.... ———————————————————————————————————————————————————————————— VERAXA Biotech (VRXA), Secarna Partnership Milestone Opens New Potential Market for Conjugation Technology 2026-08-28 · NewMediaWire · Healthcare, Retail https://www.newmediawire.com/news/veraxa-biotech-vrxa-secarna-partnership-milestone-opens-new-potential-market-for-conjugation-technology-7089036 VERAXA Biotech and Secarna Pharmaceuticals have reported an initial in vitro proof of concept for an antibody oligonucleotide conjugate (“AOC”) developed through their research alliance. The AOC candidate demonstrated greater potency than the equivalent unconjugated oligonucleotide in early testing, providing a first experimental validation of the collaboration. AOCs are an emerging class of antibody-guided therapies designed to use an antibody to deliver therapeutic oligonucleotides selectively to disease-relevant cells. VERAXA contributes antibody conjugation expertise and proprietary click chemistry, allowing it to participate in AOCs without shifting its core oncology strategy. The collaboration adds to VERAXA’s growing partnering track record, which also includes its bispecific ADC di ———————————————————————————————————————————————————————————— 10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences 2026-08-28 · PR Newswire · Finance, Healthcare https://www.prnewswire.com/news-releases/10x-genomics-wins-patent-infringement-verdict-against-parse-biosciences-302863074.html Jury finds Parse willfully infringed Scale Biosciences' patents and rejects Parse's invalidity challenge PLEASANTON, Calif., Aug. 28, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today... ———————————————————————————————————————————————————————————— Regenerative Hydrogel Is Redefining Cartilage Repair as Regentis Advances GelrinC 2026-08-28 · NewMediaWire · Healthcare, Retail https://www.newmediawire.com/news/regenerative-hydrogel-is-redefining-cartilage-repair-as-regentis-advances-gelrinc-7089035 Researchers are developing new regenerative approaches, including stem cells, 3D-printed scaffolds and smart biomaterials designed to help the body repair damaged tissue. Focused on smart biomaterials, Regentis is advancing a hydrogel-based approach through GelrinC, a cell-free, off-the-shelf implant designed to support the regeneration of damaged knee cartilage. With encouraging clinical results, European approval and an ongoing U.S. pivotal trial, GelrinC is advancing toward a potential new approach to cartilage repair. LOS ANGELES, CA - August 28, 2026 ( NEWMEDIAWIRE ) - Regenerative medicine is increasingly focused on a simple but ambitious goal: rather than simply treating damaged tissue, can medicine help the body rebuild it? One company pursuing a regenerative approach is Regentis B ———————————————————————————————————————————————————————————— AM Best Affirms Credit Ratings of UnitedHealth Group Incorporated and Its Subsidiaries 2026-08-28 · mlpr-businesswire · Finance, Healthcare https://finance.yahoo.com/healthcare/articles/am-best-affirms-credit-ratings-182700862.html OLDWICK, N.J., August 28, 2026--AM Best has affirmed the Long-Term Issuer Credit Rating (Long-Term ICR) of "a-" (Excellent) and the Long and Short-Term Issue Credit Ratings (Long-Term IR; Short-Term IR) of UnitedHealth Group Incorporated (UnitedHealth Group) (Minnetonka, MN) [NYSE: UNH]. Concurrently AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term ICRs of "a+" (Excellent) of the health and dental insurance subsidiaries of UnitedHealth Group, collective ———————————————————————————————————————————————————————————— Dr. Steven Shannon Scholarship Opens Applications for Undergraduate Students Pursuing Careers in Medicine 2026-08-28 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/dr-steven-shannon-scholarship-opens-applications-for-undergraduate-students-pursuing-careers-in-medicine-302863061.html LINCOLN, Neb., Aug. 28, 2026 /PRNewswire/ -- The Dr. Steven Shannon Scholarship for Medical Students is accepting applications from undergraduate students across the United States who are preparing for careers in medicine and related healthcare fields. The one-time scholarship opportunity... ———————————————————————————————————————————————————————————— ByHeart Update: FDA Confirms Review of ByHeart's Root Cause Investigation and Action Plan, Following Completion of Facility Inspections 2026-08-28 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/byheart-update-fda-confirms-review-of-byhearts-root-cause-investigation-and-action-plan-following-completion-of-facility-inspections-302863037.html FDA found no factors that could explain the cause of the outbreak in ByHeart facilities FDA responded with no further questions on ByHeart's investigation and Action Plan ByHeart introduces new C. botulinum testing protocols 1000x more sensitive than the standard industry test methodology... ———————————————————————————————————————————————————————————— Sense Neuro Diagnostics Appoints Scott D. Wampler as Chief Executive Officer 2026-08-28 · PR Newswire · SaaS, Healthcare https://www.prnewswire.com/news-releases/sense-neuro-diagnostics-appoints-scott-d-wampler-as-chief-executive-officer-302863030.html Experienced medical device executive to lead the company through its next phase of clinical, regulatory and strategic development CINCINNATI, Aug. 28, 2026 /PRNewswire/ -- Sense Neuro Diagnostics, a medical technology company developing a novel, non-invasive platform designed to rapidly... ———————————————————————————————————————————————————————————— Class Action Filed Against Fractyl Health, Inc. (GUTS) Over Securities ... 2026-08-28 · PR-Inside · Finance, Healthcare https://pr-inside.com/class-action-filed-against-fractyl-health-inc-guts-over-securities-r5217199.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 28, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Fractyl Health, Inc. (NASDAQ:GUTS) securities. If you suffered a loss on your Fractyl Health, Inc. investment and would like to explore a potential recovery under the federal securities laws, Learn about Fractyl Health, Inc. Class Action or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit was filed .. ———————————————————————————————————————————————————————————— C5 Artist Foundation Presents Dance Divas October 10-11 2026-08-28 · PRWeb · Healthcare https://www.prweb.com/releases/c5-artist-foundation-presents-dance-divas-october-10-11-302861920.html Chicago's leading professional dancers return to The Rhapsody Theater stage for three unforgettable performances benefiting the Chicago Dance Health Fund CHICAGO, Aug. 28, 2026 /PRNewswire-PRWeb/ -- The C5 Artists Foundation, a non-profit organization established to support the Chicago... ———————————————————————————————————————————————————————————— Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ... 2026-08-28 · PR-Inside · Finance, Healthcare https://pr-inside.com/bronstein-gewirtz-grossman-llc-announces-an-investigation-against-r5217186.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 28, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Hims & Hers Health, Inc. ("Hims" or "the Company") (NYSE:HIMS). Investors who purchased Hims securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/cases/hims-hers-health-inc-hims-class_action_lawsuit. Hims Investigation Details On July 29, 2026, the Federal Trade Commission ("FTC") filed a lawsuit against Hims, accusing it of sharing customers' medical information with third-party advertisers. The FTC's criminal complaint accuses Hims of "deceptive and unlawful privacy practices," including sharing sensitive details about patient .. ———————————————————————————————————————————————————————————— Tampa General Hospital and Florida Orthopaedic Institute First in World to Use New EVOS Pelvic and Acetabular System 2026-08-28 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/tampa-general-hospital-and-florida-orthopaedic-institute-first-in-world-to-use-new-evos-pelvic-and-acetabular-system-302862998.html World-first procedure marks a significant advancement in the surgical treatment of complex pelvic trauma and underscores the power of academic medicine to bring innovations from development to the operating room. TAMPA, Fla., Aug. 28, 2026 /PRNewswire/ -- Tampa General Hospital and... ———————————————————————————————————————————————————————————— The Emily Program to Join Minnesota Mental Health Organizations at 2026 Minnesota State Fair 2026-08-28 · mlpr-businesswire · Finance, Healthcare, Education https://finance.yahoo.com/healthcare/articles/emily-program-join-minnesota-mental-165600595.html ST. PAUL, Minn., August 28, 2026--The Emily Program, a national leader in eating disorder treatment and recovery, will participate in the ninth annual Mental Health Awareness at the Minnesota State Fair on Monday, August 31, joining dozens of Minnesota mental health organizations to connect fairgoers with resources, education, and support. With one in nine Minnesotans experiencing an eating disorder in their lifetime, the organization aims to raise awareness, reduce stigma, and provide vital con ———————————————————————————————————————————————————————————— Hagens Berman Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to FDA Review Extension for Deramiocel Amid Ongoing Securities Class Action and September 28 Lead Plaintiff Deadline 2026-08-28 · PR Newswire · Finance, Healthcare https://www.prnewswire.com/news-releases/hagens-berman-alerts-capricor-therapeutics-inc-nasdaq-capr-investors-to-fda-review-extension-for-deramiocel-amid-ongoing-securities-class-action-and-september-28-lead-plaintiff-deadline-302862977.html SAN FRANCISCO, Aug. 28, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP—a national plaintiffs' rights law firm with a premier securities practice group—notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the upcoming September 28, 2026 lead plaintiff deadline in the... ———————————————————————————————————————————————————————————— Energy Efficiency and Cost Savings: Dryer Vent Wizard Blog Reveals How Dryer Vent Health Matters 2026-08-28 · PRUnderground · Healthcare, Energy https://prunderground.com/energy-efficiency-and-cost-savings-dryer-vent-wizard-blog-reveals-how-dryer-vent/cmtczw6g2000704i2acff48md Dryer Vent Cleaning is essential in both commercial and home dryer vent systems. Proper Installation is also key to dryer safety. The post Energy Efficiency and Cost Savings: Dryer Vent Wizard Blog Reveals How Dryer Vent Health Matters first appeared on ———————————————————————————————————————————————————————————— The brain health movement just got bigger with BrainHealth.com 2026-08-28 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/the-brain-health-movement-just-got-bigger-with-brainhealthcom-302862984.html American Academy of Neurology launches new public website MINNEAPOLIS, Aug. 28, 2026 /PRNewswire/ -- The American Academy of Neurology (AAN) has launched BrainHealth.com, a new public resource offering expert-reviewed information, tools and stories to help people improve and protect their... ———————————————————————————————————————————————————————————— LifeTech Scientific Corporation Announces 2026 Interim Results 2026-08-28 · PR Newswire · Finance, Healthcare https://www.prnewswire.com/news-releases/lifetech-scientific-corporation-announces-2026-interim-results-302862975.html HONG KONG, Aug. 28, 2026 /PRNewswire/ -- LifeTech Scientific Corporation ("LifeTech" or the "Company", together with its subsidiaries, the "Group", stock code: 1302.HK), a medical device company specializing in minimally invasive interventional solutions for cardio-cerebrovascular and... ———————————————————————————————————————————————————————————— Dr. Mark Huh of Rapha Dental Recognized by NJ Top Dentists for 2026 2026-08-28 · PR.com · Healthcare, Education https://www.pr.com/press-release/977608 Rapha Dental is pleased to announce that Dr. Mark Huh, DMD, has been reviewed and approved by NJ Top Dentists for 2026. Based in Cinnaminson, NJ, Dr. Huh provides family, cosmetic, implant, restorative, and emergency dental care with an emphasis on conservative treatment, patient education, and personalized care for patients throughout Burlington County. [PR.com] ———————————————————————————————————————————————————————————— Orsini to Serve as Specialty Pharmacy Partner for Priovant's LISRAYA™ (brepocitinib) 2026-08-28 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/orsini-to-serve-as-specialty-pharmacy-partner-for-priovants-lisraya-brepocitinib-302862937.html LISRAYA is the first FDA-approved targeted therapy for dermatomyositis. ELK GROVE VILLAGE, Ill., Aug. 28, 2026 /PRNewswire/ -- Orsini, a leader in rare disease pharmacy solutions, announced today that it is a specialty pharmacy partner for Priovant's LISRAYA™ (brepocitinib), a once-daily... ———————————————————————————————————————————————————————————— Mobile Healthcare Takes a Bigger Role in Rural Communities 2026-08-28 · PRWeb · Healthcare https://www.prweb.com/releases/mobile-healthcare-takes-a-bigger-role-in-rural-communities-302861352.html New national toolkit highlights how mobile healthcare can expand access in rural communities. COLUMBUS, Ohio, Aug. 28, 2026 /PRNewswire-PRWeb/ -- Mobile healthcare is gaining greater attention as hospitals, health systems and community organizations look for practical ways to bring care... ———————————————————————————————————————————————————————————— Intermountain Health Athletic Trainers Keep Kids Safe At High School Sports 2026-08-28 · PRUnderground · Healthcare, Education https://prunderground.com/intermountain-health-athletic-trainers-keep-kids-safe-at-high-school-sports/cmtd2msdc000m04l3q4b0unbe Intermountain Health athletic trainers at high schools across Utah will be monitoring athletes and helping coaches plan workouts and keeping kids safe from heat illness. The post Intermountain Health Athletic Trainers Keep Kids Safe At High School Sports first appeared on ———————————————————————————————————————————————————————————— Taking a BiTE Out of Cancer at Intermountain Health 2026-08-28 · PRUnderground · Healthcare https://prunderground.com/taking-a-bite-out-of-cancer-at-intermountain-health/cmtd1onlk000f04l2vs5nthze Bispecific T-cell Engager (BiTE) therapy through the Intermountain Health Oncology Clinical Program is Bringing Care Close to Home The post Taking a BiTE Out of Cancer at Intermountain Health first appeared on ———————————————————————————————————————————————————————————— /C O R R E C T I O N -- FlyteHealth/ 2026-08-28 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/flytehealth-achieves-general-availability-in-the-cms-health-technology-ecosystem-recognized-at-one-year-anniversary-event-in-washington-dc-302836748.html In the news release, FlyteHealth Achieves General Availability in the CMS Health Technology Ecosystem, Recognized at One-Year Anniversary Event in Washington, D.C., issued 28-Jul-2026 by FlyteHealth over PR Newswire, we are advised by the company that changes have been made. The complete,... ———————————————————————————————————————————————————————————— Vadzo Imaging Validates Dynamic ROI in the AR1335 13MP Monochrome M12 VCM USB Camera Falcon-1335MRH 2026-08-28 · Newswire.com · Healthcare, Retail https://www.newswire.com/news/vadzo-imaging-validates-dynamic-roi-in-the-ar1335-13mp-monochrome-m12-22852336 Vadzo Imaging has validated Dynamic ROI operation on the Falcon-1335MRH, a 13MP monochrome USB camera product built on the Onsemi AR1335 back-side-illuminated CMOS sensor. The module pairs rolling shutter readout with software-controlled VCM autofocus on M12 optics to deliver 4K low-noise imaging across a USB 3.2 Gen 1 UVC interface. It targets machine vision, inspection, medical, retail automation, and embedded vision programs where resolution, sensitivity, and variable working distance appear in the same requirement list. ———————————————————————————————————————————————————————————— Global Healthy Living Foundation Partners with RhAPP to Expand Polymyalgia Rheumatica Patient Education 2026-08-28 · mlpr-businesswire · Healthcare, Education https://finance.yahoo.com/healthcare/articles/global-healthy-living-foundation-partners-140000463.html UPPER NYACK, N.Y., August 28, 2026--GHLF and RhAPP partner for polymyalgia rheumatica education and support ———————————————————————————————————————————————————————————— AI Health Analysis Delivers Deep Health Insights in One Minute 2026-08-28 · PRWeb · AI, Healthcare https://www.prweb.com/releases/ai-health-analysis-delivers-deep-health-insights-in-one-minute-302862555.html **HealthRestore launches HealthySelfie, a new AI-powered health analysis delivering 20+ personalised health insights in approximately one minute. Using a smartphone as the interface, HealthySelfie gives users rapid access to detailed health intelligence, personalised food-response... ———————————————————————————————————————————————————————————— Dogtopia Marks Record First Half of 2026 with National Recognition for Innovation and Growth 2026-08-28 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/dogtopia-marks-record-first-half-of-2026-with-national-recognition-for-innovation-and-growth-302862422.html Leading Pet Wellness Franchise Celebrates Customer Loyalty and Continued Growth PHOENIX, Aug. 28, 2026 /PRNewswire/ -- Following a record first half of 2026, Dogtopia, the nation's leading pet wellness franchise, has earned two new national honors: a Health-Focused Product of the Year... ———————————————————————————————————————————————————————————— CIMC Group Announces 2026 Interim Results 2026-08-28 · mlpr-acnnewswire · Finance, AI, SaaS, Healthcare, Energy, Retail, Automotive https://www.acnnewswire.com/press-release/english/109593/ Financial Highlights RMB (million) 1H2025 1H2026 1Q2026 2Q2026 Quarter-on-Quarter Change Revenue 76,090 78,913 32,664 46,249 +42% Operating Profit 2,817 1,962 607 1,355 +123% Foreign Exchange Losses 47 803 228 574 The expanded loss is attributable to the expansion of business scale. Pre-FX Loss Operating Profit [1] 2,864 2,764 835 1,929 +131% Profit Before Income Tax 2,798 1,969 615 1,353 +120% Gross Profit 9,643 9,380 3,770 5,611 +49% Gross Profit Margin 12.67% 11.89% 11.54% 12.13% +0.6pct Net Profit 1,764 1,373 412 961 +133% Net Profit Attributable to Shareholders and Other Equity Holders of the Company [2] 1,278 740 209 531 +154% Notes: 1. Pre-FX Loss Operating Profit = Operating Profit + Foreign Exchange Losses 2. Net profit attributable to shareholders and other equity holders of the Company, with interest on perpetual bonds of approximately RMB47.8 million Results Highlights 1. Profitability of energy-related businesses continued to be released, with net profit increasing by RMB1.36 billion: The combined net profit of the offshore engineering segment and the finance and asset management segment (mainly drilling rig leasing) increased by approximately RMB1.339 billion, while that of the energy, chemical and liquid food equipment segment increased by RMB20 million. Among them, the gross profit margin of the offshore engineering segment increased by 10.1 percentage points year-on-year (“YoY”) to 20.9%, with net profit reaching RMB718 million, making it the Company’s largest profit-generating segment. The finance and asset management segment successfully turned losses into profits, with a net profit margin of 9.8%. As at the end of June, total orders on hand amounted to approximately RMB83.6 billion, with production schedules extending to 2030: orders on hand for the offshore engineering and energy, chemical and liquid food equipment segments amounted to US$7.62 billion and RMB31.77 billion, respectively. In particular, CIMC Raffles secured one FPSO and one FLNG EPCIC / EPC general contracting order during the year, making it the first offshore engineering enterprise in China with dual-project general contracting capabilities (EPCIC / EPC). Benefiting from rising demand for increased deepwater oil and gas production, new orders accelerated in the third quarter. 2. Double breakthroughs in modular data center deliveries and orders: The modular data center business recorded explosive growth, with revenue increasing by more than five times YoY. During the Reporting Period, new contracts were signed for 200MW of cloud computing and AI computing power data center projects. 3. Logistics-related businesses consolidated their industry positions, with demand bottoming out and recovering quarter-on-quarter: Core products including standard dry containers, reefer containers, chemical tank containers and semi-trailers maintained their global No. 1 positions. During the Reporting Period, the overall gross profit margin declined due to exchange rate fluctuations and pressure on demand, while demand for containers, road transportation vehicles, airport facilities and logistics equipment, and recycled load bottomed out and recovered quarter-on-quarter. 4. Interest expenses continued to be optimised, with a more robust financial structure: As at the end of Reporting Period, interest-bearing debt amounted to RMB34.8 billion, down RMB6.4 billion from the end of June 2025, with the interest-bearing debt ratio at approximately 20%. Benefiting from the optimisation of financing rates and scale, net interest expenses decreased by approximately RMB218 million YoY during the Reporting Period, and the financial structure continued to be optimised. HONG KONG, August 28, 2026 - (ACN Newswire) - China International Marine Containers (Group) Co., Ltd. (“CIMC Group” or the “Group”, stock code: 000039.SZ/02039.HK) is pleased to announce its unaudited interim results for the six months ended 30 June 2026 (the “Reporting Period”). The management of CIMC Group stated that in the first half of 2026, global changes unseen in a century accelerated, geopolitical conflicts reshaped the energy and trade landscape, while global merchandise trade demonstrated resilience amid fluctuations. Against a backdrop of opportunities and challenges, the Group closely followed the main business tone of “focusing on high-quality development and cultivating new growth drivers”, coordinated the reasonable growth of “quantity” and the effective improvement of “quality”, and, leveraging its diversified business portfolio and global operating platform, mitigated fluctuations in individual regions to achieve steady and high-quality development. In the first half of 2026, the Group achieved revenue of RMB78.9 billion and net profit of RMB1.37 billion, while net profit attributable to shareholders and other equity holders of the Company amounted to RMB740 million. During the Reporting Period, domestic revenue accounted for approximately 53.62%, while overseas revenue accounted for approximately 46.38%, maintaining a balanced market structure. To effectively safeguard shareholder value and convey confidence in long-term development, the Company repurchased H Shares amounting to approximately HKD173 million during the first half of 2026, with approximately 19.28 million H Shares repurchased in aggregate. As at the end of June, the Company had completed the implementation of its 2025 H Share repurchase plan. Meanwhile, to further enhance shareholder confidence, the Company announced in July 2026 its plan to repurchase a portion of its H Shares, with the total repurchase amount not exceeding HKD173 million. In respect of A Shares, the Company recently announced a proposal to change the use of the A Shares repurchased in 2023 and cancel such shares and reduce its registered capital, namely, to cancel the 24.65 million A Shares repurchased by the Company in 2023 and correspondingly reduce the registered capital of the Company, thereby adopting multiple measures to safeguard the interests of its investors. Segments Results (RMB million) 1H2026 Business Indicators Revenue % of Total Revenue Gross Profit % of Total Gross Profit Gross Profit Margin Net Profit Container manufacturing 21,920 27.78% 1,827 19.48% 8.34% 272 Road transportation vehicles 10,737 13.61% 1,551 16.53% 14.44% 356 Energy, chemical, and liquid food equipment 13,396 16.98% 1,962 20.92% 14.65% 480 Offshore engineering 7,935 10.06% 1,659 17.69% 20.91% 718 Airport facilities and logistics equipment, fire safety and rescue equipment 3,357 4.25% 706 7.52% 21.03% 71 Logistics services 13,945 17.67% 910 9.70% 6.53% 240 Finance and asset management 1,710 2.17% 287 3.06% 16.77% 167 The above major segments 72,999 92.52% 8,902 94.90% 12.19% 2,304 Core Business Performance 1. In the Logistics Field Container Manufacturing Business: During the Reporting Period, although global trade continued to face adverse factors such as high inflation and geopolitical frictions, the growth of global merchandise trade continued to maintain a certain degree of resilience. According to Container Trades Statistics, global container trade volume increased by approximately 5.2% YoY in the first half of 2026, mainly benefiting from the growth of trade related to the global technology industry. Meanwhile, the low efficiency of container shipping caused by the blockage of the Strait of Hormuz, disruption to the resumption of shipping routes in the Red Sea and port congestion supported demand for containers. During the Reporting Period, the growth in demand for container shipping together with the replacement and renewal requirements for the massive existing container fleet drove a steady rebound in new container sales across the industry in the second quarter, reversing the downward trend seen in the first quarter, while prices also stabilised simultaneously. During the Reporting Period, the Group’s container manufacturing business achieved growth in both production and sales volume. In particular, the accumulated sales volume of dry containers reached 1.1385 million TEUs, representing a YoY increase of approximately 1.12%; meanwhile, benefiting from the bountiful harvest of fresh fruits in South America and the harvest season in the Northern Hemisphere, sales volume of reefer containers reached 108,200 TEUs, representing a YoY increase of approximately 17.61%. During the Reporting Period, the container segment recorded revenue of RMB21.920 billion, representing a YoY increase of 0.85%, and net profit of RMB272 million, mainly affected by the YoY decline in the price of standard containers and exchange rates. Logistics Services Business: During the Reporting Period, the multimodal transport market environment gradually improved, particularly the container shipping market, where freight rates continued to rise since March. During the Reporting Period, the segment achieved revenue of RMB13.945 billion, representing a YoY increase of 2.70%, and net profit of RMB240 million, representing a YoY increase of 18.81%. CIMC Wetrans actively captured the upward trend by deepening customer relationship management, optimising product mix, accelerating overseas expansion and strengthening operational efficiency. During the Reporting Period, the proportion of direct customers in the sea transportation business continued to increase; the port logistics business added route, extra sailing and vessel space agency services for multiple leading shipping companies; the industry logistics business added new cold chain equipment deployment, with cold chain business volume increasing by 14% YoY; the customer structure of the air transportation business continued to be optimised, with business volume increasing by 11% YoY; and the service network of the land transportation business continued to expand. CIMC Wetrans ranked TOP 13 in the 2026 Top 50 Ocean Freight Forwarders list issued by Transport Topics, an authoritative magazine in the global logistics industry, up one place from last year and ranking fifth among Chinese enterprises. Road Transportation Vehicles Business: During the Reporting Period, CIMC Vehicles achieved revenue of RMB10.737 billion, representing a YoY increase of 10.09%, and net profit of RMB356 million. Among them, the global semi-trailer business achieved revenue of RMB7.602 billion, representing a YoY increase of 9.79%. In 2026, CIMC Vehicles continued to extend the production and marketing models of the StarLink Project to more product lines and regions, deepening ecosystem cooperation while improving efficiency and reducing costs. The core production efficiency of the semi-trailer business under the StarLink Project continued to improve, and its domestic market share remained No. 1 for seven consecutive years. In overseas markets, revenue and sales volume in the Global South increased significantly, while gross profit margin remained basically flat due to fluctuations in ocean freight rates; production in the European market recovered, while freight rates and equipment orders in the North American market showed marginal improvement in the second quarter. The market share of core DTB products further increased, with a total of 13,238 truck bodies products products sold. Meanwhile, sales volume of EV-DTB truck bodies products for new energy heavy-duty trucks increased significantly, with deliveries of EV-DTB dump truck and mixer truck truck bodies products continuing to rise. The pure electric tractor and trailer business officially established the world’s first EV-RT offline experience center. Airport Facilities & Logistics Equipment / Fire Safety & Rescue Equipment Business: During the Reporting Period, revenue amounted to RMB3.357 billion, representing a YoY increase of 7.58%; net profit amounted to RMB71 million, representing a YoY decrease of 11.25%, mainly due to exchange rate fluctuations. During the Reporting Period, orders on hand maintained steady growth. The airport facilities and logistics equipment business secured a series of major benchmark orders, including boarding bridge projects worth hundreds of millions of RMB for Paris Airport and Orly Airport in France, as well as bulk orders for A380 catering vehicles in Singapore, further enhancing its global competitiveness. The logistics automation business successfully implemented multiple e-commerce projects in Southeast Asia, and also secured new orders and contracts in newly expanded industries such as State Grid and China Tobacco. The operating results of the fire safety and rescue equipment business showed significant improvement, with the successful securing of a major procurement order for 13 dual-boom water tower fire trucks under the national government subsidy-funded project for hazardous chemical emergency rescue teams. Cumulative new orders reached RMB1.675 billion, achieving steady growth. II. In the Energy Industries Field In respect of the energy, chemical and liquid food equipment business, revenue amounted to RMB13.396 billion, representing a YoY increase of 2.98%; net profit amounted to RMB480 million, representing a YoY increase of 4.35%. Among them, CIMC Enric achieved revenue of RMB12.87 billion, representing a YoY increase of 2.0%; newly signed orders amounted to RMB13.71 billion, representing a significant YoY increase of 27.7%; and as at the end of June, orders on hand amounted to RMB31.77 billion, representing a YoY increase of 8.9%. Specifically, revenue of the clean energy segment grew steadily. Benefiting from expanding demand in areas such as semiconductors and off-grid distributed power generation, the segment delivered electronic specialty gas clean gas cylinders (Y-type cylinders) and specialty tube skid containers in batches, and launched new hydrogen-rich power generation module products. CIMC Enric successfully delivered an integrated LNG liquefaction plant in Indonesia, while implementing its third benchmark steelmaking coke integrated project — the Shougang Shuicheng Steel project in Liupanshui, Guizhou. It also secured newly signed domestic Panzhihua Iron and Steel projects and its first overseas steelmaking coke integrated project with Tsingshan in Indonesia. In the hydrogen energy field, it contributed to the construction of Hong Kong’s first commercial building hydrogen energy charging station and launched China’s first 20-foot Type IV cylinder hydrogen tube skid container. During the Reporting Period, the clean energy segment recorded newly signed orders of RMB10.61 billion, representing a YoY increase of 18.3%, among which newly signed orders for waterborne clean energy reached RMB4.535 billion, representing a significant YoY increase of 40.1%, with shipbuilding orders scheduled through 2029. The chemical and environment segment benefited from the recovery of the chemical industry and high-growth industries such as semiconductors, with demand for tank containers improving, while the medical equipment components business maintained steady growth. As at the end of June 2026, orders on hand increased by 86.8% YoY to RMB1.57 billion. The liquid food segment focused on the non-alcoholic beverage and new consumption sectors, successfully securing and signing multiple turnkey projects, including projects for Japanese breweries and Chinese whisky distilleries. Cumulative newly signed orders reached RMB1.44 billion, representing a strong YoY increase of 108.4%. In respect of the offshore engineering business, benefiting from the cost advantages of deepwater locations, the deepwater offshore engineering market for FPSO/FLNG continued to strengthen. CIMC Raffles, the main operating entity, achieved an important breakthrough in the international high-end offshore engineering general contracting market by signing China’s first FPSO EPCIC general contracting contract, further enhancing its industry competitiveness. During the Reporting Period, revenue amounted to RMB7.935 billion, representing a YoY decrease of 0.98%; net profit amounted to RMB718 million, representing a YoY increase of 155.52%. In terms of market orders, new orders amounted to US$3.2 billion during the Reporting Period, a substantial increase from US$106 million in the same period last year. As at the end of June, CIMC Raffles had cumulative orders on hand of US$7.62 billion, reaching a record high. In terms of project construction and delivery, in January, the PCTC with a capacity of 7,000 vehicles, “NOCC ADRIATIC”, constructed for a Norwegian shipowner, was delivered 70 days ahead of its contractual delivery schedule; in February, the Norse Energi, the world’s largest fully DC wind turbine installation vessel in terms of lifting capacity, completed its seaworthiness delivery; in March, construction commenced on the first vessel of a new generation of seabed rock dumping vessels built for Van Oord, a leading Dutch offshore engineering company; in April, the fore-body module of the P85 hull was slid onto a barge at the Haiyang base, laying a solid foundation for the subsequent successful major assembly of the P85 project; in May, construction of the VLCC tanker officially commenced, entering the substantive construction stage; and in June, the main upper module structure of the project constructed for Golar was successfully capped, marking a key milestone in the project’s construction. In respect of the offshore engineering asset operation and management business, all offshore engineering assets of the Group currently under lease have been operating normally under their respective lease contracts, and the Group continued to provide high-quality services to customers. Benefiting from the successful lease of the Blue Whale No. 1 platform, increased prices upon the renewal of contracts for multiple drilling platforms, and lower operating costs resulting from refined management, operating profit improved during the Reporting Period. During the Reporting Period, the sixth-generation semi-submersible drilling platform “Deepsea Yantai” secured a new drilling contract, injecting momentum into revenue growth; the semi-submersible lifting/life support platform Blue Gretha successfully arrived at its designated operating area to provide high-quality services to clients. Meanwhile, several semi-submersible drilling and life support platforms and other offshore engineering assets of the Group actively pursued new contracts. Future Development and Prospects The management of the Group stated, “2026 is the first year of the ‘15th Five-Year Plan’. The Group will be based on the new development stage, closely follow national policy guidance, and closely focus on ‘focusing on high-quality development and cultivating new growth drivers’. With a more proactive strategic approach, we will cultivate new opportunities and open up new prospects amid complex changes, striving to build ‘a high-quality and respected world-class enterprise’.” About China International Marine Containers (Group) Co., Ltd. The CIMC Group is a world-leading equipment and solution provider in the logistics and energy industries, and its industry clusters mainly cover the logistics and energy fields. In the logistics field, the Group has established a general transportation equipment portfolio covering “sea, land and air”: its container manufacturing business provides key circulation equipment for the container shipping industry; its road transportation vehicles business connects the arteries of land transportation; its airport facilities and logistics equipment/fire safety and rescue equipment businesses expand into aviation hubs and specialised scenarios; its logistics services business provides professional services across the entire-value chain; and its recycled load business provides professional supporting services. In the energy field, the Group is principally engaged in the energy, chemical, and liquid food equipment business and offshore engineering business. Meanwhile, the Group also continuously develops emerging industries and has finance and asset management businesses that serve the Group itself. As a diversified multinational industrial group serving the global market, CIMC has over 300 member enterprises across Asia, North America, Europe, and Australia, with a total of four listed companies, and customers and sales networks covering more than 100 countries and regions worldwide. In 2025, the Group recorded revenue of RMB 156.6 billion, ranking 154th on the 2025 Fortune 500 China list. The Group has maintained the world’s No.1 position for many consecutive years in core products such as standard dry containers, reefer containers, tank containers and semi-trailers. For more information, please visit http://www.cimc.com/. Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com ———————————————————————————————————————————————————————————— Cosmos Health Strengthens Balance Sheet and Streamlines Capital Structure; Retires $8M ATW Convertible Note One Year Ahead of Maturity, Eliminating Further Dilution From Conversions 2026-08-28 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/28/3352713/0/en/cosmos-health-strengthens-balance-sheet-and-streamlines-capital-structure-retires-8m-atw-convertible-note-one-year-ahead-of-maturity-eliminating-further-dilution-from-conversions.html Cosmos Health strengthens balance sheet and streamlines capital structure. Retires $8M ATW convertible note, eliminating further dilution. ———————————————————————————————————————————————————————————— Pinion Immunotherapeutics Publishes Preclinical Data Supporting Clinical-Ready RNA Immunotherapy for HPV-16 Cervical Precancer 2026-08-28 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/pinion-immunotherapeutics-publishes-preclinical-data-130800970.html NORTH BETHESDA, Md., August 28, 2026--Pinion Immunotherapeutics has published preclinical data supporting ARV-2001, its lead RNA immunotherapy, in the peer-reviewed journal Vaccines. With an Investigational New Drug application cleared by the FDA, Pinion is ready to begin clinical development for women with HPV-16-positive high-grade cervical precancer (CIN2/3). ———————————————————————————————————————————————————————————— Sustainable Innovation & Health Dividend Fund Normal Course Issuer Bid 2026-08-28 · GlobeNewswire · Finance, Healthcare, Education https://www.globenewswire.com/news-release/2026/08/28/3352711/0/en/sustainable-innovation-health-dividend-fund-normal-course-issuer-bid.html TORONTO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Sustainable Innovation & Health Dividend Fund (the “Fund”) (TSX: SIH.UN) announced that it has filed a notice with the Toronto Stock Exchange (the “TSX”) and received its approval to make a normal course issuer bid (“NCIB”). Purchases pursuant to the NCIB will be made in the open market through the facilities of the TSX and Alternative Canadian Trading Systems. This NCIB will commence on September 3, 2026 and will terminate on September 2, 2027. In accordance with the Declaration of Trust by which the Fund is governed, market purchases pursuant to its NCIB may be effected by the Fund. ———————————————————————————————————————————————————————————— Simplify Healthcare Names Kamal Ahuja Chief Growth Officer to Accelerate Expansion of Its Payer AI Platform 2026-08-28 · mlpr-businesswire · AI, SaaS, Healthcare https://finance.yahoo.com/healthcare/articles/simplify-healthcare-names-kamal-ahuja-125200623.html AURORA, Ill., August 28, 2026--Simplify Healthcare®, a Simplify Group™ company and leading provider of technology solutions for payers, today announced Kamal Ahuja’s promotion to Chief Growth Officer. In this role, Kamal will lead the growth strategy and market expansion for the Payer AI Platform, helping health plans modernize operations through connected workflows, intelligent automation, and a unified data foundation. ———————————————————————————————————————————————————————————— Dr. Irfan Atcha Marks 30 Years in Chicago Implant Dentistry 2026-08-28 · PR-Inside · Healthcare, Education https://pr-inside.com/dr-irfan-atcha-marks-30-years-in-chicago-implant-dentistry-r5217115.htm (PR-inside.com) Chicago dentist reflects on three decades of changing technology, complex patient care, and the evolution of dental implant treatment. CHICAGO, IL / ACCESS Newswire / August 28, 2026 / Dr. Irfan Atchais marking 30 years of practising dentistry in Chicago, reaching a career milestone that spans major changes in dental implant technology, treatment planning, and approaches to complex dental rehabilitation. Atcha began practising in Chicago in 1996 after earning his Doctor of Dental Surgery degree from the University of Illinois College of Dentistry. Over the three decades since, his work has become increasingly focused on dental implants and patients with complex needs, .. ———————————————————————————————————————————————————————————— Tees Valley Tennis Foundation Opens Applications for Financial Support 2026-08-28 · Pressat · Healthcare https://pressat.co.uk/releases/tees-valley-tennis-foundation-opens-applications-for-financial-support-b6a356030cada74a59a7527108a78f55/ Friday 28 August, 2026 Applications now open for support with coaching, equipment, competition costs and travel for young tennis and padel players Teesside, 28 August 2026: Tees Valley Tennis Foundation has opened its main support application route for young people facing financial barriers to taking part in tennis or padel. Parents and guardians can now apply to the Foundation for support where cost is making it difficult for a young person to start, continue or progress in the sport. The Foundation can consider requests relating to: coaching and participation;essential tennis or padel equipment;competition and tournament costs;travel connected with tennis or padel; andother reasonable tennis or padel-related costs. Support is intended for young people aged 8-18 who live at a TS postcode ———————————————————————————————————————————————————————————— Choose Health Launches Most Comprehensive At-Home Liver Function Test with 20+ Biomarkers and Clinical Risk Scores 2026-08-28 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/choose-health-launches-most-comprehensive-at-home-liver-function-test-with-20-biomarkers-and-clinical-risk-scores-302862404.html New Test Brings Fatty Liver Risk Screening Home as Roughly 100 million Americans Live with Liver Disease, Most Undiagnosed AUSTIN, Texas, Aug. 28, 2026 /PRNewswire/ -- Choose Health, an at-home blood testing company, announced the launch of the Comprehensive Liver Function Test, a... ———————————————————————————————————————————————————————————— Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season 2026-08-28 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/novavaxs-partnership-strategy-continues-to-deliver-with-xfg-adapted-nuvaxovid-approvals-in-the-us-eu-and-japan-for-2026-2027-vaccination-season-302862775.html COVID-19 remains a public health challenge, particularly among older adults and high-risk populations1 Novavax's partners are ready to bring its protein-based, non-mRNA vaccine with a favorable tolerability profile to global markets, providing an important option for healthcare providers... ———————————————————————————————————————————————————————————— Tenon Medical Announces Pricing of $3M Private Placement Offering 2026-08-28 · PR-Inside · Finance, Healthcare https://pr-inside.com/tenon-medical-announces-pricing-of-3m-private-placement-offering-r5217112.htm (PR-inside.com) LOS GATOS, CA / ACCESS Newswire / August 28, 2026 / Tenon Medical, Inc.(NASDAQ:TNON), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, today announced that on August 27, 2026 it has entered into a securities purchase agreement with an institutional investor to sell 597,610 shares of common stock (or pre-funded warrants in lieu thereof), together with a warrant to purchase up to an aggregate 1,058,517 shares of common stock, in a private placement offering. The combined effective offering price for each share of common stock and accompanying warrants to be issued is $5.02. The .. ———————————————————————————————————————————————————————————— Glucose Health, Inc. (OTCID: GLUC) Appoints Consumer Products Industry Veteran John Duffy as Chief Executive Officer to Accelerate Growth, Elevate Brand Leadership, and Maximize Long-Term Shareholder Value 2026-08-28 · GlobeNewswire · Healthcare, Retail https://www.globenewswire.com/news-release/2026/08/28/3352665/0/en/glucose-health-inc-otcid-gluc-appoints-consumer-products-industry-veteran-john-duffy-as-chief-executive-officer-to-accelerate-growth-elevate-brand-leadership-and-maximize-long-term.html Glucose Health, Inc. (OTCID: GLUC) Appoints Consumer Products Industry Veteran John Duffy as Chief Executive Officer to Accelerate Growth ———————————————————————————————————————————————————————————— Lobe Sciences Expands Leadership Team with New CFO Appointment 2026-08-28 · PR-Inside · Healthcare https://pr-inside.com/lobe-sciences-expands-leadership-team-with-new-cfo-appointment-r5217111.htm (PR-inside.com) Dr. David Kideckel, PhD, MBA, joins as Chief Financial Officer, bringing nearly two decades of life sciences, capital markets and corporate advisory experience Current CFO, Mirza Rahimani, transitions to Vice President of Finance, providing continuity across financial reporting and operations Appointment strengthens Lobe's leadership team as the Company advances L-130, its differentiated conjugated psilocin therapeutic being developed at sub-hallucinogenic doses for chronic cluster headache VANCOUVER, BC / ACCESS Newswire / August 28, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FSE:LOBE.F) ("Lobe" or the "Company"), a clinical-stage biopharmaceutical company advancing differentiated therapeutics for serious conditions with significant unmet medical needs, today announ ———————————————————————————————————————————————————————————— BetterLife Pharma Inc. Announces Pricing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants 2026-08-28 · mlpr-newsfile · Healthcare https://www.newsfilecorp.com/release/311933/BetterLife-Pharma-Inc.-Announces-Pricing-of-US100-Million-Public-Offering-of-Common-Shares-and-PreFunded-Warrants AMENDED AND RESTATED PRELIMINARY PROSPECTUS ACCESSIBLE ON SEDAR+Vancouver, British Columbia--(Newsfile Corp. - August 28, 2026) - BetterLife Pharma Inc. (CSE: BETR) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, is pleased to announce today that it has priced its previously announced public offering (the "Offering") of common shares of the Company ("Common Shares") and/or pre-funded common share purchase warrants of the Company... ———————————————————————————————————————————————————————————— BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement 2026-08-28 · mlpr-prnewswire-wire · Finance, Healthcare https://www.prnewswire.com/news-releases/biolinerx-announces-3-75-million-registered-direct-offering-and-concurrent-private-placement-302862746.html TEL AVIV, Israel, Aug. 28, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into a definitive... ———————————————————————————————————————————————————————————— ENvue Medical, Inc. Announces 1-for-12 Reverse Stock Split 2026-08-28 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/28/3352655/0/en/envue-medical-inc-announces-1-for-12-reverse-stock-split.html TYLER, Texas, Aug. 28, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) ("ENvue" or the "Company"), a commercial-stage medical technology company, today announced that a reverse stock split of the Company’s issued and outstanding common stock, par value $0.001 per share (the “Common Stock”) at a ratio of 1-for-12 is expected to become effective on September 1, 2026. The Company's Common Stock will begin trading on the Nasdaq Capital Market on a post-split basis at the market open on September 1, 2026, under the Company's existing trading symbol "FEED", but will trade under a new CUSIP number, 63008J876. ———————————————————————————————————————————————————————————— HiRO and Differentia Biotech Forge Strategic Alliance to Redefine Clinical Trial Design Through AI-Powered Simulation 2026-08-28 · mlpr-prnewswire-wire · AI, Healthcare https://www.prnewswire.com/news-releases/hiro-and-differentia-biotech-forge-strategic-alliance-to-redefine-clinical-trial-design-through-ai-powered-simulation-302862508.html Memorandum of Understanding establishes a framework for joint development of clinical trial simulation capabilities The partnership unites global clinical operations excellence with advanced digital twin technology, delivering simulation-first drug development to biotech sponsors... ———————————————————————————————————————————————————————————— Minerva Neurosciences to Participate in Two Upcoming Investor Conferences 2026-08-28 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/28/3352656/32445/en/minerva-neurosciences-to-participate-in-two-upcoming-investor-conferences.html BURLINGTON, Mass., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that management will participate in two upcoming investor conferences. ———————————————————————————————————————————————————————————— If You Can't Start Your Day Without Coffee, This Article Is for You 2026-08-28 · PR-Inside · Healthcare, Energy https://pr-inside.com/if-you-can-t-start-your-day-without-coffee-this-article-is-for-you-r5217106.htm (PR-inside.com) LOS ANGELES, CA / ACCESS Newswire / August 28, 2026 / It starts with a morning coffee. Then perhaps another cup before lunch. By midafternoon, focus starts to fade, and an espresso, energy drink, or other caffeinated pick-me-up begins to sound tempting. Wait Before You Take Another Sip: Do You Know How Much Caffeine You're Really Drinking? But coffee isn't the only source of caffeine throughout the day. Tea, energy drinks, pre-workout supplements, and other caffeinated products can all contribute to total daily intake-and those seemingly small sources can add up. According to the U.S. Food and Drug Administration (FDA), an 8-ounce cup .. ———————————————————————————————————————————————————————————— Shareholders of Fractyl Health, Inc. (GUTS): Protect Your Rights Before ... 2026-08-28 · PR-Inside · Finance, Healthcare https://pr-inside.com/shareholders-of-fractyl-health-inc-guts-protect-your-rights-before-r5217105.htm (PR-inside.com) NEW YORK, NY / ACCESS Newswire / August 28, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Fractyl Health, Inc. (NASDAQ:GUTS) securities. If you suffered a loss on your Fractyl Health, Inc. investment and would like to explore a potential recovery under the federal securities laws, Learn about Fractyl Health, Inc. Class Action or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit was filed against .. ———————————————————————————————————————————————————————————— La FDA aprueba Mounjaro (tirzepatida) de Lilly para reducir el riesgo cardiovascular en adultos con diabetes tipo 2 2026-08-28 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/la-fda-aprueba-mounjaro-tirzepatida-de-lilly-para-reducir-el-riesgo-cardiovascular-en-adultos-con-diabetes-tipo-2-843973142.html Mounjaro es el primer y único agonista de los receptores GIP y GLP-1 que ha demostrado reducir el riesgo de ataque al corazón, derrame cerebral o muerte cardiovascular en adultos con diabetes tipo 2 y con alto riesgo de sufrir dichos eventos, además de sus beneficios consolidados en lo... ———————————————————————————————————————————————————————————— Pomerantz LLP Announces Commencement of Class Action Lawsuit Against ... 2026-08-28 · PR-Inside · Finance, Healthcare https://pr-inside.com/pomerantz-llp-announces-commencement-of-class-action-lawsuit-against-r5217067.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 28, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Fractyl Health, Inc. ("Fractyl" or the "Company") (NASDAQ:GUTS) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 26-cv-07167, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fractyl securities between January 13, 2025 and January 29, 2026, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations .. ———————————————————————————————————————————————————————————— VMRD Launches Rapid Horse-Side Insulin Test to Decrease Risk of Laminitis in Metabolic Horses 2026-08-28 · PR.com · SaaS, Healthcare https://www.pr.com/press-release/977735 VMRD, Inc. is thrilled to share the launch of their exciting new test for horse-side measurement of insulin in horses. Run on the same palm-sized reader as VMRD SAA and Foal IgG, this highly portable multi-functional testing platform embodies VMRD’s vision of improving animal health through high-quality, practical diagnostics. Equine Metabolic Syndrome and insulin dysregulation are incredibly common in the equine [PR.com] ———————————————————————————————————————————————————————————— Bionic Bloom Integrated Health Welcomes Celeste Verastegui as New Provider 2026-08-28 · Newswire.com · Healthcare https://www.newswire.com/news/bionic-bloom-integrated-health-welcomes-celeste-verastegui-as-new-provider Vibrational therapist and educator brings sound healing, breathwork and integrative mentorship to the organization's expanding provider network ———————————————————————————————————————————————————————————— FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes 2026-08-28 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/fda-approves-lillys-mounjaro-tirzepatide-to-reduce-cardiovascular-risk-in-adults-with-type-2-diabetes-302862415.html Mounjaro is the first and only GIP and GLP-1 receptor agonist proven to lower heart attack, stroke or cardiovascular death risk in adults with type 2 diabetes at high risk for these events – in addition to its established A1C and weight loss benefits It is estimated that as many as one in... ———————————————————————————————————————————————————————————— InxMed Announces Publication in The Lancet Oncology Featuring Encouraging Antitumor Activity of Ifebemtinib in Combination with Garsorasib in Previously Treated Metastatic Colorectal Cancer (CRC) Harboring KRAS G12C Mutation 2026-08-28 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/inxmed-announces-publication-in-the-lancet-oncology-featuring-encouraging-antitumor-activity-of-ifebemtinib-in-combination-with-garsorasib-in-previously-treated-metastatic-colorectal-cancer-crc-harboring-kras-g12c-mutation-302862617.html NANJING, China, Aug. 28, 2026 /PRNewswire/ -- InxMed Co., Ltd ("InxMed"), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting cancer treatment resistance and metastasis, today announced that the clinical results of ifebemtinib (IN10018), a highly... ———————————————————————————————————————————————————————————— Avricore Grants Options 2026-08-28 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/28/3352606/0/en/avricore-grants-options.html VANCOUVER, British Columbia, Aug. 28, 2026 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) today announces that the Company’s board of directors has approved the granting of stock options (the “Options”) exercisable for a total of 3,300,000 common shares to its directors, officers, employees and consultants at an exercise price of CAD $0.06 per common share. ———————————————————————————————————————————————————————————— Cryofocus Announces 2026 Interim Results: Loss Narrows 37.9% to RMB 16.9 Million, Gross Margin Improves to 68.5% 2026-08-28 · mlpr-acnnewswire · Finance, SaaS, Healthcare https://www.acnnewswire.com/press-release/english/109571/ HONG KONG, August 28, 2026 - (ACN Newswire) - Cryofocus Medtech (Shanghai) Co., Ltd. (“Cryofocus” or the “Company,” stock code: 6922.HK), a leading innovative medical device platform specializing in minimally-invasive interventional cryotherapy, today announced its interim results for the six months ended June 30, 2026. During the Reporting Period, the Company continued to expand its product pipeline, with a significant 37.9% narrowing of its loss for the period to RMB 16.9 million. Gross profit margin improved to 68.5% from 67.1% in the same period last year, while cash and cash equivalents surged 69.2% to RMB 59.3 million compared to the end of 2025, underscoring enhanced operational quality and financial resilience. Product Pipeline Continues to Expand, Commercial Footprint Widens As a pioneer in the field of minimally-invasive interventional cryotherapy in China, Cryofocus has established a comprehensive product portfolio covering both vascular intervention and natural orifice transluminal endoscopic surgery (NOTES). As of June 30, 2026, the Company had a total of 25 products and product candidates, of which 11 had been commercialized. These include the Atrial Fibrillation Cryoablation System, Malignant Stenosis Cryoablation System, Cryoadhesion System, Bladder Cryoablation System, and Pulmonary Nodule Localization Needle, among others. In January 2026, the Company’s Endoscopic Additional Working Channel Catheter received approval from the Zhejiang Medical Products Administration, further enriching its commercial product matrix. Meanwhile, several high-value product candidates have entered the critical confirmatory clinical trial stage and are expected to receive approvals sequentially between 2027 and 2029. These include: - Vascular Intervention: Cryofocus Renal Denervation System (Cryo-RDN System): Designed to be the world’s first cryoablation product specifically targeting hypertension. It was granted Breakthrough Device designation by the U.S. FDA in December 2022. - Respiratory Intervention: COPD Cryospray System, Peri-Pulmonary Nodule Cryoablation System, Asthma Cryoablation System, and Benign Stenosis Cryoablation System: These products form a matrix of investigational devices targeting the same hospital department. As they receive approvals in the coming period, the synergistic effect of this product matrix is expected to amplify. The Company’s R&D team comprises 40 professionals. As of June 30, 2026, Cryofocus held 179 patents and 35 patent applications domestically and internationally, continuously deepening its technological moat. Loss Narrows Significantly, Gross Margin Improves Against Headwinds Alongside steady progress in its product pipeline, the Company delivered impressive financial metrics. For the first half of 2026, Cryofocus recorded revenue of RMB 40.7 million and gross profit of RMB 27.9 million. The loss for the period amounted to RMB 16.9 million, a decrease of RMB 10.3 million or 37.9% from RMB 27.2 million in the same period of 2025. Against the backdrop of an active adjustment in revenue scale, the Company’s overall gross profit margin rose from 67.1% to 68.5%, primarily driven by process improvements and optimizations for certain products. This indicates that structural improvements in the product mix and enhanced production efficiency have effectively offset the impact of revenue fluctuations on profitability. Comprehensive Cost Optimization Boosts Operating Efficiency Significantly  The substantial narrowing of losses was underpinned by the Company’s holistic cost control measures: - Administrative expenses decreased by 34.0% from RMB 33.7 million to RMB 22.3 million, mainly due to reductions in staff costs and share-based payments. - Selling and distribution expenses fell by 14.5% from RMB 9.2 million to RMB 7.8 million. - Research and development expenses declined by 15.1% from RMB 17.9 million to RMB 15.2 million. - Finance costs dropped by 22.7% from RMB 1.1 million to RMB 0.8 million. Furthermore, other income and gains surged over 550% from RMB 0.5 million to RMB 3.2 million, primarily attributable to an increase in government grants. The combined effect of comprehensive cost optimization and growth in non-recurring income enabled the Company to achieve a sharp compression of losses despite a temporary decline in revenue. Cash Reserves Surge 69.2%, Strengthening Capital Position As of June 30, 2026, the Company’s cash and cash equivalents stood at RMB 59.3 million, an increase of RMB 24.2 million or 69.2% from RMB 35.0 million as of December 31, 2025. This growth was mainly driven by the completion of an H-share placing in January 2026, under which the Company issued 5,595,000 H-shares and raised net proceeds of approximately HK$29.73 million. Additionally, the Company’s current ratio improved from 1.5 to 1.7, the quick ratio rose from 1.0 to 1.2, and the gearing ratio decreased from 64.7% to 61.8%, reflecting enhanced short-term solvency and overall financial safety. Outlook: Committed to Becoming a Global Minimally-Invasive Interventional Cryotherapy Medical Device Platform, Bringing Benefits to Patients and Physicians Worldwide In the first half of 2026, the Company proactively adjusted its sales strategy to align with evolving industry demands, leading to a temporary dip in revenue. However, earnings quality improved markedly, signaling a positive trend of “structural revenue adjustment with clear profit elasticity.” Looking ahead, the Company will: - Rapidly advance the clinical development and commercialization of its product candidates based on cryotherapy technology; - Continue to focus on minimally-invasive interventional cryotherapy and further expand its product portfolio leveraging its technology platform; - Persistently research and develop various underlying and supporting technologies; and - Selectively expand its global footprint. With high-value products such as the Cryofocus Renal Denervation System, COPD Cryospray System, and Peri-Pulmonary Nodule Cryoablation System entering the regulatory submission and launch cycle, coupled with a significantly strengthened cash position and continuous loss reduction, Cryofocus is steadily accelerating toward its vision of becoming a “global minimally-invasive interventional cryotherapy medical device platform.” Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com ———————————————————————————————————————————————————————————— Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy 2026-08-28 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/28/3352601/0/en/teva-announces-proposed-acquisition-of-a-novel-neuroscience-product-reinforcing-disciplined-business-development-approach-under-pivot-to-growth-strategy.html Teva Pharmaceuticals proposes acquiring BXCL501, expanding its neuroscience portfolio with a novel agitation treatment under FDA review ———————————————————————————————————————————————————————————— Analogue Announces 2026 Interim Results 2026-08-28 · mlpr-acnnewswire · Finance, AI, SaaS, Healthcare, Real Estate, Energy https://www.acnnewswire.com/press-release/english/109565/ HONG KONG, August 28, 2026 - (ACN Newswire) - Analogue Holdings Limited (“Analogue” or the “Company”, together with its subsidiaries, the “Group”) (stock code: 1977), a leading provider of electrical and mechanical (“E&M”) engineering solutions, and information and communications technology services for smart cities, today announced its interim results for the six months ended 30 June 2026 (the “Period”) with interim contracts-in-hand continuing their record-setting performance, providing a solid foundation for the business over the next three years and beyond. Business Highlights - Interim contracts-in-hand surged by 34.9% to HK$17,649.3 million, attaining yet another record high - Revenue was HK$3,036.6 million, up by 5.7%, primarily driven by steady project execution in the Building Services and Environmental Engineering segments - Profit attributable to owners of the Company increased 88.1% to HK$152.0 million. The increase was partly attributable to the disposal of an approximately 3% equity stake in Nanjing Canatal Data-Centre Environmental Tech Co., Ltd.(Shanghai Stock Code: 603912) - The Group maintained a strong cash position, with bank balances and cash at HK$1,214.1 million - Interim dividend amounted to HK4.9 cents per share, with a year-on-year increase of more than 88% - Artificial Intelligence (AI) has been integrated into Analogue’s interconnected smart ecosystem to create value for customers, by realising a smart platform for buildings, and advanced operational solutions for water and sewage treatment, as evidenced by the prestigious accolades across both the research and adoption categories at the inaugural Construction Industry Council AI Award 2026 and at the ASHRAE Region XIII Technology Award 2026 Chairman Dr Mak Kin Wah said, “Building on our outstanding achievement of record-high contracts-in-hand in 2025, the Group maintained steady business performance in the first half of 2026. By integrating research, development and application of AI technologies, we have achieved optimised operations and enhanced quality that earn wide recognition from the industry. Committed to innovation, the Group will further promote integration of AI, Digital Twin, and the Internet of Things (“IoT”), develop cross-technology integrated solutions, and enhance performance in engineering operations, safety, and sustainable development, to create greater value for clients.” “Our commitment to business ethics, quality, safety, health and environmental sustainability remains at the core of everything we do, guiding our decisions, shaping our culture, and contributing to a more sustainable future." Business Review: Building Services - This segment remains the largest revenue contributor, with revenue reaching HK$1,649.6 million. - Interim contracts-in-hand reached a record-high level of HK$7,996.6 million, with order intake standing at HK$1,348.8 million and many of the tenders submitted in the Period due for determination in phases later this year. - Many projects in the Northern Metropolis, including Fanling and Kwu Tung housing projects and various hospitals, were prioritised for commencement and progress in execution. - The Group’s expertise in Building Information Modelling (BIM), Design for Manufacture and Assembly (DfMA) and Modular Integrated Mechanical, Electrical and Plumbing (MiMEP) continued to gain market traction and helped secure major contracts. - Leveraging our comprehensive interdisciplinary capacity and new engineering techniques, this segment maintained our industry leadership, and was broadening our market reach to different parts of Asia. Environmental Engineering - This segment achieved record-high interim contracts-in-hand, which surged substantially by 78.3% year-on-year to HK$8,164.2 million. Order intake stood at HK$910.1 million with active ongoing tendering activities and many of the tenders submitted in the period due for determination in phases later this year. Segment revenue increased by 17.2% year-on-year or HK$123.2 million. - A number of projects, including a landmark engineering contract to reprovision critical sewage treatment works to caverns, were prioritised for commencement and execution. - New term contracts for sewage and E&M systems were also added to the recurrent operation, maintenance, and facility management services provided by the segment. - By deploying AI and Digital Twin under our industry-recognised AlgoWater® brand, the segment continued to strengthen our industry leading position by advancing in intelligent automation, predictive asset management, and real-time process optimisation that significantly enhance treatment efficiency and energy savings for industrial operations. - Continued to pursue project opportunities with partners in the Chinese Mainland and different parts in Asia and Europe. Information, Communications and Building Technologies (“ICBT”) - Segment revenue amounted to HK$290.9 million. Contracts-in-hand totalled HK$830.8 million. Order intake was HK$269.9 million. - As an early mover backed by its own R&D capability and extensive project experience, this segment was well positioned to continue to advance innovation. A robust digital foundation was established through the Digital Plant and Centralised Management Platform (CMP) that enables real-time insights and data-driven decisions. - Integration of IoT and advanced Building Management System (BMS) under our acclaimed DigiFusion® AI Smart Building Platform delivers optimised operational efficiency and enhanced tenant experiences in smart buildings and city infrastructure, as well as resource circularity for our clients. Lifts and Escalators - Revenue and contracts-in-hand were at HK$255.9 million and HK$657.7 million respectively. - Order intake totalled HK$278.4 million, with ongoing tendering activities in different parts of the world. - Transel Elevator & Electric Inc. (TEI), the associate company in the United States, maintained its strength as one of the largest independent lift and escalator companies in New York and continued to expand in the southeastern part of the country, strengthening our market positioning and future growth. - Competitiveness was strengthened with enhanced automation in production lines and strict quality controls, to anchor the end-to-end business model from design, through manufacturing, to installation and maintenance services. - The product portfolio was broadened in line with the expanding international market reach and enhanced with next-generation product innovations. For further details of the 2026 Interim Results, please refer to the announcement filed with The Stock Exchange of Hong Kong Limited. About Analogue Holdings Limited Established in 1977, Analogue Holdings Limited is a leading provider of electrical and mechanical (“E&M”) engineering solutions and information and communications technology (“ICT”) services for smart cities, with headquarters in Hong Kong and operations in the Chinese Mainland, Macau, the United States, the United Kingdom, Germany, Singapore and Malaysia. Serving a wide spectrum of customers from public and private sectors, the Group provides multidisciplinary and comprehensive E&M engineering and technology services in four major segments, including Building Services, Environmental Engineering, Information, Communications and Building Technologies (“ICBT”) and Lifts & Escalators. The Group also manufactures and sells lifts and escalators internationally and has entered into an alliance with Transel Elevator & Electric Inc. (“TEI”), one of the largest independent lifts and escalators companies in New York, the United States. The Group’s associate partner, Nanjing Canatal Data-Centre Environmental Tech Co., Ltd. (Shanghai Stock Code: 603912), specialises in precision environmental control technologies and related energy-saving and temperature control equipment for data centres. Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com ———————————————————————————————————————————————————————————— Tigermed Announces 2026 Interim Results 2026-08-28 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/tigermed-announces-2026-interim-results-302862702.html HANGZHOU, China, Aug. 28, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its 2026 interim results (the "Reporting... ———————————————————————————————————————————————————————————— “Declutter Your Home, Declutter Your Life,” Best-Selling Book Free for One More Day (Ending Soon) (Until 8/28/26) 2026-08-28 · WebWire · Healthcare, Energy, Retail https://www.webwire.com/ViewPressRel.asp?aId=359243 Best Seller Publishing announces the release Michele Rase's new book, “Declutter Your Home, Declutter Your Life.” The book is currently free and available for download on Amazon for one more day. - - “Declutter Your Home, Declutter Your Life” is about creating a home that gives you energy instead of quietly draining it. Life and Health Coach Michele Rase explores how clutter can create emotional and mental noise, especially when tied to memories, guilt, unfinished decisions, or past... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=359243 ———————————————————————————————————————————————————————————— Philips Korea and HoneyNaps Sign Strategic MOU to Advance Sleep and Cardiovascular Health 2026-08-28 · PR Newswire · SaaS, Healthcare https://www.prnewswire.com/news-releases/philips-korea-and-honeynaps-sign-strategic-mou-to-advance-sleep-and-cardiovascular-health-302862454.html Partnership will explore new healthcare opportunities arising from the link between sleep disorders and cardiovascular disease Collaboration to span the integration of sleep data with cardiovascular risk factors, academic initiatives, and more Philips' health technology expertise and... ———————————————————————————————————————————————————————————— Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million 2026-08-28 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/28/3352590/0/en/quoin-pharmaceuticals-announces-private-placement-financing-of-up-to-50-0-million.html ASHBURN, Va., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has entered into a securities purchase agreement with new and existing healthcare-focused institutional investors to raise up to approximately $50.0 million in gross proceeds, including initial upfront funding of approximately $30.8 million and up to an additional approximately $19.2 million upon the potential cash exercise of accompanying ordinary warrants at the election of the investors. ———————————————————————————————————————————————————————————— Recent Release, "365 Days of Wholeness," from Christian Faith Publishing Author Laverne Williams, is a Transformative Journal Guiding Readers Toward Spiritual Renewal 2026-08-28 · PR.com · Healthcare https://www.pr.com/press-release/977176 Laverne Williams has completed a new book, "365 Days of Wholeness: A Year of Spiritual Renewal, Emotional Clarity, and Holistic Health," offering readers a comprehensive companion for their wellness journey. This thoughtfully crafted journal combines monthly themes, inspirational quotes on wholeness, reflective prompts for deepening self-awareness, uplifting affirmations, and practical health advice to help [PR.com] ———————————————————————————————————————————————————————————— Recent Release, "Diary of a Stroked-Out, Stroked-Up Sista Girl," from Christian Faith Publishing Author Twana Hall-Scott, Explores Faith Amid Life's Trials 2026-08-28 · PR.com · Healthcare https://www.pr.com/press-release/977179 Twana Hall-Scott has completed a new book, titled, "Diary of a Stroked-Out, Stroked-Up Sista Girl," a candid exploration of overcoming relationship drama and health trauma. When a stroke altered her life in October 2015, Hall-Scott faced unexpected losses—her ability to read and vision in half of each eye—yet discovered unexpected blessings through the experience. This memoir captures the raw, [PR.com] ———————————————————————————————————————————————————————————— Recent Release, "Priscilla," from Christian Faith Publishing Author Lois Jean Lee, Follows a Woman Confronting Life's Most Unexpected Challenge with Courage and Grace 2026-08-28 · PR.com · Healthcare https://www.pr.com/press-release/977203 Lois Jean Lee has completed a new book, titled, "Priscilla," a poignant exploration of resilience and human connection. The narrative centers on a 63-year-old secretary whose ordinary life shifts dramatically when a routine doctor's visit reveals a devastating diagnosis: Non-Hodgkin's Lymphoma. What begins as concern over a seemingly minor physical symptom becomes a journey through medical testing, treatment [PR.com] ———————————————————————————————————————————————————————————— Veterans and Military Families Get More Access to Ketamine-Based Mental Health Care for PTSD Across Tampa Bay 2026-08-28 · Newswire.com · Healthcare https://www.newswire.com/news/veterans-and-military-families-get-more-access-to-ketamine-based-mental-health Bionic Bloom Integrated Health accepts TRICARE insurance for eligible therapeutic services within individualized treatment plans, helping reduce the overall cost of care ———————————————————————————————————————————————————————————— Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of Medicine 2026-08-28 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/28/3352576/35409/en/cytokinetics-announces-positive-results-from-acacia-hcm-presented-in-hot-line-session-at-the-european-society-of-cardiology-esc-congress-2026-and-published-in-the-new-england-journ.html ACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant Improvements Across Both Patient-Reported and Physician-Assessed Endpoints in Non-Obstructive HCM ———————————————————————————————————————————————————————————— DC Healthcare Q2 EBITDA Surges to RM2.91 Million on Stronger Operating ... 2026-08-28 · PR-Inside · Finance, Healthcare https://pr-inside.com/dc-healthcare-q2-ebitda-surges-to-rm2-91-million-on-stronger-operating-r5217023.htm (PR-inside.com) KUALA LUMPUR, MY / ACCESS Newswire / August 28, 2026 / DC Healthcare Holdings Berhad("DC Healthcare" or the "Group"), a medical aesthetic services provider specialising in non-invasive and minimally invasive procedures, today announced its financial results for the second quarter ended 30 June 2026 ("Q2 FY2026"), delivering higher revenue and a strong year-on-year improvement in operating performance, with earnings before interest, tax, depreciation and amortisation ("EBITDA") rising significantly during the quarter. For Q2 FY2026, DC Healthcare recorded revenue of RM22.62 million, representing a 10% increase from RM20.60 million in the corresponding quarter ended 30 June 2025 ("Q2 FY2025"). The improvement was .. ———————————————————————————————————————————————————————————— International Plus Opens Ongoing London Consultation Service for UK Dental Patients 2026-08-28 · mlpr-newsfile · Healthcare https://www.newsfilecorp.com/release/311385/International-Plus-Opens-Ongoing-London-Consultation-Service-for-UK-Dental-Patients London, United Kingdom--(Newsfile Corp. - August 28, 2026) - International Plus, a Turkish dental group, announced the opening of an ongoing consultation service in London for UK patients considering dental treatment at the group's Istanbul facility. The service provides an in-person clinical assessment and treatment-planning stage in the United Kingdom before a patient decides whether to proceed with treatment in Istanbul.Image Description: Exterior view of the International Plus clinic,... ———————————————————————————————————————————————————————————— Fosun International Delivers 160.3% YoY Profit Growth in 1H2026 2026-08-28 · mlpr-acnnewswire · Finance, SaaS, Healthcare, Real Estate, Automotive https://www.acnnewswire.com/press-release/english/109551/ HONG KONG, August 28, 2026 - (ACN Newswire) - On the evening of 27 August, Fosun International announced its 2026 interim results. During the Reporting Period, its total revenue reached RMB86.96 billion; profit attributable to owners of the parent reached RMB1.72 billion, representing a year-on-year increase of 160.3%; overseas revenue reached RMB49.16 billion, with its share of total revenue rising to 56.5%; total debt to total capital ratio decreased to 55.7%. These figures show that Fosun’s results fall in the upper-middle range of the Company’s profit alert (profit attributable to owners of the parent is expected to range from approximately RMB1.5 billion to RMB1.8 billion, representing a year-on-year increase of approximately 127% to 172%) issued on 29 July. This marks Fosun’s return to a growth trajectory following the completion of a systematic realignment of “repairing the roof on a sunny day”. Over the past few years, Fosun has taken a rather unconventional path. Since 2022, in response to the severe market disruption caused by the pandemic, the Company has advanced its business streamlining and core business-focused strategy, divesting assets and businesses and generating cumulative cash proceeds of approximately RMB75 billion. In March 2026, pursuant to the principle of prudence, Fosun made one-off, non-cash impairment provisions and value revaluations on certain real estate projects with impairment indicators and goodwill and intangible assets of certain non-core business segments. The move drew considerable market attention at the time. At the Company’s 2025 annual results presentation at the end of March, Guo Guangchang, Chairman of Fosun International, explained, “This is about ‘repairing the roof on a sunny day’, allowing Fosun to focus its resources and efforts more effectively on core, high-growth areas.” The market has now responded to Fosun’s “repairing the roof on a sunny day” initiative. From the announcement of profit alert in early March to 25 August, before its interim results announcement, Fosun’s share price rose sharply from HKD3.6 to HKD5.41, representing an increase of more than 50%. The market has gradually recognized and priced in the Group’s “risk clearance” efforts. More importantly, the earnings growth driven by the Group’s businesses has begun to materialize. At the 2026 interim results presentation held in Hong Kong on 28 August, Guo Guangchang said: “The strong results recovery we delivered in the first half of the year reflects the outcome of the strategic adjustments we have made over the past few years. Our ‘repairing the roof on a sunny day’ strategy has paid off, allowing us to put historical burdens behind us. These results mark the beginning of Fosun’s continued progress along a trajectory of steady growth.” Solid Core Businesses, with Pharmaceuticals and Insurance Posting Strong Results First, let us look at Fosun’s core businesses. In the first half of 2026, its four core businesses — Fosun Pharma, Yuyuan, Fosun Insurance Portugal (Fidelidade), and the Tourism segment — generated a total revenue of RMB63.88 billion, accounting for 73.5% of the Group’s total revenue, further demonstrating the results of its core business-focused strategy. Among them, the pharmaceutical and insurance segments delivered particularly strong performance. In the first half of the year, Fosun Pharma achieved operating revenue of RMB20.377 billion. Revenue from innovative drugs recorded a year-on-year increase of 13.84%, with their contribution to pharmaceutical business revenue rising to 33.35%, establishing innovative drugs as a key growth driver. Its innovative biopharmaceutical platform, Henlius, reported revenue of RMB3.5882 billion, representing a year-on-year increase of 27.3%, while net profit amounted to RMB430.4 million, up 10.3% year-on-year, sustaining growth momentum in revenue and profit. Commercialization of innovative drugs continued to gain traction. During the Reporting Period, Fosun Pharma had a total of 20 indications of 7 innovative drugs approved for launch both domestically and overseas. With their revenue share on a steady rise, innovative drugs have become the main growth engine driving the pharmaceutical business forward. The insurance segment delivered a stellar performance, with Fosun’s domestic and overseas insurance companies all posting broad-based improvements. Fidelidade’s overall market share in Portugal reached 30.1%, and its international business accounted for 26.7% of its consolidated total business. In the first half of the year, Fidelidade recorded net profit attributable to owners of the parent of EUR165 million, up 23.8% year-on-year, maintaining steady growth. In Chinese mainland, Pramerica Fosun Life Insurance recorded gross written premiums of RMB8.38 billion in the first half of 2026, up 52.2% year-on-year. Net profit reached RMB780 million, representing a year-on-year increase of 270% and exceeding its net profit for the full year of 2025. Fosun United Health Insurance reported a 36.2% year-on-year increase in revenue and net profit of RMB572 million. Peak Reinsurance’s reinsurance revenue and gross written premiums increased by 25% and 11.8% year-on- year, respectively, while net profit after tax reached USD89.70 million. In April 2026, Moody’s upgraded Peak Re’s rating from Baa1 to A3, with a “stable” outlook. Guo Guangchang said at the results presentation: “Integrating our insurance business with industries in which we have established competitive advantages has been a strategic priority for Fosun for over three decades — a critical linkage we have long sought to unlock. I believe we have now achieved it. This integration will significantly strengthen our industrial operational capabilities and future profitability, providing sustained momentum for Fosun’s development.” “Successfully navigating another cycle” is how the market has described Fosun’s latest round of adjustments. A closer look reveals how Fosun has successfully navigated the cycle. On the one hand, the Group has continued to streamline its business to generate cash proceeds. In the first half of the year, the Group generated proceeds equivalent to more than RMB12.0 billion from the divestment of non-strategic and non-core assets. Its total debt to total capital ratio was reduced to 55.7%, while its cash, bank balances and term deposits amounted to RMB61.214 billion. On the other hand, the innovation and globalization strategy that the Group has been pursuing for years has entered a value-realization phase, serving as the core engine driving profit recovery. Integrated Innovation Strategy Bears Fruit Since innovative drugs took off in the domestic market in 2025, Fosun has repeatedly broken into the spotlight, with multiple innovative drug business development (BD) drawing significant market attention. In fact, as the saying goes, “One minute on stage takes ten years of hard work off stage”. This series of innovation achievements is the result of Fosun’s forward-looking innovation strategy established nearly two decades ago. Notably, for more than a decade, Fosun has built a globally integrated innovation system across its core business areas, combining “independent R&D + investment incubation + ecosystem collaboration”, and has consistently made substantial investments in technology innovation. In the first half of this year alone, investment in technology innovation reached RMB4.2 billion, representing a year-on-year increase of 16.7%. In the first half of this year, Fosun saw a series of innovations come to fruition. HANSIZHUANG, independently developed by Henlius, received approval from the National Medical Products Administration (NMPA) for its perioperative indication in gastric cancer, pioneering a postoperative “chemo-sparing” regimen and making it the world’s first and only anti-PD-1 monoclonal antibody approved for this indication. Its core pipeline asset, HLX43, as a potential best-in-class (BIC) broad-spectrum anti-tumor PD-L1 ADC, has demonstrated preliminary clinical efficacy characterized by high efficacy and low toxicity across multiple solid tumors, including non-small cell lung cancer (NSCLC), with over 1,500 patients enrolled globally. To date, Henlius has 10 products approved in over 60 countries and regions, and has benefited over 1.1 million patients. In addition, FUMAINING (luvoxmetinib tablets), independently developed by Fosun Pharma, was approved for the treatment of paediatric and adolescent patients with relapsed or refractory Langerhans cell histiocytosis (LCH), continuing to fill the gap in the treatment of rare diseases. In terms of neurodegenerative diseases, Fosun Pharma expanded its global collaboration with AriBio on AR1001, extending its rights to develop and commercialize the product to key markets including the U.S., Europe and Japan. Meanwhile, post-marketing confirmatory clinical trials for sodium oligomannate capsules have progressed steadily, with more than 1,000 patients enrolled as of 31 July 2026. In addition, HT001, an oral NLRP3 inhibitor for the treatment of Parkinson’s disease in-licensed by Hengtai Bio, an investee and incubated company of Fosun Pharma, commenced its Phase I clinical trial in Australia. Fosun’s innovation achievements demonstrate the forward-looking nature of its innovation strategy and its ability to identify the right opportunities in R&D. As Guo Guangchang remarked at the results presentation, through years of effort, Fosun has built globally integrated innovation capabilities rooted in China. This distinctive strength of Fosun is expected to create greater value for all in the years ahead. “Fosun has never pursued innovation behind closed doors. Instead, we leverage our resource-integration capabilities and a global perspective to drive smart innovation, bringing together the best technologies, teams and supply chains from around the world to solve real problems. This is how we unlock vast market potential,” said Guo Guangchang. Unlocking Value through Global Operations Globalization has been another forward-looking strategic move for Fosun. Since its listing in Hong Kong in 2007, when many Chinese companies were still focused primarily on their domestic markets, Fosun had already begun expanding overseas ahead of its peers. Nearly two decades later, as a growing number of Chinese companies embrace the view that they must go global or risk being left behind, and seek to capture overseas markets by taking their products overseas, Fosun has already established a profound business presence in more than 40 countries and regions. With local teams operating overseas, it has successfully operated a number of companies within the Fosun ecosystem. “Global operations” have become a defining feature of Fosun’s globalization strategy and a core engine underpinning the development of its businesses. Guo Guangchang said at the interim results presentation that Fosun continues to strengthen its global operational capabilities. On the one hand, it is helping Chinese products and services enter overseas markets. On the other hand, it is introducing high-quality products and services from around the world into China. Drawing on the global resource-mobilization capabilities it has built over the years, Fosun is able to identify high-quality projects and technologies worldwide and rapidly mobilize the resources needed to advance them. In the first half of 2026, Fosun’s overseas revenue reached RMB49.16 billion, accounting for 56.5% of total revenue, up 3 percentage points as compared to the same period of 2025 and marking a record high in the proportion of overseas revenue. In the field of pharmaceuticals and healthcare, Fosun made substantial progress in the global expansion of innovative drugs and commercial business development. Henlius’ HANSIZHUANG was approved for three new indications in the European Union (EU), while HLX11 (pertuzumab injection) was approved in the EU and HLX14 (denosumab injection) was approved in Canada. At the beginning of 2026, Fosun Pharma entered into a strategic partnership with Eisai for HANSIZHUANG, with an aggregate potential consideration exceeding USD300 million, underscoring how the global value of Chinese innovative drugs is being repriced by international markets. In the first half of the year, Yuyuan generated revenue of RMB532 million in Hong Kong SAR and Macau SAR in the first half of 2026, representing a year-on-year increase of 285.83%, while revenue from the Japanese market reached RMB306 million, representing a year-on-year increase of 6.09%. Laomiao has 15 stores in Hong Kong SAR, Macau SAR, overseas markets and duty-free channels. Club Med has also continued to expand its global footprint, with Club Med Urban Oasis Hangzhou Longwu already open and Club Med South Africa Beach & Safari now in soft opening. Leveraging Fosun’s global ecosystem, Fidelidade in the insurance segment has expanded its business from Portugal to Portuguese-speaking countries and markets across Europe, Latin America, and Africa. Its international business now accounts for 26.7% of its consolidated total business, with continued growth in Portuguese-speaking countries. Meanwhile, Peak Reinsurance has maintained steady growth thanks to its global business footprint. The guiding principle behind Fosun’s globalization strategy is “Combining Global Resources with China’s Capabilities”, deeply integrating China’s manufacturing capabilities, service capabilities, and innovation dividends, with global markets.  Starting with leveraging China’s growth momentum to establish its business presence, and progressing to a two-way engagement of “mutual empowerment between China and the world”, Fosun has now entered the 3.0 phase of “global organization + local operations”. In this phase, Fosun “truly operates with a global perspective”, having developed the ability to foster cross-regional, cross-cultural, and cross-organizational synergies within its business ecosystem and support the continued growth of its overseas revenue. At the interim results presentation held on 28 August, Guo Guangchang said: “Fosun’s future development goal is to ‘spur the horse to full speed’.  We have already positioned ourselves on a trajectory of steady growth. Going forward, we will continue to advance innovation-driven and global development in industries where we have established competitive advantages, building on our momentum and accelerating further.” Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com ———————————————————————————————————————————————————————————— Invitation to presentation of Sectra's three-month report 2026/2027 2026-08-28 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/invitation-to-presentation-of-sectras-three-month-report-20262027-302862639.html LINKÖPING, Sweden, Aug. 28, 2026 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) invites investors, analysts, and the media to a presentation of the company's three-month report with President Torbjörn Kronander and CFO Jessica Holmquist.... ———————————————————————————————————————————————————————————— Evonik expands lipid-based drug delivery capabilities with new GMP manufacturing facility in Vancouver 2026-08-28 · PR Newswire · Finance, Healthcare https://www.prnewswire.com/news-releases/evonik-expands-lipid-based-drug-delivery-capabilities-with-new-gmp-manufacturing-facility-in-vancouver-302862186.html New GMP (good manufacturing practice) facility to meet increasing demand for lipid nanoparticle (LNP) development and clinical drug product manufacturing Evonik invests over 150 million CAD (93 million EUR) Project is supported with up to 68 million CAD (42 million EUR) external funding... ———————————————————————————————————————————————————————————— Healthcare Can't Afford to Wait Until People Get Sick, SCU Says 2026-08-28 · PR Newswire · Healthcare, Education https://www.prnewswire.com/news-releases/healthcare-cant-afford-to-wait-until-people-get-sick-scu-says-302862360.html New perspective from Southern California University of Health Sciences (SCU) argues that prevention must play a larger role in the future of U.S. healthcare WHITTIER, Calif., Aug. 28, 2026 /PRNewswire/ -- What if one of the biggest opportunities to reduce America's healthcare burden... ———————————————————————————————————————————————————————————— Roche’s Vabysmo demonstrates sustained two-year results in a difficult-to-treat form of neovascular age-related macular degeneration (nAMD) 2026-08-28 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/08/28/3352514/0/en/roche-s-vabysmo-demonstrates-sustained-two-year-results-in-a-difficult-to-treat-form-of-neovascular-age-related-macular-degeneration-namd.html Basel, 28 August 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new two-year data from the Phase IIIb/IV SALWEEN study of Vabysmo ® (faricimab), presented at the 19 th Asia-Pacific Vitreo-retina Society (APVRS) Congress in Australia. 1 The results showed significant improvements in vision and retinal health in patients with polypoidal choroidal vasculopathy (PCV), a severe sub-type of neovascular age-related macular degeneration (nAMD), the leading cause of vision loss in people over the age of 60. 1-3 ———————————————————————————————————————————————————————————— Smart Scale Market: Connected Health Devices Get More Intelligent 2026-08-28 · Express Press Release · Healthcare https://express-press-release.net/news/2026/08/28/1769688 The global smart scale market was valued at USD 1.8 billion in 2025 and is expected to reach USD 1.9 billion in 2026. The market is projected to expand to USD [read full press release...] ———————————————————————————————————————————————————————————— DualityBio Enters a Global Collaboration and License Agreement with Genentech to Develop Next-Generation ADCs Built on DualityBio's DUPAC Novel-Payload Platform 2026-08-28 · PR Newswire · SaaS, Healthcare https://www.prnewswire.com/news-releases/dualitybio-enters-a-global-collaboration-and-license-agreement-with-genentech-to-develop-next-generation-adcs-built-on-dualitybios-dupac-novel-payload-platform-302862514.html Collaboration leverages DualityBio's proprietary DUPAC payload platform and early global clinical development capabilities, with Genentech assuming further clinical development and global commercialization DUPAC, one of the DualityBio's four proprietary ADC technology platforms, comprises... ———————————————————————————————————————————————————————————— Redion Holiday Barometer 2026: Singapore Sets a Global Benchmark for the Most Insured Travelers as Expectations for Travel Support Rise 2026-08-28 · mlpr-acnnewswire · AI, SaaS, Healthcare, Automotive https://www.acnnewswire.com/press-release/english/109546/ SINGAPORE, August 28, 2026 - (ACN Newswire) - Singapore has emerged as the world’s most mature travel protection market, with 86% of travelers covered by travel insurance when they travel, the highest rate recorded globally according to the latest Holiday Barometer 2026 report by Redion (formerly Europ Assistance) and Ipsos.  Alongside strong risk awareness among Singaporeans, the findings highlight growing expectations for comprehensive protection for a broader scope of travel risks, with real-time assistance and seamless digital support increasingly viewed as essential elements of the travel journey. As one of the region's most active outbound travel markets with frequent, high-spending travelers and digitally engaged consumers, Singapore offers a glimpse into how traveler expectations are evolving amid growing awareness of global risks. The increasing demand for reassurance through travel protection and assistance is posing a challenge for insurers and travel providers beyond driving insurance penetration towards delivering broader protection, stronger assistance capabilities and more integrated travel solutions that support travelers throughout their journeys. Travel protection has become a standard expectation Singapore ranks highest globally for travel insurance and protection coverage, with 86% of travelers covered when traveling and more than half (51%) intending to continue subscribing to travel insurance in the future. This market maturity is reflected in the types of risks Singaporeans choose to protect against, including loss of personal belongings, transportation accidents and health-related incidents, suggesting that travelers increasingly value comprehensive protection that extends beyond basic policy coverage. Singaporeans also remain among the world’s highest-spending travelers, with an average leisure holiday budget of USD 2,818. Yet affordability and company reputation remain important purchasing considerations when selecting travel protection, indicating that consumers are willing to invest in coverage when it offers clear value, trusted service and meaningful benefits. Virginie Babinet, CEO Travel Insurance & Assistance – Redion Group, said, "Building on the record levels seen last year, the desire to travel remains strong and undiminished, despite tougher trade-offs and the cost of living remaining a top global concern. What is changing, however, is the travel landscape itself. Security considerations are weighing more heavily on destination choices, with decisions increasingly shaped by risk considerations. At the same time, artificial intelligence is now a genuine planning tool for a growing number of travelers worldwide, as demonstrated by the distinct jump in numbers, particularly in emerging and high growth markets." Hassen Bennour, CEO of Redion Asia Pacific, said, “Singapore continues to set the pace for travel protection in the region, with 86% of travelers already covered, among the highest levels in the world. What is changing, however, is what travelers now expect this protection to deliver. Beyond coverage, Singaporeans want broader multi-risk protection, embedded assistance and reassurance that travels with them across every trip. At the same time, artificial intelligence is helping travelers plan faster, but confidence in the final decision still rests with human expertise. For insurers and industry partners, this is where the next opportunity lies: pairing digital speed with trusted human guidance to meet the standards of one of the most demanding travel markets globally." AI and digital tools help Singaporeans travel smarter, but human control still leads Singapore's strong digital adoption is also reshaping how travellers research, plan and manage their journeys. Nearly half (45%) of Singaporeans have used AI in holiday planning or booking, primarily to research destinations, compare travel options and build itineraries. A similar proportion (48%) would consider allowing AI to make bookings on their behalf, provided they retain the ability to review and approve decisions before purchase. The same trend is emerging in travel insurance. While the use of AI to compare travel insurance products remains relatively limited today, many travelers (47%) expect to rely on it more in the future because of the convenience and speed it offers. Interest is also growing in digital services that complement insurance policies, including emergency assistance, 24/7 customer support, real-time alerts, mobile access and digital claims services. The implication is evident that AI is preferred as a tool in the planning process, but decision-making and the trust that comes with it still needs a human checkpoint built into the journey. Rather than replacing human involvement, the findings suggest that travelers want digital convenience supported by visible human oversight, combining the speed of technology with the confidence of expert guidance. Frequent outbound and experience-driven travelers expect reassurance throughout the journey Singaporeans remain among the region’s most active travelers. More than 9 in 10 take at least one leisure trip annually, while the majority (84%) intend to travel internationally, despite persisting geopolitical uncertainty. Travel is increasingly experience-driven, with nearly 7 in 10 preferring city destinations, citing relaxation, exploration and local food and cultural discovery among their key motivations. Combined with high travel spending, these behaviors reflect a market that increasingly prioritizes quality experiences alongside value. As travellers invest more in their trips, expectations around protection and support naturally rise. The research found that concerns around natural disasters, epidemic outbreaks, terrorism and travel disruptions continue to influence travel decisions. Rather than discouraging travel, these concerns are driving demand for greater reassurance, flexibility and support before, during and after each journey. This creates opportunities for insurers and travel providers to embed safety, assistance and peace of mind into the overall customer journey as enablers of worry-free travel experiences. With most travelers taking their longest trips during the year-end period, particularly in November and December, the final quarter remains a critical window for travel providers to engage consumers through premium offerings, bundled experiences and integrated protection solutions. As expectations around travel continue to evolve, Singapore's world-leading level of protection coverage underscores a broader shift in how travellers view insurance and assistance. Increasingly, travellers are seeking protection that delivers peace of mind throughout the entire journey, supported by digital convenience, responsive assistance and trusted expertise whenever they need it. About Redion (formerly Europ Assistance) Redion is a world leader in assistance, travel insurance and employee benefits. The name, revealed in 2026, reflects the full maturity of the global Care platform that has been operating under Generali Care, bringing together Europ Assistance and Generali Employee Benefits (GEB). Operating in more than 190 countries, with over 12,000 employees and €5.8 billion in annual business volume, Redion delivers services spanning travel insurance, emergency and medical assistance, employee protection (life, disability, accident, medical), health and mobility solutions, as well as global B2B2C and embedded insurance programmes. Within its employee benefits offering, Redion builds on a global network of 224 active partners to provide multinational clients with protection, health, pension and wellbeing solutions across markets, combining global scale, local expertise and deep technical capabilities. For media enquiries, please contact: Benedict Gerald Rozario, Marketing & Communication, Redion East Asia M: +60-12 979 7238 E: benedict.rozario@eastasia.redion.com Nadzwan Tahir, Senior Executive Narro Communications M: +60-18 399 1646 E: nadzwan@narrocomms.com  Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com ———————————————————————————————————————————————————————————— San Diego Disability Lawyer Craig Fahey Explains What Happens During a Continuing Disability Review 2026-08-28 · PressReleaseNews · Healthcare https://pressreleasenews.org/pressroom/san-diego-disability-lawyer-craig-fahey-explains-what-happens-during-a-continuing-disability-review SSDI attorney Craig Fahey explains how SSA's Continuing Disability Reviews work, what triggers one, and what's changing as the agency shifts processing to a new federal unit in 2026, helping San Diego recipients protect benefits they still qualify for. ———————————————————————————————————————————————————————————— Singclean 2nd Leaders Summit Charts New Course in Global Aesthetics 2026-08-28 · PR Newswire · Healthcare, Education https://www.prnewswire.com/news-releases/singclean-2nd-leaders-summit-charts-new-course-in-global-aesthetics-302862468.html SHANGHAI, Aug. 28, 2026 /PRNewswire/ -- Hosted within the IMCAS China Conference venue at W Shanghai - The Bund, Singclean 2nd International Medical Aesthetic Leaders Summit themed "Global Vision, Embark on a New Chapter" came to a successful conclusion. Gathering top global doctors and... ———————————————————————————————————————————————————————————— Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's 2026-08-28 · PR Newswire · Finance, Healthcare https://www.prnewswire.com/news-releases/akeso-2026-interim-results-strong-commercialization-momentum-io2-0-global-strategy-redefining-clinical-standards-bispecific-advancement-in-adc-ii-and-alzheimers-302862455.html HONG KONG, Aug. 27, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced its 2026 interim results. During the reporting period, the Company achieved record-high drug sales revenue, further advanced its global immuno-oncology (IO) 2.0 strategy, progressively... ———————————————————————————————————————————————————————————— Central Ohio Primary Care Physicians Data Breach: Edelson Lechtzin LLP Launches Investigation Into Exposure of Patient and Employee Information 2026-08-28 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/central-ohio-primary-care-physicians-data-breach-edelson-lechtzin-llp-launches-investigation-into-exposure-of-patient-and-employee-information-302862451.html National class action firm offering free case evaluations to Central Ohio Primary Care Physicians patients and employees affected by the COPCP data breach and Chaos ransomware attack WESTERVILLE, Ohio, Aug. 27, 2026 /PRNewswire/ -- Edelson Lechtzin LLP, a national class action law firm,... ———————————————————————————————————————————————————————————— Supporting Thailand’s next generation of AI startups 2026-08-28 · mlpr-openai · AI, Healthcare, Education https://openai.com/index/supporting-next-generation-ai-startups-thailand OpenAI and Thailand’s MHESI launch an eight-week accelerator helping 10 health, wellness, and education startups turn AI prototypes into trusted products. ———————————————————————————————————————————————————————————— Midi Health Supplements Review 2026: Is This the Midlife Wellness Line Worth Adding to Your Daily Routine? 2026-08-28 · Newswire.com · Healthcare https://www.newswire.com/news/midi-health-supplements-review-2026-is-this-the-midlife-wellness-line-worth As interest in midlife-focused wellness continues growing in 2026, this Midi Health Supplements review explores the brand-stated formulas for stress, cognitive, metabolic, digestive, muscle, and GLP-1 nutritional support, while breaking down the ingredients, pricing, testing disclosures, subscription terms, and buyer considerations consumers are comparing before adding a new supplement to their daily routine. ———————————————————————————————————————————————————————————— Modern Dental Group Announces 2026 Interim Results 2026-08-28 · mlpr-acnnewswire · Finance, AI, Healthcare, Retail, Education https://www.acnnewswire.com/press-release/english/109542/ RESULTS HIGHLIGHTS: - The Revenue for the six months ended 30 June 2026 was approximately HK$2,032.5 million, representing an increase of approximately 10.8% as compared to the same period in 2025. The growth in revenue was primarily attributable to the continued organic growth of the Group—driven by the accelerating adoption of digitalization across the global dental industry, particularly in Europe and Australia—alongside the stabilization and operational turnaround of the Mainland China market. This expansion was partially offset by a revenue decline in North America, which was impacted by a softer macroeconomic environment affecting high-value discretionary procedures, as well as management’s strategic decision to rationalize loss-making Dental Service Organization (DSO) accounts to optimize customer mix and protect margins. - The Gross Profit Margin for the six months ended 30 June 2026 was approximately 58.1%; the gross profit was approximately HK$1,180.9 million, reflecting an increase of approximately 17.4% as compared to the same period in 2025. - The Group’s EBITDA for the six months ended 30 June 2026 was approximately HK$ 560.7 million, representing an increase of approximately 22.8% as compared to the same period in 2025. - The Group’s Net Profit for the six months ended 30 June 2026 was approximately HK$ 377.6 million, representing an increase of 30.8% as compared to the same period in 2025. - Basic earnings per share for the six months ended 30 June 2026 amounted to HK40.07 cents, representing an increase of approximately 31.9% as compared to the same period in 2025. - The Board declared an interim dividend of HK14.0 cents per ordinary share for the six months ended 30 June 2026. ADDITIONAL HIGHLIGHTS: - For the six months ended 30 June 2026, the Group’s digital solution cases that are produced from its Mainland China, Thailand and Vietnam production facilities increased to approximately 627,773 cases, reflecting an increase of 29.2% as compared with the same period in 2025 as a result of our clients’ continued adoption of intra-oral scanners. HONG KONG, August 28, 2026 - (ACN Newswire) - 27 August 2026, Modern Dental Group Limited (“Modern Dental” or “the Group”, stock code: 03600.HK), a leading global dental prosthetic device provider, is pleased to announce the unaudited interim results for the six months ended 30 June, 2026 (“the Period”). In the first half of 2026, the global macroeconomic environment remains uncertain, with geopolitical tensions and potential tariff changes continuing to create headwinds. However, the Group’s geographically diversified production footprint and global distribution network position us strongly to navigate these challenges. Unlike many competitors reliant on single-country manufacturing, our operations across China, Vietnam and Thailand (including the newly acquired Hexa Ceram) provide superior resilience and flexibility. This strategy, combined with our ability to adapt quickly to local market conditions, enables the Group to mitigate risks and capitalise on opportunities across regions. The dental industry has continued to demonstrate remarkable resilience, underpinned by irreversible demographic trends, including aging populations and increasing awareness of oral health, which drive consistent long-term demand. Building on our well performance, the Group is well placed to sustain momentum and further strengthen its market leadership. Digitalisation remains an irreversible industry trend that is accelerating consolidation of the dental prosthetics industry. We are at the forefront of this transformation, with digital solution cases now representing approximately 35–43% of total volume. Our centralized digital workflows, intra-oral scanner partnerships, proprietary solutions and global education centers have enhanced operational efficiency, reduced turnaround times and delivers superior customer experiences. These initiatives create high entry barriers and will continue to drive margin expansion and market share gains in the coming years. European Businesses During the period under review, the European market recorded a revenue of approximately HK$1,093.3 million, representing an increase of approximately HK$173.0 million as compared with the six months ended 30 June 2025. This geographic market accounted for approximately 53.8% of the Group’s total revenue. The increase of revenue from the European market was attributable to the increase in sales order volume driven by the launch of new products, such as digital dentures, and our state-of-the-art digital workflows. North American Businesses During the period under review, the North American market recorded a revenue of approximately HK$331.3 million, representing a decrease of approximately HK$34.4 million as compared with the six months ended 30 June 2025. This geographic market accounted for approximately 16.3% of the Group’s total revenue. The top-line contraction in North America was primarily driven by a softer macroeconomic environment, which temporarily weighed on consumer sentiment and demand for high-value discretionary cosmetic procedures. In response, management proactively initiated a strategic rationalization of loss-making Dental Service Organization (DSO) accounts aimed at optimizing the customer mix, protecting gross margins, and focusing resources on higher-margin accounts. Concurrently, the Group’s diversified production footprint across the US, China, Vietnam, and Thailand continues to afford significant supply chain agility to navigate trade and tariff complexities—a key differentiator in the market. Demonstrating the resilience of this strategy, our US import business unit delivered a 1.4% period-on-period sales growth in the first half of 2026. This performance underscores how the accelerating trend toward clinical digitalization and the cost-competitiveness of our imported product lines have effectively mitigated and offset the impact of US tariffs. Greater China Businesses During the period under review, the Greater China market recorded a revenue of approximately HK$300.0 million, representing an increase of approximately HK$6.8 million as compared with six months ended 30 June 2025. This geographic market accounted for approximately 14.8% of the Group’s total revenue. Regional performance reflected diverging market dynamics across territories. In local currency terms, sales in Mainland China increased by approximately 0.9% year-on-year, signalling that the market has largely bottomed out from the initial impact of Volume-Based Procurement (VBP) policies and prolonged price competition. To protect sustainable profitability, the Group deliberately pivoted away from low-margin segments to focus on serving mid- to high-value customers. Conversely, sales in the Hong Kong market decreased by approximately 8.5% in local currency year-on-year. This contraction was primarily driven by a temporary reduction in local patient visits, as cross-border dental consumption increased due to aggressive promotions for dental treatments offered by Mainland China clinics targeting Hong Kong residents. Despite these near-term shifts, the Group remains optimistic about the mid- to long-term outlook for the Greater China region. Government procurement measures in Mainland China are expected to standardize prosthetic pricing and enhance market transparency, creating a more level playing field where the Group’s leading brand reputation, production scale, and operational efficiency serve as distinct competitive advantages. To capture evolving market demand, the Group is actively expanding its product portfolio, particularly in mid-end offerings and products. Australian Businesses During the period under review, the Australian market recorded a revenue of approximately HK$162.8 million, representing an increase of approximately HK$24.9 million as compared with the six months ended 30 June 2025. This geographic market accounted for approximately 8.0% of the Group’s total revenue. The increase in revenue from Australia was primarily driven by strong adoption of digital dental products and anti-snoring devices, and wins in dental service organization (DSO) customers. Other Markets Other markets primarily include Indian Ocean countries, Malaysia, Taiwan, Singapore and Thailand. For the six months ended 30 June 2026, these markets recorded a revenue of approximately HK$145.2 million, representing an increase of approximately HK$27.4 million as compared with the six months ended 30 June 2025. This geographic market accounted for approximately 7.1% of the Group’s total revenue. The increase in revenue from Other markets was primarily driven by the strong revenue contributions from Thailand, Singapore and Malaysia. The scaled manufacturing hubs in Thailand and Vietnam have enhanced regional supply efficiency, broadened product availability, and strengthened the Group’s competitive footprint in the region. Future Prospects and Strategies Looking ahead, the Group remains committed to reinforcing its worldwide leading position through a multi-dimensional approach. We will continue to pursue selective acquisitions, joint ventures and partnerships to expand and complement our product offerings, particularly in our high-growth clear aligner, Trioclear, while strengthening our distribution and sales networks. Ongoing investments in mass-scale production facilities, AI, automation, research and development, and digital innovation will drive efficiency gains and secure our position at the forefront of the industry. With the Board’s extensive experience and prudent governance, the Group is well positioned to seize new business opportunities while remaining strict financial discipline to safeguard Shareholders’ interests. The Board expresses its sincere gratitude to our dedicated employees, loyal customers, suppliers, and business partners for their unwavering commitment. Their collective efforts have been instrumental in delivering another year of record results and will continue to support the Group’s long-term success. About Modern Dental Group Modern Dental Group Limited (Stock code: 03600.HK) is a leading global dental prosthetics provider, distributor and consultant with a focus on providing custom-made prostheses to customers in the growing prosthetics industry. Our product portfolio is broadly categorized into three product lines: fixed prosthetic devices, such as crowns and bridges; removable prosthetic devices, such as removable dentures; and other devices, such as orthodontic devices, sports guards, clear aligners, and anti-snoring devices. Modern Dental Group has a global portfolio of respected brands, including Labocast, Permadental and Elysee Dental in Western Europe, YZJ Dental in China, Modern Dental Lab in Hong Kong, Modern Dental USA and MicroDental in the United States, Modern Dental Pacific in Australia and New Zealand, Modern Dental SG in Singapore, Modern Dental TW in Taiwan, Apex Digital Dental in Malaysia and Hexa Ceram in Thailand. We have grown these brands by providing premium and consistent quality products and superior customer service. We have more than 80 service centers in over 30 countries and serve over 35,000 customers. Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com ———————————————————————————————————————————————————————————— /C O R R E C T I O N -- O Positiv Health/ 2026-08-28 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/o-positiv-health-launches-uro-hair-growth--volume-to-address-common-causes-of-hair-loss-in-women-302853352.html In the news release, O Positiv Health Launches URO Hair Growth + Volume to Address Common Causes of Hair Loss in Women, issued 18-Aug-2026 by O Positiv Health over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows: O Positiv... ———————————————————————————————————————————————————————————— As Postpartum Psychosis Draws National Attention, The Motherhood Center Offers Clinical Expertise to Help Newsrooms Cover It Responsibly 2026-08-28 · PRWeb · Healthcare https://www.prweb.com/releases/as-postpartum-psychosis-draws-national-attention-the-motherhood-center-offers-clinical-expertise-to-help-newsrooms-cover-it-responsibly-302862380.html Dr. Catherine Birndorf, Co-Founder and Medical Director of the nation's leading perinatal mental health treatment center, is available to provide evidence-based information and context on postpartum psychosis and the full spectrum of Perinatal Mood and Anxiety Disorders (PMADs). NEW YORK,... ———————————————————————————————————————————————————————————— Notice of Data Privacy Incident 2026-08-27 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/notice-of-data-privacy-incident-302862348.html Psychiatry of Texas PLLC HOUSTON, Aug. 27, 2026 /PRNewswire/ -- Psychiatry of Texas PLLC writes to notify you of a data privacy event that involved protected health information (PHI). What Happened? On March 31, 2026, we learned of an anomaly on our network and launched an immediate... ———————————————————————————————————————————————————————————— INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teladoc Health, Inc. - TDOC 2026-08-27 · PR Newswire · Finance, Healthcare https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-teladoc-health-inc---tdoc-302862337.html NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Teladoc Health, Inc. ("Teladoc" or the "Company") (NYSE: TDOC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The... ———————————————————————————————————————————————————————————— Knight Therapeutics Announces Supplemental Regulatory Submission for MINJUVI® (tafasitamab) in Brazil 2026-08-27 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/08/27/3352450/0/en/knight-therapeutics-announces-supplemental-regulatory-submission-for-minjuvi-tafasitamab-in-brazil.html MONTREAL, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI ® (tafasitamab) in combination with lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). The supplemental application for the additional indication was selected for review under Project Orbis. ———————————————————————————————————————————————————————————— U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens 2026-08-27 · mlpr-businesswire · Finance, Healthcare https://finance.yahoo.com/healthcare/articles/u-fda-approves-gilead-bixlenvo-214700290.html FOSTER CITY, Calif., August 27, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. ———————————————————————————————————————————————————————————— Emerging Growth Research Issues Updated Press Release Announcing Company-Sponsored Research on SBC Medical Group Holdings Incorporated 2026-08-27 · Newswire.com · Healthcare https://www.newswire.com/news/emerging-growth-research-issues-updated-press-release-announcing-2182896 ———————————————————————————————————————————————————————————— NuGen Announces Filing of Corrective Disclosure Pursuant to OSC Review 2026-08-27 · mlpr-newsfile · Healthcare https://www.newsfilecorp.com/release/311906/NuGen-Announces-Filing-of-Corrective-Disclosure-Pursuant-to-OSC-Review Toronto, Ontario--(Newsfile Corp. - August 27, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company") announces that further to the review by the Ontario Securities Commission ("OSC") of the Company's continuous disclosure, the Company has made corrective disclosure with respect to the following:the Company has included in its recently filed management information circular dated August 17, 2026 (the "Circular") the executive compensation disclosure for the year ended December... ———————————————————————————————————————————————————————————— Kane Biotech Announces Second Quarter 2026 Financial Results 2026-08-27 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/08/27/3352435/0/en/kane-biotech-announces-second-quarter-2026-financial-results.html WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results. ———————————————————————————————————————————————————————————— Emerging Growth Research Issues Company-Sponsored Research Flash Report ... 2026-08-27 · PR-Inside · Finance, Healthcare https://pr-inside.com/emerging-growth-research-issues-company-sponsored-research-flash-report-r5216916.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 27, 2026 / Emerging Growth Research, LLC ("Emerging Growth Research" or "EGR") today announced the release of its company-sponsored research flash report on OSR Health, Inc. (NASDAQ:OSRH), a global healthcare holding company advancing oral immunotherapies for cancer and age-related disease, non-invasive glucose monitoring technology, and fourth-party logistics (4PL) operations. This release is being issued as an updated version of EGR's previously published press release. The updated release is intended to clarify the company-sponsored nature of the research and provide additional disclosure regarding EGR's financial relationship with the Company. The flash report highlights OSRH's .. ———————————————————————————————————————————————————————————— Emerging Growth Research Issues Company-Sponsored Research Flash Report on OSR Health, Inc. 2026-08-27 · Newswire.com · Healthcare https://www.newswire.com/news/emerging-growth-research-issues-company-sponsored-research-flash-report-on-osr ———————————————————————————————————————————————————————————— Before Recommending an International Student Health Insurance Company: What Five U.S. Universities Actually Require in 2026–2027 2026-08-27 · PressReleaseNews · Healthcare, Education https://pressreleasenews.org/pressroom/before-recommending-an-international-student-health-insurance-company-what-five-u-s-universities-actually-require-in-2026-2027 ———————————————————————————————————————————————————————————— SpyGlass Pharma Celebrates Grand Opening of New Irvine Headquarters, Positioning Itself for First Product Launch and Custom R&D Space 2026-08-27 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/spyglass-pharma-celebrates-grand-opening-of-new-irvine-headquarters-positioning-itself-for-first-product-launch-and-custom-rd-space-302862270.html Future portfolio expansion will advance a new era of ophthalmic care while driving continued growth of Irvine's MedTech and life sciences sector. IRVINE, Calif., Aug. 27, 2026 /PRNewswire/ -- SpyGlass Pharma, a biopharmaceutical clinical-stage company dedicated to transforming treatment... ———————————————————————————————————————————————————————————— INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Hims & Hers Health, Inc. - HIMS 2026-08-27 · PR Newswire · Finance, Healthcare https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-hims--hers-health-inc---hims-302862268.html NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE: HIMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The... ———————————————————————————————————————————————————————————— Advanced Recovery Systems and Promises Behavioral Health Combine to Advance Behavioral Health Care Delivery 2026-08-27 · PR.com · Healthcare https://www.pr.com/press-release/977591 Advanced Recovery Systems and Promises Behavioral Health have combined, bringing together two organizations focused on evidence-based, compassionate care for people experiencing addiction and mental health conditions. [PR.com] ———————————————————————————————————————————————————————————— Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine 2026-08-27 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/27/3352417/0/en/pfizer-and-biontech-receive-u-s-fda-approval-for-xfg-adapted-covid-19-vaccine.html NEW YORK and MAINZ, GERMANY, August 27, 2026 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies’ 2026-2027 COVID-19 vaccine formula targeting the XFG variant (COMIRNATY ® XFG; COVID-19 Vaccine, mRNA) for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19. 1 ———————————————————————————————————————————————————————————— Vanta Announces Engagement of Independent Trading Group for Market-Making ... 2026-08-27 · PR-Inside · Healthcare, Retail https://pr-inside.com/vanta-announces-engagement-of-independent-trading-group-for-market-making-r5216900.htm (PR-inside.com) VANCOUVER, BC / ACCESS Newswire / August 27, 2026 /Vanta Holdings Inc. (CSE:VNTA)(OTC:VNTXF)(FSE:7BC, WKN:A4205J) ("Vanta" or the "Company"), a consumer health sciences and longevity company focused on preventative wellness and healthspan extension, and parent of the Vanta premium longevity brand, announces that it has engaged the services of Independent Trading Group (ITG) Inc. ("ITG") to provide market-making services in accordance with Canadian Securities Exchange ("CSE") policies, effective August 27, 2026. The engagement of ITG forms part of the Company's broader strategic capital markets initiatives, aimed at enhancing trading liquidity, supporting orderly market conditions, and improving overall market quality for the Company's .. ———————————————————————————————————————————————————————————— IQVIA Wins Multiple Industry Awards for AI and Technology Innovation Across Life Sciences and Healthcare 2026-08-27 · mlpr-businesswire · Finance, AI, Healthcare https://finance.yahoo.com/healthcare/articles/iqvia-wins-multiple-industry-awards-201500808.html RESEARCH TRIANGLE PARK, N.C., August 27, 2026--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced it received recognition this year from multiple independent industry awards programs for its use of AI to help healthcare and life sciences organizations improve decisions, strengthen regulated workflows, protect patient privacy and optimize clinical trial execution ———————————————————————————————————————————————————————————— Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines ... 2026-08-27 · PR-Inside · Finance, Healthcare https://pr-inside.com/moderna-receives-u-s-fda-approval-for-updated-2026-2027-covid-19-vaccines-r5216895.htm (PR-inside.com) CAMBRIDGE, MA / ACCESS Newswire / August 27, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applications (sBLA) for the 2026-2027 formulas for Spikevax® (COVID-19 Vaccine, mRNA) and mNEXSPIKE® (COVID-19 Vaccine, mRNA), containing the JN.1-lineage XFG subvariant of SARS-CoV-2 to help prevent COVID-19. The updated formula for Spikevax is now approved for individuals 6 months through 64 years of age with at least one underlying condition placing them at high risk for severe outcomes from COVID-19, and all adults 65 years of age and older. mNEXSPIKE, Moderna's latest .. ———————————————————————————————————————————————————————————— Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines 2026-08-27 · Newswire.com · Healthcare https://www.newswire.com/news/moderna-receives-u-s-fda-approval-for-updated-2026-2027-covid-19-vaccines ———————————————————————————————————————————————————————————— American College of Lifestyle Medicine Annual Conference to highlight lifestyle medicine implementation, clinical value and successful behavior change 2026-08-27 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/american-college-of-lifestyle-medicine-annual-conference-to-highlight-lifestyle-medicine-implementation-clinical-value-and-successful-behavior-change-302862217.html The American College of Lifestyle Medicine (ACLM) has announced a full lineup of 145 keynote and concurrent sessions for its accredited, hybrid 2026 Lifestyle Medicine Annual Conference, set for November 8 to 11. The event presentations will showcase implementation of lifestyle medicine... ———————————————————————————————————————————————————————————— Hoomanely Unveils AI-Native Platform to Build the Health Intelligence ... 2026-08-27 · PR-Inside · AI, SaaS, Healthcare, Education https://pr-inside.com/hoomanely-unveils-ai-native-platform-to-build-the-health-intelligence-r5216893.htm (PR-inside.com) By Learning an Animal's Patterns Over Its Lifetime, the Company Aims to Make Interspecies Health Communication Possible During an 18-Month Beta, EverBowl Generated More Than 5 Million Multimodal Data Points Across 80-Plus Dogs PALO ALTO, CA / ACCESS Newswire / August 27, 2026 / Every day, animals reveal information about their health through how they eat, drink, move, sound and behave. Today, Hoomanely unveiled an AI-native platform designed to gather these signals and translate them into individualized, longitudinal health intelligence. (Left to Right) Vipin Ravindran (CTO)_Harshal Hinger (COO)_Sai Supriya Sharath (CEO) with dog Starting with dogs, the platform learns what is normal for each .. ———————————————————————————————————————————————————————————— Vadzo Imaging Validates Onvif Profile S, T, and G on Innova-234MGS AR0234 2MP Monochrome Gigabit Ethernet Camera for Patient Monitoring Applications 2026-08-27 · Newswire.com · Healthcare https://www.newswire.com/news/vadzo-imaging-validates-onvif-profile-s-t-and-g-on-innova-234mgs-22851059 Built for continuous patient monitoring and clinical imaging that must resolve motion accurately without adding heat or complexity to a patient room, this camera pairs the Onsemi AR0234 global shutter sensor with Onvif compliance and low operational power over GigE Vision, giving healthcare technology providers dependable monochrome imaging that integrates directly with hospital network infrastructure already in place. ———————————————————————————————————————————————————————————— Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S. 2026-08-27 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/27/3352365/34323/en/roivant-announces-fda-approval-of-lisraya-brepocitinib-for-adults-with-dermatomyositis-now-available-in-the-u-s.html BASEL, Switzerland and LONDON and NEW YORK, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that the U.S. Food and Drug Administration (FDA) has approved LISRAYA™ (brepocitinib) 30 mg for the treatment of adults with dermatomyositis (DM). LISRAYA is a pill taken once daily. ———————————————————————————————————————————————————————————— Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S. 2026-08-27 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/27/3352364/34323/en/priovant-announces-fda-approval-of-lisraya-brepocitinib-for-adults-with-dermatomyositis-now-available-in-the-u-s.html DURHAM, N.C., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved LISRAYA™ (brepocitinib) 30 mg for the treatment of adults with dermatomyositis (DM). LISRAYA is a pill taken once daily. ———————————————————————————————————————————————————————————— Florida's First Pediatric Cardiac Robotic Surgery Performed at Nicklaus Children's Hospital 2026-08-27 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/floridas-first-pediatric-cardiac-robotic-surgery-performed-at-nicklaus-childrens-hospital-302862142.html Cardiovascular Surgeons within Nicklaus Children's Hospital Heart Institute Have Completed the First Robotics-Assisted Atrial Septal Defect (ASD) Repair in Florida and One of Few in the Nation MIAMI, Aug. 27, 2026 /PRNewswire/ -- The cardiovascular surgery team at Nicklaus Children's... ———————————————————————————————————————————————————————————— Nano-X Imaging (NNOX) to Report Second-Quarter 2026 Financial Results Sept. 9 2026-08-27 · NewMediaWire · Finance, SaaS, Healthcare, Retail https://www.newmediawire.com/news/nano-x-imaging-nnox-to-report-second-quarter-2026-financial-results-sept-9-7088982 LOS ANGELES, CA - August 27, 2026 ( NEWMEDIAWIRE ) - Nanox (NASDAQ: NNOX) , an innovative medical imaging technology company, announced it will report financial results for the quarter ended June 30, 2026, before market open on Sept. 9, 2026. CEO and Acting Chairman Erez Meltzer and CFO Guy Nathanzon will host a conference call beginning at 8:30 a.m. ET to review the results and provide a business update. A live webcast will also be available through the Investor Relations section of the Nanox website. To view the full press release, visit https://ibn.fm/y877D About Nanox Nanox is focused on driving the world’s transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform. Nanox combines affordable imaging hardware, advanced A ———————————————————————————————————————————————————————————— Sports Research® Expands Creatine Portfolio as the Category Evolves Beyond Traditional Sports Performance into Everyday Wellness 2026-08-27 · PR Newswire · Healthcare, Retail https://www.prnewswire.com/news-releases/sports-research-expands-creatine-portfolio-as-the-category-evolves-beyond-traditional-sports-performance-into-everyday-wellness-302862115.html New Creatine Capsules launch at Costco and Amazon, delivering 5 grams of creatine monohydrate per serving in a convenient capsule format. LOS ANGELES, Aug. 27, 2026 /PRNewswire/ -- Sports Research®, a leading health and wellness company, today announced the launch of its new Creatine... ———————————————————————————————————————————————————————————— Fractyl Health, Inc. (GUTS) Class Action Lawsuit: Levi & Korsinsky ... 2026-08-27 · PR-Inside · Finance, Healthcare https://pr-inside.com/fractyl-health-inc-guts-class-action-lawsuit-levi-korsinsky-r5216869.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 27, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Fractyl Health, Inc. (NASDAQ:GUTS) securities. If you suffered a loss on your Fractyl Health, Inc. investment and would like to explore a potential recovery under the federal securities laws, Learn about Fractyl Health, Inc. Class Action or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit was filed .. ———————————————————————————————————————————————————————————— Incuvio Health Expands Business Process Outsourcing (BPO) Capabilities to Help Healthcare Organizations Scale with Confidence 2026-08-27 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/incuvio-health-expands-business-process-outsourcing-bpo-capabilities-to-help-healthcare-organizations-scale-with-confidence-302862111.html Expanded BPO services strengthen Incuvio Health's ability to support healthcare organizations through technology-enabled operational excellence, clinical expertise, and scalable workforce solutions. LOS ANGELES, Aug. 27, 2026 /PRNewswire/ -- Incuvio Health today announced the expansion of... ———————————————————————————————————————————————————————————— Intermountain Medical Center First in Utah to Offer Innovative MRI for Cancer and Heart Patients 2026-08-27 · PRUnderground · Healthcare https://prunderground.com/intermountain-medical-center-first-in-utah-to-offer-innovative-mri-for-cancer-an/cmtbo66j800gh04jvyzrz8u9b As a first in Utah, Intermountain Health brings Innovative MRI technology to Intermountain Medical Center to enhance care for cancer and heart patients. The post Intermountain Medical Center First in Utah to Offer Innovative MRI for Cancer and Heart Patients first appeared on ———————————————————————————————————————————————————————————— How Avel eCare's Virtual Health System Helps Rural Physicians Stay ... 2026-08-27 · PR-Inside · Healthcare https://pr-inside.com/how-avel-ecare-s-virtual-health-system-helps-rural-physicians-stay-r5216858.htm (PR-inside.com) See how Avel's Virtual Health System supports rural physicians through collaboration, reduced burnout, and better access to specialist care. SIOUX FALLS, SD / ACCESS Newswire / August 27, 2026 / When a massive explosion happened in a small rural town, the local hospital suddenly faced a situation that would challenge even a large trauma center. Five burn patients were on the way. For the physician working that shift, the moment was especially overwhelming. She was a traveling physician-not a full-time emergency medicine specialist-and she was covering in her hometown community. Dr. Kelly Rhone, Chief Medical Officer at Avel eCare, remembers the moment clearly. "We knew .. ———————————————————————————————————————————————————————————— Oryon Cell Therapies Appoints Kenny Choi, Ph.D. as Chief Technical Officer 2026-08-27 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/oryon-cell-therapies-appoints-kenny-170200811.html WATERTOWN, Mass., August 27, 2026--Oryon Cell Therapies ("Oryon"), a clinical-stage biotechnology company focused on developing autologous neuron replacement medicines for Parkinson’s disease and other neurodegenerative disorders, today announced the appointment of Kenny Choi, Ph.D., as Chief Technical Officer (CTO). Dr. Choi will lead Oryon’s technical operations and Chemistry, Manufacturing, and Controls (CMC) strategy, including transfer of the manufacturing process for the company’s autologo ———————————————————————————————————————————————————————————— ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the First Half of 2026 2026-08-27 · mlpr-businesswire · SaaS, Healthcare https://finance.yahoo.com/healthcare/articles/abionyx-pharma-provides-activity-cash-165900783.html TOULOUSE, France & FULLERTON, Calif., August 27, 2026--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a next-generation biopharmaceutical company developing innovative therapies for sepsis and critical care based on a proprietary apoA-I-based technology platform, today provides an update on its activity and cash position as of June 30, 2026. ———————————————————————————————————————————————————————————— GLOBO Language Solutions Shortlisted for The 2026 A.I. Awards 2026-08-27 · PR Newswire · AI, Healthcare https://www.prnewswire.com/news-releases/globo-language-solutions-shortlisted-for-the-2026-ai-awards-302862076.html First-to-market AI medical interpretation levels up every step of the LEP patient's healthcare journey PHILADELPHIA, Aug. 27, 2026 /PRNewswire/ -- GLOBO Language Solutions ("GLOBO"), the leading B2B provider of interpreting and translation services, today announced being shortlisted in... ———————————————————————————————————————————————————————————— Groundbreaking Healthcare Training Provider Launches 48 Week Associate Degree in Medical Assisting, Breaking the Mold on the Two-Year Associate Degree 2026-08-27 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/groundbreaking-healthcare-training-provider-launches-48-week-associate-degree-in-medical-assisting-breaking-the-mold-on-the-two-year-associate-degree-302861896.html The College of Health Care Professions unveils new accelerated Medical Assistant Associate designed for learners to complete full 61.5 credits in under a year. HOUSTON, August 27, 2026 /PRNewswire/ -- The College of Health Care Professions (CHCP) today announced the launch of an... ———————————————————————————————————————————————————————————— AMA introduces Ethical AI Use in Medicine Series 2026-08-27 · WebWire · AI, Healthcare, Education https://www.webwire.com/ViewPressRel.asp?aId=359610 The American Medical Association (AMA) today announced the Ethical AI Use in Medicine Series, a new continuing medical education (CME) program that helps physicians safely, effectively and ethically utilize augmented/artificial intelligence (AI) in clinical practice. “As AI rapidly transforms medical practice, the AMA is committed to equipping physicians with clear, practical ethics guidance rooted in our Code of Medical Ethics,” said AMA President Willie Underwood III, MD, MSc, MPH. “By... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=359610 ———————————————————————————————————————————————————————————— UK Men’s Sheds Awards 2026 celebrate the people and projects making a difference across the UK 2026-08-27 · Pressat · Healthcare https://pressat.co.uk/releases/uk-mens-sheds-awards-2026-celebrate-the-people-and-projects-making-a-difference-across-the-uk-86596205b110365d7876e2ea163d8452/ Thursday 27 August, 2026 The UK Men’s Sheds Association (UKMSA) is inviting its entries to the UK Men’s Sheds Awards 2026, celebrating the people, projects and partnerships that make Men’s Sheds such an important part of communities across the UK. Men’s Sheds offer friendship and support, skills sharing, and support for veterans whilst often improving local environments by delivering community projects. With around 1,100 Sheds in the UK, the Awards sponsored by Diageo/DrinkiQ, recognise those achievements and provide an opportunity to showcase the impact of the UK’s growing Shed movement on the men themselves, their families and the wider community. Whether it is a long-established Shed, a newly formed group or an individual Shedder making a difference, UKMSA wants to hear the stories behi ———————————————————————————————————————————————————————————— Norstella Launches Capsul, A Free Daily Intelligence Brief for the Pharma and Biotech Industry 2026-08-27 · PRWeb · Healthcare https://www.prweb.com/releases/norstella-launches-capsul-a-free-daily-intelligence-brief-for-the-pharma-and-biotech-industry-302861315.html A new weekday brief from the newsroom behind Pink Sheet, Scrip and In Vivo, distilling the day's most consequential drug development, regulatory and dealmaking news into a single, six-minute read NEW YORK, Aug. 27, 2026 /PRNewswire-PRWeb/ -- Norstella, the leading global provider of... ———————————————————————————————————————————————————————————— The World's Leading Minds in Biotechnology Will Meet in Riyadh This September 2026-08-27 · mlpr-acnnewswire · AI, SaaS, Healthcare, Energy, Education https://www.acnnewswire.com/press-release/english/109521/ RIYADH, KSA, Aug 28, 2026 - (ACN Newswire) - The Riyadh Global Medical Biotechnology Summit has published the scientific program for its fourth edition, and the names on it belong to the people currently deciding what medicine will be able to do in the next twenty years. Sixty confirmed speakers and moderators from eleven countries are named across three days, from 14 to 16 September 2026, at the Sofitel Riyadh Hotel and Convention Centre. Among them are Prof. Jin-Soo Kim of KAIST, whose work on mitochondrial DNA editing reaches beyond CRISPR; Dr. Matthew H. Porteus of Stanford University, engineering genetic circuits into cell-based medicines; Dr. Alex Shalek of MIT; Prof. Vijay Kuchroo of Harvard Medical School; Prof. Keith T. Flaherty of the Massachusetts General Hospital Cancer Center and President of the American Association for Cancer Research; Prof. George F. Gao of the Chinese Academy of Sciences; President Mitsuo Ochi of Hiroshima University; and Dr. Zdenko Herceg of the International Agency for Research on Cancer. They are joined by the people who move science into the world. Dr. Steve Yang, Co-CEO of WuXi AppTec, and Mr. Alec Reynolds of Flagship Pioneering open the program on global partnership. Mr. Kasim Kutay, Chief Executive Officer of Novo Holdings, speaks on where capital should go next. Dr. Hyun-Young Park, Deputy Minister of the Korea National Institute of Health, delivers the closing keynote. Alongside them stand the Saudi institutions building a biotechnology sector in real time: KAIMRC, Lifera, HUMAIN, SPIMACO, KAUST, the Saudi Food and Drug Authority, and Astronaut Rayyanah Barnawi on what the human immune system does in space. The program runs across six tracks: artificial intelligence in biotechnology, multi-omics, biotech investment, immunology, bioengineering and synthetic biology, and biotech workforce development. Its defining feature is that discovery and delivery share the same stage. Genome editing and population genomics sit beside regulation, domestic manufacturing, and procurement, and in several sessions the scientists and the regulators are on the same panel. That is the premise of the Kingdom's National Biotechnology Strategy, which targets $34.6 billion in non-oil GDP from biotechnology by 2040: a discovery is worth only as much as the system available to carry it to a patient. "Biotechnology is where the health of every nation will be decided over the next twenty years. Saudi Arabia has chosen not to watch that happen from a distance. We are building the laboratories, the manufacturing, the regulatory ecosystems, and above all, the bio-workforce talent. And we are building it in partnership with the world, under one roof. That is what this Summit is for. Its themes highlight where medicine and biotechnology converge to shape the future of biosciences. Discoveries and breakthroughs are transforming how we care for patients. The diversity of emerging technologies and therapies is creating significant opportunities to explore, advance, invest, and translate scientific progress into better health outcomes. Please join us in Riyadh this September." H.E. Prof. Bandar bin Abdulmohsen Al-Knawy, Chief Executive Officer of Health Affairs, Ministry of National Guard, and President, King Saud bin Abdulaziz University for Health Sciences The Summit is organized and supervised by the Ministry of National Guard, represented by its Health Affairs sector, and hosted by King Abdullah International Medical Research Center (KAIMRC) and King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), with the Ministry of Investment and Invest Saudi serving as strategic partners. The fourth edition is expected to welcome more than 15,000 visitors, over 200 biotechnology and healthcare brands, and delegations from more than 70 countries, under the theme Building the Foundations of Biotechnology Excellence. The full scientific program is attached and available at rgmbs.org, where registration is open for delegates, exhibitors, and industry partners. Follow the Summit at #RGMBS2026. For further information regarding summit programing visit: https://rgmbs.org/program#conference-agenda  About the Riyadh Global Medical Biotechnology Summit The Riyadh Global Medical Biotechnology Summit is the Kingdom of Saudi Arabia's flagship platform for medical biotechnology, convening the global scientific, investment, and policy communities in Riyadh. Organized and supervised by the Ministry of National Guard, represented by its Health Affairs sector, and hosted by KAIMRC and KSAU-HS, the Summit advances the goals of the National Biotechnology Strategy and supports the Kingdom's emergence as a global destination for health innovation. The fourth edition takes place from 14 to 16 September 2026 in Riyadh. For Media Inquiry Email: PR@legends.sa  Telephone: +966 559 810 777 Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com ———————————————————————————————————————————————————————————— Azalea Health Expands Patient Engagement Options Through Partnership with Curogram 2026-08-27 · PRUnderground · SaaS, Healthcare https://prunderground.com/azalea-health-expands-patient-engagement-options-through-partnership-with-curogr/cmt8wewio001h04l4xm3x5pcd Curogram joined Azalea Apps Integration Partnership Program, making its patient communication platform available to healthcare organizations using Azalea Health's EHR. The post Azalea Health Expands Patient Engagement Options Through Partnership with Curogram first appeared on ———————————————————————————————————————————————————————————— Mission Therapeutics and NeuraLight Partner to Bring Precision Brain Function Biomarkers to a Global Parkinson's Disease Clinical Trial 2026-08-27 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/mission-therapeutics-neuralight-partner-bring-155800943.html CAMBRIDGE, England & NEW YORK & TEL AVIV, Israel, August 27, 2026--Mission Therapeutics, a clinical-stage biotechnology company developing first-in-class therapeutics that enhance mitophagy to protect cell and organ health and NeuraLight, a leader in precision brain function measures, today announced a partnership to deploy NeuraLight's brain function biomarker assessments across Mission's multinational trial of MTX325 in Parkinson's disease. ———————————————————————————————————————————————————————————— State Networks, Community-based Organizations, and Healthcare Organizations Critical to Community Health Worker Sustainability, says new research from National Association of CHWs (NACHW) 2026-08-27 · PR Newswire · Healthcare, Education https://www.prnewswire.com/news-releases/state-networks-community-based-organizations-and-healthcare-organizations-critical-to-community-health-worker-sustainability-says-new-research-from-national-association-of-chws-nachw-302862004.html NACHW marks National Community Health Worker Awareness Week #NCHWAW with new resources for cross-sector education BOSTON, Aug. 27, 2026 /PRNewswire/ -- In recognition of National Community Health Worker (CHW) Awareness Week #NCHWAW, an expanded report with new tools, Strengthening Public... ———————————————————————————————————————————————————————————— AssureCare's Carlton Rodrigo Named to Cincinnati Business Courier's 2026 '40 Under 40' 2026-08-27 · PR Newswire · AI, Healthcare https://www.prnewswire.com/news-releases/assurecares-carlton-rodrigo-named-to-cincinnati-business-couriers-2026-40-under-40-302862003.html A ten-year journey at AssureCare, four promotions, a leader who has been raising the bar since day one. CINCINNATI, Aug. 27, 2026 /PRNewswire/ -- AssureCare®, a leading AI-powered population health management company, today announced that Carlton Rodrigo, Senior Director of Account... ———————————————————————————————————————————————————————————— Kansas City University President Warns New Federal Student Loan Limits Could Deepen Physician Shortage 2026-08-27 · PR Newswire · Healthcare, Education https://www.prnewswire.com/news-releases/kansas-city-university-president-warns-new-federal-student-loan-limits-could-deepen-physician-shortage-302861986.html KANSAS CITY, Mo., Aug. 28, 2026 /PRNewswire/ -- Kansas City University President and Chief Executive Officer Marc B. Hahn, DO, is raising concerns about how new federal student loan limits could affect medical education and worsen the nation's growing physician shortage. In an op-ed... ———————————————————————————————————————————————————————————— Connecting clinical knowledge with care delivery: NCODA and Cureety partner to bring trusted regimen guidance at the point of care 2026-08-27 · mlpr-prnewswire-wire · SaaS, Healthcare, Education https://www.prnewswire.com/news-releases/connecting-clinical-knowledge-with-care-delivery-ncoda-and-cureety-partner-to-bring-trusted-regimen-guidance-at-the-point-of-care-302861946.html Collaboration brings evidence-based patient education and regimen resources into Cureety's oncology care platform to support informed, patient-centered care. CAZENOVIA, N.Y. and PARIS, Aug. 27, 2026 /PRNewswire/ -- NCODA and Cureety, an oncology-specialized digital health platform, today... ———————————————————————————————————————————————————————————— Innovation durch Zusammenarbeit macht Precision BioLogic zu einem festen Begriff in der Diagnostik und Forschung im Bereich der Hämostase 2026-08-27 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/innovation-durch-zusammenarbeit-macht-precision-biologic-zu-einem-festen-begriff-in-der-diagnostik-und-forschung-im-bereich-der-hamostase-302861956.html HALIFAX, NS, 27. August 2026 /PRNewswire/ -- Das gebündelte Fachwissen von Precision BioLogic Inc., einem führenden Entwickler von Diagnostikprodukten für die Hämostase, und dessen Tochtergesellschaften Affinity Biologicals sowie George King Bio-Medical, zieht die Aufmerksamkeit von... ———————————————————————————————————————————————————————————— 39 Years, $39 Million: Walmart and Sam's Club Continue Longstanding Support of Children's Miracle Network 2026-08-27 · PR Newswire · Finance, Healthcare https://www.prnewswire.com/news-releases/39-years-39-million-walmart-and-sams-club-continue-longstanding-support-of-childrens-miracle-network-302860917.html Dedicated associates, customers and members unite to celebrate campaign success, funding critical children's hospital needs to make big change for all kids SALT LAKE CITY, Aug. 27, 2026 /PRNewswire/ -- As Children's Miracle Network celebrates 39 years of partnership with Walmart and Sam's... ———————————————————————————————————————————————————————————— Capline Healthcare Management Introduces AR Follow-Up Strategy to Help Practices Recover Up to 35% More Revenue While Reducing 90+ Day Aging Claims 2026-08-27 · PR Newswire · Finance, Healthcare https://www.prnewswire.com/news-releases/capline-healthcare-management-introduces-ar-follow-up-strategy-to-help-practices-recover-up-to-35-more-revenue-while-reducing-90-day-aging-claims-302861286.html Houston-based RCM company rolls out a disciplined, age-based accounts receivable follow-up model to help medical practices recover aging claims and reduce balances stuck past 90 days. HOUSTON, Aug. 27, 2026 /PRNewswire/ -- Capline Healthcare Management, a U.S.-based revenue cycle... ———————————————————————————————————————————————————————————— Overseas Growth Gathers Momentum as CanSinoBIO's Global Strategy Unlocks New Opportunities 2026-08-27 · mlpr-acnnewswire · Finance, SaaS, Healthcare, Automotive https://www.acnnewswire.com/press-release/english/109499/ HONG KONG, August 27, 2026 - (ACN Newswire) - CanSino Biologics Inc. (“CanSinoBIO,” 06185.HK/688185.SH) released its financial results for the first half of 2026. The Company reported revenue of approximately RMB 550 million, up 43.8% year on year, while its net loss attributable to shareholders narrowed significantly.  Notably, while demand in China’s vaccine market remains challenging, CanSinoBIO’s international business maintained strong growth momentum, generating overseas revenue of RMB 150 million during the reporting period.  As established products accelerate their expansion into overseas markets, and collaboration models such as technology partnerships and localized industrialization continue to take shape, CanSinoBIO’s overseas business is evolving from a strategic initiative into an increasingly important contributor to the Company’s performance. This reflects the Company’s forward-looking understanding of global vaccine market trends and evolving demand in international markets. At a time when the vaccine industry is facing changes in demand structure, the combination of domestic innovation capabilities and access to international markets is becoming an increasingly important measure of corporate growth resilience. Overseas Growth Accelerates In the first half of 2026, China’s vaccine industry continued to face demand-side pressure. As the target population for infant and young-child vaccination continues to decline, demand pressure on traditional pediatric vaccines has become increasingly visible. “Volume contraction and price decline” has emerged as a widespread challenge across the industry. Based on disclosed financial results across the sector, this pressure appears to be industry-wide. In 2025, Zhifei Biological generated RMB1.187 billion in revenue from self-developed products, up 1.23% year on year. Walvax Biotechnology reported 2025 revenue of RMB2.418 billion, down 14.29% year on year; despite a 53.36% year-on-year increase in batch-release volume for its core 13-valent pneumococcal conjugate vaccine, revenue remained under pressure. Kangtai Biological reported revenue of RMB1.273 billion in the first half of 2026, down 8.55% year on year. Against this industry backdrop, the growth of CanSinoBIO’s international business is particularly noteworthy. The Company reported overseas revenue of RMB 150 million in the first half of 2026. This growth was driven, on the one hand, by the continued expansion of mature products into overseas markets and, on the other, by the further deepening of the Company’s international partnership models. For CanSinoBIO, this also means that its products, manufacturing processes and quality control capabilities, validated in the domestic market, are beginning to unlock value overseas through more diversified approaches. Meanwhile, the Company continues to advance its international market footprint. Registration filings and commercialization efforts remain underway across Southeast Asia, South America and the Middle East. Menhycia(R) has obtained registration approvals in Indonesia and Argentina, and product supply has already commenced in Indonesia. As more products progress through overseas registration and commercialization, CanSinoBIO’s international business is expected to develop more diversified revenue streams and further strengthen its commercial resilience. From this perspective, CanSinoBIO’s globalization strategy is evolving. Overseas markets are no longer merely destinations for mature products, but are increasingly becoming markets in which products, technologies and industrial capabilities can jointly create value. For an innovative vaccine company, this shift from “exporting products” to “exporting capabilities and systems” creates greater room for long-term growth in its overseas business. Portfolio Upgrades Strengthen the Commercial Foundation Sustained overseas expansion is underpinned by a stable product portfolio and strong technological capabilities. According to the Company’s interim report, domestic revenue continued to grow despite factors such as changes in value-added tax, reflecting opportunities created by ongoing innovation. Menhycia(R), China’s first quadrivalent meningococcal conjugate vaccine, expanded its indicated population in February to children aged 3 months to 6 years, broadening its addressable population. Meanwhile, iPneucia(R), a 13-valent pneumococcal conjugate vaccine featuring dual-carrier technology (CRM197/TT), offers a differentiated option for pediatric pneumococcal disease prevention in China. Since its launch in September 2025, iPneucia(R) has continued to expand market access and is now available in nearly 30 provincial-level markets across China. From meningococcal disease to pneumococcal disease, CanSinoBIO is using innovative products to address vaccine segments that continue to offer meaningful unmet demand. As traditional vaccine categories face pressure on volumes, structural growth driven by product and technology upgrades is providing important support for the Company’s commercial resilience. More importantly, the product-development and industrialization capabilities established in the domestic market also provide a foundation for overseas expansion. For an innovative vaccine company, successful commercialization in China not only broadens revenue sources, but also validates the manufacturing, quality-control and supply systems required to replicate and extend those capabilities into international markets. Domestic product upgrades and overseas business growth are thereforeclosely connected rather than separate. The former provides the foundation in products and technologies, while the latter expands the geographic boundaries within which those products can realize their value. Multi-Layered Pipeline Takes Shape to Support Future Growth For an innovative vaccine company, long-term growth depends not only on the commercial performance of existing products, but also on the ability to maintain a steady flow of new products. By pursuing continued ramp-up of marketed products, advancing products under regulatory review and developing next-generation candidates, CanSinoBIO is building a more sustainable and well-sequenced product pipeline. Tripecia(R) (DT3cP Infant), CanSinoBIO’s three-component acellular diphtheria, tetanus and pertussis combined vaccine for infants, received NDA approval in April 2026, becoming the first approved three-component DTP vaccine in China. In August 2026, the first commercial batches received the Certificate for Batch Release of Biological Products. Provincial tendering and market-access processes are progressing in an orderly manner, and the product has begun entering the market supply stage. While Tripecia(R) represents an upgrade in pertussis vaccination for infants, the Td5cp vaccine for adolescents and adults — which has also been granted Priority Review status — is expected to extend CanSinoBIO’s pertussis vaccine portfolio to a broader population. The New Drug Application for Td5cp has been accepted by China’s National Medical Products Administration (NMPA). In addition, CanSinoBIO’s independently developed Adsorbed Tetanus Vaccine, Tetcia(R), has been formally approved, further strengthening the Company’s adult vaccine portfolio. From infants to adolescents and adults, and from individual products to a multi-product portfolio, this strategy is broadening the foundation for future commercial growth. In pneumococcal vaccines, CanSinoBIO’s 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) (PCV24) formally initiated Phase I/II clinical trials in May 2026, and participant enrollment across different cohorts is progressing as planned. At the same time, the Company continues to advance development of its DT3cP-Hib-MCV4 combination vaccine, extending its portfolio toward increasingly multivalent and combination vaccine formats. Over the longer term, CanSinoBIO is continuing to build its mRNA platform and explore applications in preventive vaccines and therapeutic biologics. The Company is conducting early-stage research into mRNA applications for glioblastoma, rhabdomyosarcoma and cervical cancer, while also exploring in vivo CAR therapies. These programs remain at an early stage, with the Company continuing to assess the potential of mRNA and related technologies in disease treatment. Additionally, on August 25, CanSinoBIO announced that its subsidiary, CanSino Shanghai, had entered a strategic collaboration with deepGeneAI on mRNA therapeutic cancer vaccines. The two parties will leverage their respective strengths in mRNA vaccine technology and tumor neoantigen discovery and design to jointly advance the development and commercialization of personalized mRNA therapeutic cancer vaccines. These pipeline programs represent extensions of CanSinoBIO’s existing technology platforms and product-development experience. The Company’s core platforms — including viral vector vaccines, synthetic vaccines, protein structure design and VLP assembly, mRNA vaccines, as well as formulation and delivery technologies — provide a foundation for continued product iteration and technology translation. Innovation Supports Long-Term Development Viewed in the context of its 2026 interim results, CanSinoBIO’s story is not simply one of revenue growth. Against a changing domestic vaccine demand structure, innovative products have continued to deliver solid commercial performance, demonstrating the resilience created by product upgrades. Overseas business model expanded beyond finished-product exports to include technology collaboration and local manufacturing capabilities, indicating that international markets are becoming a new source of growth. At the same time, Tripecia(R) has entered the market supply stage, the Td5cp vaccine for adolescents and adults is progressing through regulatory review, and pipeline programs including PCV24, multivalent and combination vaccines, and mRNA technologies continue to advance, providing both product succession and technology reserves for the future. These three pathways ultimately point to the same growth logic: domestic innovation capabilities form the product foundation, overseas expansion broadens the commercial opportunity, and sustained R&D determines whether growth can continue over the long term. In an environment where demand for traditional vaccines is under pressure and industry competition is intensifying, growth is increasingly shifting away from reliance on product-volume expansion alone and toward a model jointly driven by product upgrades, technological innovation and global markets. For CanSinoBIO, continued growth in the overseas business is providing increasingly visible financial evidence of this transition. As more innovative products enter the market, more mature products expand overseas and the Company’s technical capabilities extend further into international value chains, CanSinoBIO’s growth runway is expanding from a single domestic market to the global market. For the Company, internationalization is not only about broadening geographic reach; it is also an important pathway for innovative products and technologies to realize greater commercial value while contributing to global public health. Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com ———————————————————————————————————————————————————————————— Fractyl Health, Inc. (GUTS) Lawsuit - Investors Urged to Contact Levi ... 2026-08-27 · PR-Inside · Finance, Healthcare https://pr-inside.com/fractyl-health-inc-guts-lawsuit-investors-urged-to-contact-levi-r5216748.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 27, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Fractyl Health, Inc. (NASDAQ:GUTS) securities. If you suffered a loss on your Fractyl Health, Inc. investment and would like to explore a potential recovery under the federal securities laws, Learn about Fractyl Health, Inc. Class Action or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit was filed .. ———————————————————————————————————————————————————————————— Dave's Killer Bread reveals new consumer insights for Organic Month 2026-08-27 · PR Newswire · Healthcare, Retail https://www.prnewswire.com/news-releases/daves-killer-bread-reveals-new-consumer-insights-for-organic-month-302861852.html DKB survey indicates Gen Z is more aware of organic health benefits than previous generations MILWAUKIE, Ore., Aug. 27, 2026 /PRNewswire/ -- Dave's Killer Bread® (DKB), the nation's No. 1 organic bread brand*, reveals findings from new research about consumer preferences and purchasing... ———————————————————————————————————————————————————————————— SpendRule Names Health System Transformation Leader Beth Graefe, EdD, as Strategic Advisor 2026-08-27 · PR Newswire · AI, SaaS, Healthcare https://www.prnewswire.com/news-releases/spendrule-names-health-system-transformation-leader-beth-graefe-edd-as-strategic-advisor-302861875.html Veteran of more than 100 hospital margin improvement initiatives joins SpendRule's Advisory Board as the healthcare industry confronts mounting pressures to reduce costs DALLAS, Aug. 27, 2026 /PRNewswire/ -- SpendRule, healthcare's first AI-native contract-to-payment integrity platform,... ———————————————————————————————————————————————————————————— CORRECTION FROM SOURCE: DataMeds AI and Tollo Health Announce Fall ... 2026-08-27 · PR-Inside · Finance, Crypto, AI, SaaS, Healthcare, Retail https://pr-inside.com/correction-from-source-datameds-ai-and-tollo-health-announce-fall-r5216740.htm (PR-inside.com) This version includes the correct image. 50% off available online at www.TolloHealth.Shop and www.CorexaRx.com Soon to become available at Health Lives Here™ pharmacies and on Amazon.com TAMPA, FL / ACCESS Newswire / August 27, 2026 /DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), an integrated healthcare company leveraging its Health IT infrastructure and artificial intelligence platform EinsteinRx™ combined with blockchain-enabled smart contracts platform PharmacyChain™ to provide integrated solutions for the tokenization of pharmaceutical serialization and the compliant delivery of healthcare and monetization of health data, today announced the U.S. ‘direct-to consumer' (DTC) launch of medical food Galectovid for the 2026 Cold & Flu .. ———————————————————————————————————————————————————————————— CORRECTION FROM SOURCE: DataMeds AI and Tollo Health Announce Fall 2026 Cold & Flu #Back2School50% Marketing Campaign for Viral Infections Medical Food Galectovid(TM) 2026-08-27 · Newswire.com · AI, Healthcare, Retail https://www.newswire.com/news/correction-from-source-datameds-ai-and-tollo-health-announce-fall-2026-cold-flu This version includes the correct image. 50% off available online at  www.TolloHealth.Shop and  www.CorexaRx.com Soon to become available at Health Lives Here™ pharmacies and on Amazon.com  ———————————————————————————————————————————————————————————— VSee Health Poised for Growth 2026-08-27 · Newswire.com · Healthcare https://www.newswire.com/news/vsee-health-poised-for-growth VSee Health announces Annual Meeting Results ———————————————————————————————————————————————————————————— NeuroOne Announces Successful Robotic-Assisted Drug Delivery Using Next-Generation StereoCED™ Platform 2026-08-27 · NewMediaWire · Finance, SaaS, Healthcare, Retail https://www.newmediawire.com/news/neuroone-announces-successful-robotic-assisted-drug-delivery-using-next-generation-stereoced-tm-platform-7088976 Successful Large-Animal Procedures Build Momentum Toward Planned Launch of the StereoCED™ Platform for Human Investigational Clinical Studies Later This Quarter Related StereoCED™ Revenue Expected to be Recognized in the Current Fiscal Quarter EDEN PRAIRIE, MINN. - August 27, 2026 ( NEWMEDIAWIRE ) - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today reported the successful completion of three separate large-animal procedures using its next-generation StereoCED™ platform. In two of the three procedures, NeuroOne’s drug delivery electrodes both delivered a study agent directly into targeted brain tissue and recorded intracranial ele ———————————————————————————————————————————————————————————— CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" ... 2026-08-27 · PR-Inside · Finance, Healthcare, Media https://pr-inside.com/cns-pharmaceuticals-participates-in-the-virtual-investor-why-now-r5216737.htm (PR-inside.com) Video webcast now available here HOUSTON, TX / ACCESS Newswire / August 27, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in the Virtual Investor "Why Now" on-demand conference. Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals, highlighted the Company's strategic transformation that is being built on the strength of its newly assembled executive leadership team, enhanced financial position following its recent financing, and disciplined approach to evaluating differentiated assets. Mr. Levin emphasized the Company's efforts to .. ———————————————————————————————————————————————————————————— enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand ... 2026-08-27 · PR-Inside · Finance, Healthcare, Media https://pr-inside.com/envveno-medical-participates-in-the-virtual-investor-why-now-on-demand-r5216735.htm (PR-inside.com) Video Webcast Now Available Here IRVINE, CA / ACCESS Newswire / August 27, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company") today announced that Robert Berman, Chief Executive Officer of enVVeno Medical, participated in the Virtual Investor "Why Now" on-demand conference. For the event, Mr. Berman highlighted the Company's investment opportunity, including the significant unmet need for effective treatment options for patients with severe Deep Venous Insufficiency (DVI) and the substantial market opportunity for Company's non-surgical replacement venous valve called enVVe. He also discussed the Company's recent achievement of the FDA IDE approval for a U.S. pivotal study evaluating .. ———————————————————————————————————————————————————————————— VVater Expands Global Presence Through New Partnership in Asia-Pacific and the Middle East 2026-08-27 · mlpr-acnnewswire · Healthcare, Energy, Retail https://www.acnnewswire.com/press-release/english/109475/ AUSTIN, TX, Aug 27, 2026 - (ACN Newswire) - VVater, America's Next Water Company and the world's premier innovator in advanced water treatment solutions, today announced an expanded international presence across Asia-Pacific Middle East (APME) as the company continues to scale its innovative water treatment technology globally and support new sectors. Via a new partnership agreement, VVater APME will be established. This newly formed venture will bring VVater's technology to a wide range of markets and strategic customers around the world as water scarcity, water quality, regulatory expectations and long-term water stewardship become increasingly important drivers of operational resilience and economic performance. VVater APME is a partnership formed between VVater and Ecosafe International, a regionally recognised water risk management and water stewardship consultancy, which supports organisations to navigate their water journey through governance, assurance, risk reduction and practical innovation. With an extensive track record supporting organisations including BHP, Rio Tinto, Chevron, Shell, JLL and NEOM, Ecosafe advises governments, mining operators, healthcare and industrial organisations on achieving safer, more sustainable and more resilient water outcomes across APME. VVater APME will operate with dedicated sector exclusivity in Australia, New Zealand, Saudi Arabia, Qatar and the UAE. "What drew us to this partnership is how much overlap there already was," said Kevin Gast, CEO and Chairman of VVater. "Ecosafe has spent years building trust with operators in some of the toughest water environments in the world. Pairing that with our technology means we can move faster into markets that badly need it." "For years we've watched clients wrestle with sourcing credible, provable water treatment technology once a risk assessment tells them what they're up against," said Ryan Milne, Founder of Ecosafe International. "This partnership closes a critical gap for us. We've always helped clients understand and govern water risk. Now we can combine that trusted advisory capability with proven technology solutions that accelerate the transition from water risk to water certainty." VVater APME is designed with a defined path to expand into installation, operations, and eventually in-territory manufacturing, creating long-term capability and supporting regional water security outcomes as the partnership matures. The agreement gives VVater APME access to VVater's full suite of proprietary technology, led by the Farady Reactor, a breakthrough in water treatment. Wherever it's deployed, from remote, self-managed water systems and mine sites to municipal water systems and industrial plants, the Farady Reactor transforms wastewater, sewage and drinking water alike, offering a glimpse of what next-generation water infrastructure can look like. VVater APME is the latest step in the company's international growth, following recognition from TIME, CES and Fast Company, and deployments with partners including Nestle and the City of Bastrop, Texas. The agreement reflects VVater's continued push to bring advanced treatment and reuse technology into markets facing mounting water stress. About VVater VVater is America's Next Water Company, delivering the future of purification through its award-winning Farady Reactor (Time Best Invention Award 2025, CES Best of Innovation 2025, World Future Award 2025. The first company in history to win all 3 in 1 year achieving a Triple Crown), proprietary ALTEP (Advanced Low Tension Electroporation Process), Advanced Dissolved Air Flotation, and Micro & Nano Bubble technologies. Unlike outdated chemical, filtration, and membrane systems, VVater's electric-field breakthroughs eliminate microplastics, microorganisms, and other contaminants with record retention times, without producing toxic byproducts or requiring costly consumables. With over 4.3B gallons treated and validation from global leaders, VVater is scaling into municipal drinking water and wastewater, DPR/IPR, onsite reuse for data centers, commercial buildings, and resorts, residential purification, and consumer health water, delivering a 60% smaller footprint, 40% CapEx savings, 80% OpEx savings, and 40% less energy use. For more information, please visit www.vvater.com. Contact Information VVATER Media Office Global Media Room media@vvater.com Nicholas Koulermos vvater@5wpr.com SOURCE: VVater LLC Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com ———————————————————————————————————————————————————————————— Rongtao Medical Publishes Legacy Ultrasound Cybersecurity Framework Built on FDA, CISA and OEM Evidence 2026-08-27 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/rongtao-medical-publishes-legacy-ultrasound-cybersecurity-framework-built-on-fda-cisa-and-oem-evidence-302861814.html Analysis finds nine in ten cleared ultrasound system designs predate the US cyber-device statute — and all four CISA advisories naming ultrasound lines had incomplete patch coverage GUANGZHOU, China, Aug. 27, 2026 /PRNewswire/ -- Guangzhou Rongtao Medical Technology Co., Ltd. ("Rongtao... ———————————————————————————————————————————————————————————— VEMERIX Report Reveals the True Cost of Mesotherapy Consumables and the 2026 Rules Reshaping Injector Sourcing 2026-08-27 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/vemerix-report-reveals-the-true-cost-of-mesotherapy-consumables-and-the-2026-rules-reshaping-injector-sourcing-302861786.html Deep-research analysis of 15.3 million injectable procedures finds markups of up to 330x on single-use tips — and a new China requirement for delivery needles to carry their own registration WEIHAI, China, Aug. 27, 2026 /PRNewswire/ -- VEMERIX, the international brand of medical device... ———————————————————————————————————————————————————————————— DataMeds AI and Tollo Health Announce Fall 2026 Cold & Flu #Back2School50% ... 2026-08-27 · PR-Inside · Finance, Crypto, AI, SaaS, Healthcare, Retail https://pr-inside.com/datameds-ai-and-tollo-health-announce-fall-2026-cold-flu-back2school-r5216731.htm (PR-inside.com) 50% off available online at www.TolloHealth.Shop and www.CorexaRx.com Soon to become available at Health Lives Here™ pharmacies and on Amazon.com TAMPA, FL / ACCESS Newswire / August 27, 2026 /DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), an integrated healthcare company leveraging its Health IT infrastructure and artificial intelligence platform EinsteinRx™ combined with blockchain-enabled smart contracts platform PharmacyChain™ to provide integrated solutions for the tokenization of pharmaceutical serialization and the compliant delivery of healthcare and monetization of health data, today announced the U.S. ‘direct-to consumer' (DTC) launch of medical food Galectovid for the 2026 Cold & Flu Season through its #Back2School50% for .. ———————————————————————————————————————————————————————————— DataMeds AI and Tollo Health Announce Fall 2026 Cold & Flu #Back2School50% Marketing Campaign for Viral Infections Medical Food Galectovid(TM) 2026-08-27 · Newswire.com · AI, Healthcare, Retail https://www.newswire.com/news/datameds-ai-and-tollo-health-announce-fall-2026-cold-flu-back2school50 50% off available online at  www.TolloHealth.Shop and  www.CorexaRx.com Soon to become available at Health Lives Here™ pharmacies and on Amazon.com  ———————————————————————————————————————————————————————————— HUM Nutrition Launches Stack & Sculpt™, a Peptide-Powered Creatine for Toning 2026-08-27 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/hum-nutrition-launches-stack--sculpt-a-peptide-powered-creatine-for-toning-302860131.html Introducing Advanced Toning Technology™. This refreshing formula pairs 5g of creatine monohydrate with 2.4g of clinically studied PeptiStrong® from Nuritas, bringing HUM's clean and clinical approach to the fastest-growing category in women's wellness. LOS ANGELES, Aug. 27, 2026... ———————————————————————————————————————————————————————————— ICU Medical to Participate in Upcoming Investor Conferences 2026-08-27 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/27/3351997/8573/en/icu-medical-to-participate-in-upcoming-investor-conferences.html SAN CLEMENTE, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced its participation in the following investor conferences: ———————————————————————————————————————————————————————————— Shellharbour Rising: Investing Platform Spotlights the NSW Coastal ... 2026-08-27 · PR-Inside · SaaS, Healthcare, Real Estate https://pr-inside.com/shellharbour-rising-investing-platform-spotlights-the-nsw-coastal-r5216718.htm (PR-inside.com) SYDNEY, AU / ACCESS Newswire / August 27, 2026 / Investing Platform, the home of brand-new property in Australia, is turning its spotlight on Shellharbour on the NSW South Coast, where the NSW Government this month placed two major rezoning proposals on public exhibition that could unlock up to 11,700 new homes and 1,750 new jobs across a revitalised Shellharbour City Centre and the new Shellharbour Hospital Precinct. The Government projects the area's population to surge by around 28,000 people to more than 100,000 residents by 2041, describing Shellharbour as one of the fastest growing communities in the state. The public .. ———————————————————————————————————————————————————————————— The Hidden Cost of Fragmented Contracts in Community Hospitals 2026-08-27 · PR-Inside · Healthcare https://pr-inside.com/the-hidden-cost-of-fragmented-contracts-in-community-hospitals-r5216712.htm (PR-inside.com) WOODSTOCK, GA / ACCESS Newswire / August 27, 2026 / Community hospitals run on contracts. Payer agreements, vendor terms, credentialing requirements, supply arrangements, compliance obligations, all of it is contract-driven. And for most small and mid-sized hospitals, those contracts live in three different places: a shared drive no one fully trusts, an email thread from 18 months ago, and someone's desk drawer. That fragmentation has a price. Industry research from World Commerce and Contracting estimates that organizations lose 5 to 9% of total contract value every year through missed obligations, unenforced terms, and poor visibility. For a rural hospital already operating .. ———————————————————————————————————————————————————————————— Black Health & Social Services Hub to Celebrate Grand Opening with Community Health, Culture and Wellness Celebration in Brampton 2026-08-27 · mlpr-newsfile · Healthcare https://www.newsfilecorp.com/release/311365/Black-Health-Social-Services-Hub-to-Celebrate-Grand-Opening-with-Community-Health-Culture-and-Wellness-Celebration-in-Brampton Brampton, Ontario--(Newsfile Corp. - August 27, 2026) - The Black Health and Social Services (BHSS) Hub Peel will officially celebrate its grand opening on Friday, August 28 inviting residents from across Peel Region to experience a new approach to culturally responsive healthcare, mental health, addictions and social services designed with Black, African and Caribbean communities at the centre.Located at 19 Rutherford Road South, Unit 2, Brampton, the BHSS Hub is a partnership between Roots... ———————————————————————————————————————————————————————————— Piramal Pharma renforce ses opérations prêtes pour l'avenir avec une réduction de 22,6 % des émissions, 41 % des énergies renouvelables et « zéro observation » de l'OAI par la FDA américaine 2026-08-27 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/piramal-pharma-renforce-ses-operations-pretes-pour-lavenir-avec-une-reduction-de-22-6--des-emissions-41--des-energies-renouvelables-et--zero-observation--de-loai-par-la-fda-americaine-302861782.html Les émissions de portée 1 et 2 les plus faibles jamais enregistrées marquent une année charnière dans le parcours de décarbonisation approuvé par la SBTi de l'entreprise MUMBAI, Inde, 27 août 2026 /PRNewswire/ -- Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), une société... ———————————————————————————————————————————————————————————— BrainsWay Deep TMS™ Study Shows 70% Reduction in Patients Experiencing Suicidal Ideation 2026-08-27 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/27/3351903/17676/en/brainsway-deep-tms-study-shows-70-reduction-in-patients-experiencing-suicidal-ideation.html Peer-reviewed secondary analysis adds to growing body of clinical evidence supporting the potential role of Deep TMS in addressing suicidal ideation among patients with major depressive disorder Peer-reviewed secondary analysis adds to growing body of clinical evidence supporting the potential role of Deep TMS in addressing suicidal ideation among patients with major depressive disorder ———————————————————————————————————————————————————————————— Hydreight Technologies Announces Timing of Q2 2026 Financial Results and Investor Webcast Featuring Live Analyst Q&A 2026-08-27 · PR Newswire · SaaS, Healthcare https://www.prnewswire.com/news-releases/hydreight-technologies-announces-timing-of-q2-2026-financial-results-and-investor-webcast-featuring-live-analyst-qa-302861464.html VANCOUVER, BC and LAS VEGAS, Aug. 27, 2026 /PRNewswire/ -- Hydreight Technologies Inc. ("Hydreight" or the "Company") (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6), a rapidly growing digital health platform and provider of compliant healthcare infrastructure across the United States, today... ———————————————————————————————————————————————————————————— African Bundibugyo ebolavirus vaccine candidate to be advanced to clinical trials 2026-08-27 · PR Newswire · SaaS, Healthcare https://www.prnewswire.com/news-releases/african-bundibugyo-ebolavirus-vaccine-candidate-to-be-advanced-to-clinical-trials-302861771.html CEPI backs Minapharm's Bundibugyo ebolavirus vaccine candidate, based on ProBioGen's proprietary MVA-CR19 platform OSLO, Norway, CAIRO and BERLIN, Aug. 27, 2026 /PRNewswire/ -- Leading African biopharmaceutical company Minapharm Group, headquartered in Egypt with subsidiaries in Berlin,... ———————————————————————————————————————————————————————————— Piramal Pharma stärkt zukunftsfähige Betriebsabläufe durch Emissionsreduktion von 22,6 %, Anteil erneuerbarer Energien von 41 % und null Beanstandungen im Rahmen des OAI-Verfahrens der US-Lebensmittelüberwachungs- und Arzneimittelbehörde (USFDA) 2026-08-27 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/piramal-pharma-starkt-zukunftsfahige-betriebsablaufe-durch-emissionsreduktion-von-22-6--anteil-erneuerbarer-energien-von-41--und-null-beanstandungen-im-rahmen-des-oai-verfahrens-der-us-lebensmitteluberwachungs--und-arzneimittel-302861765.html Die niedrigsten Scope-1- und Scope-2-Emissionen aller Zeiten markieren ein Meilensteinjahr auf dem von der SBTi zugelassenen Weg des Unternehmens zur Dekarbonisierung MUMBAI, Indien, 27. August 2026 /PRNewswire/ -- Piramal Pharma Limited (NSE: PPLPHARMA. BSE: 543635), ein weltweit... ———————————————————————————————————————————————————————————— Herbalife to Participate in Fireside Chat at Barclays Global Consumer Conference on September 9 2026-08-27 · mlpr-businesswire · Finance, SaaS, Healthcare, Retail https://finance.yahoo.com/healthcare/articles/herbalife-participate-fireside-chat-barclays-110500579.html LOS ANGELES, August 27, 2026--Herbalife Ltd. (NYSE: HLF), a premier health and wellness company, community and platform, today announced Stephan Gratziani, Chief Executive Officer, John DeSimone, Chief Financial Officer and Scott Schaefer, SVP of Finance and Transformation and incoming CFO, will participate in a fireside chat at the Barclays 19th Annual Global Consumer Conference on Wednesday, September 9, 2026 at 7:30 a.m. ET (4:30 a.m. ———————————————————————————————————————————————————————————— RMTG's Cellgenic Division Introduces MUSE Cell Product Line Across ... 2026-08-27 · PR-Inside · Healthcare https://pr-inside.com/rmtg-s-cellgenic-division-introduces-muse-cell-product-line-across-r5216690.htm (PR-inside.com) A second cellular-technology launch in close succession broadens Cellgenic's portfolio into Latin America, the Middle East, Europe, and Southeast Asia, demonstrating a repeatable product-development motion. MIAMI, FL / ACCESS Newswire / August 27, 2026 / Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, today announced the introduction, through its Cellgenic division, of a multilineage-differentiating stress-enduring (MUSE) cell product line for selected international markets - including Latin America, the Middle East, Europe, and Southeast Asia - subject to applicable local regulatory requirements. MUSE cells are a class .. ———————————————————————————————————————————————————————————— The Economics of Healthcare Have Changed 2026-08-27 · PR-Inside · Healthcare https://pr-inside.com/the-economics-of-healthcare-have-changed-r5216688.htm (PR-inside.com) As employer health insurance costs approach $19,000 per worker, FUL.Health is building healthcare for the workforce traditional health insurance was never built to serve. NEW YORK CITY, NY / ACCESS Newswire / August 27, 2026 / Employer healthcare costs are projected to rise 9.5% in 2027, pushing average costs above $19,000 per employee, according to Aon. Against those economics, it is hardly surprising that only 27% of large firms offering health benefits offered them to part-time workers in 2025, according to KFF. But while the cost of health insurance continues to climb at a record pace, innovation and technology have changed the .. ———————————————————————————————————————————————————————————— New Hampshire Chiropractor Develops Riveo, a New Approach to At-Home Lumbar Traction Without Inversion 2026-08-27 · Send2Press · Healthcare https://www.send2press.com/wire/new-hampshire-chiropractor-develops-riveo-a-new-approach-to-at-home-lumbar-traction-without-inversion/ PLYMOUTH, N.H., Aug. 27, 2026 (SEND2PRESS NEWSWIRE) -- After years of working with patients with lower back problems, New Hampshire chiropractor Dr. James Pamplin saw a practical challenge: people looking for a way to apply traction at home often encounter inversion tables, uncomfortable restraints, or bulky and cumbersome equipment. That challenge ultimately led Pamplin to develop Riveo, a new home lumbar traction device designed to provide a simpler and more comfortable way to apply controlled traction to the lower back. ———————————————————————————————————————————————————————————— Covalon Reports Fiscal 2026 Third Quarter Results 2026-08-27 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/covalon-reports-fiscal-2026-third-110000819.html MISSISSAUGA, Ontario, August 27, 2026--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its fiscal 2026 third quarter results for the period ended June 30, 2026. Full financial statements and management’s discussion and analysis are available on the Company’s profile at www.sedarplus.ca. ———————————————————————————————————————————————————————————— DS1025 Enters Clinical Development in Patients with Advanced Solid Tumors as Novel CD25 Directed ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo 2026-08-27 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/ds1025-enters-clinical-development-patients-110000994.html TOKYO, August 27, 2026--The first patient has been dosed in a first-in-human phase 1 trial evaluating DS1025 in adult patients with advanced or metastatic solid tumors with disease progression on or after at least one prior line of standard therapy. ———————————————————————————————————————————————————————————— BD Extends Leadership in Advanced Tissue Regeneration Through Continued Clinical Innovation 2026-08-27 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/bd-extends-leadership-in-advanced-tissue-regeneration-through-continued-clinical-innovation-302860968.html STANCE trial surpasses a key enrollment milestone, advancing the clinical evaluation of GalaFLEX LITE™ Scaffold and generating evidence to support its use in breast revision surgery for capsular contracture FRANKLIN LAKES, N.J., Aug. 27, 2026 /PRNewswire/ -- BD (Becton, Dickinson and... ———————————————————————————————————————————————————————————— Medical Foam Market: Why Asia Pacific Could Become the Fastest-Growing Regional Opportunity 2026-08-27 · Express Press Release · Healthcare https://express-press-release.net/news/2026/08/27/1769598 Numbers That Matter The global medical foam market stood at USD 30.8 billion in 2025 and is expected to reach USD 33.3 billion in 2026, climbing to [read full press release...] ———————————————————————————————————————————————————————————— Watch & Clock Fair, Salon de TIME return this September 2026-08-27 · mlpr-acnnewswire · AI, SaaS, Healthcare, Retail, Automotive, Education https://www.acnnewswire.com/press-release/english/109494/ HONG KONG, August 27, 2026 - (ACN Newswire) - The 45th Hong Kong Watch & Clock Fair and the 14th Salon de TIME, jointly organised by the Hong Kong Trade Development Council (HKTDC), Hong Kong Watch Manufacturers Association Limited, and the Federation of Hong Kong Watch Trades & Industries Limited, will be held from 1 to 5 September at the Hong Kong Convention and Exhibition Centre (HKCEC). Salon de TIME will be fully open to the public throughout the event. The 45th HKTDC Hong Kong Watch & Clock Fair and 14th Salon de TIME take place from 1 to 5 September at the Hong Kong Convention and Exhibition Centre. Introducing fair highlights at a press conference are Smilely Lam, HKTDC Associate Executive Director (fifth from the left), SK Chong (fourth from the right) and Frankie Lam (fourth from the left), Co-Chairmen, HKTDC Hong Kong Watch & Clock Fair Organising Committee 2026, and celebrity Joey Thye (fifth from the right). Under the theme “Sparkling Moments Through Time”, the two fairs are expected to attract more than 630 exhibitors from 16 countries and regions, showcasing a wide range of watches, clocks and related products to meet evolving market trends and consumer demand. The Click2Match AI-powered business matching platform has been available since 25 August and will remain open until 12 September, enabling exhibitors and buyers from around the world to connect and conduct business discussions online during and beyond the physical fairs. Hong Kong Watch & Clock Fair marks 45th Milestone HKTDC Associate Executive Director Smilely Lam said: “The Hong Kong Watch & Clock Fair and Salon de TIME together form the world's largest one-stop watch and clock marketplace. As the Hong Kong Watch & Clock Fair celebrates its 45th edition this year, the two fairs are continuing to grow in both international reach and diversity, leveraging Hong Kong’s strengths as an international trading hub and Asia’s premier sourcing centre for watches and clocks. This year’s fairs welcome, for the first time, a pavilion from Hengyang, Hunan Province, alongside group pavilions from France, Switzerland, Guangzhou and Taiwan. New exhibitors from Norway, Singapore and the US are joining this year's fair, further strengthening the international profile of the fairs. Salon de TIME is expected to feature more than 150 global brands, reaching a new post-pandemic high. Participation from Hong Kong brands and Guochao-inspired brands has increased by more than 20%, while more brands from Italy, the United Kingdom and the US are joining, alongside the debut of Singaporean brands. This fully demonstrates Hong Kong’s unique role as an important bridge connecting the Chinese Mainland with international markets, as well as the global watch industry’s confidence in the Hong Kong market.” According to the latest trade statistics, Hong Kong is the world’s largest importer and second largest exporter of wristwatches. In the first seven months of this year, the total export value of watches reached approximately HK$30.5 billion, representing a 7.8% year-on-year increase. Several other Hong Kong export markets recorded double-digit growth, including Germany (+21%), Switzerland (+25%) and the United Arab Emirates (+91%). In addition, the watch industry’s export confidence index rose from 50.4 to 51.9 in the second quarter, reflecting the industry’s cautiously optimistic outlook for exports. Microbrand participation doubles, bringing greater diversity to the fair Located in Hall 3FG, Salon de TIME features six themed zones: World Brand Piazza, Chic & Trendy, Craft Treasure, Renaissance Moment, Wearable Tech, and Microbrands. The Microbrands zone has attracted 29 brands from eight countries and regions, with both the number of participating brands and the number of represented countries and regions doubling compared with last year. World Brand Piazza showcases prestigious international watch brands For the 16th consecutive year, the World Brand Piazza zone is organised in partnership with Prince Jewellery & Watch, featuring limited-edition and rare timepieces from some of the world’s most prestigious watch brands. This year, Prince Jewellery & Watch will showcase exceptional creations from six internationally renowned brands: Baume & Mercier, Corum, DeWitt, Franck Muller, Montblanc and Sarcar. World Brand Piazza will feature a selection of limited-edition and highly collectible timepieces. Among the highlights, Franck Muller will present a ladies’ watch created in collaboration with French street artist Jisbar, marking the second partnership between the two parties. The brand will also host a product introduction seminar on 2 September titled “Franck Muller 2026 WPHH Novelties ‘Vanguard Lady Crazy Hours Jisbar’”. Meanwhile, Sarcar has specially created a unique platinum version of its Medusa timepiece exclusively for the World Brand Piazza. The one-of-a-kind watch is set with 228 diamonds, complemented by red garnets and green agates, showcasing exceptional high jewellery craftsmanship. Two marquise-cut diamonds are used to represent Medusa’s eyes. At the same time, the signature snake-hair motif extends seamlessly from the dial to the case and lugs, all meticulously sculpted from solid gold, offering the charm of ancient Roman stone sculptures of beautiful women. The Renaissance Moment zone will also welcome the debut appearance of WOLF, the luxury watch storage box and winder brand from the United Kingdom. Built around the concept of preserving heritage, WOLF provides professional care solutions for high-end mechanical timepieces. On the opening day of the fair (1 September), the brand will unveil its latest innovation, The Rocket, the world's most compact travel watch winder, highlighting WOLF's commitment to innovative design and exceptional craftsmanship. Guochao timepieces showcase the strength of Chinese watchmaking Designs incorporating traditional Chinese cultural elements have gained strong market appeal in recent years. This year, Salon de TIME will bring together five leading independent watchmakers from the Chinese Mainland, all of whom will attend the fair in person. The Académie Horlogère des Créateurs Indépendants (AHCI) which is widely regarded as one of the most prestigious independent watchmaking institutions, maintains exceptionally stringent membership requirements. Currently, only four AHCI members are from the Chinese Mainland, and this year's exhibition will feature three of them including Xushu Ma, who was the first watchmaker from the Chinese Mainland admitted to the association, as well as Zehua Tan and Lin Yong Hua. The opportunity to see such a distinguished line-up in one place is particularly rare. In addition, several Guochao-inspired brands and Chinese watchmakers will showcase their outstanding creations. Highlights include: Chinese watchmaker Qian Guobiao will present the limited-edition AB-05S “Skylight Sun”, restricted to just 18 pieces worldwide. The self-developed AB-05 manual-winding movement powers the timepiece. At the same time, its semi-skeletonized dial reveals the balance wheel and gear train, highlighting the watch's intricate mechanics and technical expertise. Shanghai Watch will present the ORIGINATE Collection A623 Revival Watch, a modern recreation of China’s first calendar watch, modelling after the original A623 timepiece worn for many years by Zhou Enlai, the first Premier of the People’s Republic of China. The brand will also unveil the Hong Kong Exclusive Edition featuring two interchangeable straps in grey and green, with colours inspired by the Zhongshan suits frequently worn by Premier Zhou, evoking a spirit and memory that transcend generations. Award-winning timepieces showcase innovation and craftsmanship This year’s fair brings together award-winning timepieces, highlighting the watch industry’s pursuit of technical excellence and design innovation. Highlights include: AGELOCER’s 29.51-Day MoonPhase Original Astronomer reimagines the traditional moon phase display by featuring an industry-first 28.5mm oversized moon phase aperture. Blending astronomical imagery with mechanical aesthetics, the timepiece has earned nine international design awards, including the German Design Award 2022, MUSE Design Awards Gold 2023, and European Design Award 2023. Making its debut at the exhibition, Singaporean brand Vario will present the Vario VERSA Reversible Dual Time Watch. With an innovative reversible case design, the watch features two independent dials, each showing a different time zone. Users can easily switch between the two displays, making it a practical companion for international travellers. The unique design earned the watch the 2025 iF Design Award. Collaborations, innovation and limited-edition collectibles cater to diverse market tastes The fairs will also feature collaborative, limited-edition, and debut timepieces, showcasing different styles and innovations to meet evolving consumer preferences, including: LINK2CARE has partnered with Swiss watch brand MARVIN to launch a luxury smartwatch that integrates LINK2CARE’s patented leather strap with concealed medical-grade vital sensor. The watch provides comprehensive health monitoring capabilities, including real-time tracking of mental resilience and stress levels, with data displayed directly on the watch dial. This year’s two major overseas pavilions, the Swiss Independent Watchmakers Pavilion (SIWP) and France’s Francéclat, together with other European exhibitors, will bring together around 80 brands from across Europe. Among the highlights, Swiss watchmaker Pilo & Co Genève will showcase the Corleone Mini Collection, created to celebrate the brand’s 25th anniversary. Reimagining the iconic Corleone design as a refined ladies’ timepiece, the collection blends elegance with contemporary sophistication, with each colour variant limited to just 10 pieces worldwide. Several product zones showcase industry strength; Time Tunnel celebrates 45th edition The Hong Kong Watch & Clock Fair, to be held in Hall 1, features seven dedicated product zones. Among them, Pageant of Eternity will showcase premium finished watches from Original Equipment Manufacturers (OEM) and Original Design Manufacturers (ODM). One example is Hong Kong exhibitor Time Grand Ltd, which has more than 20 years of experience in product development, engineering design, and manufacturing services for global watch brands. Through its network of partnerships with Swiss watchmaking companies, the firm offers one-stop watchmaking solutions, demonstrating the strength of Hong Kong’s watch industry in connecting international watchmaking markets. Other zones include Complete Watches, Clocks, Machinery & Equipment, Packaging & Display, Parts, Components & Accessories. To celebrate the 45th edition of the Hong Kong Watch & Clock Fair, organisers will present a special “Time Tunnel” exhibition, taking visitors on a journey through three key stages in the fair’s evolution since its debut in 1982. The exhibition will revisit the period from the 1980s to the 1990s, when the fair established itself as a major global sourcing platform for the watch and clock industry. It then traces the transformation of Hong Kong’s watch industry between 2000 and 2020, as the sector evolved from OEM manufacturing toward brand development, with the fair becoming an important platform for industry promotion, networking, and exchange. The final section covers the period from 2020 to the present, when the fair expanded beyond manufacturing, sourcing, and brand promotion. Through cross-sector collaboration and the integration of resources from different industries, it has evolved into a multifaceted platform that brings together craftsmanship, design, technology, lifestyle, culture and consumer engagement, reflecting the continuous transformation of both the watch industry and the fair itself. Experts to share insights on emerging global watch industry trends More than 40 events will take place throughout the fair, including forums, seminars, watch parades, and networking activities, giving industry professionals valuable insights into the latest market developments and business opportunities. On the opening day (1 September), the Hong Kong International Watch Forum will bring together leaders of watch industry associations from Chinese Mainland, Germany, France, Switzerland, Japan and Korea to share the latest trade statistics and industry trends in their respective markets. Speakers will also explore new opportunities arising from the convergence of traditional watchmaking craftsmanship and technological innovation. On the second day (2 September), the Asian Watch Conference will be held under the theme “Hong Kong as the hub of International Watch Trades”. Senior analysts from international research firm Euromonitor International (Hong Kong) will present the latest developments in the global watch market. Representatives from online watch resale platform Chrono24 will discuss how businesses can connect with global demand through digital channels. At the same time, speakers from Lazada HK will share insights on how to leverage e-commerce platforms to accelerate market expansion and reach new customer segments. The 43rd Hong Kong Watch & Clock Design Competition, jointly organised by the HKTDC, the Hong Kong Watch Manufacturers Association Limited, and the Federation of Hong Kong Watch Trades & Industries Limited, aims to promote watch design exchanges and nurture local talent. This year, the themes for the Open Group and Student Group are “Transcending Time” and “Contours of the Breeze” respectively. The competition will continue to feature The Made-to-sell Award, recognising student entries with outstanding commercial potential. The award presentation ceremony will be held on 5 September at the fair’s event stage, with celebrity Joey Thye attending as a guest. Public activities and lucky draws offer an exciting visitor experience Salon de TIME will host a variety of special activities and luxury watch showcases open to the public. Among the highlights, renowned watch art specialist and collector Labeg will lead a workshop on 4 September, demonstrating how to craft wristwatches from corrugated cardboard. This year, the exhibition also introduces the “Time Arena” activity zone, combining sports and luxury watch elements to offer visitors a fresh and interactive experience. A key feature will be the “Watch2Care Smart x Lifestyle Experience Days”, taking place from 4 to 5 September, featuring a range of interactive activities. Visitors will also have the opportunity to try pickleball, one of the fastest-growing sports in recent years. Other highlights include yoga and body mobility sessions, watch parades, and product launch events. Memorigin will unveil the Verdant Resonance Tourbillon watch, and invite several celebrity guests to attend its activities, including celebrity Vic Teo, Hong Kong basketball star Wong Lut Yiu, and renowned face-changing performer Hathor Wai. A Lucky Draw will be held daily throughout the fair, offering visitors the chance to win premium watches sponsored by brands including Memorigin, SAGA, ELMER INGO, Allied Asia Enterprise (PVT) Limited, Alexus Christy, Claudia Koch and FOKSY. In addition, CENTRESTAGE, Hong Kong’s premier fashion event, will take place concurrently at the HKCEC from 2 to 5 September, bringing together fashion brands and designer collections from around the world. The co-location of the events will create strong synergies, allowing visitors to explore the latest collections from more than 400 watch and fashion brands under one roof. Photo download: https://bit.ly/4xqIloM The 45th HKTDC Hong Kong Watch & Clock Fair and 14th Salon de TIME take place from 1 to 5 September at the Hong Kong Convention and Exhibition Centre. Introducing fair highlights at a press conference are Smilely Lam, HKTDC Associate Executive Director (fifth from the left), SK Chong (fourth from the right) and Frankie Lam (fourth from the left), Co-Chairmen, HKTDC Hong Kong Watch & Clock Fair Organising Committee 2026, and celebrity Joey Thye (fifth from the right). Celebrity Joey Thye to host exclusive watch unboxing session, showcasing eight timepieces. The World Brand Piazza, organised in partnership with Prince Jewellery & Watch for the 16th consecutive year, has long been one of the exhibition’s signature attractions and remains a favourite among watch collectors. This year, Prince Jewellery & Watch is presenting luxury creations from six internationally renowned watch brands, including the Vanguard Lady Crazy Hours Jisbar (left), a collaboration between Franck Muller and French street artist Jisbar, as well as a unique platinum version of the Medusa timepiece (right) created exclusively for the exhibition by Sarcar.     Chinese watchmaker Qian Guobiao will present the limited-edition AB-05S “Skylight Sun”, restricted to just 18 pieces worldwide. The self-developed AB-05 manual-winding movement powers the timepiece. At the same time, its semi-skeletonized dial reveals the balance wheel and gear train, highlighting the watch's intricate mechanics and technical expertise. AGELOCER’s 29.51-Day MoonPhase Original Astronomer reimagines the traditional moon phase display by featuring an industry-first 28.5mm oversized moon phase aperture. Blending astronomical imagery with mechanical aesthetics, the timepiece has earned nine international design awards, including the German Design Award 2022, MUSE Design Awards Gold 2023, and European Design Award 2023. Vario VERSA Reversible Dual Time Watch’s innovative reversible case design, the watch features two independent dials, each showing a different time zone. Users can easily switch between the two displays, making it a practical companion for international travellers. The unique design earned the watch the 2025 iF Design Award. LINK2CARE has partnered with Swiss watch brand MARVIN to launch a luxury smartwatch that integrates LINK2CARE’s patented leather strap with concealed medical-grade biometric sensors. The watch provides comprehensive health monitoring capabilities, including real-time tracking of resilience and stress levels, with data displayed directly on the watch dial. Memorigin will unveil the “Verdant Resonance Tourbillon watch”, inspired by the refined lifestyle of ancient Chinese scholars, particularly the tradition of playing the zither while enjoying incense. It combines Chinese cultural aesthetics with contemporary haute horlogerie craftsmanship.    The 43rd Hong Kong Watch & Clock Design Competition features two categories, the Open Group and the Student Group, with design themes of “Transcending Time” and “Contours of the Breeze” respectively. Award-winning and shortlisted entries will be exhibited throughout the fair, showcasing the creativity and design talent of Hong Kong’s emerging and established watch designers. Photo shows representatives of the watch and clock industry together with the competition judges. Websites: Hong Kong Watch & Clock Fair: https://www.hktdc.com/event/hkwatchfair/en Salon de TIME: https://www.hktdc.com/event/te/en Media enquiries Please contact the HKTDC’s Communications & Public Affairs Department:  Johnny Tsui Tel: (852) 2584 4395 Email : johnny.cy.tsui@hktdc.org About HKTDC The Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.  Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com ———————————————————————————————————————————————————————————— Biovica Expands Pharma Services Business with New Master Services Agreement ... 2026-08-27 · PR-Inside · Healthcare https://pr-inside.com/biovica-expands-pharma-services-business-with-new-master-services-agreement-r5216669.htm (PR-inside.com) UPPSALA, SE / ACCESS Newswire / August 27, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a company specializing in blood-based cancer monitoring, today announces that it has entered into a Master Services Agreement (MSA) with an operating subsidiary of a U.S.-based biotechnology company developing next-generation precision medicines for cancer. The agreement establishes a framework for the use of Biovica's DiviTum® TKa testing services in the customer's oncology drug development programs. The customer is developing a portfolio of next-generation cancer therapies, including drugs targeting key cell-cycle pathways known to take benefit from TKa measurements. Individual projects under the MSA will be initiated through .. ———————————————————————————————————————————————————————————— Willow Wellness Elevates Pregnancy Massage Dublin With Luxury Prenatal Care 2026-08-27 · Express Press Release · Healthcare https://express-press-release.net/news/2026/08/27/1769586 Dublin, Ireland, 2026-08-27 — /EPR Network/ — Willow Wellness is bringing a new level of care with its pregnancy massage Dublin service. This service is [read full press release...] ———————————————————————————————————————————————————————————— NYU Langone Health Names Sunil Rao, MD, Director of the Leon H. Charney Division of Cardiology and Welcomes Susheel Kodali, MD, to Lead Interventional Cardiology 2026-08-27 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/nyu-langone-health-names-sunil-rao-md-director-of-the-leon-h-charney-division-of-cardiology-and-welcomes-susheel-kodali-md-to-lead-interventional-cardiology-302861339.html NEW YORK, Aug. 27, 2026 /PRNewswire/ -- NYU Langone Health has appointed Sunil Rao, MD, an internationally recognized clinician-investigator whose work has introduced new approaches to treating patients with complex cardiovascular conditions, as director of the Leon H. Charney Division of... ———————————————————————————————————————————————————————————— Stroke Rehab Should Start Early and Address Physical, Cognitive and Mental Health 2026-08-27 · NewMediaWire · Healthcare, Retail https://www.newmediawire.com/news/stroke-rehab-should-start-early-and-address-physical-cognitive-and-mental-health-7088965 Guideline Highlights: Rehabilitation after a stroke should begin as soon as the individual is medically stable, ideally within 48 hours of the stroke, and should be personalized to address the person’s physical, cognitive, language and mental health needs. A coordinated multidisciplinary care team is crucial for effective post-stroke rehabilitation, and evaluation of treatment goals should be ongoing until the person who had the stroke is able to achieve their highest possible level of function for daily activities. The guideline also calls for continued monitoring for post-stroke complications and related conditions, including depression and anxiety, and emphasizes the need to also support caregivers and family members. DALLAS - August 27, 2026 ( NEWMEDIAWIRE ) - A stroke can change life ———————————————————————————————————————————————————————————— Joseph Spine Institute Launches Patient Education Program to Help Patients Make Informed Decisions About Spine Care 2026-08-27 · PR Newswire · Healthcare, Education https://www.prnewswire.com/news-releases/joseph-spine-institute-launches-patient-education-program-to-help-patients-make-informed-decisions-about-spine-care-302861082.html TAMPA BAY, Fla., Aug. 27, 2026 /PRNewswire/ -- Joseph Spine Institute (JSI) is announcing the launch of a new Patient Education Program designed to provide patients and their families with accessible, physician-led information to help them better understand spine conditions, treatment... ———————————————————————————————————————————————————————————— AlzeCure Pharma to Present at The Pareto Securities 17th Annual Healthcare ... 2026-08-27 · PR-Inside · Healthcare https://pr-inside.com/alzecure-pharma-to-present-at-the-pareto-securities-17th-annual-healthcare-r5216650.htm (PR-inside.com) STOCKHOLM, SE / ACCESS Newswire / August 27, 2026 / AlzeCure Pharma AB ("AlzeCure" or "The Company") (STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer's disease and pain, announced today that it will participate in the Pareto Securities 17th Annual Healthcare Conference on September 2, where CEO Martin Jönsson will give a company presentation and answer questions about the latest developments and AlzeCure's plans for the future. Venue: Hotel At Six, Brunkebergstorg 6, Stockholm Format: Presentation and 1×1 meetingsPresentation time: September 2, 2026, 17:05-17:25 CEST (room: Event Small) The presentation will also be available afterwards on .. ———————————————————————————————————————————————————————————— 3D Cell Culture Market: How FDA Support for NAMs Could Reshape Cell-Based Research 2026-08-27 · Express Press Release · Healthcare https://express-press-release.net/news/2026/08/27/1769568 The way researchers study cells are changing rapidly as advances in biotechnology create more realistic and sophisticated models for understanding biological processes. Traditional two-dimensional cell [read full press release...] ———————————————————————————————————————————————————————————— How Electronic Health Records Are Increasing Clinical Decision Support Systems Adoption 2026-08-27 · Express Press Release · Healthcare https://express-press-release.net/news/2026/08/27/1769562 Healthcare organizations are increasingly turning to technology to make clinical decisions more accurate, consistent, and patient-focused. Against this backdrop, the clinical decision support systems market [read full press release...] ———————————————————————————————————————————————————————————— Patient Engagement Solutions Market: Why Patient Expectations Are Pushing Healthcare Beyond Portals 2026-08-27 · Express Press Release · Healthcare https://express-press-release.net/news/2026/08/27/1769553 Healthcare is becoming increasingly connected, digital, and patient-centric, changing how people interact with providers before, during, and after receiving care. From appointment reminders and secure [read full press release...] ———————————————————————————————————————————————————————————— Baltimore Community Leaders Unite to Fuel Research and Hope at Maryland Night of Champions 2026-08-27 · PR.com · Finance, Healthcare, Education https://www.pr.com/press-release/977533 The Crohn's & Colitis Foundation's DC/Maryland/Virginia Chapter will host the 2026 Maryland Night of Champions on October 8 at the Baltimore Museum of Industry. The event will honor Dr. Tony Guerrerio as the 2026 Medical Champion and LT Marie "May" Oberlin with the Chloe Hannah Leadership Award. The evening aims to raise $150,000 to support groundbreaking research, patient programs, education, and advocacy for the 1 in [PR.com] ———————————————————————————————————————————————————————————— ENT Devices Market: How the Aging Population Is Driving Demand 2026-08-27 · Express Press Release · Healthcare https://express-press-release.net/news/2026/08/27/1769539 Hearing loss has quietly become one of the most widespread health conditions on the planet. It’s not confined to the elderly, it’s not always obvious, [read full press release...] ———————————————————————————————————————————————————————————— hVIVO acquires CRS Berlin, expanding expertise into dermatology and women's health markets 2026-08-27 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/27/3351780/0/en/hvivo-acquires-crs-berlin-expanding-expertise-into-dermatology-and-women-s-health-markets.html London, UK – 27 August 2026 , hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, announces the acquisition of CRS Clinical Research Services Berlin GmbH ("CRS Berlin"). ———————————————————————————————————————————————————————————— Orlando Workers' Compensation Attorney Explains Heat Illness Claims for Outdoor Workers 2026-08-27 · PressReleaseNews · Healthcare https://pressreleasenews.org/pressroom/orlando-workers-compensation-attorney-explains-heat-illness-claims-for-outdoor-workers Central Florida's summer heat puts outdoor workers at real risk. Orlando workers' compensation attorney Thomas Vaughan explains when heat stroke, exhaustion, dehydration, and cramps qualify for workers' comp benefits, and why documenting a heat illness quickly matters most for building a strong claim. ———————————————————————————————————————————————————————————— Nicox annonce avril 2027 comme date PDUFA pour NCX 470 dans le traitement du glaucome 2026-08-27 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/08/27/3351772/0/fr/nicox-annonce-avril-2027-comme-date-pdufa-pour-ncx-470-dans-le-traitement-du-glaucome.html 1 La date PDUFA correspond à la date cible à laquelle la Food and Drug Administration (FDA) américaine prévoit d’achever la revue d’une demande d’autorisation de mise sur le marché (NDA) et de rendre sa décision, conformément au Prescription Durg User Fee Act (PDUFA). ———————————————————————————————————————————————————————————— Nicox Announces April 2027 PDUFA Date for NCX 470 in Glaucoma 2026-08-27 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/08/27/3351772/0/en/nicox-announces-april-2027-pdufa-date-for-ncx-470-in-glaucoma.html 1 A PDUFA date is the target date by which the U.S. Food and Drug Administration (FDA) aims to complete its review and issue a decision on a New Drug Application (NDA) under the Prescription Drug User Fee Act (PDUFA). ———————————————————————————————————————————————————————————— Lindora Metabolic Health + Wellness Is Now Open in Waxhaw, NC 2026-08-27 · PRUnderground · Healthcare https://prunderground.com/lindora-metabolic-health-wellness-is-now-open-in-waxhaw-nc/cmta44gxj000a04l7znstttet Offering EMS workout training, GLP-1 medical weight loss, IV therapy, NAD+ therapy, peptide therapy, HRT, TRT, metabolic supplements and vitamin injections The post Lindora Metabolic Health + Wellness Is Now Open in Waxhaw, NC first appeared on ———————————————————————————————————————————————————————————— Materialise Reports Second Quarter and Half-Year 2026 Results 2026-08-27 · mlpr-businesswire · Finance, Healthcare https://finance.yahoo.com/healthcare/articles/materialise-reports-second-quarter-half-050000010.html LEUVEN, Belgium, August 27, 2026--Materialise NV (Euronext & NASDAQ:MTLS), a global leader in 3D-printed medical devices and software, and a pioneer in additive manufacturing software and services, today announced its financial results for the second quarter and the six months ended June 30, 2026. ———————————————————————————————————————————————————————————— Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth 2026-08-27 · PR Newswire · Finance, AI, Healthcare https://www.prnewswire.com/news-releases/viva-biotech-announces-its-2026-interim-results-ai-sparks-new-paradigm-in-drug-rd-cdmo-commercial-manufacturing-accelerates-revenue-growth-302861178.html Results Highlights for Interim Results ended 30 June 2026 Revenue reached RMB1,006.5 million, increasing by 21.0% YoY Gross profit amounted to RMB341.7 million, increasing by 0.7% YoY Gross profit margin was 34.0% HONG KONG, Aug. 27, 2026 /PRNewswire/ -- On August 26, 2026, Viva Biotech... ———————————————————————————————————————————————————————————— Exascend Deploys Advanced Medical-Grade Storage Solutions to Power Next-Generation Healthcare Systems 2026-08-27 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/exascend-deploys-advanced-medical-grade-storage-solutions-to-power-next-generation-healthcare-systems-302858483.html TAIPEI, Aug. 26, 2026 /PRNewswire/ -- Exascend announced the successful deployment of its Medical-Grade Storage Solutions in collaboration with a leading healthcare technology provider, supporting the demanding requirements of next-generation medical systems. The enterprise-grade solution... ———————————————————————————————————————————————————————————— Seegnal Inc. Announces Closing of First Tranche and Upsize and Extension of Private Placement 2026-08-27 · GlobeNewswire · SaaS, Healthcare https://www.globenewswire.com/news-release/2026/08/27/3351756/0/en/seegnal-inc-announces-closing-of-first-tranche-and-upsize-and-extension-of-private-placement.html CALGARY, AB, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Seegnal Inc. (TSXV: SEGN) (“ Seegnal ” or the “ Company ”), a global leader in SaaS clinical decision support solutions, is pleased to announce, further to its news releases dated June 2, 2026 and July 21, 2026, that it has closed the first tranche (“ Tranche 1 ”) of its previously announced non-brokered private placement of units in the capital of the Company (each, a “ Unit ”). The Company is also pleased to announce that it has upsized the private placement to up to CDN$1,850,000 and is expected to close the second tranche by September 30, 2026. ———————————————————————————————————————————————————————————— REJIMUS Expands In 21 CFR Part 11 Software Validation Services for CPG Supply Chains 2026-08-27 · PRWeb · AI, Healthcare https://www.prweb.com/releases/rejimus-expands-in-21-cfr-part-11-software-validation-services-for-cpg-supply-chains-302860195.html REJIMUS empowers FDA-regulated businesses throughout the GPG supply-chain to more quickly audit, validate, document and maintain electronic systems - including AI-enabled workflows - within their existing quality and compliance programs subject to regulations under 21 CFR Part 11. NORTH... ———————————————————————————————————————————————————————————— China Shengmu Returns to Profitability in 1H2026 with Revenue Up 7.1% and Profit Attributable to Owners Reaches RMB64.0 Million 2026-08-27 · mlpr-acnnewswire · Finance, SaaS, Healthcare, Energy https://www.acnnewswire.com/press-release/english/109478/ Highlights (RMB thousand)   Six months ended 30 June Year-on-Year (“YoY”) Change 2026 2025 Revenue 1,546,145 1,444,274 7.1% Gross profit 447,839 364,866 22.7% Profit/(loss) for the period 19,454 (45,601) N/A Profit/(loss) attributable to owners of the parent company 64,007 (48,322) N/A Raw milk sales volume (tons) 424,902 372,973 13.9% Annualized milk yield per milkable cow (tons/year head) 13.14 12.27 +7,1% Cost of sales per kilogram of milk (RMB/kg) 2.58 2.89 -10.7% HONG KONG, August 27, 2026 - (ACN Newswire) - China Shengmu Organic Milk Limited (“China Shengmu” or the “Group”) (Stock Code: 1432.HK), the organic raw milk producer in China, today announced its financial results for the six months ended June 30, 2026 (the “Period” or “1H 2026”). In the first half of 2026, as the raw milk industry continued to undergo supply-demand rebalancing and end-market demand remained under pressure, the Group adhered to its operating strategy of “production based on demand, controlling volume while improving quality, and prioritizing efficiency”. The Group continued to focus on improving milk yield, optimizing its herd structure, and enhancing cost efficiency. During the Period, the Group recorded sales revenue of RMB1,546.1 million, representing a year-on-year increase of 7.1%. Gross profit increased by 22.7% year-on-year to RMB447.8 million, with gross profit margin improving from 25.3% to 29.0%. Profit attributable to owners of the parent amounted to RMB64.0 million, compared with a loss of RMB48.3 million in the same period last year, marking a return to profitability. The Group’s annualized yield per milking cow further increased to 13.14 tons, representing a year-on-year increase of 7.1% and a new historical high. This drove raw milk sales volume to 424,902 tons in the first half of the year, representing a year-on-year increase of 13.9%. Premium raw milk accounted for 79.5% of total raw milk sales, while the Group continued to enrich its product portfolio with differentiated products, including organic raw milk, organic A2 raw milk, and DHA raw milk. Although the average selling price of raw milk decreased by 6.0% year-on-year during the Period, the Group benefited from higher milk yield, lower feed costs, and refined feeding management. The cost of milk production per kilogram decreased to RMB2.58, representing a year-on-year decrease of 10.7%. As the decline in unit cost exceeded the decline in average selling price, the Group effectively enhanced its earnings resilience amid the industry downturn. During the Period, the Group continued to optimize its herd structure. Total cattle inventory stood at 140,521 head, with milking cows accounting for 48.5%, representing an increase of 0.7 percentage points from the end of 2025. Adhering to its “production based on demand” approach, the Group focused on optimizing low-efficiency and high-parity cows, increasing the proportion of high-efficiency milking cows, and reasonably controlling the scale of replacement heifers. Benefiting from the recovery in beef cattle market prices, the Group further optimized the grading, pricing, and sales management of culled cattle. During the first half of the year, the Group’s feedlot cattle business recorded sales volume of 8,099 head and sales revenue of RMB42.9 million, while net gain surged by 275% to RMB11.0 million, further enhancing the value of the Group’s cattle business across the full life cycle. In terms of smart farming and sustainable development, the Group continued to integrate herd data, environmental monitoring, and equipment operations into its digital management systems. Through the use of tools including wearable collars, thermal imaging, and data analytics, the Group improved the efficiency of heat stress management, precision feeding, and herd health management, while steadily advancing the application of smart feeding systems, robotic milking systems, and electric equipment. Leveraging the resource advantages of the Ulan Buh Desert, the Group continued to enhance its organic circular agriculture system covering “planting–breeding–returning to farmland,” promote the use of high-quality domestically produced forage, and advance manure resource utilization, as well as water- and energy-saving initiatives, further strengthening the distinctive advantages of its desert organic milk source. Mr. ZHANG Jiawang, Chief Executive Officer and Executive Director of China Shengmu, said: “In the first half of 2026, amid continued supply-demand adjustment and the raw milk industry remaining at the bottom of its cycle, China Shengmu further improved the quality of its operations by continuously increasing milk yield, optimizing its herd structure, and reducing unit costs. Raw milk sales volume increased by 13.9% year-on-year, annualized yield per milking cow reached a new historical high, and the cost of milk production per kilogram decreased by 10.7% year-on-year, enabling the Company to return to profitability. Looking ahead, we will continue to prioritize efficiency and maintain prudent operations, consolidate our advantages in organic and differentiated milk sources, deepen collaboration with key customers and industry partners, and continuously enhance asset productivity and profitability.” Looking ahead to the second half of 2026, the Group expects the domestic raw milk industry to remain in a phase of supply-demand rebalancing and recovery from the bottom of the cycle. The Group will continue to adhere to its strategy of “production based on demand, controlling volume while improving quality, and prioritizing efficiency,” further improve herd quality and milk yield, strengthen its cost curve advantage, deepen customer and product collaboration for organic and differentiated raw milk products, and advance digitalization and green production. Following the mandatory cash offer proposed by China Modern Dairy becoming unconditional in all respects on July 20, 2026, the Group will proceed with subsequent industry collaboration in accordance with applicable laws and regulations. While maintaining the distinctive characteristics of its organic milk sources and operational continuity, the Group will prudently assess and unlock potential synergies in areas including centralized procurement, cost management, breeding, and digital management. China Shengmu Organic Milk Limited China Shengmu Organic Milk Limited (“China Shengmu” or the “Group”; stock code: 1432.HK) is an organic raw milk producer in China. The principal business of the Group is dairy farming, production and sales of high-end desert-based organic raw milk and quality non-organic raw milk. The Group focuses on the production and sales of desert-based organic milk, while satisfying the diversified needs of customers for quality raw milk and continues to develop a variety of functional raw milk to enrich the Company’s product combination and enhance its profitability. As of June 30, 2026, China Shengmu owns 34 daily farms, including 1 fattening cow farm. The Company had 140,521 cows in stock. For investor and media enquiry: Christensen China Limited Email: Shengmu@christensencomms.com Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com ———————————————————————————————————————————————————————————— October 20, 2026 Deadline: Join Class Action Lawsuit Against Fractyl ... 2026-08-27 · PR-Inside · Finance, Healthcare https://pr-inside.com/october-20-2026-deadline-join-class-action-lawsuit-against-fractyl-r5216609.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 26, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Fractyl Health, Inc. (NASDAQ:GUTS) securities. If you suffered a loss on your Fractyl Health, Inc. investment and would like to explore a potential recovery under the federal securities laws, Learn about Fractyl Health, Inc. Class Action or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit was filed .. ———————————————————————————————————————————————————————————— Pomerantz LLP Announces The Filing of a Class Action Against Fractyl ... 2026-08-27 · PR-Inside · Finance, Healthcare https://pr-inside.com/pomerantz-llp-announces-the-filing-of-a-class-action-against-fractyl-r5216598.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 26, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Fractyl Health, Inc. ("Fractyl" or the "Company") (NASDAQ:GUTS) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 26-cv-07167, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fractyl securities between January 13, 2025 and January 29, 2026, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations .. ———————————————————————————————————————————————————————————— Back-to-School Health: Helping Children Start the School Year Strong with Accordia Health 2026-08-26 · PR Newswire · Healthcare, Education https://www.prnewswire.com/news-releases/back-to-school-health-helping-children-start-the-school-year-strong-with-accordia-health-302861054.html SARALAND, Ala., Aug. 26, 2026 /PRNewswire/ -- As students return to school, parents are busy with supply lists, shopping for clothes, and getting ready for a great year. One of the best ways to help children succeed is to make sure they are healthy, both physically and emotionally. Dr.... ———————————————————————————————————————————————————————————— Regeneron Pharmaceuticals, Inc. (REGN) Investors: September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit 2026-08-26 · PR Newswire · Finance, Healthcare https://www.prnewswire.com/news-releases/regeneron-pharmaceuticals-inc-regn-investors-september-14-2026-lead-plaintiff-deadline-in-class-action-lawsuit-302860996.html SAN FRANCISCO, Aug. 26, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to... ———————————————————————————————————————————————————————————— As National Wellness Month Comes to a Close, Periodontal Specialist Reminds Patients That Wellness Includes Oral Health 2026-08-26 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/as-national-wellness-month-comes-to-a-close-periodontal-specialist-reminds-patients-that-wellness-includes-oral-health-302860974.html Dr. Jose Arauz of the Carolina Dental Specialty Center says healthy gums are an important part of overall wellness and is warning patients to recognize the signs and symptoms of periodontal disease before they become more serious. JACKSONVILLE, N.C., Aug. 26, 2026 /PRNewswire/ -- As... ———————————————————————————————————————————————————————————— Globus Medical Announces Acquisition of Higgs Boson Health to Transform Healthcare Experience Through AI-Driven Digital Solutions 2026-08-26 · GlobeNewswire · Finance, AI, Healthcare, Education https://www.globenewswire.com/news-release/2026/08/26/3351730/0/en/globus-medical-announces-acquisition-of-higgs-boson-health-to-transform-healthcare-experience-through-ai-driven-digital-solutions.html AUDUBON, Pa., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the acquisition of Higgs Boson Health, a digital healthcare experience company based in Durham, NC and incubated out of Duke University. With a mission to transform healthcare experience through digital innovation, Higgs Boson will position Globus Medical to shape patient and provider experience throughout the full episode of care. ———————————————————————————————————————————————————————————— Bionic Bloom Integrated Health Welcomes Erica Veno, MSW, RCSWI, as New Therapy Provider 2026-08-26 · Newswire.com · Healthcare https://www.newswire.com/news/bionic-bloom-integrated-health-welcomes-erica-veno-msw-rcswi-as-new-therapy Behavioral-Health Professional Brings More Than a Decade of Experience in Trauma-Informed Care, Crisis Intervention and Substance-Use Treatment ———————————————————————————————————————————————————————————— Supporting earthquake response in Colombia 2026-08-26 · WebWire · Healthcare https://www.webwire.com/ViewPressRel.asp?aId=359556 A powerful 7.4 magnitude earthquake struck western Colombia on 10 August, causing widespread damage across the Pacific region. In response, H&M Foundation is donating USD 150,000 to Save the Children to support immediate relief efforts and early recovery for children and families affected by the disaster. - - Preliminary reports indicate significant humanitarian impacts, including loss of life, injuries, damaged homes, schools and health facilities. Affected communities continue to face d... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=359556 ———————————————————————————————————————————————————————————— MiiHealth AI Closes Seed Round for an Undisclosed Amount to Reinvent Patient Intake and Give Providers Back Two Hours a Day 2026-08-26 · mlpr-businesswire · Finance, AI, Healthcare https://finance.yahoo.com/healthcare/articles/miihealth-ai-closes-seed-round-214100415.html PHOENIX, August 26, 2026--MiiHealth AI, maker of the first agentic AI medical assistant purpose-built to automate patient intake, today announced the closing of a seed funding round for an undisclosed amount led by Russell Glass, former CEO of Headspace and founder of Arteria Capital. The round includes participation from a select group of physician angels, healthcare operators, and digital health founders. ———————————————————————————————————————————————————————————— Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients 2026-08-26 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/26/3351722/0/en/immuneering-comments-on-today-s-fda-approval-in-second-line-metastatic-pancreatic-cancer-reiterates-focus-on-first-line-patients.html Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients ———————————————————————————————————————————————————————————— Heidelberg Pharma AG and Huadong Medicine Receive NMPA Approval for Clinical Trial of HDP-101 Combination Therapy in China 2026-08-26 · NewMediaWire · Healthcare https://www.newmediawire.com/news/heidelberg-pharma-ag-and-huadong-medicine-receive-nmpa-approval-for-clinical-trial-of-hdp-101-combination-therapy-in-china-7088946 LADENBURG, GERMANY - August 26, 2026 ( NEWMEDIAWIRE ) - Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that the China National Medical Products Administration (NMPA) has granted Clinical Trial Approval for a Phase Ib/II clinical trial evaluating pamlectabart tismanitin (HDP-101), the Company’s novel BCMA-targeting ADC, in combination therapy for the treatment of patients with relapsed/refractory multiple myeloma. The trial will evaluate the safety, tolerability, and preliminary efficacy of pamlectabart tismanitin in combination either with pomalidomide and dexamethasone, or with daratumumab and dexamethasone, in adult patients with relapsed/refractory multiple myeloma who have received at least one p ———————————————————————————————————————————————————————————— Little Rock Selected for Largest American Kidney Patient Meeting 2026-08-26 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/little-rock-selected-for-largest-american-kidney-patient-meeting-302860991.html WASHINGTON, Aug. 26, 2026 /PRNewswire/ -- The American Association of Kidney Patients (AAKP), the nation's oldest and largest fully independent kidney patient advocacy organization, will host its 51st annual National Patient Meeting September 10 – 13, 2026, in Little Rock, Arkansas. Event... ———————————————————————————————————————————————————————————— My Mountain Mover Recognized Among the 2026 Inc. 5000 Fastest-Growing U.S. Companies 2026-08-26 · mlpr-businesswire · Finance, Healthcare https://finance.yahoo.com/healthcare/articles/mountain-mover-recognized-among-2026-203600937.html SAN DIEGO, August 26, 2026--My Mountain Mover (MMM), the leading provider of Medical & Dental Virtual Assistants, has earned a place on the 2026 Inc. 5000, ranking No. 1,384 among America’s fastest-growing private companies after achieving 254% revenue growth over three years. ———————————————————————————————————————————————————————————— Blueberries Medical Announces Closing of C$1.1 Million Non-Brokered ... 2026-08-26 · PR-Inside · Healthcare, Retail https://pr-inside.com/blueberries-medical-announces-closing-of-c-1-1-million-non-brokered-r5216518.htm (PR-inside.com) TORONTO, ON / ACCESS Newswire / August 26, 2026 / Blueberries Medical Corp. (CSE:BBM)(OTCID:BBRRF)(FRA:1OA) (the "Company" or "Blueberries"), a consumer science company focused on health, wellness and longevity, and a licensed producer of both psychoactive and non-psychoactive cannabis derivatives in Colombia, announces a non-brokered private placement consisting of the sale of 84,615,385 common shares ("Common Shares") at a price of C$0.013 per Common Share for aggregate gross proceeds of approximately C$1,100,000 (or approximately US$781,000) (the "Offering"). The net proceeds from the sale of the Common Shares are expected to fund and expand operations, for general corporate and working capital purposes. The .. ———————————————————————————————————————————————————————————— Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance 2026-08-26 · mlpr-businesswire · Finance, Healthcare https://finance.yahoo.com/healthcare/articles/phibro-animal-health-corporation-reports-202000111.html TEANECK, N.J., August 26, 2026--Phibro Animal Health Corporation (Nasdaq: PAHC) ("Phibro" or the "Company") today announced financial results for its fourth quarter and fiscal year ended June 30, 2026 and provided its financial guidance for the fiscal year ending June 30, 2027. ———————————————————————————————————————————————————————————— Vimy Pharmaceuticals Announces Brokered Private Placement of Subscription Receipts 2026-08-26 · mlpr-newsfile · Healthcare https://www.newsfilecorp.com/release/311659/Vimy-Pharmaceuticals-Announces-Brokered-Private-Placement-of-Subscription-Receipts Toronto, Ontario--(Newsfile Corp. - August 26, 2026) - Vimy Pharmaceuticals Inc. ("Vimy Pharma" or the "Company") and Harmony Acquisitions Corp. (TSXV: MONY.P) ("Harmony") are pleased to jointly announce that, further to their press release dated August 6, 2026 announcing the entering into of a non-binding letter of intent to complete a business combination transaction which will constitute a reverse take-over of Harmony (the "Transaction"), Vimy Pharma has launched a "best efforts" brokered... ———————————————————————————————————————————————————————————— BD to Present at Wells Fargo 21st Annual Healthcare Conference 2026-08-26 · PR Newswire · Finance, Healthcare https://www.prnewswire.com/news-releases/bd-to-present-at-wells-fargo-21st-annual-healthcare-conference-302860873.html FRANKLIN LAKES, N.J., Aug. 26, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m. Eastern... ———————————————————————————————————————————————————————————— First Tracks Biotherapeutics Announces Participation in September Investor Conferences 2026-08-26 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/26/3351693/0/en/first-tracks-biotherapeutics-announces-participation-in-september-investor-conferences.html SAN DIEGO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that members of its executive team are scheduled to participate in multiple upcoming investor conferences: ———————————————————————————————————————————————————————————— Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma eligible for ZIIHERA 2026-08-26 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/roche-receives-fda-approval-for-companion-diagnostic-tests-to-identify-patients-with-her2-positive-metastatic-gastroesophageal-adenocarcinoma-eligible-for-ziihera-302860908.html The PATHWAY HER2 (4B5) test and VENTANA HER2 Dual ISH DNA Probe Cocktail help identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma. Differential diagnosis of these cancers, often aggressive and diagnosed at an advanced stage, is critical to... ———————————————————————————————————————————————————————————— Nano-X Imaging (NNOX) Is 'One to Watch' 2026-08-26 · NewMediaWire · Finance, AI, SaaS, Healthcare, Retail https://www.newmediawire.com/news/nano-x-imaging-nnox-is-one-to-watch-7088943 The company combines proprietary imaging hardware, FDA-cleared AI applications, cloud software, radiology services and healthcare IT within an end-to-end platform spanning scan, analysis and interpretation. Nanox is expanding its commercial reach through its U.S. commercial activities and collaboration with healthcare organizations. First-quarter 2026 revenue increased to $4.3 million from $2.8 million in the prior-year period, with contributions from teleradiology, imaging systems, OEM services, AI, software and Health IT. Nanox has secured FDA clearance for Nanox.ARC, Nanox.ARC X and three Nanox.AI medical imaging solutions, while its commercial and clinical activities involve organizations including RadNet, Cedars-Sinai, Corewell Health and Brigham and Women’s Hospital. LOS ANGELES, CA ———————————————————————————————————————————————————————————— ReferralMD Powers Integrated Management for Accountable Care and Clinically Integrated Networks 2026-08-26 · PRWeb · AI, Healthcare https://www.prweb.com/releases/referralmd-powers-integrated-management-for-accountable-care-and-clinically-integrated-networks-302860187.html Parent-Child Account Architecture, Centralized Provider Management, and Network Performance Dashboards Eliminate Manual Administration Across Distributed Healthcare Organizations MT. PLEASANT, S.C., Aug. 26, 2026 /PRNewswire-PRWeb/ -- ReferralMD, the leading AI-powered patient journey... ———————————————————————————————————————————————————————————— Uniform Advantage Opens New Wesley Chapel Store with Grand Opening Event 2026-08-26 · mlpr-prnewswire-wire · Healthcare, Retail https://www.prnewswire.com/news-releases/uniform-advantage-opens-new-wesley-chapel-store-with-grand-opening-event-302860853.html TAMPA, Fla., Aug. 26, 2026 /PRNewswire/ -- Uniform Advantage expanded its Florida footprint this week with the opening of a new retail location at 6009 Wesley Grove Blvd. in Wesley Chapel. Situated to serve healthcare professionals at AdventHealth, BayCare Health System, and Tampa General... ———————————————————————————————————————————————————————————— Nobel Laureate Dr. Louis J. Ignarro Joins the Angiogenesis Foundation's Advisory Board 2026-08-26 · PRWeb · Healthcare https://www.prweb.com/releases/nobel-laureate-dr-louis-j-ignarro-joins-the-angiogenesis-foundations-advisory-board-302859451.html Dr. Ignarro, whose groundbreaking discoveries established nitric oxide as a critical signaling molecule in cardiovascular health, will advise the Foundation on vascular science, disease prevention, and the effects of diet and lifestyle on circulation. His appointment coincides with the... ———————————————————————————————————————————————————————————— Medical Care Technologies (OTC PINK:MDCE) Advances AI Longitudinal ... 2026-08-26 · PR-Inside · AI, SaaS, Healthcare https://pr-inside.com/medical-care-technologies-otc-pink-mdce-advances-ai-longitudinal-r5216495.htm (PR-inside.com) Company reviews methods designed to assist users in tracking visible skin changes over time with more accuracy. MESA, AZ / ACCESS Newswire / August 26, 2026 / Medical Care Technologies, Inc. (OTC PINK:MDCE) ("MDCE" or the "Company") today announced it's improved longitudinal body-map monitoring capabilities within its MDCE Melanoma Scan Beta platform. The review focuses on methods intended to help users organize, catalog, and track visible skin images over time through structured, repeatable imaging workflows. The MDCE Melanoma Scan Beta is being developed as an AI-assisted imaging and body-map monitoring application. It incorporates an interactive body-map interface designed to allow users to .. ———————————————————————————————————————————————————————————— Medical Care Technologies (OTC PINK:MDCE) Advances AI Longitudinal Body-Map Monitoring Capabilities Within its Melanoma Scan Beta App 2026-08-26 · Newswire.com · AI, Healthcare https://www.newswire.com/news/medical-care-technologies-otc-pink-mdce-advances-ai-longitudinal-body-map Company reviews methods designed to assist users in tracking visible skin changes over time with more accuracy. ———————————————————————————————————————————————————————————— Patients Representing the Power of Advanced Therapies to Take Center Stage at Emily Whitehead Foundation's 2026 Believe Ball 2026-08-26 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/patients-representing-the-power-of-advanced-therapies-to-take-center-stage-at-emily-whitehead-foundations-2026-believe-ball-302860845.html Gathering in Philadelphia on Sept. 25 Will Bring Patients and Cell and Gene Therapies Community Together to Grow Support for Greater Access to Life-Saving Treatments PHILIPSBURG, Pa., Aug. 26, 2026 /PRNewswire/ -- Nine leading voices in advanced therapies and patient advocacy will be... ———————————————————————————————————————————————————————————— OncoLens' AI-Powered Analytics Platform Helps Large Academic Cancer Center in Florida Cut Referral Delays and Surface Care Gaps Hidden in Clinical Notes 2026-08-26 · PRWeb · AI, SaaS, Healthcare https://www.prweb.com/releases/oncolens-ai-powered-analytics-platform-helps-large-academic-cancer-center-in-florida-cut-referral-delays-and-surface-care-gaps-hidden-in-clinical-notes-302860173.html Case study finds nearly 9 in 10 actionable cancer data points existed only in unstructured text invisible to standard EMR reporting; OncoLens Analytics helped the center lift on-time plastic surgery referrals from 58% to more than 83%, eliminate a 6-to-12-month registry lag, and reinforce... ———————————————————————————————————————————————————————————— Veterinary Practice Partners Earns Three 2026 Newsweek Workplace Recognitions 2026-08-26 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/veterinary-practice-partners-earns-three-171500863.html WALTHAM, Mass., August 26, 2026--Veterinary Practice Partners (VPP), a national Veterinary Partnership Community (VPC), today announced it has earned recognition across three of Newsweek's 2026 workplace rankings: America's Greatest Workplaces in Health Care, America's Greatest Workplaces for Women, and America's Greatest Workplaces by State in California, Florida, and Pennsylvania. These lists recognize organizations that build outstanding workplace cultures for their teams, based on independen ———————————————————————————————————————————————————————————— Logan University Health Centers Partners with Arete Healthcare to Expand Patient Access and Modernize the Clinical Experience 2026-08-26 · mlpr-businesswire · Healthcare, Education https://finance.yahoo.com/healthcare/articles/logan-university-health-centers-partners-170300135.html CHESTERFIELD, Mo., August 26, 2026--Logan University Health Centers has entered a strategic partnership with Arete Healthcare to expand access to care, strengthen clinical operations, and connect with a broader network of healthcare providers. As part of the partnership, Logan University Health Centers will implement a new electronic health record (EHR) and practice management system. Through Arete’s clinically integrated network (CIN), the Health Centers will gain access to shared technology an ———————————————————————————————————————————————————————————— GUTS STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces ... 2026-08-26 · PR-Inside · Finance, Healthcare https://pr-inside.com/guts-stockholder-alert-bronstein-gewirtz-and-grossman-llc-announces-r5216470.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 26, 2026 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Fractyl Health, Inc. (NASDAQ:GUTS) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Fractyl securities between January 13, 2025 and January 29, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site:bgandg.com/cases/fractyl-health-inc-guts-class_action_lawsuit. Fractyl Case Details The .. ———————————————————————————————————————————————————————————— Clinect Healthcare Named to the 2026 Inc. 5000 List of America's Fastest-Growing Private Companies. 2026-08-26 · PRWeb · Healthcare https://www.prweb.com/releases/clinect-healthcare-named-to-the-2026-inc-5000-list-of-americas-fastest-growing-private-companies-302859218.html Clinect Healthcare, a healthcare technology company specializing in digital patient engagement and outcomes solutions, has been named to the 2026 Inc. 5000 list of the fastest-growing private companies in America. CHARLOTTE, N.C., Aug. 26, 2026 /PRNewswire-PRWeb/ -- Clinect ranked No.... ———————————————————————————————————————————————————————————— U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer 2026-08-26 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/26/3351615/0/en/u-s-fda-approves-revolution-medicines-rasonque-daraxonrasib-the-first-broad-ras-targeted-medicine-in-metastatic-pancreatic-cancer.html This release contains multimedia assets available for download here ———————————————————————————————————————————————————————————— Flo Health Appoints Rina Hahn as Chief Marketing Officer 2026-08-26 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/flo-health-appoints-rina-hahn-163900252.html LONDON, August 26, 2026--Flo Health, the #1 OB-GYN-recommended women’s health app, announces today the appointment of Rina Hahn as its Chief Marketing Officer (CMO). Hahn brings nearly 20 years of valuable experience growing digital organizations through customer-focused marketing functions. ———————————————————————————————————————————————————————————— Honnas Veterinary Raises Awareness of Accessible Pet Care 2026-08-26 · PR-Inside · Healthcare https://pr-inside.com/honnas-veterinary-raises-awareness-of-accessible-pet-care-r5216429.htm (PR-inside.com) Honnas Veterinary in Austin, Texas, is encouraging greater awareness of the barriers that can keep pets from receiving regular veterinary care. AUSTIN, TX / ACCESS Newswire / August 26, 2026 / Routine veterinary care can play an important role in supporting an animal's health throughout its life. Yet for many pet owners, getting a dog or cat through the clinic door is not always simple. Honnas Veterinary is raising awareness about the importance of making veterinary care more accessible, welcoming, and less stressful for pets and their owners. The Austin practice was founded in 2023 by Dr. Cheri Honnas with a clear objective. .. ———————————————————————————————————————————————————————————— Investor Alert: Deadline Approaching to Join Fractyl Health, Inc. (GUTS) ... 2026-08-26 · PR-Inside · Finance, Healthcare https://pr-inside.com/investor-alert-deadline-approaching-to-join-fractyl-health-inc-guts-r5216424.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 26, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Fractyl Health, Inc. (NASDAQ:GUTS) securities. If you suffered a loss on your Fractyl Health, Inc. investment and would like to explore a potential recovery under the federal securities laws, Learn about Fractyl Health, Inc. Class Action or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit was filed .. ———————————————————————————————————————————————————————————— Robbins LLP Reminds REGN Stockholders of the Pending Lead Plaintiff Deadline in the Class Action Against Regeneron Pharmaceuticals, Inc. 2026-08-26 · mlpr-newsfile · Finance, Healthcare https://www.newsfilecorp.com/release/311603/Robbins-LLP-Reminds-REGN-Stockholders-of-the-Pending-Lead-Plaintiff-Deadline-in-the-Class-Action-Against-Regeneron-Pharmaceuticals-Inc. San Diego, California--(Newsfile Corp. - August 26, 2026) - Robbins LLP reminds investors that a securities class action has been filed on behalf of investors who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between August 1, 2025 and May 15, 2026, inclusive (the "Class Period").The lawsuit alleges that Regeneron Pharmaceuticals misled investors regarding the viability and prospects of its Phase 3 Fianlimab-Libtayo clinical trial for patients with... ———————————————————————————————————————————————————————————— Apta Health Targets Multi-Million Dollar Employer Healthcare Savings ... 2026-08-26 · PR-Inside · Healthcare https://pr-inside.com/apta-health-targets-multi-million-dollar-employer-healthcare-savings-r5216421.htm (PR-inside.com) Managed cash-pay healthcare program combines more than a decade of experience, direct primary care, proprietary fintech and guided member support to help employers reduce costs while improving access to care. CENTENNIAL, CO / ACCESS Newswire / August 26, 2026 / Apta Health today announced the nationwide expansion of Apta Cash, its fully managed cash-pay healthcare program designed to help employers significantly reduce healthcare spending while giving members a simpler, more guided way to access care. This initiative comes at a critical time for employers looking to curb record rate hikes, as The Wall Street Journal recently reported that 2027 will see the .. ———————————————————————————————————————————————————————————— WeInfuse and 4U Medical Partner to Streamline the Infusion Patient Journey from Check-In to Care 2026-08-26 · PR Newswire · SaaS, Healthcare https://www.prnewswire.com/news-releases/weinfuse-and-4u-medical-partner-to-streamline-the-infusion-patient-journey-from-check-in-to-care-302860754.html DALLAS, Aug. 26, 2026 /PRNewswire/ -- WeInfuse, the premier software platform for infusion providers and pharmacies, announced a strategic partnership with 4U Medical to create a more seamless patient experience from arrival to treatment. This integration modernizes the patient intake... ———————————————————————————————————————————————————————————— Mauna Kea Technologies Announces Publication of a Landmark Systematic Review and Meta-Analysis Reinforcing the Diagnostic Accuracy and Clinical Impact of Cellvizio in Upper Gastrointestinal Cancer 2026-08-26 · mlpr-businesswire · SaaS, Healthcare https://finance.yahoo.com/healthcare/articles/mauna-kea-technologies-announces-publication-154500034.html PARIS & BOSTON, August 26, 2026--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces the publication of a landmark independent systematic review and meta-analysis of probe-based confocal laser endomicroscopy (pCLE) in upper gastrointestinal cancer, conducted and funded by Korea's national health technology assessment agency. ———————————————————————————————————————————————————————————— Labor and Employment Firm Zakay Law Group APLC Files A Class Action Lawsuit Against Heritage Health Network Alleging Failure to Pay All Wages Due 2026-08-26 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/labor-and-employment-firm-zakay-law-group-aplc-files-a-class-action-lawsuit-against-heritage-health-network-alleging-failure-to-pay-all-wages-due-302856726.html The lawsuit alleges Heritage Health Network violated the California Labor Code by failing to pay its employees for all time worked. RIVERSIDE, Calif., Aug. 26, 2026 /PRNewswire/ -- The Riverside labor law attorneys at Zakay Law Group, APLC, filed a class action complaint against Heritage... ———————————————————————————————————————————————————————————— ACLM names 2026 scholars committed to expanding access to lifestyle medicine 2026-08-26 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/aclm-names-2026-scholars-committed-to-expanding-access-to-lifestyle-medicine-302860539.html Since 2021, ACLM has provided 110 underrepresented in medicine (UIM) clinicians and public health leaders with training and certification in lifestyle medicine at no-cost, leading the charge to diversify the lifestyle medicine workforce. ST. LOUIS, Aug. 26, 2026 /PRNewswire/ -- The... ———————————————————————————————————————————————————————————— Anthem Blue Cross and Blue Shield Foundation Launches Impact Investment Fund to Strengthen Ohio Communities 2026-08-26 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/anthem-blue-cross-blue-shield-153100516.html COLUMBUS, Ohio, August 26, 2026--The Anthem Blue Cross and Blue Shield Foundation, the charitable arm of Anthem Blue Cross and Blue Shield, launched a new program that deploys capital into mission-driven organizations working to improve health-related social needs. ———————————————————————————————————————————————————————————— International experts gather in Manchester to tackle risks from skin exposure to chemicals 2026-08-26 · Pressat · Healthcare https://pressat.co.uk/releases/international-experts-gather-in-manchester-to-tackle-risks-from-skin-exposure-to-chemicals-4152012fdc09741aaf4beda7fc6c769e/ Wednesday 26 August, 2026 The British Occupational Hygiene Society (BOHS), the Chartered Society for Worker Health Protection, will bring together international experts in occupational health, dermatology, toxicology and exposure science in Manchester this September to examine the latest evidence and approaches to protecting people from harmful exposure to chemicals through the skin. The Occupational and Environmental Exposure of Skin to Chemicals (OEESC) Conference will take place from 14–16 September 2026, bringing together specialists from around the world to share new research, practical approaches and emerging technologies for understanding, assessing and controlling skin exposure. “Skin is the largest human organ and it is our major defence against substances in the environment that ———————————————————————————————————————————————————————————— October 20, 2026 Deadline Approaching: Join Class Action Against Fractyl ... 2026-08-26 · PR-Inside · Finance, Healthcare https://pr-inside.com/october-20-2026-deadline-approaching-join-class-action-against-fractyl-r5216417.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 26, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Fractyl Health, Inc. (NASDAQ:GUTS) securities. If you suffered a loss on your Fractyl Health, Inc. investment and would like to explore a potential recovery under the federal securities laws, Learn about Fractyl Health, Inc. Class Action or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit was filed .. ———————————————————————————————————————————————————————————— Cizzle Bio Highlights CIZ1B Biomarker Blood Test for Lung Cancer at Next Generation Dx Summit 2026-08-26 · mlpr-prnewswire-wire · Healthcare https://www.prnewswire.com/news-releases/cizzle-bio-highlights-ciz1b-biomarker-blood-test-for-lung-cancer-at-next-generation-dx-summit-302860699.html Moffitt Cancer Center's Dr. Lary Robinson discusses blood-based biomarkers in early lung cancer detection and ongoing CIZ1B clinical study WASHINGTON, Aug. 26, 2026 /PRNewswire/ -- Cizzle Bio Inc., a biotechnology company advancing biomarker blood tests for early cancer detection, today... ———————————————————————————————————————————————————————————— Thyme Care Earns NCQA Accreditation for Both Its Cancer Case Management and Population Health Programs 2026-08-26 · mlpr-prnewswire-wire · SaaS, Healthcare https://www.prnewswire.com/news-releases/thyme-care-earns-ncqa-accreditation-for-both-its-cancer-case-management-and-population-health-programs-302860065.html NCQA evaluated Thyme Care's cancer programs against two separate sets of national standards, covering care planning and monitoring, data integration, staff licensure and training. NASHVILLE, Tenn., Aug. 26, 2026 /PRNewswire/ -- Thyme Care, the oncology company aligning accountability... ———————————————————————————————————————————————————————————— Levi & Korsinsky Notifies Fractyl Health, Inc. (GUTS) Shareholders ... 2026-08-26 · PR-Inside · Finance, Healthcare https://pr-inside.com/levi-korsinsky-notifies-fractyl-health-inc-guts-shareholders-r5216414.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 26, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Fractyl Health, Inc. (NASDAQ:GUTS) securities. If you suffered a loss on your Fractyl Health, Inc. investment and would like to explore a potential recovery under the federal securities laws, Learn about Fractyl Health, Inc. Class Action or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit was filed .. ———————————————————————————————————————————————————————————— Assembly Health Appoints Peter Roehmholdt as President and Chief Operating Officer 2026-08-26 · PR Newswire · Finance, Healthcare https://www.prnewswire.com/news-releases/assembly-health-appoints-peter-roehmholdt-as-president-and-chief-operating-officer-302860710.html Experienced healthcare executive brings deep operational, financial and leadership expertise to support Assembly Health's continued growth CHICAGO, Aug. 26, 2026 /PRNewswire/ -- Assembly Health, a leading provider of tech-enabled revenue cycle management services serving more than 5,000... ———————————————————————————————————————————————————————————— China State Construction International Delivers Significant Results in Low-Carbon Construction 2026-08-26 · mlpr-acnnewswire · Finance, SaaS, Healthcare, Real Estate, Energy https://www.acnnewswire.com/press-release/english/109461/ HONG KONG, August 26, 2026 - (ACN Newswire) - China State Construction International Holdings Limited (“China State Construction International” or the “Group”, stock code: 03311), a pioneer in construction industrialisation, has continued to deepen its deployment of technologies including Modular Integrated Construction (“MiC”), Multi-trade Integrated Mechanical, Electrical and Plumbing (“MiMEP”) and Building-integrated Photovoltaics (“BIPV”). As governments in different markets accelerate the development of green buildings, ultra-low energy buildings and new construction industrialisation, demand for efficient and low-carbon construction solutions continues to grow. These businesses have become an important pillar supporting the Group’s transformation towards smart construction. Policy Support and Market Demand Drive Green Construction The construction industry is facing multiple requirements to improve energy efficiency, reduce carbon emissions and minimise construction waste. The Chinese Mainland’s 15th Five-Year Plan promotes coordinated progress in carbon reduction, pollution control, green expansion and economic growth, and proposes the wider adoption of green and low-carbon construction methods, as well as the scaled development of ultra-low-energy buildings and prefabricated buildings. Relevant action plans for the construction sector also encourage the advancement of building-integrated photovoltaics, greater use of renewable energy and stronger efforts to enhance building energy conservation and carbon reduction. Hong Kong’s Climate Action Plan 2050 promotes energy-saving green buildings and waste reduction, with the target of achieving carbon neutrality before 2050 while progressively reducing building energy consumption and reliance on landfills. The Group’s subsidiary, China State Construction Hailong, has continued to promote the scaled application of MiC technology. Data show that carbon emissions during the construction phase of concrete MiC and steel-structure MiC can be reduced by 66.78% and 49.61%, respectively. Compared with traditional construction methods, construction waste can be reduced by more than 75%, material wastage by more than 25%, site electricity consumption by 60% and water consumption by 66%. Over the past five years, the Group has supplied more than 129,155 MiC modules across 116 projects, fully demonstrating the replicability of its technological achievements and its capability for large-scale implementation. Benchmark Projects Demonstrate Technological Advantages In Hong Kong, the Chinese Medicine Hospital of Hong Kong and the Government Chinese Medicines Testing Institute project is the city’s first permanent hospital to adopt MiC and MiMEP. The Group designed and produced more than 7,000 MiMEP prefabricated modules for the project, compressing the mechanical, electrical and plumbing construction cycle from the traditional two to three years to within six months, shortening the construction period by more than 75%. Compared with conventional construction methods, the project reduced carbon dioxide emissions by approximately 1,596 tonnes, representing a carbon reduction of 43%. In addition, the IL9088 New Central Harbourfront Development Project applies approximately 2,500 MiMEP modules. Through standardised and interchangeable design, the project enhances construction efficiency for a high-end commercial complex and provides flexibility for future tenant changes and spatial reconfiguration, thereby reducing repeated construction works and renovation waste. In Shenzhen, the Huazhang New Affordable Housing Project, a development in which the Group participated, successfully passed the 2025 ultra-low-energy building review and became the only residential development among Shenzhen’s first batch of pilot projects. The project comprises five residential towers and 6,028 concrete modules, integrating standardised, industrialised, digitalised, intelligent and green solutions. It was completed and delivered within 365 days, providing 2,740 units of government-subsidised rental housing. In Guangzhou, the Dachong Resettlement Housing Project in Nansha District became China’s first modular building project to receive a 6% floor area ratio incentive in 2025, reflecting the effective integration of the Group’s MiC technology with local policies and public housing needs. ESG Performance Continues to Receive Market Recognition With the practical application of low-carbon technologies and quantifiable results, the Group’s MSCI ESG rating was upgraded from BBB to A, representing a three-notch improvement within two years. The Group has also been selected as a constituent of the FTSE4Good Index Series for 10 consecutive years and included in S&P Global Sustainability Yearbook (China Edition) for four consecutive years, reflecting the capital markets’ recognition of the Group’s green transformation strategy and long-term sustainable development capabilities. China State Construction International will continue to leverage its integrated “Technology + Investment + Construction + Asset Operation” strategy, and capitalise on its technological strengths in MiC, MiMEP and BIPV. The Group will further expand the large-scale application of green construction solutions and explore green finance and green asset operation models, creating long-term value for shareholders, investors and society with both environmental benefits and financial returns. Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com ———————————————————————————————————————————————————————————— Jeremy Hayes Joins Dr Ted Injury Law Legal Team 2026-08-26 · PR-Inside · Healthcare https://pr-inside.com/jeremy-hayes-joins-dr-ted-injury-law-legal-team-r5216413.htm (PR-inside.com) CHARLOTTE, NC / ACCESS Newswire / August 26, 2026 / Dr. Ted Injury Law has announced the hiring of attorney Jeremy Hayes at the firm's Charlotte location. He will represent plaintiffs in matters involving Auto Accidents and other personal injury matters, wrongful death, workers' compensation, nursing home abuse and neglect, and medical negligence. Hayes joins Dr. Ted Injury Law after most recently practicing in South Carolina, where he worked as a trial lawyer. His addition strengthens Dr. Ted Injury Law's team of attorneys representing people injured due to the negligence of others. Licensed to practice law in North Carolina, South Carolina and .. ———————————————————————————————————————————————————————————— Piramal Pharma Strengthens Future Ready Operations with 22.6% Emissions Reduction, 41% Renewable Energy and Zero USFDA OAI Observations 2026-08-26 · PR Newswire · Healthcare, Energy https://www.prnewswire.com/news-releases/piramal-pharma-strengthens-future-ready-operations-with-22-6-emissions-reduction-41-renewable-energy-and-zero-usfda-oai-observations-302860704.html Lowest-ever Scope 1 and Scope 2 emissions mark a milestone year in the Company's SBTi-approved decarbonisation journey MUMBAI, India, Aug. 26, 2026 /PRNewswire/ -- Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceuticals company, today released its... ———————————————————————————————————————————————————————————— SimuTech Group Engineers Co-Author Chapter in Open-Access Medical Device VVUQ Handbook 2026-08-26 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/simutech-group-engineers-co-author-chapter-in-open-access-medical-device-vvuq-handbook-302860701.html The multi-author book was funded by Ansys — part of Synopsys — and Johnson & Johnson. The authors will present key applications during a webinar on September 10. ROCHESTER, N.Y., Aug. 26, 2026 /PRNewswire/ -- SimuTech Group announces the publication of a new chapter co-authored by two of... ———————————————————————————————————————————————————————————— Kaplan Fox & Kilsheimer LLP is Investigating Hims & Hers Health, Inc. (HIMS) for Possible Securities Law Violations 2026-08-26 · mlpr-newsfile · Finance, Healthcare https://www.newsfilecorp.com/release/311215/Kaplan-Fox-Kilsheimer-LLP-is-Investigating-Hims-Hers-Health-Inc.-HIMS-for-Possible-Securities-Law-Violations New York, New York--(Newsfile Corp. - August 26, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS).CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATIONIf you are a Hims & Hers investor and have suffered losses, or if you have information that could assist in the Hims & Hers investigation, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing... ———————————————————————————————————————————————————————————— Oncolytic Virus Cancer Therapy Market Expected to Expand Rapidly During the Forecast Period (2026-2036) Amid Rising Investments in Next-Generation Cancer Treatments| DelveInsight 2026-08-26 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/oncolytic-virus-cancer-therapy-market-expected-to-expand-rapidly-during-the-forecast-period-20262036-amid-rising-investments-in-next-generation-cancer-treatments-delveinsight-302860210.html The oncolytic virus cancer therapy market is poised for significant growth, driven by increasing research and development of genetically engineered viruses that selectively target and destroy cancer cells while stimulating anti-tumor immune responses. The expanding clinical pipeline of... ———————————————————————————————————————————————————————————— Flo Health’s GDPR Compliance and Privacy, Security Protections Stand Up to Independent ISO Scrutiny 2026-08-26 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/flo-health-gdpr-compliance-privacy-143700362.html LONDON, August 26, 2026--Flo Health, the #1 female health app used by more than 300 million people worldwide, has completed its annual ISO 27001 and ISO 27701 audits, which returned zero findings. This means independent auditors identified no areas for improvement in the company's privacy and security management systems. ———————————————————————————————————————————————————————————— U.S. FDA approves ViiV Healthcare’s Tivicay PD, helping close a critical HIV treatment gap for young children 2026-08-26 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/u-fda-approves-viiv-healthcare-141400668.html LONDON, August 26, 2026--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced that the U.S. Food and Drug Administration (FDA) has approved Tivicay PD (dolutegravir (DTG)), for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in paediatric patients (treatment-naïve or -experienced but integrase strand transfer inhibitor (INSTI)-naïve) weighing at least 2 kg. ———————————————————————————————————————————————————————————— Berger Montague PC Investigates Hims & Hers Health, Inc.'s Board of Directors for Breach of Fiduciary Duty (HIMS) 2026-08-26 · mlpr-newsfile · Finance, Healthcare https://www.newsfilecorp.com/release/311544/Berger-Montague-PC-Investigates-Hims-Hers-Health-Inc.s-Board-of-Directors-for-Breach-of-Fiduciary-Duty-HIMS Philadelphia, Pennsylvania--(Newsfile Corp. - August 26, 2026) - National plaintiffs' law firm Berger Montague PC announces an investigation into the Board of Directors of Hims & Hers Health, Inc. (NYSE: HIMS) ("Hims & Hers" or the "Company") for potential breaches of fiduciary duties owed to the Company and its shareholders. The investigation is focused on whether the Company improperly shared private user health data with advertisers, engaged in deceptive billing practices, and made... ———————————————————————————————————————————————————————————— How to Teach T Cells to Track Cancer Like a Hound Dog 2026-08-26 · WebWire · Healthcare https://www.webwire.com/ViewPressRel.asp?aId=359535 The immune system is full of T cells that could hunt down and destroy tumors, if they were primed. Now, a UC San Francisco team has invented a way to do this by combining immune cells that are grown in the lab with samples from a patient's tumor. - - Like giving a scent to a hound dog, it provides direction to the immune system on how to track down the cancer. - - To catch the scent, the T cells need to be trained using rare dendritic immune cells that are hard to obtain from cancer patients... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=359535 ———————————————————————————————————————————————————————————— Monod Bio Licenses AI-designed Protein Technologies to SignalChem Biotech for Custom Discovery Assays 2026-08-26 · NewMediaWire · AI, SaaS, Healthcare, Education https://www.newmediawire.com/news/monod-bio-licenses-ai-designed-protein-technologies-to-signalchem-biotech-for-custom-discovery-assays-7088935 Partnership brings Monod Bio’s LuxSit luciferase and NovoBodies to SignalChem Biotech’s custom assay services Agreement expands Sino Biological’s specialized CRO capabilities through integration of AI-enabled life science tools SEATTLE and RICHMOND, BRITISH COLUMBIA - August 26, 2026 ( NEWMEDIAWIRE ) - Monod Bio, a Seattle-based AI-enabled protein design company, and SignalChem Biotech Inc., a wholly-owned subsidiary of Sino Biological, Inc. (SZSE: 301047), today announced a non-exclusive licensing agreement covering Monod Bio’s proprietary LuxSit de novo luciferase technology and NovoBodies. Under the terms of the agreement, SignalChem Biotech may incorporate the Monod Bio technologies into custom luminescent assay development and protein-fusion services offered to third-party customers f ———————————————————————————————————————————————————————————— NeOnc’s Clinical Story Is Now the Main Event 2026-08-26 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/26/3351481/0/en/neonc-s-clinical-story-is-now-the-main-event.html NeOnc’s (NASDAQ: NTHI) Clinical Story Is Now the Main Event ———————————————————————————————————————————————————————————— Webinar Equips Youth Sports Leaders With Tools to Respond in a Cardiac Emergency 2026-08-26 · NewMediaWire · Retail, Education, Healthcare https://www.newmediawire.com/news/webinar-equips-youth-sports-leaders-with-tools-to-respond-in-a-cardiac-emergency-7088937 DALLAS - August 26, 2026 ( NEWMEDIAWIRE ) - Sudden cardiac arrest is the leading cause of death for student-athletes nationwide, with nearly 75% of cases among young athletes occurring in basketball, football and soccer players. [1] To help youth sports coaches and league leaders prepare for these emergencies, the American Heart Association, devoted to changing the future to a world of healthier lives for all, is hosting a free one-hour webinar focused on Cardiac Emergency Response Plans and safe play practices. The webinar, taking place Wednesday, Sept. 30, at 1 p.m. CT, reflects the American Heart Association's ongoing commitment to improving cardiac emergency preparedness and advances the goals of its Nation of Lifesavers™ movement, which aims to double survival rates from cardiac arres ———————————————————————————————————————————————————————————— Cytrellis Launches ellacor® Micro-Coring® Technology for Full-Body Skin Resurfacing in Australia 2026-08-26 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/cytrellis-launches-ellacor-micro-coring-technology-for-full-body-skin-resurfacing-in-australia-302860047.html WOBURN, Mass., Aug. 26, 2026 /PRNewswire/ -- Cytrellis Biosystems, Inc. ("Cytrellis") a medical aesthetics company bridging the gap in skin health and restoration, today announced the commercial launch of ellacor® with Micro-Coring Technology in Australia following regulatory approval... ———————————————————————————————————————————————————————————— Inspire Medical Systems, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference 2026-08-26 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/26/3351428/0/en/inspire-medical-systems-inc-to-present-at-the-wells-fargo-21st-annual-healthcare-conference.html MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Wells Fargo 21 st Annual Healthcare Conference on Wednesday, September 9, 2026. ———————————————————————————————————————————————————————————— StrainScan Pro Demonstrates Versatility as MDCE Applies Core AI Vision ... 2026-08-26 · PR-Inside · AI, SaaS, Healthcare, Retail https://pr-inside.com/strainscan-pro-demonstrates-versatility-as-mdce-applies-core-ai-vision-r5216390.htm (PR-inside.com) Proprietary Platform Highlights the Strength of a Single AI Vision System Serving Multiple Trillion Dollar Industries MESA, AZ / ACCESS Newswire / August 26, 2026 / Medical Care Technologies Inc. (OTCID:MDCE) today emphasized the cross-industry versatility of its StrainScan Pro platform, underscoring how a single proprietary AI vision system is being applied across both regulated retail environments and large-scale agricultural operations. StrainScan Pro is designed to deliver consistent visual analysis capabilities that support quality verification for licensed retail operators while also addressing agricultural needs such as early detection of pests, crop stress, and quality indicators. By leveraging the same core computer-vision architecture .. ———————————————————————————————————————————————————————————— Commercial Launch Initiated for Neonorm Dog, Jaguar Health's Non-Prescription ... 2026-08-26 · PR-Inside · Finance, Healthcare, Retail https://pr-inside.com/commercial-launch-initiated-for-neonorm-dog-jaguar-health-s-non-prescription-r5216377.htm (PR-inside.com) Neonorm® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI fluid balance in dogs Jaguar expects to make Neonorm Dog available through both Amazon and Chewy soon SAN FRANCISCO, CA / ACCESS Newswire / August 26, 2026 /Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced the initiation of the commercial launch of Neonorm Dog, a new extension of Jaguar's Neonorm franchise for companion and production animals. Neonorm Dog is designed to provide dog owners with access to a plant-based, non-prescription product intended to .. ———————————————————————————————————————————————————————————— Commercial Launch Initiated for Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs 2026-08-26 · Newswire.com · Healthcare, Retail https://www.newswire.com/news/commercial-launch-initiated-for-neonorm-dog-jaguar-health-s-non-prescription Neonorm ® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI fluid balance in dogs Jaguar expects to make Neonorm Dog available through both Amazon and Chewy soon ———————————————————————————————————————————————————————————— NextNRG Secures 25-Year Microgrid Contract with Taft Medical Complex, Expanding Its Healthcare Infrastructure Model into Florida 2026-08-26 · GlobeNewswire · Finance, Healthcare, Energy https://www.globenewswire.com/news-release/2026/08/26/3351368/0/en/nextnrg-secures-25-year-microgrid-contract-with-taft-medical-complex-expanding-its-healthcare-infrastructure-model-into-florida.html Agreement helps Taft Medical Complex meet Florida's 96-hour backup power healthcare mandate while extending NextNRG's repeatable, own-and-operate energy model Agreement helps Taft Medical Complex meet Florida's 96-hour backup power healthcare mandate while extending NextNRG's repeatable, own-and-operate energy model ———————————————————————————————————————————————————————————— Watson Realty Corp. Deploys Bond's AI-Powered Preventative Personal Security to Protect 800 Real Estate Agents 2026-08-26 · NewMediaWire · Finance, AI, SaaS, Real Estate, Retail, Healthcare https://www.newmediawire.com/news/watson-realty-corp-deploys-bond-s-ai-powered-preventative-personal-security-to-protect-800-real-estate-agents-7088936 Major Florida and Georgia Brokerage Gives Agents 24/7 Access to the World’s Only AI-powered Preventative Personal Security Platform JACKSONVILLE, FL and NEW YORK, NY - August 26, 2026 ( NEWMEDIAWIRE ) - Watson Realty Corp. , one of the Southeast’s leading residential real estate brokerages, and Bond (Nasdaq: OBAI), the world’s only AI-powered Preventative Personal Security company, today announced an agreement to provide Bond’s personal security platform to approximately 800 Watson real estate agents across Florida and Georgia. The deployment gives Watson agents access to Bond’s combination of proprietary AI technology and 24/7 live Personal Security Agents, providing professional personal security support as they conduct the everyday work of real estate: meeting prospective clients, showi ———————————————————————————————————————————————————————————— Patients, Caregivers from 4 Hospitals Celebrate UTAH Cardiac Transplant Program's 40th Anniversary 2026-08-26 · PRUnderground · Healthcare https://prunderground.com/patients-caregivers-from-4-hospitals-celebrate-utah-cardiac-transplant-program-s/cmt9as8ub007n04ieu3kq5zmq Transplant patients, physicians, and caregivers from four hospitals celebrate UTAH Cardiac Transplant Program's 40th Anniversary The post Patients, Caregivers from 4 Hospitals Celebrate UTAH Cardiac Transplant Program's 40th Anniversary first appeared on ———————————————————————————————————————————————————————————— All Five Longitude Health Governing Member Systems to Serve as Design and Development Partners for Cell and Gene Therapy Utility 2026-08-26 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/all-five-longitude-health-governing-member-systems-to-serve-as-design-and-development-partners-for-cell-and-gene-therapy-utility-302859986.html FALLS CHURCH, Va., Aug. 26, 2026 /PRNewswire/ -- Longitude Health today announced that all five of its governing member health systems—Michigan Medicine, Novant Health, Baylor Scott & White Health, Memorial Hermann Health System, and Providence—will serve as design and development... ———————————————————————————————————————————————————————————— Daré Bioscience’s Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society 2026-08-26 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/26/3351360/30757/en/dar%C3%A9-bioscience-s-sildenafil-cream-data-in-postmenopausal-women-published-in-menopause-the-journal-of-the-menopause-society.html Daré’s proprietary formulation of topical sildenafil cream, 3.6% was well tolerated across all evaluated doses in the clinical study, with minimal systemic exposure Company continues activities necessary to advance its Sildenafil Cream toward the FDA’s 505(b)(2) regulatory pathway* while in parallel launching DARE to PLAY™ Sildenafil Cream, the 503B compounded version of its proprietary sildenafil cream formulation** ———————————————————————————————————————————————————————————— Fifty 1 Labs, Inc. Acquires MSK Signal Recovery Product Line to Accelerate ... 2026-08-26 · PR-Inside · Finance, SaaS, Healthcare https://pr-inside.com/fifty-1-labs-inc-acquires-msk-signal-recovery-product-line-to-accelerate-r5216330.htm (PR-inside.com) Acquisition expands Fifty 1 Labs' portfolio with a five-product musculoskeletal recovery platform focused on injury recovery, rehabilitation, connective tissue support, joint health, and peptide-focused research VANCOUVER, BC / ACCESS Newswire / August 26, 2026 /Fifty 1 Labs, Inc. (OTCID:FITY), an emerging biotechnology and health innovation company focused on peptide science, musculoskeletal health, sports performance, injury recovery, rehabilitation, and evidence-driven wellness, today announced that it has acquired a musculoskeletal recovery product line from MSK Signal, a Canadian Biotech Company. The acquired product line includes five key product concepts designed to support Fifty 1 Labs' growth strategy in the peptide and musculoskeletal health markets. .. ———————————————————————————————————————————————————————————— Autonomix Medical Expands Intellectual Property Portfolio with New U.S. Patent Covering Feedback-Guided Precision Neuromodulation and Targeted Therapy Delivery 2026-08-26 · GlobeNewswire · Finance, Healthcare, Real Estate https://www.globenewswire.com/news-release/2026/08/26/3351326/0/en/autonomix-medical-expands-intellectual-property-portfolio-with-new-u-s-patent-covering-feedback-guided-precision-neuromodulation-and-targeted-therapy-delivery.html New patent broadens protection around systems integrating real-time physiological feedback, sensing and imaging with controlled therapeutic delivery, including neural ablation approaches for cancer pain ———————————————————————————————————————————————————————————— Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer 2026-08-26 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/26/3351327/0/en/celcuity-submits-snda-to-fda-for-revtorpyk-gedatolisib-for-hr-her2-pik3ca-mutant-locally-advanced-or-metastatic-breast-cancer.html MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced the submission of its supplemental New Drug Application (“sNDA”) to the U.S. Food and Drug Administration (“FDA”) for REVTORPYK™ (gedatolisib) for the treatment of patients with hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”), locally advanced or metastatic breast cancer (“ABC”) with a PIK3CA mutation, following progression on or after treatment with at least one line of endocrine therapy. ———————————————————————————————————————————————————————————— GeoVax Announces a Warrant Inducement Transaction 2026-08-26 · NewMediaWire · Finance, Healthcare https://www.newmediawire.com/news/geovax-announces-a-warrant-inducement-transaction-7088933 ATLANTA, GA - August 26, 2026 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, today announced its entry into a warrant inducement agreement with an existing institutional investor of the Company for the immediate exercise of existing warrants (the "Existing Warrants") to purchase up to 5,697,628 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at an exercise price of $0.64 for gross cash proceeds of approximately $3,646,482, before deducting financial advisor fees and other transaction expenses. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes. In consideration for the immediate exercise in full of th ———————————————————————————————————————————————————————————— IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001 2026-08-26 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/26/3351335/0/en/imunon-to-host-2026-r-d-day-highlighting-phase-3-ovation-3-trial-and-the-clinical-potential-of-imnn-001.html Leading oncology experts and company management will discuss the Phase 3 OVATION 3 study, supporting science and data, clinical progress, and upcoming milestones ———————————————————————————————————————————————————————————— SEALSQ’s Subsidiary ICAlps Advances QASIC Roadmap for Sovereign, Quantum-Resistant Application-Specific Integrated Circuits 2026-08-26 · GlobeNewswire · Finance, Healthcare, Automotive https://www.globenewswire.com/news-release/2026/08/26/3351329/0/en/sealsq-s-subsidiary-icalps-advances-qasic-roadmap-for-sovereign-quantum-resistant-application-specific-integrated-circuits.html Geneva, Switzerland, Aug. 26, 2026 (GLOBE NEWSWIRE) -- QASIC initially targets the cybersecurity, medical and automotive sectors by combining SEALSQ’s post-quantum security technologies with IC’Alps’ advanced custom-chip design capabilities ———————————————————————————————————————————————————————————— ConV2X Expands Cambridge Executive Summit With New Healthcare, FDA, AI, and Cybersecurity Leaders 2026-08-26 · WebWire · AI, Healthcare https://www.webwire.com/ViewPressRel.asp?aId=359477 ConV2X today announced a new group of in-person speakers joining its September 24–25 executive summit at The Foundry in Cambridge, Massachusetts, expanding the multidisciplinary dialogue around AI infrastructure, decentralized health, cybersecurity, regulation, clinical implementation and the technologies reshaping healthcare and life sciences. - - The newly announced in-person participants bring experience from healthcare delivery, FDA leadership and regulation, enterprise AI, cybersecurit... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=359477 ———————————————————————————————————————————————————————————— DEA's Own Witness Admitted Marijuana Failed the Medical-Use Test-Then ... 2026-08-26 · PR-Inside · Healthcare https://pr-inside.com/dea-s-own-witness-admitted-marijuana-failed-the-medical-use-test-then-r5216243.htm (PR-inside.com) The corrected official transcripts are now public. FDA's supervising scientist named who directed the change in standard: the Assistant Secretary for Health - the same office that produced the government's headline evidence and never sent a witness. WASHINGTON, D.C. / ACCESS Newswire / August 26, 2026 / The Drug Enforcement Administration has released the corrected official transcripts from all 11 days of its marijuana-rescheduling hearing. MMJ International Holdings, Inc. ("MMJ") has reviewed them against the Government's 50-page closing brief. Buried inside thousands of pages is one admission that cuts through nearly every political argument surrounding Schedule III: Marijuana would not have passed .. ———————————————————————————————————————————————————————————— DEA's Own Witness Admitted Marijuana Failed the Medical-Use Test-Then the Government Buried It in Silence 2026-08-26 · Newswire.com · Healthcare https://www.newswire.com/news/deas-own-witness-admitted-marijuana-failed-the-medical-use-test-then-the The corrected official transcripts are now public. FDA's supervising scientist named who directed the change in standard: the Assistant Secretary for Health - the same office that produced the government's headline evidence and never sent a witness. ———————————————————————————————————————————————————————————— Eikon Therapeutics to Participate in Investor Conferences in September 2026 2026-08-26 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/26/3351236/0/en/eikon-therapeutics-to-participate-in-investor-conferences-in-september-2026.html MILLBRAE, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that Roger M. Perlmutter, M.D., Ph.D., Chairman and Chief Executive Officer, and Freddie Bowie, Ph.D., Chief Financial Officer, will participate in two upcoming investor conferences taking place in September: ———————————————————————————————————————————————————————————— Xeris Announces Details for XP-8121 Program Overview Webinar 2026-08-26 · mlpr-businesswire · Finance, Healthcare https://finance.yahoo.com/healthcare/articles/xeris-announces-details-xp-8121-113000188.html CHICAGO, August 26, 2026--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced details for a dedicated Program Overview webinar for XP-8121, the Company’s Phase 3-ready, once-weekly subcutaneous levothyroxine injection in development for the treatment of hypothyroidism. ———————————————————————————————————————————————————————————— Tate & Lyle adds new purpose target to improve everyday consumer health through fibre fortification 2026-08-26 · WebWire · Healthcare, Retail https://www.webwire.com/ViewPressRel.asp?aId=359508 Tate & Lyle PLC ('Tate & Lyle'), a global leader in ingredient solutions for healthier food and beverages, has set an ambitious new target to fill consumer's daily 'fibre gap' by delivering an additional 15g of fibre per day to people's diets, 35 billion times by 2030. This fibre fortification goal has been added to Tate & Lyle's 2030 purpose targets. - - The recommended global intake of fibre is around 30g each day. However, the average global daily adult intake falls well short of this by... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=359508 ———————————————————————————————————————————————————————————— Definium Therapeutics to Participate at Upcoming Investor Conferences and Events 2026-08-26 · mlpr-businesswire · Finance, Healthcare https://finance.yahoo.com/healthcare/articles/definium-therapeutics-participate-upcoming-investor-110100610.html NEW YORK, August 26, 2026--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences and events: ———————————————————————————————————————————————————————————— TROPION-Urothelial04 Phase 3 Trial of Datroway® Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer 2026-08-26 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/tropion-urothelial04-phase-3-trial-110000047.html TOKYO, August 26, 2026--The first patient has been dosed in the TROPION-Urothelial04 phase 3 trial evaluating Datroway® (datopotamab deruxtecan) plus rilvegostomig or Datroway monotherapy versus current standard of care (durvalumab monotherapy or nivolumab monotherapy or enfortumab vedotin plus pembrolizumab) as an adjuvant treatment (after surgery) in patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection with or without prior neoa ———————————————————————————————————————————————————————————— Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study 2026-08-26 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/zepbound-linked-to-lower-healthcare-costs-in-adults-over-age-55-with-obesity-according-to-a-real-world-study-302859960.html First-of-its-kind study shows sustained Zepbound use in older adults with obesity lowers costs, reinforcing the potential value of the Medicare GLP-1 Bridge program Individuals treated with Zepbound had lower rates of hospital admissions and emergency department visits INDIANAPOLIS, Aug.... ———————————————————————————————————————————————————————————— Commercialization Roadmap Validated with Three-digit Million-dollar Revenue: Insilico Medicine Announces Interim Results for the First Half of 2026 2026-08-26 · PR Newswire · Finance, AI, Healthcare https://www.prnewswire.com/news-releases/commercialization-roadmap-validated-with-three-digit-million-dollar-revenue-insilico-medicine-announces-interim-results-for-the-first-half-of-2026-302860466.html CAMBRIDGE, Mass., Aug. 26, 2026 /PRNewswire/ -- Insilico Medicine (HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, recently released its interim results report for 2026. The report shows that the Company achieved total revenue of US$106.... ———————————————————————————————————————————————————————————— ASCEND Cardiovascular and Epsilon Imaging Partner to Streamline Adult ... 2026-08-26 · PR-Inside · SaaS, Healthcare https://pr-inside.com/ascend-cardiovascular-and-epsilon-imaging-partner-to-streamline-adult-r5216173.htm (PR-inside.com) SPRINGFIELD, IL / ACCESS Newswire / August 26, 2026 /ASCEND Cardiovascular, a leader in cardiovascular structured reporting and workflow solutions, and Epsilon Imaging, a leading provider of vendor-neutral advanced echocardiography analysis software, today announced a strategic non-exclusive partnership. The partnership is designed to deliver an integrated, "best-of-breed" solution for clinical echo analysis, reading and reporting. By natively connecting ASCEND's enterprise structured reporting with Epsilon's EchoInsight® Zero Footprint (ZF) advanced echo analysis with strain imaging platform, the integrated solution eliminates workflow friction, simplifies clinical workflow, and expands access to critical cardiac function measurements like speckle tracking strain imaging. ———————————————————————————————————————————————————————————— “Declutter Your Home, Declutter Your Life,” Best-Selling Book Offered for Free (Ending Soon) (Until 8/28/26) 2026-08-26 · WebWire · Healthcare, Energy, Retail https://www.webwire.com/ViewPressRel.asp?aId=359242 Best Seller Publishing announces the release of Michele Rase's new book, “Declutter Your Home, Declutter Your Life”. It will be available in the Amazon store for free for two more days. - - “Declutter Your Home, Declutter Your Life” is about creating a home that gives you energy instead of quietly draining it. Life and Health Coach Michele Rase explores how clutter can create emotional and mental noise, especially when tied to memories, guilt, unfinished decisions, or past identities.... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=359242 ———————————————————————————————————————————————————————————— EUDA Health Subsidiary Melana International Wins SME100 Awards 2026 Singapore 2026-08-26 · GlobeNewswire · Finance, Healthcare, Real Estate https://www.globenewswire.com/news-release/2026/08/26/3351149/0/en/euda-health-subsidiary-melana-international-wins-sme100-awards-2026-singapore.html SINGAPORE, AUGUST, Aug. 26, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based distributor of third-party wellness and non-invasive healthcare products and services in Singapore, Malaysia and China, as well as property management services in Singapore, today announced that its subsidiary, Melana International Pte. Ltd. (“Melana”), was recognised as one of the winners of the SME100 Awards 2026 Singapore, organised by Business Media International. ———————————————————————————————————————————————————————————— Kestra Appoints Curtis Kopf as Senior Vice President of Customer Experience 2026-08-26 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/26/3351145/0/en/kestra-appoints-curtis-kopf-as-senior-vice-president-of-customer-experience.html KIRKLAND, Wash., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today announced the appointment of Curtis Kopf as Senior Vice President of Customer Experience. In this newly created role, Mr. Kopf will lead the patient experience from approval of a patient order through completion of therapy and device return, aligning the people, processes and technology that support providers and their patients throughout the use of the ASSURE ® WCD. ———————————————————————————————————————————————————————————— Recent Release, "The Road to Happy Destiny," from Covenant Books Author David Sequeira, Ph.D., Offers Transformative Therapeutic Wisdom from Decades of Practice 2026-08-26 · PR.com · Healthcare https://www.pr.com/press-release/976877 David Sequeira, Ph.D. has completed a new book, "The Road to Happy Destiny," which invites readers into his distinctive approach to healing and personal transformation. Drawing on his extensive background in clinical and social psychology, Dr. Sequeira shares the therapeutic methodologies that have guided countless individuals toward wholeness and meaningful change. The book serves as both a personal testimony [PR.com] ———————————————————————————————————————————————————————————— Patient-Controlled Data Is Reshaping the Personal Health Record Market 2026-08-26 · Express Press Release · Healthcare https://express-press-release.net/news/2026/08/26/1769422 The global personal health record software market is entering a period of sustained expansion as patients increasingly expect convenient, secure, and real-time access to their medical information. The [read full press release...] ———————————————————————————————————————————————————————————— VirTus Respiratory Research Supports Development of Apollo Therapeutics’ APL-10456 from Preclinical Proof of Concept to Positive Phase 1 Data 2026-08-26 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/virtus-respiratory-research-supports-development-080000328.html LONDON, August 26, 2026--VirTus Respiratory Research Ltd, a specialist respiratory contract research organisation (CRO), founded by Imperial College London investigators Professor Sebastian Johnston and Dr Michael Edwards, today highlighted its role in the preclinical development of Apollo Therapeutics’ and Imperial’s APL-10456, following the announcement of positive initial data from the vaccine’s Phase 1 clinical trial. ———————————————————————————————————————————————————————————— Preclinical Imaging Market: Why Drug Developers Are Outsourcing More of Their Imaging Needs 2026-08-26 · Express Press Release · Healthcare https://express-press-release.net/news/2026/08/26/1769404 A researcher tracking how immune cells behave inside a tumor used to have one option: euthanize the animal and section the tissue. Today, that same [read full press release...] ———————————————————————————————————————————————————————————— Mind Body Genes Spotlights Its Genetic Blueprint Coaching for the Back to Routine Season 2026-08-26 · PressReleaseNews · Healthcare https://pressreleasenews.org/pressroom/mind-body-genes-spotlights-its-genetic-blueprint-coaching-for-the-back-to-routine-season ———————————————————————————————————————————————————————————— Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition 2026-08-26 · GlobeNewswire · Finance, SaaS, Healthcare https://www.globenewswire.com/news-release/2026/08/26/3351102/0/en/nxera-pharma-s-partner-neurocrine-biosciences-receives-ind-acceptance-from-the-fda-for-phase-2-study-of-nbi-1117567-for-alzheimer-s-cognition.html Tokyo, Japan and Cambridge, UK, 26 August 202 6 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has received IND Acceptance from the U.S. Food and Drug Administration (FDA) for a Phase 2 study of NBI-1117567 (“NBI-’567”) for Alzheimer's cognition. Nxera will receive an IND Acceptance milestone payment of US$10 million from Neurocrine pursuant to the agreement. The milestone payment is expected to be recognised in full as revenue in Q3 FY2026. NBI-’567 is an investigational, orally administered, muscarinic M1 receptor preferring agonist discovered using Nxera’s proprietary NxWave™ drug discovery platform. ———————————————————————————————————————————————————————————— SALON VO Expands Hair Care Services with Permanent Hair Straightening in Denver, Colorado 2026-08-26 · Express Press Release · Healthcare https://express-press-release.net/news/2026/08/26/1769370 Denver,United States, 2026-08-26 — /EPR Network/ — SALON VO has expanded its hair care offerings with professional permanent hair straightening services designed to help clients [read full press release...] ———————————————————————————————————————————————————————————— BioNxt Advances Cladribine Clinical Program for MS with Completion ... 2026-08-26 · PR-Inside · Healthcare https://pr-inside.com/bionxt-advances-cladribine-clinical-program-for-ms-with-completion-r5216169.htm (PR-inside.com) VANCOUVER, BC / ACCESS Newswire / August 26, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce the completion of the Investigational Medicinal Product Dossier ("IMPD") for BNT23001, the Company's lead proprietary sublingual cladribine oral dissolvable film (ODF) product candidate for the treatment of relapsing forms of multiple sclerosis (MS). Completion of the IMPD represents a significant regulatory milestone and advances BioNxt's lead development program toward its planned first human bioequivalence study. The IMPD is currently undergoing final technical and regulatory review prior to its planned submission .. ———————————————————————————————————————————————————————————— Hawaii Family Dental Notifies Patients of Cyberattack 2026-08-26 · PR.com · Healthcare https://www.pr.com/press-release/977420 Hawaii Family Dental is notifying affected patients and the community about a cyberattack discovered on July 20, 2026, involving unauthorized access to certain patient information between July 19 and July 20, 2026. The information may have included contact details, date of birth, dental insurance information, portions of medical information, and dental treatment information; Social Security numbers and financial account [PR.com] ———————————————————————————————————————————————————————————— AI in Mental Health Market: Why Responsible Design Will Separate Useful Tools From Risky Ones 2026-08-26 · Express Press Release · AI, Healthcare https://express-press-release.net/news/2026/08/26/1769363 Mental health care is undergoing one of the most significant transformations in its history, and AI in mental health is at the center of it. [read full press release...] ———————————————————————————————————————————————————————————— 4basebio and Genezen Enter into Strategic Collaboration to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufacturing 2026-08-26 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/08/26/3351088/0/en/4basebio-and-genezen-enter-into-strategic-collaboration-to-advance-synthetic-cell-free-dna-platforms-for-next-generation-viral-vector-manufacturing.html Commercial collaboration combines 4basebio’s synthetic DNA technology with Genezen’s viral vector development and manufacturing expertise to support gene therapy programs from early development through clinical and commercial manufacturing. ———————————————————————————————————————————————————————————— Corline intensifierar kommersiell satsning i USA 2026-08-26 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/08/26/3351086/0/sv/corline-intensifierar-kommersiell-satsning-i-usa.html Corline Biomedical AB intensifierar sin kommersiella satsning på den amerikanska marknaden för att ta tillvara det momentum som skapats efter FDA-godkännandet av Kardiums Globe® Pulsed Field System. Satsningen omfattar förstärkta resurser inom Corlines befintliga amerikanska agentstruktur, en ökad marknadsnärvaro samt ett förenklat och standardiserat erbjudande för medicinteknikbolag som vill utvärdera CHS™. Målet är att rekrytera och/eller konvertera ytterligare 3–5 betydande kunder till kommersiell fas till år 2029. ———————————————————————————————————————————————————————————— New book calls Christians to strengthen biblical discernment in an age of spiritual deception 2026-08-26 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/new-book-calls-christians-to-strengthen-biblical-discernment-in-an-age-of-spiritual-deception-302859871.html 'The Devil In Bethel: How to Discern Satan's Demonic Teachers, Prophets, Idols, and Tools in God's Church' released RANCHO CUCAMONGA, Calif., Aug. 26, 2026 /PRNewswire/ -- Christian clinical counselor Aaron G. Cisneros invites believers to take a closer look at biblical discernment in... ———————————————————————————————————————————————————————————— Caliway's CBL-514 Combination Therapy Cleared by U.S. FDA for Phase 2 Trial; Pivotal Phase 3 Trial SUPREME-01 Initiates Enrollment 2026-08-26 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/caliways-cbl-514-combination-therapy-cleared-by-us-fda-for-phase-2-trial-pivotal-phase-3-trial-supreme-01-initiates-enrollment-302859956.html FDA IND Clearance for CBL-0201WR—Caliway has cleared its Investigational New Drug application for CBL-0201WR, a Phase 2 trial evaluating CBL-514 in combination with tirzepatide. U.S. IRB Approval for Pivotal Phase 3 Trial SUPREME-01 (CBL-0301)—The protocol amendment for the pivotal Phase... ———————————————————————————————————————————————————————————— FWD Group reports record profit amid continued growth 2026-08-25 · mlpr-acnnewswire · Finance, AI, Healthcare, Energy, Retail https://www.acnnewswire.com/press-release/english/109421/ HONG KONG, August 26, 2026 - (ACN Newswire) -  FWD Group Holdings Limited (“FWD Group” or “FWD”) today announced interim results for the six months ended 30 June 2026[1]. - New business sales were up seven per cent on the prior corresponding period to US$1.35 billion on an annualised premium equivalent (APE) basis. New business contractual service margin was US$996 million, with year-on-year growth of 25 per cent. - Operating profit after tax was up 20 per cent to US$298 million with positive contributions from all four reportable segments: Hong Kong SAR & Macau SAR; Thailand & Cambodia; Japan; and Expansion Markets. Net profit after tax of US$172 million was a three-fold increase on the first half of 2025 and represents another record result. - Shareholder value creation indicators continued to trend positively, with comprehensive tangible equity up five per cent to US$8.83 billion and Group embedded value up five per cent to US$6.95 billion compared to 31 December 2025. FWD Group retained a solvency ratio[2] of 203 per cent, after the adoption of economic value-based solvency regulation in Japan. - Announced a key hire in May for the high-net-worth (HNW) business, which serves the global HNW insurance market with diversified asset allocation, wealth management, and legacy planning. - Received globally recognised certification in July for the development, procurement, deployment, and use of artificial intelligence (AI) systems, reflecting the growing maturity and responsible use of AI at FWD Group with the ISO/IEC 42001 standard achieved from the International Organisation for Standardisation/International Electrotechnical Commission. Huynh Thanh Phong, Group Chief Executive Officer and Executive Director of FWD Group, said, “FWD Group had a very strong start to our first full year as a listed company. Once again, we’ve demonstrated our ability to sustain growth, and to convert that growth into rising bottom-line profitability, while expanding margins. This was driven by the diversification built into our geographic footprint and multi-channel distribution model over the past 13 years, as well as a capital structure that positions FWD Group well for the future.” In the company’s home market of Hong Kong SAR, momentum continued despite record prior-year growth, supported by resilient domestic demand and the city’s role as one of the world’s largest cross-border wealth hubs. Excellent growth in Japan was driven by the company’s expansion into the savings and retirement needs segment in July 2025, complementing its existing protection business as a rapidly ageing society continues to fuel the longevity economy. In Thailand, the focus on profitable new business continued in the company’s market-leading exclusive bancassurance partnership with Siam Commercial Bank and agency distribution channels. The transition to a new Chief Executive Officer for Thailand was completed in May when Khun Knattapisit Krutkrongchai (KK) joined the company. Strong growth in Expansion Markets – comprised of Indonesia, Malaysia, the Philippines, Singapore, and Vietnam – was achieved despite the macroeconomic uncertainty in some countries in this segment. “These results are the latest example of the strong track record we’re building as a listed company serving more than 40 million customers across 10 markets in Asia. At FWD Group, we remain heavily focused on anchoring around the customer – aided by the golden age of transformational technological innovation that we’re living in,” added Huynh Thanh Phong. Across the region, 21 new products were introduced in the first half of 2026 in response to emerging customer needs. The FWD Group consumer outlook survey released in February 2026, prior to the outbreak of conflict in the Middle East and the associated global energy economic shocks, showed that most of Asia’s middle-class feel financially anxious and underprepared for retirement. About FWD Group FWD Group (1828.HK) is a pan-Asian life and health insurance business that serves over 40 million customers across 10 markets, including BRI Life in Indonesia. FWD’s customer-led and tech-enabled approach aims to deliver innovative propositions, easy-to-understand products and a simpler insurance experience. Established in 2013, the company operates in some of the fastest-growing insurance markets in the world with a vision of changing the way people feel about insurance. FWD Group is listed on the Hong Kong Stock Exchange under the stock code 1828. For more information, please visit www.fwd.com For media inquiries, please contact: groupcommunications@fwd.com Source: FWD Group Holdings Limited [1] The results are for the six months ended 30 June 2026 and are compared to the same period in 2025. Growth rates are represented on a constant exchange rate (CER) basis. The results are based on the unaudited interim condensed consolidated financial statements and embedded value supplementary report for the first half of 2026, unless otherwise stated. Operating profit after tax and net profit after tax represent the amounts attributable to equity holders of the company and are presented net of non-controlling interests. New business sales are calculated on an annualised premium equivalent (APE) basis, based on 100 per cent annualised first year premiums and 10 per cent single premiums. Group LCSM cover ratio, group embedded value and comprehensive tangible equity 2025 values are December 2025 balances/ratios and growth rates are shown accordingly. [2] Prescribed capital requirement (PCR) basis Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com ———————————————————————————————————————————————————————————— Concordare Trials Secures Funding Round to Accelerate Digitization of Clinical Trial Protocols 2026-08-25 · mlpr-businesswire · Finance, Healthcare https://finance.yahoo.com/healthcare/articles/concordare-trials-secures-funding-round-231000062.html NEW YORK, August 25, 2026--Concordare converts clinical trial protocols into a digital format, automating workflows that reduce the time, cost and error rate of clinical trials. ———————————————————————————————————————————————————————————— SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4) 2026-08-25 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/25/3351035/0/en/scynexis-announces-inducement-award-under-nasdaq-listing-rule-5635-c-4.html JERSEY CITY, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with significant unmet medical need, today announced the grant of an inducement equity award to a new Senior Director, with a grant date of August 24, 2026. The award was granted in connection with the commencement of the Senior Director’s employment with the Company, as a material inducement to the employee’s acceptance of employment, and was approved in accordance with Nasdaq Listing Rule 5635(c)(4). ———————————————————————————————————————————————————————————— Memorial Healthcare System Appoints Irfan Mirza as Chief Financial Officer 2026-08-25 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/memorial-healthcare-system-appoints-irfan-mirza-as-chief-financial-officer-302859818.html HOLLYWOOD, Fla., Aug. 25, 2026 /PRNewswire/ -- Memorial Healthcare System has named Irfan Mirza as its Chief Financial Officer, recognizing his leadership in aligning Memorial's financial strategy with its mission to deliver exceptional patient care, support strategic growth and... ———————————————————————————————————————————————————————————— Avetta Appoints Lynda Richards as APAC Principal, Health and Safety 2026-08-25 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/avetta-appoints-lynda-richards-apac-220000233.html SYDNEY, August 25, 2026--Avetta®, the leader in intelligent work readiness across global supply chains, today announced the appointment of Lynda Richards as APAC Principal, Health and Safety. Richards will work across Avetta's Risk Advisory, Product Management and regional leadership teams to strengthen the company's health and safety capabilities and help shape innovation that addresses the evolving needs of businesses across APAC. ———————————————————————————————————————————————————————————— Miles for Mercy raises more than $4,000 before riders hit the road 2026-08-25 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/miles-for-mercy-raises-more-than-4-000-before-riders-hit-the-road-302859790.html Frederick-area businesses push annual fundraiser for Frederick Health Hospice toward its $5,000 goal FREDERICK, Md., Aug. 25, 2026 /PRNewswire/ -- American Iron Speed-n-Cycle has raised more than $4,000 for Frederick Health Hospice through community sponsorships for the 2nd Annual Miles... ———————————————————————————————————————————————————————————— Padilla Announces Health Leadership Promotions as Agency Accelerates Growth in Sector 2026-08-25 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/padilla-announces-health-leadership-promotions-214900985.html MINNEAPOLIS, August 25, 2026--Padilla names new Health sector leaders, strengthening its integrated expertise and positioning the agency for continued growth. ———————————————————————————————————————————————————————————— As DEA Rules Marijuana's Medical Status, Cannabis Giants Face RICO ... 2026-08-25 · PR-Inside · Healthcare https://pr-inside.com/as-dea-rules-marijuana-s-medical-status-cannabis-giants-face-rico-r5216114.htm (PR-inside.com) Federal courts are confronting allegations that major MSOs marketed recreational cannabis as medicine without FDA clinical trials, while MMJ's cases challenge a system that penalized the company that followed the federal drug-development pathway. WASHINGTON, D.C. / ACCESS Newswire / August 25, 2026 / MMJ International Holdings today called attention to a rapidly developing collision between federal marijuana policy, unsupported medical marketing allegations and insurance coverage that could have consequences across the cannabis industry. As DEA Administrative Law Judge Derek C. Julius considers his recommendation in the federal marijuana-rescheduling proceeding-and federal courts consider MMJ-related challenges-major cannabis multistate operators are facing proposed class a ———————————————————————————————————————————————————————————— As DEA Rules Marijuana's Medical Status, Cannabis Giants Face RICO Claims-and Insurers Head for the Exits 2026-08-25 · Newswire.com · Healthcare https://www.newswire.com/news/as-dea-rules-marijuanas-medical-status-cannabis-giants-face-rico-claims-and Federal courts are confronting allegations that major MSOs marketed recreational cannabis as medicine without FDA clinical trials, while MMJ's cases challenge a system that penalized the company that followed the federal drug-development pathway. ———————————————————————————————————————————————————————————— Lakewood-Amedex Biotherapeutics Becomes a B2i Digital Featured Company 2026-08-25 · NewMediaWire · Finance, Healthcare, Retail https://www.newmediawire.com/news/lakewood-amedex-biotherapeutics-becomes-a-b2i-digital-featured-company-7088903 Clinical-Stage Biotechnology Company Is Preparing a Phase 2a Trial of Nu-3, a Topical Bisphosphocin® Gel, in Infected Diabetic Foot Ulcers B2i Digital Campaign to Center on Nu-3, the Upcoming Phase 2a Trial, and the Bisphosphocin® Class Behind It NEW YORK, NY - August 25, 2026 ( NEWMEDIAWIRE ) - B2i Digital, Inc. today welcomed Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) as its newest Featured Company. The Sarasota, Florida clinical-stage biotechnology company develops the Bisphosphocin® class, a novel group of fast-acting, broad-spectrum antimicrobials for infectious diseases and antibiotic-resistant bacterial strains, and B2i Digital will bring that work, and the clinical program built around it, to its network of retail and institutional market participants. A full company profi ———————————————————————————————————————————————————————————— UNIVERSAL HEALTH SERVICES, INC. TO PRESENT AT SEPTEMBER HEALTHCARE CONFERENCES 2026-08-25 · PR Newswire · Finance, Healthcare https://www.prnewswire.com/news-releases/universal-health-services-inc-to-present-at-september-healthcare-conferences-302858593.html KING OF PRUSSIA, Pa., Aug. 25, 2026 /PRNewswire/ -- Universal Health Services, Inc. (NYSE: UHS) is scheduled to present at the following conferences: September 8, 2026, at 8:45am ET at the Wells Fargo Healthcare Conference September 14, 2026, at 8:30am ET at the Morgan Stanley Global... ———————————————————————————————————————————————————————————— The Inner Circle acknowledges Susan K. Sparkman, MD as a 2026 Legacy Achiever 2026-08-25 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/the-inner-circle-acknowledges-susan-k-sparkman-md-as-a-2026-legacy-achiever-302859831.html BELLAIRE, Texas, Aug. 25, 2026 /PRNewswire/ -- Prominently featured in The Inner Circle, Susan K. Sparkman, MD is acknowledged as a 2026 Legacy Achiever for her contributions to Psychiatry and Integrative Mental Health. Dr. Susan K. Sparkman has established a remarkable legacy in... ———————————————————————————————————————————————————————————— Novogenia Sets New Standards With U.S. Launch of the Expanded MGT Plus Methylation Test and Broadens Its International Product Portfolio 2026-08-25 · NewMediaWire · Healthcare https://www.newmediawire.com/news/novogenia-sets-new-standards-with-u-s-launch-of-the-expanded-mgt-plus-methylation-test-and-broadens-its-international-product-portfolio-7088896 MUNICH, GERMANY - August 25, 2026 ( NEWMEDIAWIRE ) - Novogenia AG (ticker symbol: 7V0, formerly Darwin AG), an international healthcare company focused on human genetics and the development of personalized products based on genetic insights, announces the U.S. market launch of its new MGT Plus methylation test. With this launch, Novogenia and its U.S. partner 10X Health are further expanding their joint product pipeline and strengthening their international collaboration in the field of innovative genetic analysis and longevity. Methylation is a fundamental biochemical process involved in numerous metabolic and regulatory processes in the human body. As an integral part of key metabolic pathways, it can significantly influence the function and processing of a wide range of biological molec ———————————————————————————————————————————————————————————— In HelloNation, Medical Malpractice Attorneys Marcia Murdoch and Steven Atkinson of Rexburg, ID Clarify How Claims Work in Idaho 2026-08-25 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/in-hellonation-medical-malpractice-attorneys-marcia-murdoch-and-steven-atkinson-of-rexburg-id-clarify-how-claims-work-in-idaho-302859836.html REXBURG, Idaho, Aug. 25, 2026 /PRNewswire/ -- How do patients know whether their injury qualifies as medical malpractice under Idaho law? A HelloNation article featuring Medical Malpractice Attorneys Marcia Murdoch and Steven Atkinson of Barton Atkinson & Murdoch, P.C. offers a clear... ———————————————————————————————————————————————————————————— Tampa General Hospital Ranked No. 6 Among Florida Employers on Forbes' 2026 America's Best Employers for Women List 2026-08-25 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/tampa-general-hospital-ranked-no-6-among-florida-employers-on-forbes-2026-americas-best-employers-for-women-list-302859822.html Forbes recognizes Tampa General as the highest-ranked healthcare and social services employer in the Tampa Bay region, reflecting its commitment to helping women build careers, advance into leadership and thrive at every stage of life. TAMPA, Fla., Aug. 25, 2026 /PRNewswire/ -- Tampa... ———————————————————————————————————————————————————————————— Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference 2026-08-25 · mlpr-businesswire · Finance, Healthcare https://finance.yahoo.com/healthcare/articles/contineum-therapeutics-present-2026-morgan-200500292.html SAN DIEGO, August 25, 2026--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that management is scheduled to present at the 2026 Morgan Stanley Global Healthcare Conference on Tuesday, September 15th at 5:35 p.m. ET. ———————————————————————————————————————————————————————————— California Community Health Workers and Doulas Can Spend More Time Helping Medi-Cal Members, Thanks to Health Net's $900,000 Grant to Pear Suite 2026-08-25 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/california-community-health-workers-and-doulas-can-spend-more-time-helping-medi-cal-members-thanks-to-health-nets-900-000-grant-to-pear-suite-302859747.html The company's investment will expand access to Pear Suite technology that streamlines service documentation, referrals and Medi-Cal reimbursement for community health worker and doula services. LOS ANGELES, Aug. 25, 2026 /PRNewswire/ -- Health Net, one of California's most experienced... ———————————————————————————————————————————————————————————— Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes 2026-08-25 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/abbott-receives-fda-authorization-for-worlds-first-dual-glucose-ketone-sensing-technology-for-people-with-diabetes-302859742.html Libre Duo 10 Day is a first-of-its-kind, two-in-one biowearable that monitors glucose and helps detect rising ketone levels that can lead to diabetic ketoacidosis (DKA), a serious health condition for people living with diabetes Designed to seamlessly address a critical gap in ketone... ———————————————————————————————————————————————————————————— American Gene Technologies to Present at The Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference 2026-08-25 · mlpr-newsfile · Healthcare https://www.newsfilecorp.com/release/311493/American-Gene-Technologies-to-Present-at-The-Moody-Capital-Solutions-2026-Disruptive-Growth-Life-Sciences-Conference Rockville, Maryland--(Newsfile Corp. - August 25, 2026) - American Gene Technologies, is a clinical-stage biotechnology company developing AGT103-T, a one-time gene-modified T-cell therapy that is the only program to demonstrate elimination of the HIV viral reservoir in humans., is pleased to announce its participation at the upcoming Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, taking place September 9–10, 2026, in New York City. Drew Palin MD President AGT, will... ———————————————————————————————————————————————————————————— AcutePet Urgent Care Celebrates Grand Opening of Ninth Location in ... 2026-08-25 · PR-Inside · Healthcare https://pr-inside.com/acutepet-urgent-care-celebrates-grand-opening-of-ninth-location-in-r5216078.htm (PR-inside.com) Vet-owned urgent care provider expands access to veterinary care on Cincinnati's west side CINCINNATI, OH / ACCESS Newswire / August 25, 2026 / AcutePet Urgent Care, a veterinarian-owned urgent care network, will celebrate the opening of its ninth location in White Oak with a ribbon cutting and community open house on Thursday, August 27 at 2 p.m., ahead of opening to patients on Friday, August 28 at 10 a.m. Located on Cincinnati's west side, the new hospital expands access to urgent veterinary care for pet families in White Oak, throughout western Hamilton County and in nearby southeastern Indiana. "There has been a growing .. ———————————————————————————————————————————————————————————— Women Leaders Association Names Dr. Megan Laabs as First Washington Coaching Partner, Bringing Brain Science to Executive Coaching for the Region's Women Professionals 2026-08-25 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/women-leaders-association-names-dr-megan-laabs-as-first-washington-coaching-partner-bringing-brain-science-to-executive-coaching-for-the-regions-women-professionals-302859729.html New Coaching Partners program connects the association's Washington members with rigorously vetted, proven executive coaches — beginning with a Harvard-trained clinical neuropsychologist who spent 13 years with the Department of Defense, including nine advising senior leaders at the... ———————————————————————————————————————————————————————————— Excelsior Ambulance Appoints Marvin McLellan as Chief Executive Officer 2026-08-25 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/excelsior-ambulance-appoints-marvin-mclellan-as-chief-executive-officer-302857471.html Experienced Healthcare Executive to Lead Company's Next Phase of Accelerated Growth, Innovation, and Clinical Excellence LUDOWICI, Ga., Aug. 25, 2026 /PRNewswire/ -- Excelsior Ambulance, a leading innovator in patient transportation and emergency medical services operating across four... ———————————————————————————————————————————————————————————— Cambrex High Point achève les inspections préalables à l'autorisation menées par la FDA, la PMDA et la TGA, renforçant ainsi ses capacités de production commerciale 2026-08-25 · mlpr-prnewswire-wire · Healthcare https://www.prnewswire.com/news-releases/cambrex-high-point-acheve-les-inspections-prealables-a-lautorisation-menees-par-la-fda-la-pmda-et-la-tga-renforcant-ainsi-ses-capacites-de-production-commerciale-302859549.html ———————————————————————————————————————————————————————————— THE LANDES GROUP COMPLETES ACQUISITION OF ENCORE MEDICAL CENTER, FINALIZES LONG-TERM LEASE WITH UAMS 2026-08-25 · PR Newswire · Finance, Healthcare, Real Estate https://www.prnewswire.com/news-releases/the-landes-group-completes-acquisition-of-encore-medical-center-finalizes-long-term-lease-with-uams-302859696.html Ownership structure enables UAMS to expand while preserving institutional capital DALLAS, Aug. 25, 2026 /PRNewswire/ -- The Landes Group, a Dallas-based real estate investment firm specializing in healthcare real estate and capital solutions, today announced it has completed the... ———————————————————————————————————————————————————————————— Nihon Kohden Expands Executive Leadership to Support Continued Growth and Customer Experience 2026-08-25 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/nihon-kohden-expands-executive-leadership-172500159.html IRVINE, Calif., August 25, 2026--Nihon Kohden, a leading provider of patient monitoring, neurology, ventilation and digital health solutions, today announced an expanded executive leadership structure designed to increase organizational capacity and strengthen alignment across the customer experience. Effective August 3, Zac Ballard was promoted to executive vice president, commercial operations, taking on leadership of sales and marketing across all four of the company’s business units — Patien ———————————————————————————————————————————————————————————— OneLegacy Celebrates the Career and Contributions of Medical Director Dr. Gabriel Danovitch, the 2026 Recipient of the Medawar Prize 2026-08-25 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/onelegacy-celebrates-career-contributions-medical-172300102.html AZUSA, Calif., August 25, 2026--OneLegacy, the nonprofit organ, eye, and tissue procurement organization serving seven counties across Southern California, celebrates the extraordinary career and contributions of Dr. Gabriel Danovitch, who is retiring from his role as Medical Director after over two decades with OneLegacy, while simultaneously receiving one of the most prestigious honors of his career: The Transplantation Society’s 2026 Medawar Prize. ———————————————————————————————————————————————————————————— BlackLabel Supplements™ Supports Athlete Perseverance with Limit-Pushing 'Pre Hustle' Formulation 2026-08-25 · PRUnderground · Healthcare https://prunderground.com/blacklabel-supplements-supports-athlete-perseverance-with-limit-pushing-pre-hust/cmt8plo70000204jrvz0mzat9 The post BlackLabel Supplements™ Supports Athlete Perseverance with Limit-Pushing 'Pre Hustle' Formulation first appeared on ———————————————————————————————————————————————————————————— ECRI Expands Problem Reporting Network and Calls for More Data on AI Errors in Patient Care 2026-08-25 · PR Newswire · AI, Healthcare https://www.prnewswire.com/news-releases/ecri-expands-problem-reporting-network-and-calls-for-more-data-on-ai-errors-in-patient-care-302859649.html As the adoption of AI in healthcare continues to accelerate, ECRI calls on healthcare providers, systems, and clinicians nationwide to report AI-related incidents FORT WASHINGTON, Pa., Aug. 25, 2026 /PRNewswire/ -- Global patient safety nonprofit ECRI announced an expansion of its Problem... ———————————————————————————————————————————————————————————— GUTS DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Fractyl Investors ... 2026-08-25 · PR-Inside · Healthcare https://pr-inside.com/guts-deadline-alert-faruqi-faruqi-llp-reminds-fractyl-investors-r5215994.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 25, 2026 /Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Fractyl To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Fractyl between January 13, 2025 and January 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Fractyl Health, Inc. (""Fractyl" or the .. ———————————————————————————————————————————————————————————— Kinzeno Captures Market 2026 Attention with Launch of Triple-Action Magnetic Kinzeno Massage Gel Roller 2026-08-25 · PressReleaseNews · Healthcare https://pressreleasenews.org/pressroom/kinzeno-captures-market-2026-attention-with-launch-of-triple-action-magnetic-kinzeno-massage-gel-roller Kinzeno introduces its Triple-Action Magnetic Massage Gel Roller, a topical product combining application and massage for various body areas. The formula includes magnesium, MSM, arnica, and frankincense, offering a cooling, non-greasy experience. Customer reviews are mostly positive, though some mention upselling and delivery issues. ———————————————————————————————————————————————————————————— APLA HEALTH'S 42ND ANNUAL AIDS WALK LOS ANGELES RETURNS TO WEST HOLLYWOOD ON OCTOBER 18, 2026 2026-08-25 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/apla-healths-42nd-annual-aids-walk-los-angeles-returns-to-west-hollywood-on-october-18-2026-302859081.html With the theme "Defend Care, Demand Action," the walk spotlights the urgent need for affordable HIV care, prevention, and treatment LOS ANGELES, Aug. 25, 2026 /PRNewswire/ -- On Sunday, October 18 at 10:30 a.m., thousands of Angelenos will fill West Hollywood Park for the 42nd annual AIDS... ———————————————————————————————————————————————————————————— OmicsBank Raises $2.25M to Expand Clinical Data Infrastructure Globally for Healthcare, Life Sciences, and Frontier AI Labs 2026-08-25 · PR Newswire · Finance, AI, Healthcare https://www.prnewswire.com/news-releases/omicsbank-raises-2-25m-to-expand-clinical-data-infrastructure-globally-for-healthcare-life-sciences-and-frontier-ai-labs-302859623.html Seed funding from Redesign Health fuels U.S. expansion and broadens access to clinical and multi-omics data from Asia, bringing greater diversity to drug development and healthcare AI. SAN FRANCISCO, Aug. 25, 2026 /PRNewswire/ -- OmicsBank, a clinical data infrastructure company... ———————————————————————————————————————————————————————————— Professor Sarfaraz Niazi of Washington State University Files FDA Citizen Petition Seeking New Pathway to Make High-Cost Medicines More Accessible Worldwide 2026-08-25 · PR Newswire · Healthcare, Education https://www.prnewswire.com/news-releases/professor-sarfaraz-niazi-of-washington-state-university-files-fda-citizen-petition-seeking-new-pathway-to-make-high-cost-medicines-more-accessible-worldwide-302859625.html The petition requests that the FDA broaden the scientific principles supporting generics and biosimilars to encompass all eligible FDA-approved drugs and biological products. This initiative has the potential to foster competition for some of the most expensive therapies globally once... ———————————————————————————————————————————————————————————— Samuel Merritt University Signs 16 Enrollment Partnerships to Open a Clearer Path Into Health Care Degrees 2026-08-25 · mlpr-businesswire · Healthcare, Education https://finance.yahoo.com/healthcare/articles/samuel-merritt-university-signs-16-160000480.html OAKLAND, Calif., August 25, 2026--Samuel Merritt University (SMU) announced 16 signed partnership agreements with colleges, universities, health systems and community health organizations across Northern California, with eight more contracts under review. Students and employees at partner organizations may apply to SMU's nursing and health sciences programs under set terms and, upon approval, pay less than they would otherwise. ———————————————————————————————————————————————————————————— University of Phoenix Students Rate Online Coursework Above 9 out of 10 for Immediately Applicable Skills 2026-08-25 · PR Newswire · Healthcare, Education https://www.prnewswire.com/news-releases/university-of-phoenix-students-rate-online-coursework-above-9-out-of-10-for-immediately-applicable-skills-302859604.html University of Phoenix course surveys and enrollment data show students are building practical skills such as decision-making, communication, problem-solving, information literacy and health literacy. PHOENIX, Aug. 25, 2026 /PRNewswire/ -- University of Phoenix students are giving online... ———————————————————————————————————————————————————————————— A $10 Generic Cut LDL Cholesterol by 53%. Why Are Employers Being Pushed Toward $700-a-Month Drugs? 2026-08-25 · PRWeb · Healthcare https://www.prweb.com/releases/a-10-generic-cut-ldl-cholesterol-by-53-why-are-employers-being-pushed-toward-700-a-month-drugs-302859201.html Research from TOWARD Health and collaborating institutions reports LDL reductions nearly three times the conventional ezetimibe response and within the range reported in PCSK9 inhibitor trials BLAUVELT, N.Y., Aug. 25, 2026 /PRNewswire-PRWeb/ -- Researchers affiliated with TOWARD Health... ———————————————————————————————————————————————————————————— Kaplan Fox Alerts Fractyl Health, Inc. (GUTS) Investors to a Securities Class Action Deadline on October 20, 2026 2026-08-25 · mlpr-newsfile · Finance, Healthcare https://www.newsfilecorp.com/release/311413/Kaplan-Fox-Alerts-Fractyl-Health-Inc.-GUTS-Investors-to-a-Securities-Class-Action-Deadline-on-October-20-2026 New York, New York--(Newsfile Corp. - August 25, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Fractyl Health, Inc. ("Fractyl Health" or the "Company") (NASDAQ: GUTS) on behalf of investors that purchased or otherwise acquired Fractyl Health securities between January 13, 2025 and January 29, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in Fractyl Health and have suffered losses, you may CLICK HERE to contact us.... ———————————————————————————————————————————————————————————— China State Construction International Empowers Market Expansion through Technology 2026-08-25 · mlpr-acnnewswire · Finance, Healthcare, Real Estate, Automotive, Education https://www.acnnewswire.com/press-release/english/109409/ HONG KONG, August 25, 2026 - (ACN Newswire) - China State Construction International Holdings Limited (“China State Construction International” or the “Group”, stock code: 03311) has announced its 2026 interim results, recording net profit of RMB4,330 million for the first half of the year and a dividend payout ratio of 35.4%. Notably, the Group’s cash flow performance was particularly strong, with net operating cash flow reaching RMB3,796 million in the first half, while its cash-to-net-profit ratio stood at 87.7%, a near 15-year high. Across its business segments, the Group achieved robust growth, with its MiC (Modular Integrated Construction) business successfully securing a number of landmark projects, reflecting the strategic outcome of the Group’s steadfast efforts over the years to transform its business from traditional on-site construction towards new industrialised construction. Technology empowerment has evolved from a standalone technical advantage into a core competitive strength and a key driver of the Group’s long-term value creation. As one of the earliest companies in the Chinese Mainland to embrace construction industrialisation, the Group has reshaped the traditional construction model through its self-developed “Smart Construction – MiC technology”. By shifting from the construction site to the factory, and converting sequential processes into parallel workflows, the Group has effectively shortened construction periods, strengthened cost control, and reduced reliance on on-site labour and weather conditions. This transformation has become a core foundation for the Group to navigate industry cycles and drive improvement in its operating performance. Hong Kong: Serving Community Needs through MiC, with Landmark Projects Progressing One after Another China State Construction International’s technological practices are closely aligned with the policy direction of the Hong Kong SAR Government. Since 2017, MiC has been included in the Policy Address for eight consecutive years, while the Government has promoted new construction methods through measures such as gross floor area and building height concessions, as well as the Construction Innovation and Technology Fund. These initiatives have provided the Group with clear policy support and market opportunities. During the period, the Group secured a number of landmark projects, including the Kwu Tung North Joint User Complex, the first government facilities cluster in the Northern Metropolis, and the University of Macau campus project in the Hengqin Guangdong-Macao Intensive Cooperation Zone (North District). The Group’s Temple Street project has also topped out successfully. As Hong Kong’s first full-MiC private residential project, it achieved a pace of “one floor every three days” despite stringent road traffic restrictions. The Kai Tak Light Public Housing project, Hong Kong’s largest light public housing development, was delivered ahead of schedule, with 70% of the construction processes completed in factories in the Greater Bay Area. It achieved the installation of one module every 30 minutes and the completion of one floor every three days, substantially shortening waiting time and demonstrating the strategic positioning of “what Hong Kong needs, what the Group excels at”. The project also received a Completion Commendation Letter from the Architectural Services Department. The strategic value of the Group’s technology was demonstrated as early as during the pandemic. In 2020, the Group completed the North Lantau Hospital Hong Kong Infection Control Centre, the world’s first infectious disease hospital with full-MiC negative-pressure isolation wards, in just four months. This showcased the application value of MiC in major public emergencies, deepened recognition from the Government and the market of the Group’s construction capabilities and emergency-response capacity, and laid a strong reputational foundation for undertaking large-scale public infrastructure projects. Looking ahead, the Northern Metropolis is expected to become a new growth engine for the Group. The latest Budget proposed the first transfer of HK$150 billion in investment returns from the Exchange Fund to support infrastructure including the Northern Metropolis, while annual capital works expenditure is expected to increase from approximately HK$90 billion to around HK$120 billion over the next five years. Covering site formation, transport, public facilities and public housing, the Northern Metropolis is expected to involve total investment of more than HK$3 trillion, presenting considerable development potential. MiC modular construction can shorten construction periods by approximately 70%, aligning well with the Northern Metropolis’ need for rapid development. Together with Budget support for the direct procurement of Modular Integrated Construction units, this is expected to further unlock market demand. The Group has established 12 smart housing manufacturing bases nationwide and assembled a team of more than 300 design and R&D professionals, giving it advantages in scaled technology and production capacity. According to forecasts by the Development Bureau and the Construction Industry Council, the total MiC floor area in Hong Kong is expected to reach approximately 2.5 million square metres between 2025 and 2030, indicating substantial market opportunities. Chinese Mainland: Urban Renewal Opens a New Growth Driver as MiC Expands across Multiple Cities In May 2026, the State Council issued the 15th Five-Year Plan for Urban Renewal, the first national-level special plan for China’s urban renewal sector. Market estimates that urban renewal could drive investment of RMB15 trillion to RMB20 trillion during the period. Leveraging its MiC technology, the Group has developed benchmark redevelopment projects such as Huapichang Hutong in Beijing and Tianlin Road in Xuhui, Shanghai, achieving first-mover presence in first-tier cities. Going forward, the Group will replicate and scale mature models through its full-chain capabilities in “operation + technology + investment + construction”, positioning urban renewal as a core growth driver for its Chinese Mainland business. During the period, the Group’s newly signed MiC contracts in the Chinese Mainland increased by more than 70%, with progress across multiple first-tier cities and orderly expansion into strong second-tier cities. In Beijing, the Group has secured four rapid classroom construction projects in Fengtai District. In Guangzhou, the Group won its first MiC resettlement housing project in Conghua District. In Shanghai and Suzhou, the country’s largest concrete MiC urban renewal project — the demolition and reconstruction of old housing at Lane 65, Tianlin Road, Xuhui District — was officially delivered and well received by various stakeholders. The Group successively secured Shanghai’s second and Hongkou District’s first MiC in-situ redevelopment projects, and successfully won Suzhou’s first MiC project under an “investment + technology” model, further deepening its market presence. The positive results of the Group’s MiC modular transformation are becoming increasingly evident. Looking ahead, the Group will continue to seize the structural opportunities presented by Hong Kong’s Northern Metropolis and the urban renewal market in the Chinese Mainland, further harness technology, reinforce its industry leadership, pursue high-quality growth and create sustainable, long-term value for shareholders. Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com ———————————————————————————————————————————————————————————— Heart of the Matter Therapy in Fort Collins Now Accepting Medicaid 2026-08-25 · PR.com · Healthcare https://www.pr.com/press-release/973492 Heart of the Matter Therapy is proud to announce that they are now accepting Colorado Medicaid, marking an important step in their mission to make high-quality mental health care more accessible to individuals, couples, and families across Colorado. For founder Dr. Tasha Seiter, this milestone is about more than adding another insurance provider, it is about ensuring that financial barriers do not stand in the way of [PR.com] ———————————————————————————————————————————————————————————— NYC Council Speaker Julie Menin to Present Hospital Partner of the Year Award to Memorial Sloan-Kettering Cancer Center at Healthy Humor's 10th Anniversary Gala 2026-08-25 · PR.com · Healthcare https://www.pr.com/press-release/977418 Council Member Mercedes Narcisse, Chair of the Council's Committee on Hospitals, will also join the milestone celebration honoring leaders who have advanced arts-based, whole-person care for children and families. [PR.com] ———————————————————————————————————————————————————————————— As Fall Sports Season Approaches, Foot & Ankle Center Warns About Rising Injury Risks 2026-08-25 · PRUnderground · Education, Healthcare https://prunderground.com/as-fall-sports-season-approaches-foot-ankle-center-warns-about-rising-injury-ris/cmt8jfeo3000404jzh8xgqt95 St. George podiatry clinic urges parents to watch for early signs of foot and ankle injury before school sports take a toll on growing athletes. The post As Fall Sports Season Approaches, Foot & Ankle Center Warns About Rising Injury Risks first appeared on ———————————————————————————————————————————————————————————— Mozambique strengthens regulation of medicines and imported vaccines, boosting health protection 2026-08-25 · WebWire · Healthcare https://www.webwire.com/ViewPressRel.asp?aId=359463 Mozambique has reached a major milestone in strengthening the regulation of medicines and imported vaccines, with its national regulatory authority recognized by the World Health Organization (WHO) as having a stable, well-functioning and integrated regulatory system. - - The Autoridade Nacional Reguladora de Medicamentos de Mo�ambique (ANARME) has achieved Maturity Level 3 (ML3) for the regulation of medicines and imported vaccines under WHO's global classification of national regulatory... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=359463 ———————————————————————————————————————————————————————————— BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA 2026-08-25 · mlpr-businesswire · Finance, Healthcare https://finance.yahoo.com/healthcare/articles/beone-medicines-announces-u-fda-144000334.html SAN CARLOS, Calif., August 25, 2026--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of adult patients with unresectable locally advanced or metastatic HER2-positive (HER2+) gastric, gastroesophageal junction, ———————————————————————————————————————————————————————————— U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma 2026-08-25 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/25/3350636/0/en/u-s-fda-approves-ziihera-zanidatamab-hrii-with-and-without-tislelizumab-plus-chemotherapy-in-first-line-her2-advanced-gastroesophageal-adenocarcinoma.html VANCOUVER, British Columbia, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that its partner, Jazz Pharmaceuticals, has received U.S. Food and Drug Administration (FDA) approval for two Ziihera® (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA): Ziihera plus Tevimbra® (tislelizumab-jsgr) and fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+ and IHC 2+/ISH+), and Ziihera plus fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+). ———————————————————————————————————————————————————————————— CPKC Women's Open raises nearly $5 million for Alberta cardiac care 2026-08-25 · WebWire · Healthcare https://www.webwire.com/ViewPressRel.asp?aId=359452 This weekend in Edmonton saw more than a golf tournament. - - While bringing world-class women's professional golf to the Royal Mayfair Golf Club in Edmonton, the 2026 CPKC Women's Open raised a record $4.95 million to support cardiac healthcare in Alberta. - - On the final day of the tournament, which ran from Aug. 20 to 23, CPKC representatives presented a $4.4 million cheque to the Stollery Children's Hospital Foundation to support the advancement of their world-renowned pediatric cardi... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=359452 ———————————————————————————————————————————————————————————— Hope & Help of Central Florida Appoints Dr. Jeremy Aguinaldo as New Medical Director 2026-08-25 · PressReleaseNews · Healthcare https://pressreleasenews.org/pressroom/hope-help-of-central-florida-appoints-dr-jeremy-aguinaldo-as-new-medical-director Board-Certified HIV/AIDS Specialist and Public Health Physician to Lead Clinical Operations and Expand Integrated Care Across Central Florida ———————————————————————————————————————————————————————————— Switchboard Health Acquires Livara Health to Integrate Value-Based ... 2026-08-25 · PR-Inside · Finance, SaaS, Healthcare https://pr-inside.com/switchboard-health-acquires-livara-health-to-integrate-value-based-r5215952.htm (PR-inside.com) Acquisition brings Livara's virtual MSK care model onto Switchboard's specialty care platform; closes $5M+ round of funding BOISE, ID AND SAN DIEGO, CA / ACCESS Newswire / August 25, 2026 /Switchboard Health, creators of a digital health platform connecting patients with high-value specialty care, today announced the acquisition of Livara Health, a leader in virtual orthopedics and musculoskeletal (MSK) management. The acquisition combines Switchboard's referral management and care navigation platform with Livara's proven MSK care model for health plans and risk-bearing providers. To fuel future growth, the company also closed a $5M round of funding. Founded by Dr. Kamshad Raiszadeh, Livara Health .. ———————————————————————————————————————————————————————————— Mesothelioma Hope Interviews MD Anderson Oncologist Dr. Kanwal Raghav ... 2026-08-25 · PR-Inside · Healthcare, Education https://pr-inside.com/mesothelioma-hope-interviews-md-anderson-oncologist-dr-kanwal-raghav-r5215948.htm (PR-inside.com) The medical oncologist and peritoneal mesothelioma specialist shares insights on multidisciplinary care, promising results from his phase II immunotherapy trial, and why patients should ask about clinical trials early. CHESTNUT HILL, MA / ACCESS Newswire / August 25, 2026 / Mesothelioma Hope , a leading online resource providing education, patient advocacy, and support for those diagnosed with mesothelioma, has published a new interview with Dr. Kanwal Raghav, a medical oncologist at The University of Texas MD Anderson Cancer Center in Houston who specializes in peritoneal mesothelioma and studies new therapies for patients with advanced disease. The full interview is available atMesotheliomaHope.com . In .. ———————————————————————————————————————————————————————————— American Family Care Named to Newsweek’s List of America’s Greatest Workplaces in Health Care 2026 2026-08-25 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/american-family-care-named-newsweek-140000518.html BIRMINGHAM, Ala., August 25, 2026--American Family Care Named to Newsweek’s List of America’s Greatest Workplaces in Health Care 2026 ———————————————————————————————————————————————————————————— Memorial Hermann Health System Deepens Partnership with Strategic Investment in PartsSource 2026-08-25 · PR Newswire · SaaS, Healthcare https://www.prnewswire.com/news-releases/memorial-hermann-health-system-deepens-partnership-with-strategic-investment-in-partssource-302859366.html Investment will help strengthen healthcare technology infrastructure and clinical capacity across more than 1,600 leading hospitals through the PartsSource platform CLEVELAND, Aug. 25, 2026 /PRNewswire/ -- PartsSource, the leading performance platform for clinical technology, today... ———————————————————————————————————————————————————————————— Decent Holding Provides Operational Update: Community Healthcare Network Expands to 623 Centers and Over 210,000 Paid Members 2026-08-25 · GlobeNewswire · Finance, SaaS, Healthcare https://www.globenewswire.com/news-release/2026/08/25/3350564/0/en/decent-holding-provides-operational-update-community-healthcare-network-expands-to-623-centers-and-over-210-000-paid-members.html YANTAI, China, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Decent Holding Inc. (NASDAQ: DXST) (“Decent” or the “Company”), a technology-driven provider of wastewater treatment and community-based senior health and elderly care services in China, today provided an operational update on the continued expansion of its community-based senior healthcare and elderly care platform (the “platform”). ———————————————————————————————————————————————————————————— First Peer-Reviewed Headway Study Finds Nearly 1 in 5 Patients Report Suicidal Thoughts at Their First Mental Health Visit 2026-08-25 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/first-peer-reviewed-headway-study-finds-nearly-1-in-5-patients-report-suicidal-thoughts-at-their-first-mental-health-visit-302859421.html Peer-reviewed analysis of 189,225 intake appointments in all 50 states, published in JMIR Mental Health, is the clearest national picture to date of suicidal ideation among people starting outpatient mental health care NEW YORK, Aug. 25, 2026 /PRNewswire/ -- Headway, the company building... ———————————————————————————————————————————————————————————— MDCE Highlights StrainScan Pro's Enterprise-Ready Agricultural AI Tech ... 2026-08-25 · PR-Inside · AI, SaaS, Healthcare, Retail https://pr-inside.com/mdce-highlights-strainscan-pro-s-enterprise-ready-agricultural-ai-tech-r5215940.htm (PR-inside.com) Proprietary AI Vision Platform Designed for Simple, Scalable Deployment Across Multi-Site Retail and Agricultural Operations MESA, AZ / ACCESS Newswire / August 25, 2026 / Medical Care Technologies Inc. (OTC PINK:MDCE) today emphasized the enterprise-ready design of its StrainScan Pro platform, highlighting a proprietary AI vision architecture built for rapid and straightforward deployment across multi-location environments. StrainScan Pro is optimized for installation on iPad Air devices, enabling operators to implement advanced visual analysis without the cost or complexity of fixed industrial systems. This approach supports fast rollout across single sites or large multi-location networks, whether in regulated retail settings or agricultural operations. By .. ———————————————————————————————————————————————————————————— Covation Sponsors Family Fun Ride at the 2026 Sun Hung Kai Properties Hong Kong Cyclothon 2026-08-25 · mlpr-acnnewswire · Healthcare, Energy, Media https://www.acnnewswire.com/press-release/english/109405/ HONG KONG, August 25, 2026 - (ACN Newswire) - Covation Holdings Limited (“Covation” or the “Group”), a world-leading wheeled product innovator and manufacturer, is pleased to announce its sponsorship of the Covation Family Fun Ride at the 2026 Sun Hung Kai Properties Hong Kong Cyclothon. Organized by the Hong Kong Tourism Board (“HKTB”), the flagship international sporting spectacle will take place on 11 October (Sunday), bringing together thousands of cyclists across the city’s iconic bridges and landmarks while showcasing the unique scenery. Mr. Bruno Maier, Co-CEO of Covation, said, “We are proud to support the Hong Kong Cyclothon—a world-class sporting spectacle that showcases the energy and iconic landscape of Hong Kong. As a global force in outdoor adventure, Covation shares the event’s passion for driving health, wellness, and a vibrant cycling culture across the community, as well as its sports for charity spirit. While the Cyclothon brings together elite global competitors and cycling enthusiasts, our sponsorship of the Family Fun Ride allows us to introduce families and young riders to the transformative joy of cycling. Through our century-old children’s bicycle brand, Huffy, we have inspired generations to connect through cycling. We are thrilled to play a meaningful role in this citywide extravaganza, offering families a unique opportunity to create lasting memories together while supporting a charitable cause.” Covation – a name that merges “Collaboration” and “Innovation” — is on a mission to revolutionize how people move, connect, and explore—by developing exceptional products for bold experiences across wheeled categories and beyond. It is a Hong Kong-headquartered vertically integrated holding company, specializing in the research, development, manufacturing, distribution and global operations of cycling and outdoor brands, driven by manufacturing excellence. The Group owns multiple outdoor cycling brands, including Huffy, Batch, and Green Machine. Currently, its business serves millions of consumers across more than 50 countries and regions worldwide.  The Covation Family Fun Ride is designed to encourage outdoor recreation and family bonding. Open to participants aged 6 to 70, each entry group consists of one parent paired with one child or youth. In line with the Cyclothon’s sports for charity spirit, registration fees collected from the Covation Family Fun Ride will be donated in full to The Community Chest of Hong Kong to support local underprivileged communities. Beyond the rides, the event will host a dedicated cycling-themed carnival at the West Kowloon Cultural District, featuring a diverse programme of sports, entertainment, family-friendly activities and culinary delights, allowing locals and visitors to fully immerse themselves in the excitement of the cycling extravaganza. Covation will also host a booth at the venue, featuring its exceptional wheeled products and connecting with cycling enthusiasts. This year’s Cyclothon is further enriched new elements, including an upgraded 56km non-competitive ride on a “Five Tunnels, Three Bridges” route that will take riders along roads rarely opened to cyclists. The enhanced route provides an ideal opportunity to explore Hong Kong’s diverse urban landscapes, showcasing the unique blend of old and new districts. This, together with the 32km ride, is expected to see the participation of more than 6,500 cyclists.  Covation Family Fun Ride Highlights: Event Date: Sunday, 11 October 2026   Group Format: 1 Parent + 1 Child/Youth (6–70 years old)   Entry Fee: HK$100 per group (100% donated to charity)   Public Registration: Registration is now open via the event website   Photo:  Bruno Maier (row 2, 3rd from right), Covation Co-CEO, joins Hong Kong Tourism Board officials and event partners at the launch press conference of the 2026 Sun Hung Kai Properties Hong Kong Cyclothon. About Covation Holdings Limited Covation Holdings Limited (“Covation”) is a vertically integrated holding company headquartered in Hong Kong, specializing in the research, development, manufacturing, distribution and global operations of cycling and outdoor brands, as well as excellence in manufacturing. As a world-leading manufacturer and assembler of bicycles and components, the company operates modern smart manufacturing facilities in China, Cambodia and Vietnam. Leveraging its vertically integrated supply chain advantages and rigorous quality control system, Covation has established an efficient operational network with strategic branches across the United States, Mexico, Canada, the United Kingdom, European Union, Hong Kong, and China, consistently delivering exceptional products to global customers. Covation’s portfolio encompasses internationally renowned outdoor sports brands, including Huffy, Batch, and Green Machine. The company maintains extensive licensing partnerships with world-class partners such as Disney, Marvel, Lucasfilm, Universal Studios, Paramount, Microsoft, and Sanrio. Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com ———————————————————————————————————————————————————————————— Envision Pharma Group Names Ryan Tubbs, Senior Vice President, Commercial ... 2026-08-25 · PR-Inside · Healthcare https://pr-inside.com/envision-pharma-group-names-ryan-tubbs-senior-vice-president-commercial-r5215930.htm (PR-inside.com) New role unifies sales enablement, lead generation, and marketing under centralized leadership and expands oversight to customer success, supporting a consistent, connected client experience across Envision. FAIRFIELD, CT / ACCESS Newswire / August 25, 2026 / Envision Pharma Group (Envision) has appointed Ryan Tubbs as Senior Vice President, Commercial Growth. In this newly created role, Tubbs will lead the centralized Commercial Growth function spanning sales enablement, lead generation, marketing, and client success. He will also help shape Envision's commercial strategy and operating model to accelerate enterprise growth. Tubbs' remit also includes the Client Implementation and Client Experience teams. Connecting Envision's pre-sale and .. ———————————————————————————————————————————————————————————— 23XI Racing NASCAR Driver Tyler Reddick Reveals Sleep Apnea Diagnosis, Teams Up with Resmed to Help Others Recognize the Signs 2026-08-25 · GlobeNewswire · Finance, Healthcare, Automotive https://www.globenewswire.com/news-release/2026/08/25/3350484/0/en/23xi-racing-nascar-driver-tyler-reddick-reveals-sleep-apnea-diagnosis-teams-up-with-resmed-to-help-others-recognize-the-signs.html Reddick, a 13-time NASCAR Cup Series winner and 2026 Daytona 500 Champion, shares how prioritizing sleep health is an important part of his recovery and performance routine Reddick, a 13-time NASCAR Cup Series winner and 2026 Daytona 500 Champion, shares how prioritizing sleep health is an important part of his recovery and performance routine ———————————————————————————————————————————————————————————— Envision Pharma Group Names Ryan Tubbs, Senior Vice President, Commercial Growth 2026-08-25 · Newswire.com · Healthcare https://www.newswire.com/news/envision-pharma-group-names-ryan-tubbs-senior-vice-president-commercial-growth New role unifies sales enablement, lead generation, and marketing under centralized leadership and expands oversight to customer success, supporting a consistent, connected client experience across Envision. ———————————————————————————————————————————————————————————— NFL Mascots Inspire Kids to PLAY 60 for Better Health 2026-08-25 · NewMediaWire · Healthcare, Retail, Education https://www.newmediawire.com/news/nfl-mascots-inspire-kids-to-play-60-for-better-health-7088879 DALLAS - August 25, 2026 ( NEWMEDIAWIRE ) - Fifteen NFL (National Football League) club mascots are stepping up to inspire kids to move more to support mental and physical health. These NFL mascots are serving as members of the annual NFL PLAY 60 Ambassador class supporting the NFL and the American Heart Association’s work to help kids achieve a minimum of 60 minutes of moderate-to-vigorous physical activity each day . Rooted in the American Heart Association’s physical activity guidelines, NFL PLAY 60 supports the evidence-based guidance that students who are active learn better, focus more, think more clearly, react to stress more calmy and perform and behave better in the classroom. The NFL PLAY 60 mascot ambassadors will encourage kids to get active throughout the school year with exer ———————————————————————————————————————————————————————————— Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X 2026-08-25 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/25/3350465/0/en/incannex-announces-first-patient-dosed-in-dreamzz-phase-2-study-of-ihl-42x.html First patient dosing represents another major clinical milestone for IHL-42X, building on positive Phase 2 RePOSA results demonstrating reductions in AHI of up to 83% and FDA Fast Track designation First patient dosing represents another major clinical milestone for IHL-42X, building on positive Phase 2 RePOSA results demonstrating reductions in AHI of up to 83% and FDA Fast Track designation ———————————————————————————————————————————————————————————— Vivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine Centers 2026-08-25 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/25/3350463/0/en/vivos-therapeutics-reports-record-new-patient-referrals-at-its-nevada-sleep-airway-medicine-centers.html Vivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine Centers ———————————————————————————————————————————————————————————— GeoVax Advances GEO-MVA Toward Pivotal Phase 3 Study Implementation 2026-08-25 · NewMediaWire · Finance, Healthcare https://www.newmediawire.com/news/geovax-advances-geo-mva-toward-pivotal-phase-3-study-implementation-7088876 Selections of CRO and European Clinical Sites Represent Significant Milestones Toward Initiation of the GEO-MVA Immunobridging Study ATLANTA, GA - August 25, 2026 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and solid tumor cancers, today announced that it has selected the contract research organization (CRO) and European clinical trial sites planned to support the critical immunobridging portion of GEO-MVA-301, the Company’s pivotal Phase 3 clinical program evaluating GEO-MVA as a vaccine against mpox and smallpox. The selections represent another important operational readiness milestone as GeoVax advances preparations for the European immunobridging study. The randomized, d ———————————————————————————————————————————————————————————— Nuwellis Expands Critical Care Portfolio Through Strategic Commercial Agreement with Atrility Medical 2026-08-25 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/25/3350437/26106/en/nuwellis-expands-critical-care-portfolio-through-strategic-commercial-agreement-with-atrility-medical.html Agreement expands Nuwellis’ pediatric and critical care portfolio and provides a milestone-based pathway to U.S. distribution Agreement expands Nuwellis’ pediatric and critical care portfolio and provides a milestone-based pathway to U.S. distribution ———————————————————————————————————————————————————————————— Promptly Patient Experience Suite Accelerates Conversational AI Strategy Through Acquisition of OptiCall 2026-08-25 · PRWeb · Finance, AI, SaaS, Healthcare https://www.prweb.com/releases/promptly-patient-experience-suite-accelerates-conversational-ai-strategy-through-acquisition-of-opticall-302858020.html Promptly Technology, Inc. has acquired OptiCall, merging advanced conversational AI and specialized contact center expertise with its automated Patient Experience Suite. This strategic move provides specialty medical practices with an all-in-one patient engagement platform designed to... ———————————————————————————————————————————————————————————— RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer 2026-08-25 · GlobeNewswire · Finance, SaaS, Healthcare https://www.globenewswire.com/news-release/2026/08/25/3350436/0/en/renovorx-highlights-peer-reviewed-publication-of-pharmacokinetic-and-pharmacodynamic-pk-pd-data-supporting-tamp-platform-s-targeted-drug-delivery-in-locally-advanced-pancreatic-can.html PK/PD Data is from a Sub-Study in the Phase III TIGeR-PaC Clinical Trial ———————————————————————————————————————————————————————————— BioCorRx Announces National Drug Codes (NDCs) for LUCEMYRA (lofexidine) Brand and Authorized Generic (AG) SKUs to Ensure Uninterrupted Market Supply 2026-08-25 · NewMediaWire · Healthcare, Retail https://www.newmediawire.com/news/biocorrx-announces-national-drug-codes-ndcs-for-lucemyra-lofexidine-brand-and-authorized-generic-ag-skus-to-ensure-uninterrupted-market-supply-7088875 Updated NDC Records Advance BioCorRx’s Commercial Transition Across all Four Product Configurations While Supporting Continuity of Product Availability ANAHEIM, CA - August 25, 2026 ( NEWMEDIAWIRE ) - BioCorRx Inc (OTC: BICX) (the “Company”) , a developer and provider of innovative treatment support programs for substance abuse and related disorders, today announced that its subsidiary, BioCorRx Pharmaceuticals Inc, has successfully established its new, dedicated National Drug Code (NDC) numbers for both LUCEMYRA® (lofexidine) 0.18 mg tablets and its accompanying Authorized Generic (AG) presentation. LUCEMYRA® is an FDA-approved, non-opioid medication indicated for the mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults. The establishment of BioCo ———————————————————————————————————————————————————————————— NDEV Posts Steady Q2 2026 Revenue Growth; Self-Funded Model Yields 8.8% Debt-to-Equity Ratio 2026-08-25 · NewMediaWire · Finance, Retail, Healthcare https://www.newmediawire.com/news/ndev-posts-steady-q2-2026-revenue-growth-self-funded-model-yields-8-8-debt-to-equity-ratio-7088873 MIAMI, FLORIDA - August 25, 2026 ( NEWMEDIAWIRE ) - Novus Acquisition & Development Corp. (OTC: NDEV), doing business as Novus Cannabis MedPlan, today announced the release of its Q2 2026 Interim Report. The disclosure confirms consistent revenue growth and a defensive capital structure designed to insulate equity from the systemic debt crisis currently affecting plant-touching operators. Financial & Operational Highlights Revenue Growth: In Q2 2026, gross revenue experienced a year-over-year increase of 7.7%, reaching a total of $214,398 for the six-month period when compared to the Q2 2025 report. Solvency & Capital Efficiency: Novus follows a disciplined, self-funded business model, maintaining a conservative 8.8% debt-to-equity ratio. All existing liabilities are held inter ———————————————————————————————————————————————————————————— Black Book Releases 2026 Behavioral Health EHR and Practice Management ... 2026-08-25 · PR-Inside · Finance, SaaS, Healthcare https://pr-inside.com/black-book-releases-2026-behavioral-health-ehr-and-practice-management-r5215908.htm (PR-inside.com) Black Book study respondents rate NextGen® Behavioral Health Suite No. 1 overall across mid- and large-size clinician groups, as integrated clinical, administrative, revenue-cycle and data performance increasingly drives platform selection. CHICAGO, IL / ACCESS Newswire / August 25, 2026 / Black Book Research today released its Q3 2026 Behavioral Health EHR and Practice Management Platform Rankings for Independent Ambulatory Practices, based on feedback from 665 verified users representing 101 independent behavioral health organizations. The study examined physician-led and multidisciplinary practices with six or more clinicians, including psychiatry, psychotherapy, integrated behavioral health, ABA, substance use disorder treatment, child and adolescent care, interventiona ———————————————————————————————————————————————————————————— Black Book Releases 2026 Behavioral Health EHR and Practice Management Platform Rankings for Independent Ambulatory Physician Practices 2026-08-25 · Newswire.com · Finance, SaaS, Healthcare https://www.newswire.com/news/black-book-releases-2026-behavioral-health-ehr-and-practice-management-22849477 Black Book study respondents rate NextGen® Behavioral Health Suite No. 1 overall across mid- and large-size clinician groups, as integrated clinical, administrative, revenue-cycle and data performance increasingly drives platform selection. ———————————————————————————————————————————————————————————— Fullspan Health Announces 2027 Marketing Solutions Built to Connect Brands With Consumers and Providers Across the Health Journey 2026-08-25 · PR Newswire · AI, SaaS, Healthcare, Retail, Education https://www.prnewswire.com/news-releases/fullspan-health-announces-2027-marketing-solutions-built-to-connect-brands-with-consumers-and-providers-across-the-health-journey-302856805.html New offerings bring together trusted consumer education, HCP engagement and AI utility NEW YORK, Aug. 25, 2026 /PRNewswire/ -- Fullspan Health™, a unified B2B healthcare platform from RVO Health®, today announced its 2027 marketing solutions, a suite of offerings for pharma and healthcare... ———————————————————————————————————————————————————————————— Vascarta Outlines VAS-101's (Vasceptor®) Potential as a Non-Opioid Advance in Pain Medicine Across Sickle Cell Disease, Osteoarthritis, and Cancer 2026-08-25 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/vascarta-outlines-vas-101s-vasceptor-potential-as-a-non-opioid-advance-in-pain-medicine-across-sickle-cell-disease-osteoarthritis-and-cancer-302858963.html SUMMIT, N.J., Aug. 25, 2026 /PRNewswire/ -- Vascarta Inc., a clinical-stage pharmaceutical company advancing a transdermal curcuminoid therapeutic for pain and inflammation, today outlined converging preclinical and clinical evidence that its lead candidate, VAS-101 (Vasceptor®), targets... ———————————————————————————————————————————————————————————— Pretzel Therapeutics Advances PX578 into Phase 2 Study in Individuals Living with POLG-mediated Primary Mitochondrial Disease Following FDA Clearance of IND 2026-08-25 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/pretzel-therapeutics-advances-px578-phase-113000232.html WALTHAM, Mass., August 25, 2026--Pretzel Therapeutics, Inc., a clinical-stage biotechnology company advancing a new class of medicines designed to restore mitochondrial function, improve cellular energetics and impede disease progression across a range of neurological and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a first-in-patient clinical trial of PX578, the Company’s lead therapeutic c ———————————————————————————————————————————————————————————— Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium 2026-08-25 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/25/3350336/16626/en/zevra-therapeutics-to-present-new-long-term-real-world-data-on-miplyffa-in-niemann-pick-disease-type-c-npc-at-the-2026-ssiem-annual-symposium.html Presentations from U.S. and German early access programs highlight sustained disease stabilization and a consistent safety profile across diverse NPC patient populations Presentations from U.S. and German early access programs highlight sustained disease stabilization and a consistent safety profile across diverse NPC patient populations ———————————————————————————————————————————————————————————— Kane Biotech’s revyve® Research Presented at Military Health System Research Symposium 2026-08-25 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/08/25/3350332/0/en/kane-biotech-s-revyve-research-presented-at-military-health-system-research-symposium.html Presentation addressed potential applications in prolonged field care and military wound management settings Presentation addressed potential applications in prolonged field care and military wound management settings ———————————————————————————————————————————————————————————— Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 for University of Washington Phase 2a Trial in Cancer-Related Anxiety and Depression 2026-08-25 · mlpr-newsfile · Healthcare, Education https://www.newsfilecorp.com/release/311389/Rhelion-Life-Sciences-Wholly-Owned-Subsidiary-Filament-Health-Completes-Shipment-of-PEX010-for-University-of-Washington-Phase-2a-Trial-in-CancerRelated-Anxiety-and-Depression Filament Health's patented, naturally derived psilocybin drug candidate PEX010 will be supplied to an investigator initiated Phase 2a study evaluating a group retreat model of psilocybin therapy in people living with metastatic solid tumors or incurable hematologic malignancies.Toronto, Ontario--(Newsfile Corp. - August 25, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within... ———————————————————————————————————————————————————————————— Precigen's Strong Second Quarter Signals Significant Growth, Validates ... 2026-08-25 · PR-Inside · Finance, SaaS, Healthcare https://pr-inside.com/precigen-s-strong-second-quarter-signals-significant-growth-validates-r5215869.htm (PR-inside.com) Biotech in the News: The Longview The Company's New Drug, the First FDA-Approved Therapy for Recurrent Respiratory Papillomatosis (RRP), is Delivering Strong Commercial Traction While Highlighting the Broader Potential of Its Proprietary AdenoVerse Therapeutic Platform in HPV-Associated Cancers GERMANTOWN, MD / ACCESS Newswire / August 25, 2026 / For Germantown, MD-based Precigen Inc. (NASDAQ:PGEN), the second quarter marked a commercial inflection. PAPZIMEOS (zopapogene imadenovec-drba) generated $53.1 million in net product revenue-more than double the prior quarter-and helped the company achieve quarterly profitability. Validated Platform President and CEO Helen Sabzevari, PhD, framed the quarter as platform validation. "PAPZIMEOS demonstrates the AdenoVerse platform's a ———————————————————————————————————————————————————————————— Optimism Names Case Kenny Its First Chief Optimist 2026-08-25 · Send2Press · SaaS, Healthcare, Retail https://www.send2press.com/wire/optimism-names-case-kenny-its-first-chief-optimist/ NEWPORT BEACH, Calif., Aug. 25, 2026 (SEND2PRESS NEWSWIRE) -- Optimism, the platform for well-being, today announced that writer, podcaster, and three-time bestselling author Case Kenny has joined the company as its first Chief Optimist. Kenny will help ensure that Optimism's science-backed guidance reaches its audiences in a voice that actively builds optimism, and will lead new consumer programming, beginning with Mantra, launching September 2, 2026. ———————————————————————————————————————————————————————————— Radiology Partners to Acquire Everlight Radiology, Creating a Global Leader in Teleradiology 2026-08-25 · mlpr-businesswire · AI, Healthcare https://finance.yahoo.com/healthcare/articles/radiology-partners-acquire-everlight-radiology-110000518.html NASHVILLE, Tenn. & LONDON, August 25, 2026--Radiology Partners, Inc. ("RP"), the leading provider of technology and AI-enabled radiology services, today announced that it has entered into a definitive agreement to acquire Everlight Radiology ("Everlight"), a leading international teleradiology provider serving hospitals, health systems and imaging centers across the United Kingdom, Ireland, Australia, New Zealand and South Africa. ———————————————————————————————————————————————————————————— CAPR Investor Losses: Capricor Therapeutics Clinical Data Announcement and Corresponding 64% Stock Drop Trigger Securities Class Action for Investors 2026-08-25 · PR Newswire · Finance, Healthcare https://www.prnewswire.com/news-releases/capr-investor-losses-capricor-therapeutics-clinical-data-announcement-and-corresponding-64-stock-drop-trigger-securities-class-action-for-investors-302858881.html Capricor Therapeutics, Inc. has been sued for securities fraud over alleged misstatements about Deramiocel and the integrity of the clinical data supporting its Biologics License Application leading to a 64% stock drop. NEW YORK, Aug. 25, 2026 /PRNewswire/ -- Leading securities law firm... ———————————————————————————————————————————————————————————— Pulse Oximeter Market Disruption: Can Connected Devices Redefine the Traditional Pulse Oximeter? 2026-08-25 · Express Press Release · Healthcare https://express-press-release.net/news/2026/08/25/1769229 The pulse oximeter market is no longer simply a story about fingertip devices and the pandemic-era rush to monitor blood oxygen levels at home. Valued at USD [read full press release...] ———————————————————————————————————————————————————————————— Recent Release "Who The Health Are You?" from Hawes & Jenkins Author Amy Conrad, CHC, IEDS Offers an Innovative Framework for Understanding Wellness Foundations 2026-08-25 · PR.com · Healthcare, Education https://www.pr.com/press-release/976741 Amy Conrad, CHC, IEDS has completed "Who The Health Are You?" an educational book designed to demystify the pillars of personal wellbeing. Drawing from her extensive background in health education and counseling, Conrad distills complex wellness principles into an accessible, practical guide that speaks directly to readers seeking clarity about their own health journeys. The book addresses a genuine gap in [PR.com] ———————————————————————————————————————————————————————————— Recent Release, "Learning to Live, Learning to Die," from Fulton Books Author Blanca Diez, MD, Invites Readers to Master Their Destiny Through Consciousness Exploration 2026-08-25 · PR.com · Healthcare, Education https://www.pr.com/press-release/976763 Blanca Diez, MD has completed a new book, "Learning to Live, Learning to Die," which emerged from her groundbreaking clinical practice and evolves into a transformative guide for readers seeking to release limiting patterns and heal from past wounds. Drawing from decades of therapeutic work, Dr. Diez crafted this exploration of consciousness as an accessible manual that bridges the gap between psychiatric [PR.com] ———————————————————————————————————————————————————————————— Award-Winning Designer Christoph Gabriel Donates Creative Expertise to Hope Spring eCards 2026-08-25 · Pressat · Healthcare, Retail https://pressat.co.uk/releases/award-winning-designer-christoph-gabriel-donates-creative-expertise-to-hope-spring-ecards-f450a5b72bf1c1ed4ae60c536c057e14/ Tuesday 25 August, 2026 HEREFORD, UK – August 2026 – German designer and master stone sculptor Christoph Gabriel is donating his creative skills to Hope Spring eCards, where he will create six original Christmas eCard designs for the charity's collection. Gabriel, who is based in Witten, Germany, recently won first prize in the Journeymen and Master Craftsmen category at the 2026 European Stone Festival in Freiburg. The international event brings together stone carvers, sculptors and craftspeople from across Europe to demonstrate their creativity and technical skill. The collaboration will involve Gabriel applying his design experience to a medium different from the natural stone, sculpture and memorial design for which he is best known. The idea emerged following a conversation between Ga ———————————————————————————————————————————————————————————— Noah Noor Health Services Brings Personalised Companion Care Services 2026-08-25 · Express Press Release · Healthcare https://express-press-release.net/news/2026/08/25/1769227 Noah Noor Health Services is proud to provide Personalised Companion Care Services across Melbourne. The service helps older people, people living with disability, and people [read full press release...] ———————————————————————————————————————————————————————————— Medical Tourism Market Opportunities Rise With Personalized Healthcare Packages 2026-08-25 · Express Press Release · Healthcare https://express-press-release.net/news/2026/08/25/1769223 Medical tourism is becoming an increasingly important part of the global healthcare landscape as patients travel across borders for treatments that combine affordability, advanced medical [read full press release...] ———————————————————————————————————————————————————————————— Fifth Circuit Rejects "Ghost Rates" in Federal QPA Calculations Under the No Surprises Act 2026-08-25 · PR Newswire · Finance, Healthcare https://www.prnewswire.com/news-releases/fifth-circuit-rejects-ghost-rates-in-federal-qpa-calculations-under-the-no-surprises-act-302858877.html HOUSTON, Aug. 25, 2026 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, integrated health care delivery system comprised of 28 state-of-the-art micro hospitals and hospital outpatient departments in 12 states, as well as primary... ———————————————————————————————————————————————————————————— Specialized Home Financing Reaches St. Louis-Area Medical Professionals as Demand for Physician Loans Grows 2026-08-25 · PressReleaseNews · Healthcare, Real Estate, Education https://pressreleasenews.org/pressroom/specialized-home-financing-reaches-st-louis-area-medical-professionals-as-demand-for-physician-loans-grows Gershman Mortgage highlights physician home loan programs for medical professionals in the St. Louis area, addressing challenges like student debt and high starting salaries. These loans offer benefits such as zero down payment, no PMI, and higher loan limits. The company aims to educate eligible ———————————————————————————————————————————————————————————— Autoinjectors Market Poised for Rapid Expansion Through 2033 2026-08-25 · Express Press Release · Healthcare https://express-press-release.net/news/2026/08/25/1769184 The autoinjectors market is entering a decisive growth phase, moving from a niche delivery format into mainstream healthcare infrastructure at a pace few medical device [read full press release...] ———————————————————————————————————————————————————————————— New Publication Broadens the Potential of DiviTum TKa in Immuno-Oncology ... 2026-08-25 · PR-Inside · Healthcare https://pr-inside.com/new-publication-broadens-the-potential-of-divitum-tka-in-immuno-oncology-r5215844.htm (PR-inside.com) UPPSALA, SE / ACCESS Newswire / August 25, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a company specializing in blood-based cancer monitoring, today announced that new results involving DiviTum® TKa have been published in the peer-reviewed journal Clinical Cancer Research. The study evaluated DiviTum TKa in patients with metastatic melanoma receiving different sequences of immunotherapy and targeted therapy. These patients can receive both types of treatment, but it is not always clear which treatment should be given first. The analysis included 81 patients from the randomized Phase II SECOMBIT trial. Patients with low TKa levels before treatment initiation had substantially better long-term .. ———————————————————————————————————————————————————————————— Silicone Elastomer Market Outlook: LSR Leads the Way in 2026 2026-08-25 · Express Press Release · Healthcare https://express-press-release.net/news/2026/08/25/1769179 The global silicone elastomer market is entering a phase of accelerated growth, fueled by rising demand from electric vehicles, medical devices, and green construction. According [read full press release...] ———————————————————————————————————————————————————————————— IFF Report Finds GLP-1 Is Reshaping Food Choices and Eating Behaviors Among Indian Consumers 2026-08-25 · mlpr-businesswire · Finance, Healthcare, Retail https://finance.yahoo.com/healthcare/articles/iff-report-finds-glp-1-053000014.html NEW DELHI, August 25, 2026--IFF (NYSE: IFF) — a global leader in flavors, fragrances and health and biosciences — released new research examining how GLP-1 use is influencing food behaviors among Indian consumers and what those shifts may mean for the future of food and beverage innovation. The study is the latest in IFF’s GLP-1 global consumer insights following the company’s 2025 GLP-1 Consumer Opportunity Outlook. ———————————————————————————————————————————————————————————— SkyDrive to Evaluate Potential Routes for eVTOL Medical Logistics in India in Partnership with Air India and Suzuki 2026-08-25 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/skydrive-evaluate-potential-routes-evtol-050600526.html TOYOTA, Japan, August 25, 2026--SkyDrive Inc. ("SkyDrive"), a leading Japanese developer, manufacturer, and seller of compact eVTOL aircraft (*1), today announced that it will move forward with evaluating initial operational routes for the introduction of eVTOL medical logistics services in India, in partnership with Air India and Suzuki. This is part of the Memorandum of Understanding (MoU) that the three organizations signed in July 2026 to jointly study the feasibility of such operations.(*2) ———————————————————————————————————————————————————————————— Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study 2026-08-25 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/25/3350195/0/en/molecular-partners-reports-h1-2026-financial-results-and-corporate-highlights-dll3-radiotherapy-mp0712-successfully-advancing-to-higher-dose-level-in-phase-1-2a-study.html ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX, NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics (“Molecular Partners” or the “Company”), today reported corporate highlights and financial results for the first half of 2026. ———————————————————————————————————————————————————————————— Nissin Foods Announces 2026 Interim Results 2026-08-25 · mlpr-acnnewswire · Finance, Healthcare, Retail https://www.acnnewswire.com/press-release/english/109390/ Financial Highlights For the six months Ended 30 June 2026 (HK$ million) 2026 2025 Change Revenue 2,071.0 2,014.2 +2.8% Gross Profit 731.0 677.0 +8.0% Gross Profit margin 35.3% 33.6% +1.7pp Profit attributable to owners of the Company 175.2 157.0 +11.6% Net profit margin 8.5% 7.8% +0.7pp Adjusted EBITDA 330.8 303.2 +9.1% Earnings per share (HK cents) 16.79 15.05 +11.6% HONG KONG, August 25, 2026 - (ACN Newswire) - Nissin Foods Company Limited (“Nissin Foods” or the “Company”, together with its subsidiaries, the “Group”; Stock code: 1475) has announced its interim results for the six months ended 30 June 2026 (“the reporting period”). During the reporting period, the Group delivered solid profit growth, primarily driven by the resilient performance of its instant noodle business. Revenue increased by 2.8% year-on-year from HK$2,014.2 million in 2025 to HK$2,071.0 million in 2026, reflecting continued momentum in its core instant noodle business and broader store coverage in the Chinese Mainland. Gross profit increased by 8.0% year-on-year from HK$677.0 million to HK$731.0 million. Gross profit margin improved by 1.7 percentage points from 33.6% year-on-year to 35.3%, driven primarily by the continued expansion of the higher-margin core instant noodle business, the effective execution of raw material procurement strategies which helped mitigate the impact of raw material price volatility, and improved production efficiency. Profit attributable to owners of the Company increased by 11.6% from HK$157.0 million in 2025 to HK$175.2 million in 2026, representing a net profit margin of 8.5% for the period. The Group’s basic earnings per share increased from 15.05 HK cents to 16.79 HK cents for the period. Adjusted EBITDA increased by 9.1% from HK$303.2 million to HK$330.8 million, representing the Adjusted EBITDA margin of 16.0% for the period, reflecting improved profitability at the operating level. Review and Prospects of Different Business Regions During the reporting period, revenue from the Hong Kong and other regions operations remained stable, increasing by 0.2% to HK$793.5 million (2025: HK$792.3 million), mainly attributable to the continued steady performance of the instant noodle business in the Hong Kong market and increased demand in other regions. Revenue from Chinese Mainland operations increased by 4.5% (in local currency: -0.1%) to HK$1,277.5 million (2025: HK$1,221.9 million), mainly attributable to the increased sales volume of instant noodles and the positive impact of foreign currency translation. In Hong Kong, the instant noodles business delivered steady growth, driven by the resilient performance of flagship brands including Demae Iccho, Hokkaido Iccho, Cup Noodles and Cup Noodles BIG. To further enrich its instant noodle portfolio, the Group introduced a range of new SKUs, such as Nissin Stir Cup Noodles Seafood Flavour Instant Noodle and Nissin Viet Signature Beef Flavour Pho Noodle, and Demae Iccho Scallop and Salt Soup Flavour Instant Noodle. Continuing its IP promotion strategy, the collaboration with Japanese virtual singer “Hatsune Miku” also enhanced brand awareness and strengthened engagement with younger consumers. As for non-noodle business, the Group expanded its premium frozen food portfolio with the launch of the “Doll Dim Sum” series. The Group also introduced a series of limited-edition products to capture seasonal demand and drive sales. Meanwhile, health-focused products, including the Hong Kong-made Nissin Granola and fresh-cut vegetable, continued to gain popularity, reflecting the Company’s commitment to health and wellness. In May 2026, the Group entered into a strategic partnership with Itochu Hong Kong Limited through a joint investment in Nissin Marketing and Sales (H.K.) Limited, which is expected to support the long-term development and competitiveness of the distribution business in Hong Kong and the Chinese Mainland. In other regions, the Company continued to strengthen its presence in Vietnam with a focus on the youth segment to support instant noodles brand growth and market penetration. In Korea, Gaemi Food’s business performance was stable during the period, with the strategic focus on the expansion of its e-commerce business, enhancement of consumer engagement through “KEMY Mall”, and continuous product innovation. Gaemi Food continued to expand its presence in overseas markets including Hong Kong, Vietnam, and Taiwan. In Australia, ABC Pastry recorded stable performance supported by the launch of a range of new premium products. Australia Nissin also maintained solid business momentum during the period, driven by increased sales of instant noodles across nationwide supermarket chains and Asian supermarket channels through ongoing market development efforts and product innovation. In the Chinese Mainland, the Group continued to advance its premiumisation strategy and strengthen its business foundation, while increasing instant noodle sales volume through broader market coverage and more diversified distribution channels. It upgraded select Cup Noodles products by increasing ingredient sizes to deliver an improved tasting experience for consumers. To further enrich its product line-up, the Company also introduced new products such as Nissin U.F.O. Singapore Chilli Crab Flavour, reinforcing its premium and innovative brand positioning. The Company continued its collaboration with the Japanese virtual singer "Hatsune Miku" to raise brand awareness and strengthen connections with consumers. As for the non-noodle business, the Company continued to strengthen its snacks, beverage and frozen food businesses through product innovation to address evolving consumer demand. Mr. Kiyotaka ANDO, Executive Director, Chairman and Chief Executive Officer of Nissin Foods, said, “Despite continuing market volatility and geopolitical uncertainties, the Group delivered solid profit growth in the first half of 2026. This was supported by broader market coverage and the resulting increase in sales volume of our flagship brands. These results reflect the resilience of our business model and the effectiveness of our strategic initiatives. Our premiumisation strategy, diversified product portfolio and disciplined cost management have further strengthened our capability to navigate changing market conditions. As we continue to expand our presence in Hong Kong, the Chinese Mainland and overseas markets, we remain focused on delivering quality products and strengthening our brands. We are committed to achieving sustainable long-term growth and creating value for our shareholders.” About Nissin Foods Company Limited Nissin Foods Company Limited ("Nissin Foods”, together with its subsidiaries, the “Group”; Stock code: 1475) is a renowned food company in Hong Kong and the Chinese Mainland, with a diversified portfolio of well-known and highly popular brands, primarily focusing on the premium instant noodle segment. The Group officially established its presence in Hong Kong in 1984 and is the largest instant noodle company in Hong Kong. The Group primarily manufactures and sells instant noodles, high-quality frozen food products, including frozen dim sum and frozen noodles, and also sells and distributes other food and beverage products, including retort pouches, snacks, mineral water, sauce and vegetable products under its two core corporate brands, namely “NISSIN” and “DOLL (公仔)” together with a diversified portfolio of iconic household premium brands. The Group’s five flagship product brands, namely “Cup Noodles”, “Demae Iccho”, “Doll Instant Noodle”, “Doll Dim Sum” and “Fuku” are also among the most popular choices in their respective food product categories in Hong Kong. In the Chinese market, the Group has introduced technology innovation through the “ECO Cup” concept and primarily focuses its sales efforts in first- and second-tier cities. In addition, Nissin Foods operates business in other regions including Vietnam, Taiwan, Korea and Australia markets. Nissin Foods is currently a constituent of five Hang Seng Indexes, namely: Hang Seng Composite Index, Hang Seng Composite SmallCap Index, Hang Seng Composite Industry Index - Consumer Staples, Hang Seng SCHK Consumption Index and Hang Seng SCHK Consumer Staples Index. Nissin Foods is eligible for trading under Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect. For more information, please visit www.nissingroup.com.hk. Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com ———————————————————————————————————————————————————————————— Vibrant Wellness Brings the Most Comprehensive Gut Health Test to New ... 2026-08-25 · PR-Inside · Healthcare https://pr-inside.com/vibrant-wellness-brings-the-most-comprehensive-gut-health-test-to-new-r5215836.htm (PR-inside.com) New York State Availability for Gut Zoomer Expands Access to Comprehensive, Multi-Domain Gut Health Testing for Patients With a New York Shipping Address SANTA CLARA, CA / ACCESS Newswire / August 25, 2026 / Vibrant Wellness, a specialty laboratory company, announced New York availability for Gut Zoomer, bringing the most comprehensive gut health assessment to New York and marking a significant expansion of access to advanced microbiome testing. New York maintains rigorous state-specific requirements for clinical laboratories and laboratory-developed tests. Meeting the requirements set forth by New York's Clinical Laboratory Evaluation Program (CLEP) represents an important milestone for Vibrant and means healthcare .. ———————————————————————————————————————————————————————————— Northwoods Named to Inaugural Ohio AI25 for Advancing AI in Human Services ... 2026-08-25 · PR-Inside · AI, Healthcare https://pr-inside.com/northwoods-named-to-inaugural-ohio-ai25-for-advancing-ai-in-human-services-r5215835.htm (PR-inside.com) Recognition from OhioX and Ohio Tech News honors Northwoods among 25 companies and organizations helping shape Ohio's AI future DUBLIN, OH / ACCESS Newswire / August 25, 2026 / Northwoods, a leading provider of technology for health and human services agencies, has been named to the inauguralOhio AI25 Companies & Organizations list , presented by OhioX and Ohio Tech News. The Ohio AI25 recognizes 25 companies and organizations turning artificial intelligence into real-world impact across the state. Northwoods was recognized for applying generative AI to some of the most complex challenges facing health and human services agencies, helping frontline workers more easily .. ———————————————————————————————————————————————————————————— Vibrant Wellness Brings the Most Comprehensive Gut Health Test to New York 2026-08-25 · Newswire.com · Healthcare https://www.newswire.com/news/vibrant-wellness-brings-the-most-comprehensive-gut-health-test-to-new-22849797 New York State Availability for Gut Zoomer Expands Access to Comprehensive, Multi-Domain Gut Health Testing for Patients With a New York Shipping Address ———————————————————————————————————————————————————————————— Benedict T Palen Jr. Highlights Regenerative Agriculture for Climate-Resilient Farming 2026-08-25 · PRUnderground · Healthcare https://prunderground.com/benedict-t-palen-jr-highlights-regenerative-agriculture-for-climate-resilient-fa/cmt7djyoe000204l70fglxaxt Benedict T Palen Jr. highlights regenerative agriculture, soil health, water conservation, and precision farming as pathways toward stronger, climate-resilient farms. The post Benedict T Palen Jr. Highlights Regenerative Agriculture for Climate-Resilient Farming first appeared on ———————————————————————————————————————————————————————————— Surgeons Choice Medical Center Data Breach: Edelson Lechtzin LLP Launches Investigation Into Exposure of Personal Information 2026-08-25 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/surgeons-choice-medical-center-data-breach-edelson-lechtzin-llp-launches-investigation-into-exposure-of-personal-information-302858856.html National class action firm offering free case evaluations to individuals impacted by the Surgeons Choice Medical Center cybersecurity incident SOUTHFIELD, Mich., Aug. 24, 2026 /PRNewswire/ -- Edelson Lechtzin LLP, a national class action law firm, is investigating data privacy claims... ———————————————————————————————————————————————————————————— Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage 2026-08-25 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/25/3350174/0/en/leads-biolabs-opamtistomig-pd-l1-4-1bb-bispecific-antibody-phase-ii-clinical-study-for-first-line-treatment-of-esophageal-squamous-cell-carcinoma-advances-to-expansion-stage.html NANJING, China, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that Opamtistomig (LBL-024), the Company’s proprietary PD-L1/4-1BB bispecific antibody, as a first-line treatment for locally advanced or metastatic esophageal squamous cell carcinoma (ESCC), has completed its safety run‑in assessment and advanced to the expansion phase based on encouraging efficacy signals and a favorable safety profile. ———————————————————————————————————————————————————————————— Omaha officials announce four affordable housing projects as part of $40 million investment 2026-08-25 · WebWire · Finance, Healthcare, Real Estate https://www.webwire.com/ViewPressRel.asp?aId=359419 Omaha leaders on Monday announced four projects to expand and renovate affordable housing options in the city, including fixing up the vacant City View apartment building that was closed last summer following several health and safety concerns. - - The 225-unit property is the largest of the four projects to receive funding from the city through the Urban Core Housing Fund, a $40 million initiative created through bonds that the city committed to improving housing. The goal is to create... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=359419 ———————————————————————————————————————————————————————————— Autonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq Rules 2026-08-25 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/25/3350171/0/en/autonomix-medical-enters-into-4-9-million-warrant-inducement-priced-at-a-premium-to-market-under-nasdaq-rules.html THE WOODLANDS, TX, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it has entered into a warrant inducement agreement with an investor (“Investor”) for the immediate exercise of certain outstanding warrants that the Company issued on July 15, 2026 (the “July 2026 Warrants”). Pursuant to a warrant inducement agreement, the Investor has agreed to exercise the outstanding July 2026 Warrants to purchase an aggregate of 857,462 shares of the Company’s common stock at the exercise price of $5.75. The resale of the shares of common stock issuable upon exercise of the July 2026 Warrants has been registered pursuant to an effective registratio ———————————————————————————————————————————————————————————— Consumer Genomics Market Heads Toward $27.1B as Personalized Health Drives Growth 2026-08-25 · PressReleaseNews · Healthcare, Retail https://pressreleasenews.org/pressroom/consumer-genomics-market-heads-toward-27-1b-as-personalized-health-drives-growth ———————————————————————————————————————————————————————————— Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases 2026-08-25 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/antengene-receives-clinical-trial-approval-in-australia-for-phase-i-attract-study-of-atg-201-cd19-x-cd3-tce-in-b-cell-related-autoimmune-diseases-302858137.html SHANGHAI and HONG KONG, Aug. 24, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for... ———————————————————————————————————————————————————————————— LR Health & Beauty SE Publishes Figures for the First Half of 2026 2026-08-25 · NewMediaWire · Finance, Healthcare https://www.newmediawire.com/news/lr-health-beauty-se-publishes-figures-for-the-first-half-of-2026-7088863 H1 2026 sales reached EUR 118.6 million, with normalized EBITDA of EUR 8.7 million In the transformation year 2026, LR systematically advances strategic initiatives to position the organization for the future Business Days in September boost international partner community activities AHLEN, GERMANY - August 24, 2026 ( NEWMEDIAWIRE ) - LR Health & Beauty SE, Europe’s leading social commerce company for high-quality nutritional supplements and beauty products, has today published its figures for the second quarter and first half of 2026. In the second quarter of the 2026 financial year, LR Health & Beauty SE generated sales (revenue from goods sold) of EUR 57.8 million (Q2 2025: EUR 68.9 million), representing a decrease of 16.1% compared with the same period last year. For the first ———————————————————————————————————————————————————————————— Apptly Announces $1,000,000 Non-Brokered Private Placement 2026-08-25 · mlpr-newsfile · Healthcare https://www.newsfilecorp.com/release/311339/Apptly-Announces-1000000-NonBrokered-Private-Placement Vancouver, British Columbia--(Newsfile Corp. - August 24, 2026) - Apptly Health Technologies Corp. (CSE: APPT) (FSE: 4KL) (the "Company") is pleased to announce that it intends to complete a non-brokered private placement of up to 8,000,000 units of the Company (the "Units"), at a price of $0.125 per Unit, for aggregate gross proceeds of up to $1,000,000 (the "Offering"). The Company reserves the right to increase the size of the Offering in its sole discretion. The Offering is not subject to a... ———————————————————————————————————————————————————————————— Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma 2026-08-24 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/astellas-doses-first-patient-in-phase-3-study-of-asp2138-in-cldn18-2-postive-and-her2-negative-locally-advanced-unresectable-or-metastatic-gastric-or-gastroesophageal-junction-gej-adenocarcinoma-302858691.html - ASP2138's advancement into Phase 3 marks an important milestone in Astellas' commitment to advancing research in CLDN18.2 with its differentiated portfolio, spanning approved treatments and investigational assets - TOKYO, Aug. 24, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503,... ———————————————————————————————————————————————————————————— FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients 2026-08-24 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/fda-approves-imaavy-nipocalimab-aahu-as-first-ever-treatment-for-warm-autoimmune-hemolytic-anemia-waiha-representing-a-landmark-advancement-for-patients-302858778.html IMAAVY is an immunoselective FcRn blocker designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies while also preserving B-cell function Warm autoimmune hemolytic anemia is a rare, life-threatening disease in which autoantibodies cause the destruction of red blood... ———————————————————————————————————————————————————————————— Upland Couples Turn to Vazquez Counseling for Marriage Counseling and Mental Health Support as Local Demand for Counselors Rises 2026-08-24 · PR.com · Healthcare https://www.pr.com/press-release/977215 Vazquez Counseling, led by licensed Marriage and Family Therapist Manuel Vazquez, is seeing increased demand from Upland, CA residents searching for a marriage counselor, couples counseling, and mental health therapy near them. The practice offers individual and relationship-focused counseling, with a free consultation for new clients evaluating local counseling services. [PR.com] ———————————————————————————————————————————————————————————— BetterLife Pharma Inc. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants 2026-08-24 · mlpr-newsfile · Healthcare https://www.newsfilecorp.com/release/311170/BetterLife-Pharma-Inc.-Announces-Proposed-Public-Offering-of-Common-Shares-and-PreFunded-Warrants NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES OR FOR DISSEMINATION TO U.S. NEWS WIRE SERVICESVancouver, British Columbia--(Newsfile Corp. - August 24, 2026) - BetterLife Pharma Inc. (CSE: BETR) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, announced today that it has filed a preliminary short form prospectus (the "Preliminary Prospectus") with the securities regulatory authorities in the Provinces of British Columbia, Alberta... ———————————————————————————————————————————————————————————— 360training Acquires eMedCert, Expanding Its Healthcare Life Support Certification Portfolio 2026-08-24 · PR Newswire · Finance, Healthcare, Education https://www.prnewswire.com/news-releases/360training-acquires-emedcert-expanding-its-healthcare-life-support-certification-portfolio-302858759.html AUSTIN, Texas, Aug. 24, 2026 /PRNewswire/ -- 360training.com, Inc., recognized by Newsweek's America's Top Online Learning Providers list, today announced the acquisition of select assets from Electronic Medical Certification (eMedCert.com). The acquisition expands 360training's presence... ———————————————————————————————————————————————————————————— EYPT Investor Alert: Levi & Korsinsky Investigates EyePoint, Inc. (EYPT) ... 2026-08-24 · PR-Inside · Finance, Healthcare https://pr-inside.com/eypt-investor-alert-levi-korsinsky-investigates-eyepoint-inc-eypt-r5215749.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 24, 2026 / Levi & Korsinsky notifies investors that it has commenced an investigation into EyePoint, Inc. ("EyePoint, Inc.") (NASDAQ:EYPT) concerning potential violations of the federal securities laws. EyePoint, Inc. shares opened down 70% after the Company disclosed that DURAVYU (vorolanib intravitreal insert) failed to meet the prespecified primary endpoint -- change in best-corrected visual acuity versus on-label aflibercept -- in the full dataset of the Phase 3 LUGANO trial for wet age-related macular degeneration. The clinical trial failure occurred despite the Company repeatedly describing the program as "derisked" across at multiple .. ———————————————————————————————————————————————————————————— EYPT SHAREHOLDER INVESTIGATION: Levi & Korsinsky Investigates EyePoint, ... 2026-08-24 · PR-Inside · Finance, Healthcare https://pr-inside.com/eypt-shareholder-investigation-levi-korsinsky-investigates-eyepoint-r5215747.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 24, 2026 / Levi & Korsinsky notifies investors that it has commenced an investigation into EyePoint, Inc. ("EyePoint, Inc.") (NASDAQ:EYPT) concerning potential violations of the federal securities laws. EyePoint, Inc. shares opened down 70% after the Company disclosed that DURAVYU (vorolanib intravitreal insert) failed to meet the prespecified primary endpoint -- change in best-corrected visual acuity versus on-label aflibercept -- in the full dataset of the Phase 3 LUGANO trial for wet age-related macular degeneration. The clinical trial failure occurred despite the Company repeatedly describing the program as "derisked" across at multiple .. ———————————————————————————————————————————————————————————— Pomerantz LLP Announces Securities Class Action Litigation Against ... 2026-08-24 · PR-Inside · Finance, Healthcare https://pr-inside.com/pomerantz-llp-announces-securities-class-action-litigation-against-r5215744.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 24, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Fractyl Health, Inc. ("Fractyl" or the "Company") (NASDAQ:GUTS) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 26-cv-07167, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fractyl securities between January 13, 2025 and January 29, 2026, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations .. ———————————————————————————————————————————————————————————— Theralase(R) Closes C$3.6 Million Brokered Financing 2026-08-24 · mlpr-newsfile · Healthcare, Energy https://www.newsfilecorp.com/release/311258/TheralaseR-Closes-C3.6-Million-Brokered-Financing Toronto, Ontario--(Newsfile Corp. - August 24, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that it has closed its previously announced brokered private placement offering ("Offering"), pursuant to which the Company issued 14,812,500... ———————————————————————————————————————————————————————————— United Animal Health Adds Industry Leader Brett Kaysen, Ph.D., to Senior Leadership Team 2026-08-24 · PRWeb · Healthcare https://www.prweb.com/releases/united-animal-health-adds-industry-leader-brett-kaysen-phd-to-senior-leadership-team-302858540.html United Animal Health has named Brett Kaysen, Ph.D., Senior Vice President of Domestic Sales. Kaysen brings decades of experience in animal agriculture, commercial leadership and producer engagement and will lead the company's domestic commercial organization while supporting continued... ———————————————————————————————————————————————————————————— Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results 2026-08-24 · mlpr-businesswire · Finance, Healthcare https://finance.yahoo.com/healthcare/articles/bausch-lomb-advancing-two-first-203000791.html VAUGHAN, Ontario, August 24, 2026--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that two of its pharmaceutical pipeline assets – both first-in-class treatments – will advance to new trials based on recent clinical results. ———————————————————————————————————————————————————————————— TGH Brooksville Performs First Cardiothoracic Surgery, Expanding Access to Advanced Heart Care in Hernando County 2026-08-24 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/tgh-brooksville-performs-first-cardiothoracic-surgery-expanding-access-to-advanced-heart-care-in-hernando-county-302858693.html This milestone brings complex cardiothoracic surgical care closer to home for patients in Hernando County and surrounding communities, backed by the expertise and resources of Tampa General's academic health system. TAMPA, Fla., Aug. 24, 2026 /PRNewswire/ -- Tampa General Hospital (TGH)... ———————————————————————————————————————————————————————————— Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026 2026-08-24 · mlpr-businesswire · Finance, Healthcare https://finance.yahoo.com/healthcare/articles/savara-announces-encore-presentations-results-200500773.html YARDLEY, Pa., August 24, 2026--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at the ERS Congress in Barcelona, Spain, September 5-9, 2026. ———————————————————————————————————————————————————————————— Pioneerly's 2026 U.S. Legal Market Health Index Ranks All 50 States and D.C. for Law Firm Growth 2026-08-24 · PRUnderground · Healthcare https://prunderground.com/pioneerly-s-2026-u-s-legal-market-health-index-ranks-all-50-states-and-d-c-for-l/cmt7nlij1000504legmww33iw Free, openly licensed index scores every U.S. jurisdiction on legal demand, competition, and momentum, giving law firms a data-driven view of where to grow. The post Pioneerly's 2026 U.S. Legal Market Health Index Ranks All 50 States and D.C. for Law Firm Growth first appeared on ———————————————————————————————————————————————————————————— Amerikaanse FDA kent weesgeneesmiddelstatus toe aan Gamgertamig voor de behandeling van Pemphigus 2026-08-24 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/24/3350092/0/nl/amerikaanse-fda-kent-weesgeneesmiddelstatus-toe-aan-gamgertamig-voor-de-behandeling-van-pemphigus.html Mechelen, België; 24 augustus, 2026, 22.01 CET; gereglementeerde informatie – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) kondigt vandaag aan dat de Amerikaanse Food and Drug Administration (FDA) weesgeneesmiddelstatus heeft toegekend aan gamgertamig voor de behandeling van pemphigus. Gamgertamig was voorheen zowel versneld- als weesgeneesmiddelstatus (Fast Track and Orphan Drug Designation) toegekend door de Amerikaanse FDA voor de behandeling van auto-immuunhemolytische anemie (AIHA) en immuuntrombocytopenie (ITP). ———————————————————————————————————————————————————————————— Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026 2026-08-24 · GlobeNewswire · Finance, SaaS, Healthcare https://www.globenewswire.com/news-release/2026/08/24/3350091/0/en/avalyn-announces-multiple-presentations-at-the-european-respiratory-society-international-congress-2026.html Presentations describe integration of patient perspective into clinical trial design and data modeling AP01 distribution in the lungs Presentations describe integration of patient perspective into clinical trial design and data modeling AP01 distribution in the lungs ———————————————————————————————————————————————————————————— Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer 2026-08-24 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/24/3350090/0/en/oruka-therapeutics-appoints-todd-edwards-as-chief-commercial-officer.html MENLO PARK, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced the appointment of Todd Edwards as Chief Commercial Officer, effective August 24, 2026. ———————————————————————————————————————————————————————————— U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigus 2026-08-24 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/24/3350092/0/en/u-s-fda-grants-orphan-drug-designation-to-gamgertamig-for-the-treatment-of-pemphigus.html Mechelen, Belgium; 24 August 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to gamgertamig for the treatment of pemphigus. Gamgertamig was previously granted both Fast Track and Orphan Drug Designation by the U.S. FDA for the treatment of autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP). ———————————————————————————————————————————————————————————— GUTS Investor Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Fractyl Health, Inc. 2026-08-24 · PR Newswire · Finance, Healthcare https://www.prnewswire.com/news-releases/guts-investor-notice-shareholder-rights-law-firm-robbins-llp-reminds-investors-of-the-class-action-lawsuit-against-fractyl-health-inc-302858580.html SAN DIEGO, Aug. 24, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Fractyl Health, Inc. (NASDAQ: GUTS) securities between January 13, 2025 and January... ———————————————————————————————————————————————————————————— Emerging Growth Research Releases Q2:26 Quarterly Update on SBC Medical ... 2026-08-24 · PR-Inside · Finance, AI, Healthcare https://pr-inside.com/emerging-growth-research-releases-q2-26-quarterly-update-on-sbc-medical-r5215672.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 24, 2026 / Emerging Growth Research today announced the release of its Q2:26 Quarterly Update Report on SBC Medical Group Holdings (NASDAQ:SBC), reiterating its Buy rating and increasing its 12-month price target to $11.00 from $10.00. The Quarterly Update highlights SBC Medical Group's return to revenue growth in 2026 following the completion of pricing-related headwinds experienced during 2025, while emphasizing the Company's strong cash position, expanding clinic footprint, continued international expansion, and new AI-driven growth initiatives. Emerging Growth Research believes the Company is positioned for renewed growth following the 2025 revenue decline .. ———————————————————————————————————————————————————————————— Emerging Growth Research Releases Q2:26 Quarterly Update on SBC Medical Group; Reiterates Buy Rating and Increases Price Target to $11.00 2026-08-24 · Newswire.com · Healthcare https://www.newswire.com/news/emerging-growth-research-releases-q2-26-quarterly-update-on-sbc-medical-group ———————————————————————————————————————————————————————————— Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories 2026-08-24 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/24/3350084/0/en/cosmos-health-projects-over-6m-in-annual-revenue-and-4-3m-in-gross-profit-from-oliv18-across-the-u-s-cardiovascular-health-and-antioxidant-categories.html Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories. ———————————————————————————————————————————————————————————— 15 Students Selected for National Health Leadership Role 2026-08-24 · NewMediaWire · Finance, SaaS, Healthcare, Retail, Education https://www.newmediawire.com/news/15-students-selected-for-national-health-leadership-role-7088842 DALLAS - August 24, 2026 ( NEWMEDIAWIRE ) - As youth health challenges continue to grow in the United States [1] , 15 passionate students from across the country are stepping up to help. The American Heart Association, a relentless force changing the future of health for everyone everywhere, has named the 2026-27 class of national Youth Heart Ambassadors for Kids Heart Challenge™ and American Heart Challenge™, the Association’s school-based fundraising programs that teach students heart-healthy habits and lifesaving skills. This year’s class of national Youth Heart Ambassadors was selected from a pool of applicants nationwide. The volunteer role gives students a platform to raise awareness by sharing how they have been impacted by heart disease and stroke, while they inspire healthier habi ———————————————————————————————————————————————————————————— CMS 2027 Proposed Rule: Key Changes to RPM, RTM and Medicare Care Management ... 2026-08-24 · PR-Inside · Healthcare https://pr-inside.com/cms-2027-proposed-rule-key-changes-to-rpm-rtm-and-medicare-care-management-r5215669.htm (PR-inside.com) LIVONIA, MI / ACCESS Newswire / August 24, 2026 / CMS released the Calendar Year 2027 Medicare Physician Fee Schedule (PFS) Proposed Rule on July 14, 2026 (CMS-1848-P), highlighting potential changes to Medicare reimbursement, Remote Patient Monitoring (RPM), Remote Therapeutic Monitoring (RTM), behavioral health, care management, and other Medicare services. The rule remains proposed, and CMS may modify policies before issuing the final rule. Proposed RPM and RTM Changes RPM and RTM are key areas for healthcare organizations. CMS proposes requiring practitioners reporting RPM or RTM services to furnish a separately reportable initiating visit in association with the onset of those services. CMS .. ———————————————————————————————————————————————————————————— Memorial Healthcare System Announces Leadership Promotions at Two Hospitals 2026-08-24 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/memorial-healthcare-system-announces-leadership-promotions-at-two-hospitals-302858576.html HOLLYWOOD, Fla., Aug. 24, 2026 /PRNewswire/ -- Memorial Healthcare System has announced two leadership promotions, naming Felicia Turnley CEO of Memorial Hospital Miramar and Stephen Demers CEO of Memorial Hospital West. Turnley currently serves as CEO of Memorial Hospital Pembroke, while... ———————————————————————————————————————————————————————————— JinIX Opens Registration for Rare Disease Clinical Datathon Connecting Patients With Medical Experts 2026-08-24 · PressReleaseNews · AI, Healthcare https://pressreleasenews.org/pressroom/jinix-opens-registration-for-rare-disease-clinical-datathon-connecting-patients-with-medical-experts The JinIX Clinical Datathon is an online event that connects people living with rare diseases with verified physicians, researchers and medical specialists who analyze consented patient data using JinIX’s AI Health Navigator. The program offers a $1,000 prize pool across four medical expert winners and ———————————————————————————————————————————————————————————— Pediatric Care Expert Phillip Walker Explains What After-Hours Pediatric Urgent Care Is in HelloNation 2026-08-24 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/pediatric-care-expert-phillip-walker-explains-what-after-hours-pediatric-urgent-care-is-in-hellonation-302858612.html The article explains how after-hours pediatric urgent care gives families access to timely, child-focused care when regular medical offices are closed. NEWNAN, Ga., Aug. 24, 2026 /PRNewswire/ -- How can families handle sudden childhood illnesses or injuries that appear when the regular... ———————————————————————————————————————————————————————————— Laser Marking Technologies, LLC Announces FDA-Compliant UDI Marking Solutions for Medical Device Manufacturers Navigating New QMSR Requirements 2026-08-24 · PRWeb · Healthcare https://www.prweb.com/releases/laser-marking-technologies-llc-announces-fda-compliant-udi-marking-solutions-for-medical-device-manufacturers-navigating-new-qmsr-requirements-302858013.html A new FDA inspection standard is making Unique Device Identification marking accuracy an actively enforced requirement, and Laser Marking Technologies, LLC offers cost-conscious laser engraving systems designed to help medical device manufacturers meet it. CARO, Mich., Aug. 24, 2026... ———————————————————————————————————————————————————————————— Protecting Workers in Puerto Rico from Ototoxic Chemicals and Noise to Prevent Hearing Loss 2026-08-24 · WebWire · Healthcare https://www.webwire.com/ViewPressRel.asp?aId=359396 A recent bulletin from the National Institute for Occupational Safety and Health (NIOSH) warns that millions of workers are exposed to chemicals that may damage hearing, particularly when combined with excessive workplace noise. - - While hearing loss is commonly associated with loud noise, NIOSH explains that certain chemicals, known as ototoxic chemicals, can also damage the inner ear and auditory nerves. These substances are frequently found in paints, solvents, pesticides, industrial cl... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=359396 ———————————————————————————————————————————————————————————— VERAXA Biotech (VRXA) Builds Antibody-Based Cancer Pipeline Around Dual-Targeting Precision 2026-08-24 · NewMediaWire · SaaS, Healthcare, Retail https://www.newmediawire.com/news/veraxa-biotech-vrxa-builds-antibody-based-cancer-pipeline-around-dual-targeting-precision-7088837 VERAXA Biotech is changing how antibody-based therapies recognize and attack cancer cells, developing antibody-based cancer therapies with an emphasis on bispecific antibody-drug conjugates (“ADCs”) and T-cell engagers (“TCEs”). Its proprietary BiTAC platform uses a dual-targeting, “AND-gated” architecture designed to activate therapeutic effects preferentially at tumor sites. The company has advanced its lead BiTAC-TCE toward IND/CTA-enabling activities following cell-line development work and regulatory feedback from Germany’s Paul-Ehrlich-Institute. VERAXA’s VXA-222 bispecific ADC has moved beyond the initial discovery phase following completion of the antibody-discovery step with OmniAb. The company reported more than 50 granted owned or exclusively licensed patents across 26 patent fa ———————————————————————————————————————————————————————————— Dimora Medical Introduces New Pricing for MegaSorb™ Dressings, Expanding Access to Professional-Grade Wound Care 2026-08-24 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/dimora-medical-introduces-new-pricing-for-megasorb-dressings-expanding-access-to-professional-grade-wound-care-302858007.html NEW YORK, Aug. 24, 2026 /PRNewswire/ -- Dimora Medical, a continuous innovator in high-end medical care supplies, today announced price reductions across its entire MegaSorb™ wound dressing lineup—with select SKUs discounted by up to 29% to make advanced wound management solutions more... ———————————————————————————————————————————————————————————— RelaxBro Enters the U.S. With Its Award-Winning MX650 Massage Chair 2026-08-24 · PressReleaseNews · Healthcare https://pressreleasenews.org/pressroom/relaxbro-enters-the-u-s-with-its-award-winning-mx650-massage-chair ———————————————————————————————————————————————————————————— Dr. Dan B. Tran First in Southern California to Implant Clareon(R) ... 2026-08-24 · PR-Inside · Healthcare https://pr-inside.com/dr-dan-b-tran-first-in-southern-california-to-implant-clareon-r-r5215647.htm (PR-inside.com) Coastal Vision Medical Group Founder Among First Surgeons to Implant Alcon's Newly Launched Clareon TruPlus IOL ORANGE, CA / ACCESS Newswire / August 24, 2026 / Coastal Vision Medical Group proudly announces that Dan B. Tran, MD, Founder and Medical Director, is among the first surgeons to implant the new Clareon® TruPlus IOL and the first surgeon in Southern California to implant the Clareon TruPlus BLF IOL. The milestone procedure was performed at Los Alamitos Surgery Center, continuing Coastal Vision Medical Group's commitment to bringing the latest advancements in cataract surgery and intraocular lens technology to patients throughout Southern California. Introducing the Clareon .. ———————————————————————————————————————————————————————————— Dr. Dan B. Tran First in Southern California to Implant Clareon(R) TruPlus BLF IOL 2026-08-24 · Newswire.com · Healthcare https://www.newswire.com/news/dr-dan-b-tran-first-in-southern-california-to-implant-clareon-r-22849551 Coastal Vision Medical Group Founder Among First Surgeons to Implant Alcon's Newly Launched Clareon TruPlus IOL ———————————————————————————————————————————————————————————— Las Vegas Raiders Announce $25 Million Game-Changing Gift to Intermountain Health to Help Build Nevada's First Stand-Alone Children's Hospital 2026-08-24 · PR Newswire · Healthcare, Gaming https://www.prnewswire.com/news-releases/las-vegas-raiders-announce-25-million-game-changing-gift-to-intermountain-health-to-help-build-nevadas-first-stand-alone-childrens-hospital-302858491.html Led by Raiders owners Mark Davis, Egon Durban, and Michael Meldman, this marks the largest philanthropic commitment in franchise history LAS VEGAS, Aug. 24, 2026 /PRNewswire/ -- The Las Vegas Raiders and Intermountain Health today announced a $25 million gift to help build Nevada's first... ———————————————————————————————————————————————————————————— Tenon Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement ... 2026-08-24 · PR-Inside · Finance, Healthcare https://pr-inside.com/tenon-medical-regains-compliance-with-nasdaq-minimum-bid-price-requirement-r5215636.htm (PR-inside.com) LOS GATOS, CA / ACCESS Newswire / August 24, 2026 /Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule"). On February 25, 2026, the Company received a letter from the Listing Qualifications staff of Nasdaq (the "Staff") notifying it that, for the prior 30 consecutive business days, the closing bid price of .. ———————————————————————————————————————————————————————————— Did You Lose Money Investing in Aardvark Therapeutics, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against AARD 2026-08-24 · mlpr-newsfile · Finance, Healthcare https://www.newsfilecorp.com/release/311118/Did-You-Lose-Money-Investing-in-Aardvark-Therapeutics-Inc.-Robbins-LLP-Urges-Investors-with-Significant-Losses-to-Contact-the-Firm-for-Information-About-Their-Rights-Against-AARD San Diego, California--(Newsfile Corp. - August 24, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) (a) common stock pursuant to the Company's February 13, 2025 initial public offering ("IPO") and/or (b) securities between February 13, 2025 and May 14, 2026 (the "Class Period"). Aardvark is a clinical-stage biopharmaceutical company... ———————————————————————————————————————————————————————————— HelloNation Article Featuring Dental Expert Charles Basso, DDS, Explains How Preventive Dental Care Helps Families Avoid Costly Procedures Later 2026-08-24 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/hellonation-article-featuring-dental-expert-charles-basso-dds-explains-how-preventive-dental-care-helps-families-avoid-costly-procedures-later-302858294.html The article outlines how preventive dentistry supports oral health and helps families reduce future dental expenses. ESCONDIDO, Calif., Aug. 24, 2026 /PRNewswire/ -- What steps can families take today to avoid expensive dental procedures in the future? HelloNation has published an article... ———————————————————————————————————————————————————————————— Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman Sobol Shapiro LLP 2026-08-24 · PR Newswire · Finance, Healthcare https://www.prnewswire.com/news-releases/regeneron-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-regeneron-class-action-lawsuit--hagens-berman-sobol-shapiro-llp-302858462.html SAN FRANCISCO, Aug. 24, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to... ———————————————————————————————————————————————————————————— UT Health San Antonio names NIH expert inaugural director of stem cell transplant and cellular therapy program 2026-08-24 · PR Newswire · Healthcare, Education https://www.prnewswire.com/news-releases/ut-health-san-antonio-names-nih-expert-inaugural-director-of-stem-cell-transplant-and-cellular-therapy-program-302858351.html SAN ANTONIO, Aug. 24, 2026 /PRNewswire/ -- UT Health San Antonio, the academic health center and health system of The University of Texas at San Antonio (UT San Antonio), has named nationally recognized blood cancer and cellular therapy expert Georg Aue, MD, PhD, MBA, the director of the... ———————————————————————————————————————————————————————————— Vadzo Imaging Validates Falcon-235MGS: 2MP AR0235 Global Shutter USB 3.2 Gen 1 Camera with Dynamic ROI and Low Noise Imaging for Medical Devices 2026-08-24 · Newswire.com · Healthcare, Media https://www.newswire.com/news/vadzo-imaging-validates-falcon-235mgs-2mp-ar0235-global-shutter-usb-3-22849444 Built for surgical visualization, endoscopy, and diagnostic devices that cannot tolerate motion blur or excessive sensor noise, this camera pairs the Onsemi AR0235 HyperLux SG sensor with global shutter capture, Dynamic ROI, and low-noise monochrome imaging over USB 3.2 Gen 1, giving medical device manufacturers precise, motion-free video without a proprietary interface to manage. ———————————————————————————————————————————————————————————— Number of Shares and Voting Rights of ADOCIA as of July 31st, 2026 2026-08-24 · mlpr-businesswire · Finance, Healthcare https://finance.yahoo.com/markets/stocks/articles/number-shares-voting-rights-adocia-160000565.html LYON, France, August 24, 2026--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French "Code de Commerce" and article 223-16 of the General Regulation of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF"), ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon (Euronext Paris: FR0011184241 – ADOC – the "Company") a clinical-stage biopharmaceutical company focused on the research and development of i ———————————————————————————————————————————————————————————— Brightn Launches Complete Mental Health Benefit for Employer Groups: AI-Powered Daily Support + Licensed Therapy Nationwide Through OpenLoop Health 2026-08-24 · PR Newswire · AI, SaaS, Healthcare https://www.prnewswire.com/news-releases/brightn-launches-complete-mental-health-benefit-for-employer-groups-ai-powered-daily-support--licensed-therapy-nationwide-through-openloop-health-302858463.html CEDAR RAPIDS, Iowa and DES MOINES, Iowa, Aug. 24, 2026 /PRNewswire/ -- OpenLoop, a national leader in telehealth-enabled clinical services, and Brightn, an AI-powered upstream mental wellness platform, today announced a strategic partnership to expand access to clinically-informed,... ———————————————————————————————————————————————————————————— RPC Acquires Peracidin® Product Line 2026-08-24 · PR Newswire · Finance, Healthcare https://www.prnewswire.com/news-releases/rpc-acquires-peracidin-product-line-302858464.html MAPLE GROVE, Minn., Aug. 24, 2026 /PRNewswire/ -- RPC is pleased to announce the successful acquisition of the Peracidin® product line from Angelini Pharma, expanding our portfolio of high-quality peroxyacetic/peracetic acid (PAA) sterilants for dialysis, water treatment and life science... ———————————————————————————————————————————————————————————— As WCI 2026 Turns to Non-Surgical, Opioid-Sparing Care for Injured ... 2026-08-24 · PR-Inside · SaaS, Healthcare https://pr-inside.com/as-wci-2026-turns-to-non-surgical-opioid-sparing-care-for-injured-r5215585.htm (PR-inside.com) Peer-reviewed research on sam® Recover shows reduced opioid and NSAID use in chronic back pain patients and faster return-to-play after musculoskeletal injury. ZetrOZ is showcasing the results at Booth #701. TRUMBULL, CT / ACCESS Newswire / August 24, 2026 / Reducing reliance on opioids and surgery for injured workers is one of the throughlines of this week's WCI 2026 conference. ZetrOZ Systems, developer of the FDA-cleared sam® (Sustained Acoustic Medicine) wearable ultrasound platform, is exhibiting at the 80th Annual Workers' Compensation Educational Conference (WCI 2026), held Aug. 23-26 at the Orlando World Center Marriott, where the company is introducing sam® Recover .. ———————————————————————————————————————————————————————————— Labor & Employment Law Firm Zakay Law Group, APLC Files a Class Action Against Footprints Behavioral Interventions and Footprints Behavioral Health, Alleging Failure to Provide Meal and Rest Breaks 2026-08-24 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/labor--employment-law-firm-zakay-law-group-aplc-files-a-class-action-against-footprints-behavioral-interventions-and-footprints-behavioral-health-alleging-failure-to-provide-meal-and-rest-breaks-302856747.html The lawsuit alleges Footprints Behavioral Interventions and Footprints Behavioral Health violated the California Labor Code by failing to provide its employees with meal and rest periods. SAN DIEGO, Aug. 24, 2026 /PRNewswire/ -- The San Diego labor law attorneys at Zakay Law Group, APLC,... ———————————————————————————————————————————————————————————— Zealand Pharma – Notification of holding of treasury shares 2026-08-24 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/08/24/3349951/0/en/zealand-pharma-notification-of-holding-of-treasury-shares.html Company announcement – No. 42 / 2026 ———————————————————————————————————————————————————————————— Record $4.95 million raised for heart health in Alberta as Miyu Yamashita wins CPKC Women's Open 2026-08-24 · WebWire · Healthcare, Education https://www.webwire.com/ViewPressRel.asp?aId=359380 The 2026 CPKC Women's Open raised a record $4.95 million to support heart healthcare in Alberta, while on the golf course, Miyu Yamashita concluded a historic performance on Sunday to capture the 2026 CPKC Women's Open championship and her fourth LPGA Tour victory. - - Enthusiastic, record crowds filled the grounds at the Royal Mayfair Golf Club to watch Yamashita finish the week 23 under par, winning by nine strokes over the second place finisher. - - Earlier Sunday, CPKC representa... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=359380 ———————————————————————————————————————————————————————————— BRC Therapeutics Appoints Biopharma Veteran Chandra Ramanathan as Executive Vice President of Commercialization and Strategy 2026-08-24 · mlpr-prnewswire-wire · Healthcare https://www.prnewswire.com/news-releases/brc-therapeutics-appoints-biopharma-veteran-chandra-ramanathan-as-executive-vice-president-of-commercialization-and-strategy-302858352.html Seasoned Executive Brings Track Record of Drug Launches, External Innovation, and Portfolio Growth at Bristol Myers Squibb, Wyeth, Bayer, and Danaher to BRC's Next Phase of Growth MONTEREY, Calif., Aug. 24, 2026 /PRNewswire/ -- BRC Therapeutics (BRC), a clinical-stage pharmaceutical... ———————————————————————————————————————————————————————————— CONTRA COSTA COUNTY TEAMSTERS RATIFY TWO-YEAR AGREEMENT 2026-08-24 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/contra-costa-county-teamsters-ratify-two-year-agreement-302858400.html Contract Includes Wage Increases, Employer-Paid Medical, and Salary Study MARTINEZ, Calif., Aug. 24, 2026 /PRNewswire/ -- More than 2,100 Contra Costa County workers have overwhelmingly voted to ratify a new two-year contract, averting a strike. The members of Teamsters Local 856, who... ———————————————————————————————————————————————————————————— WHO and Peking University strengthen collaboration to advance health emergency preparedness 2026-08-24 · WebWire · Healthcare, Education https://www.webwire.com/ViewPressRel.asp?aId=359376 The World Health Organization (WHO) and Peking University have entered into a two-year project collaboration agreement to strengthen global health emergency preparedness through research, training and innovative analytical approaches. - - The collaboration, led by WHO's Department of Health Emergency Preparedness through its Risk Analytics and Action Reviews (RAR) Unit and Peking University's Institute for Global Health, will support efforts to strengthen prevention, preparedness, response... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=359376 ———————————————————————————————————————————————————————————— Vascular Innovation Takes Center Stage at The VEINS and VIVA 2026 2026-08-24 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/vascular-innovation-takes-center-stage-at-the-veins-and-viva-2026-302858397.html PALM SPRINGS, Calif., Aug. 24, 2026 /PRNewswire/ -- The VIVA Foundation will spotlight the latest advances in vascular medicine as 26 clinical trials are presented during The VEINS and VIVA 2026, taking place October 3-6 at Bellagio Las Vegas. The highly anticipated late-breaking... ———————————————————————————————————————————————————————————— GeoVax Initiates Global Health Outreach to WHO, Africa CDC and Other Agencies Regarding Ebola Vaccine Portfolio Amid Expanding Outbreak 2026-08-24 · NewMediaWire · Finance, Healthcare https://www.newmediawire.com/news/geovax-initiates-global-health-outreach-to-who-africa-cdc-and-other-agencies-regarding-ebola-vaccine-portfolio-amid-expanding-outbreak-7088835 Emerging Evidence of Potential Protection From Authorized Ebola Zaire Vaccine Against Bundibugyo Virus Provides Rationale for Evaluating GeoVax's MVA-Based Ebola Vaccine Candidates ATLANTA, GA - August 24, 2026 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, today announced that it has expanded outreach to global and regional public health organizations regarding the potential relevance of its Modified Vaccinia Ankara (MVA)-based hemorrhagic fever vaccine portfolio amid the expanding Ebola disease outbreak caused by Bundibugyo virus (BDBV) in various regions of Africa. The outreach follows GeoVax's recent announcement highlighting its willingness to contribute vaccin ———————————————————————————————————————————————————————————— DeepCura Unveils the Electronic Health Workforce (EHW) -- the Step Beyond the EHR 2026-08-24 · PR Newswire · AI, Healthcare https://www.prnewswire.com/news-releases/deepcura-unveils-the-electronic-health-workforce-ehw--the-step-beyond-the-ehr-302858389.html Architected by founder Fern Cowan, the EHW is healthcare's system of evidenced action: a clinician-supervised AI workforce that does the practice's work on a finance-style ledger, where every action — and every entry in the chart — carries its receipt. It integrates with existing EHRs, or... ———————————————————————————————————————————————————————————— Imricor Supports HRS Call for Enhanced Radiation Protection and Urges a Future Beyond Radiation Exposure 2026-08-24 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/imricor-supports-hrs-call-enhanced-141000539.html MINNEAPOLIS, August 24, 2026--Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR), the pioneer in the interventional magnetic resonance (iMR) field, welcomed the Heart Rhythm Society’s call for the urgent and immediate adoption of enhanced radiation-protection measures for clinicians and staff working in fluoroscopy-based procedure environments.1 ———————————————————————————————————————————————————————————— Kaplan Fox Reminds Hims & Hers Health, Inc. (HIMS) Investors of an Investigation into Potential Securities Law Violations 2026-08-24 · mlpr-newsfile · Finance, Healthcare https://www.newsfilecorp.com/release/311000/Kaplan-Fox-Reminds-Hims-Hers-Health-Inc.-HIMS-Investors-of-an-Investigation-into-Potential-Securities-Law-Violations New York, New York--(Newsfile Corp. - August 24, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS).CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATIONIf you are a Hims & Hers investor and have suffered losses, or if you have information that could assist in the Hims & Hers investigation, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing... ———————————————————————————————————————————————————————————— Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA 2026-08-24 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/24/3349793/0/en/capricor-therapeutics-announces-extension-of-pdufa-target-action-date-as-fda-continues-review-of-deramiocel-bla.html – New PDUFA target action date of November 22, 2026 follows submission of additional Phase 3 HOPE-3 data and analyses supporting a refined proposed indication – ———————————————————————————————————————————————————————————— The importance of indoor airflow patterns in spreading airborne disease 2026-08-24 · WebWire · Healthcare https://www.webwire.com/ViewPressRel.asp?aId=359359 Tuberculosis (TB) is a leading cause of infectious disease deaths, claiming over 1 million lives every year. It spreads through the air when an infected person coughs, sneezes, or exhales, and drug-resistant strains and asymptomatic spreading are growing concerns. Curbing TB transmission is an urgent public health challenge, yet scientists still don't understand how airflow and other environmental factors influence that spread. - - One problem is that studies of infectious disease transmiss... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=359359 ———————————————————————————————————————————————————————————— Body Morph MD Adds the Hyfrecator® 2000 to Its Skin Health Program, Expanding In-Office Treatment for Skin Tags, Warts, and Common Skin Lesions 2026-08-24 · PRWeb · Healthcare https://www.prweb.com/releases/body-morph-md-adds-the-hyfrecator-2000-to-its-skin-health-program-expanding-in-office-treatment-for-skin-tags-warts-and-common-skin-lesions-302856201.html Under the direction of founder Dr. Teresa Lantin, the physician-led medical spa with locations in Harrison, New York, and Naples, Florida, now offers electrosurgical treatment for benign skin conditions alongside its DiamondGlow microdermabrasion and microneedling collagen induction... ———————————————————————————————————————————————————————————— MDCE Advances Continuously Learning AI Models Within StrainScan Pro ... 2026-08-24 · PR-Inside · AI, SaaS, Healthcare, Retail, Education https://pr-inside.com/mdce-advances-continuously-learning-ai-models-within-strainscan-pro-r5215561.htm (PR-inside.com) Proprietary Platform Designed to Improve Over Time Through Ongoing Model Training and Real-World Visual Data MESA, AZ / ACCESS Newswire / August 24, 2026 / Medical Care Technologies Inc. (OTC PINK:MDCE) today highlighted continued technical progress within its StrainScan Pro platform, focusing on the advancement of continuously learning AI models that support greater visual accuracy across both agricultural and regulated retail environments. StrainScan Pro is built on proprietary computer-vision architecture designed to refine performance as it processes additional visual data. This continuous learning approach allows the platform to strengthen its ability to identify relevant visual patterns over time - whether supporting strain .. ———————————————————————————————————————————————————————————— Feliciano Serrano, MD Highlights the Link Between Kidney and Vascular ... 2026-08-24 · PR-Inside · Healthcare, Education https://pr-inside.com/feliciano-serrano-md-highlights-the-link-between-kidney-and-vascular-r5215558.htm (PR-inside.com) Los Angeles physician discusses how broader medical expertise can help address the complex needs of kidney patients. LOS ANGELES, CA / ACCESS Newswire / August 24, 2026 / Kidney disease can involve health challenges that extend beyond the kidneys themselves. Feliciano Serrano, MD, a Los Angeles physician with training in nephrology and vascular interventions, believes this connection highlights the value of looking at complex patient needs from a broader perspective. Serrano's interest in that relationship developed while specializing in nephrology and hypertension at the University of Vermont School of Medicine. During an NIH-supported research fellowship, he studied thrombosis and platelet dysfunction in .. ———————————————————————————————————————————————————————————— NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation 2026-08-24 · NewMediaWire · Healthcare, Real Estate https://www.newmediawire.com/news/neurothera-clearmind-collaboration-advances-mdma-n-acylethanolamines-ip-for-the-treatment-of-ptsd-amid-rising-u-s-federal-support-for-psychedelic-innovation-7088834 U.S. Publication of a Patent Application Covering the MDMA-N-acylethanolamines Combination Expands Intellectual Property Generated Through the Collaboration, and Provides Guidance Addressing Clinical Development Considerations for Psychedelic Drugs, Including MDMA TORONTO, ONTARIO - August 24, 2026 ( NEWMEDIAWIRE ) - NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage pharmaceutical company, today announced that its ongoing collaboration with Clearmind Medicine Inc. (“ Clearmind ”) has advanced with the publication in the United States of a patent application covering a novel combination of 3,4-methylenedioxymethamphetamine (“ MDMA ”) and N-acylethanolamines, such as palmitoylethanolamide (“ PEA ”), for use in methods of treating post-traumatic stress di ———————————————————————————————————————————————————————————— Investment Opportunities Emerging in the Global Drug Reference Apps Market 2026-08-24 · Express Press Release · Healthcare https://express-press-release.net/news/2026/08/24/1769060 Drug reference apps are becoming more than digital versions of traditional medication guides. As healthcare professionals increasingly work with large amounts of clinical information, these [read full press release...] ———————————————————————————————————————————————————————————— SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation 2026-08-24 · GlobeNewswire · Finance, Healthcare, Real Estate https://www.globenewswire.com/news-release/2026/08/24/3349741/0/en/scisparc-neurothera-clearmind-collaboration-advances-mdma-n-acylethanolamines-ip-for-the-treatment-of-ptsd-amid-rising-u-s-federal-support-for-psychedelic-innovation.html U.S. publication of a patent application covering the MDMA-N-acylethanolamines combination expands intellectual property generated through the collaboration, and provides guidance addressing clinical development considerations for psychedelic drugs, including MDMA ———————————————————————————————————————————————————————————— GeoVax Applauds Clinical Validation of Combination Immunotherapy Strategies 2026-08-24 · NewMediaWire · Finance, Healthcare https://www.newmediawire.com/news/geovax-applauds-clinical-validation-of-combination-immunotherapy-strategies-7088833 Moderna-Merck Positive Phase 3 Combination Results Reinforce Strategic Rationale for Planned Gedeptin® + KEYTRUDA® Study ATLANTA, GA - August 24, 2026 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and solid tumors, today highlighted positive Phase 3 results reported by Moderna and Merck evaluating intismeran autogene, an individualized neoantigen therapy, in combination with KEYTRUDA® (pembrolizumab) as further evidence of an important evolution in cancer immunotherapy directly relevant to GeoVax's Gedeptin development strategy: combining checkpoint inhibition with complementary approaches designed to generate or enhance anti-tumor immune responses. Moderna-Merck reported that the ———————————————————————————————————————————————————————————— Presidio Property Trust Extends Largest Tenant Lease 2026-08-24 · PR-Inside · Finance, Healthcare, Real Estate, Education https://pr-inside.com/presidio-property-trust-extends-largest-tenant-lease-r5215546.htm (PR-inside.com) Presidio Property Trust Extends Largest Tenant Lease SAN DIEGO, CA / ACCESS Newswire / August 24, 2026 / (NASDAQ:SQFT)(NASDAQ:SQFTP)(NASDAQ:SQFTW) Presidio Property Trust, Inc. ("Presidio" or the "Company"), an internally managed, diversified real estate investment trust ("REIT") announced that on August 20, 2026, we completed the five year lease extension of our largest tenant, Johns Hopkins University (on behalf of the Bloomberg School of Public Health), at our Baltimore property. Johns Hopkins University occupies all 31,752 square feet of the Baltimore property and the extension extends the term to December 31, 2031. "We are excited to retain this long standing tenant and are .. ———————————————————————————————————————————————————————————— BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval 2026-08-24 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/24/3349723/0/en/biocardia-announces-fda-confirms-helix-transendocardial-delivery-catheter-meeting-minutes-supporting-follow-on-de-novo-pre-submission-for-approval.html SUNNYVALE, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces receipt of FDA confirmation of the outcome of its Pre-Submission Meeting on the Helix Transendocardial Delivery Catheter System (Helix). ———————————————————————————————————————————————————————————— CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy 2026-08-24 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/24/3349722/0/en/cvrx-announces-devoted-health-medicare-advantage-coverage-policy-for-barostim-therapy.html MINNEAPOLIS, Aug. 24, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Devoted Health has issued a Medicare Advantage coverage policy for Barostim therapy, effective July 17, 2026. Devoted Health, a national health insurance company with the eighth largest Medicare Advantage enrollment in the U.S., provides coverage to approximately 466,000 Medicare Advantage members across 29 states. ———————————————————————————————————————————————————————————— Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026 2026-08-24 · mlpr-prnewswire-wire · Finance, Healthcare https://www.prnewswire.com/news-releases/edgewise-therapeutics-announces-upcoming-late-breaking-science-presentation-at-the-european-society-of-cardiology-esc-congress-2026-302857842.html – Presentation highlights positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) – BOULDER, Colo., Aug. 24, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage... ———————————————————————————————————————————————————————————— Ideal Option Releases 2025 Patient Outcomes Annual Report, Highlighting Life-Saving Impact Amid Idaho's Ongoing Opioid Crisis 2026-08-24 · PRWeb · Healthcare https://www.prweb.com/releases/ideal-option-releases-2025-patient-outcomes-annual-report-highlighting-life-saving-impact-amid-idahos-ongoing-opioid-crisis-302845857.html New data show 95% opioid abstinence rates among long-term patients as statewide overdose deaths begin to decline. BOISE, Idaho, Aug. 24, 2026 /PRNewswire-PRWeb/ -- Ideal Option, a national leader in outpatient medication-assisted treatment (MAT) for addiction to opioids, stimulants and... ———————————————————————————————————————————————————————————— Tom Orr Joins Avista Healthcare Partners as a Strategic Executive 2026-08-24 · mlpr-prnewswire-wire · Healthcare https://www.prnewswire.com/news-releases/tom-orr-joins-avista-healthcare-partners-as-a-strategic-executive-302858245.html NEW YORK, Aug. 24, 2026 /PRNewswire/ -- Avista Healthcare Partners ("Avista"), a leading private equity firm focused exclusively on healthcare, today announced that Tom Orr, a leader with deep expertise in medical device contract manufacturing, injection molding, and highly regulated... ———————————————————————————————————————————————————————————— QurAlis to Participate in Upcoming Investor Conferences in September 2026-08-24 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/quralis-participate-upcoming-investor-conferences-114500620.html CAMBRIDGE, Mass., August 24, 2026--QurAlis Corporation, a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced that Kasper Roet, Ph.D., CEO and co-founder, will participate at the following investor conferences in September. Management will also participate in one-on-one investor meetings. ———————————————————————————————————————————————————————————— AI Platform for Clinical Conversations Market: How Big Tech and EHR Giants Are Reshaping the Competition 2026-08-24 · Express Press Release · AI, SaaS, Healthcare https://express-press-release.net/news/2026/08/24/1769040 Walk into almost any exam room today, and you’ll likely find a new, quiet presence in the corner: an AI assistant listening in, turning the [read full press release...] ———————————————————————————————————————————————————————————— Black Book Announces 2026 Converged Clinical AI Platform Category and ... 2026-08-24 · PR-Inside · Finance, AI, SaaS, Healthcare https://pr-inside.com/black-book-announces-2026-converged-clinical-ai-platform-category-and-r5215514.htm (PR-inside.com) Regard, Ambience Healthcare, SmarterDx, Solventum, Waystar/Iodine and Navina ranked in new assessment of EHR-integrated clinical diagnosis, documentation and revenue-intelligence platforms CHICAGO, IL / ACCESS Newswire / August 24, 2026 / Black Book Research today announced a new healthcare technology category with the publication ofThe Converged Clinical AI Layer: EHR-Integrated Clinical Diagnosis, Documentation and Revenue Intelligence Platforms - 2026 Market Assessment and 2027 Outlook . The independent report evaluates a developing class of enterprise platforms that combine longitudinal patient-record intelligence, diagnosis support, clinical documentation, evidence traceability, coding integrity, risk adjustment, denial prevention and EHR-integrated workflow execution. ———————————————————————————————————————————————————————————— Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share 2026-08-24 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/24/3349641/14025/en/arbutus-commences-us-230-million-modified-dutch-auction-tender-offer-of-its-common-shares-at-a-price-not-greater-than-us-5-75-nor-less-than-us-5-00-per-share.html WARMINSTER, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the commencement of a modified “Dutch Auction” tender offer to purchase for cancellation up to US$230 million in value of its common shares (the “Shares”) at a price of not less than US$5.00 and not more than US $5.75 per Share, less any applicable withholding taxes and without interest, on the terms and subject to the conditions described in the offer to purchase and accompanying issuer bid circular, dated August 24, 2026 (the “Offer to Purchase and Bid Circular”), the Letter of Transmittal (the “Letter of Transmittal”) and Notice of Guaranteed Delivery (the “Notice of Guarant ———————————————————————————————————————————————————————————— Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress 2026-08-24 · mlpr-businesswire · Finance, Healthcare https://finance.yahoo.com/healthcare/articles/arrowhead-pharmaceuticals-present-clinical-data-113000125.html PASADENA, Calif., August 24, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will present important new data at the European Society of Cardiology Congress (ESC) in Munich, Germany. ———————————————————————————————————————————————————————————— Black Book Announces 2026 Converged Clinical AI Platform Category and Market Assessment 2026-08-24 · Newswire.com · Finance, AI, SaaS, Healthcare https://www.newswire.com/news/black-book-announces-2026-converged-clinical-ai-platform-category-and-market Regard, Ambience Healthcare, SmarterDx, Solventum, Waystar/Iodine and Navina ranked in new assessment of EHR-integrated clinical diagnosis, documentation and revenue-intelligence platforms ———————————————————————————————————————————————————————————— BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™ 2026-08-24 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/24/3349644/0/en/briacell-advances-personalized-melanoma-immunotherapy-vaccine-candidate-bria-mel.html PHILADELPHIA and VANCOUVER, British Columbia, Aug. 24, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that Bria-MEL+, its personalized whole cell melanoma immunotherapy vaccine candidate, has achieved a key genetic engineering milestone, advancing the program toward clinical development. ———————————————————————————————————————————————————————————— BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026 2026-08-24 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/24/3349646/0/en/bridgebio-to-present-new-acoramidis-data-from-open-label-extension-analyses-in-attr-cm-at-esc-congress-2026.html PALO ALTO, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that two oral presentations and three posters on new acoramidis data in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM) will be shared at the European Society of Cardiology (ESC) Congress 2026, taking place in Munich, Germany on August 28-31, 2026. The data will further strengthen the differentiated clinical profile of acoramidis, reinforcing it as the first-line treatment of choice for individuals with ATTR-CM. Acoramidis is the only selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer. ———————————————————————————————————————————————————————————— Harvest Declares Big Pharma Split Corp. August 2026 Distributions 2026-08-24 · mlpr-businesswire · Healthcare https://finance.yahoo.com/markets/stocks/articles/harvest-declares-big-pharma-split-113000483.html OAKVILLE, Ontario, August 24, 2026--Harvest Portfolios Group Inc. ("Harvest") declares the monthly cash distribution payable for Big Pharma Split Corp. of $0.1031 for each class A share (PRM:TSX) for the month ending August 31, 2026. ———————————————————————————————————————————————————————————— Vector Science & Therapeutics (TSXV: PAIN) Begins Peptide Production as First Suite at LyoGenesis Manufacturing Comes Online 2026-08-24 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/vector-science--therapeutics-tsxv-pain-begins-peptide-production-as-first-suite-at-lyogenesis-manufacturing-comes-online-302857980.html 55,000 vials of peptides will be produced from this production suite and are pre-sold Milestone facility meets cGMP, FDA, and ISO quality standards on schedule; remaining three suites to launch in September MEQUON, Wis., Aug. 24, 2026 /PRNewswire/ -- Vector Science & Therapeutics Corp.... ———————————————————————————————————————————————————————————— Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology 2026-08-24 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/quest-diagnostics-to-offer-fda-cleared-roche-ptau217-blood-test-to-assess-alzheimers-disease-pathology-302858247.html Test to join the company's expansive portfolio of Quest AD-Detect® blood tests for assessing symptomatic patients Quest also launching a new multi-biomarker AD-Detect® lab-developed blood test with low 10% indeterminate rate, so more patients can receive an actionable insight SECAUCUS,... ———————————————————————————————————————————————————————————— AURORA CANNABIS CORRECTS INACCURATE STATEMENTS MADE IN SUPPORT OF CURALEAF HOLDINGS' HOSTILE BID 2026-08-24 · PR Newswire · Finance, Healthcare https://www.prnewswire.com/news-releases/aurora-cannabis-corrects-inaccurate-statements-made-in-support-of-curaleaf-holdings-hostile-bid-302858032.html Curaleaf's self-serving portrayal of our business is an attempt to acquire Aurora's world class EU-GMP manufacturing facilities and global medical cannabis footprint at the lowest price possible Aurora's international strategy is working; net revenue is up 17%YOY Contrary to Curaleaf's... ———————————————————————————————————————————————————————————— Pomerantz LLP Announces Class Action Litigation Filing Against Fractyl ... 2026-08-24 · PR-Inside · Finance, Healthcare https://pr-inside.com/pomerantz-llp-announces-class-action-litigation-filing-against-fractyl-r5215508.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 24, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Fractyl Health, Inc. ("Fractyl" or the "Company") (NASDAQ:GUTS) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 26-cv-07167, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fractyl securities between January 13, 2025 and January 29, 2026, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations .. ———————————————————————————————————————————————————————————— Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer 2026-08-24 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/24/3349601/0/en/monte-rosa-therapeutics-announces-first-patient-dosed-in-modefire-1-a-phase-2-study-of-mrt-2359-in-combination-with-apalutamide-in-patients-with-ar-mutation-positive-metastatic-cas.html Monte Rosa FPD in MODeFIRe-1, a P2 Study of MRT-2359 in Combo w/ Apalutamide in Patients w/ AR Mutation-Positive Metastatic Castration-Resistant Cancer ———————————————————————————————————————————————————————————— Myocardial Solutions Expands Access to MyoStrain® Through New Advanced Heart Health Scan with Prenuvo 2026-08-24 · PRWeb · Healthcare https://www.prweb.com/releases/myocardial-solutions-expands-access-to-myostrain-through-new-advanced-heart-health-scan-with-prenuvo-302857081.html New offering adds regional myocardial strain measurement and MyoHealth® Scores to the Advanced Heart Health Scan, now available at 17 U.S. Prenuvo clinics. The Advanced Heart Health Scan is available in eligible Prenuvo Executive Memberships or as a standalone screening. RESEARCH TRIANGLE... ———————————————————————————————————————————————————————————— TwinStrand Biosciences Announces Final Judgment in Patent Infringement Suit Against Guardant Health, Awarding TwinStrand and the University of Washington More Than $245.2 Million in Damages, Accrued Royalties and Interest 2026-08-24 · mlpr-businesswire · Healthcare, Education https://finance.yahoo.com/healthcare/articles/twinstrand-biosciences-announces-final-judgment-110000950.html SEATTLE, August 24, 2026--TwinStrand Biosciences (TwinStrand), the pioneer in Duplex Sequencing® technology, today announced that the U.S. District Court for the District of Delaware entered final judgment on Aug. 21, 2026, in favor of TwinStrand and the University of Washington (UW) in their patent infringement suit against Guardant Health, Inc. ———————————————————————————————————————————————————————————— United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension 2026-08-24 · mlpr-businesswire · Finance, Healthcare https://finance.yahoo.com/healthcare/articles/united-therapeutics-corporation-announces-fda-110000004.html SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., August 24, 2026--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the New Drug Application (NDA) for ralinepag to treat PAH. The FDA has set a Prescription Drug User Fee Act target action date of June 24, 2027. ———————————————————————————————————————————————————————————— “Declutter Your Home, Declutter Your Life” Is Free to Download for Only Five Days (Until 8/28/26) 2026-08-24 · WebWire · Healthcare, Energy, Retail https://www.webwire.com/ViewPressRel.asp?aId=359241 Best Seller Publishing announces the release of Michele Rase's new book, “Declutter Your Home, Declutter Your Life.” It will be available in the Amazon store for free for only five days. - - “Declutter Your Home, Declutter Your Life” is about creating a home that gives you energy instead of quietly draining it. Life and Health Coach Michele Rase explores how clutter can create emotional and mental noise, especially when tied to memories, guilt, unfinished decisions, or past identitie... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=359241 ———————————————————————————————————————————————————————————— Recent Release, "A Distant Rainbow," from Newman Springs Publishing Author Kathleen Kearns, Explores Loss, Redemption, and Hope Through Interconnected Experiences 2026-08-24 · PR.com · Healthcare https://www.pr.com/press-release/976626 Kathleen Kearns has completed a new book, "A Distant Rainbow," an autobiographical short story that intertwines her professional calling with profound personal trials. The narrative follows her journey alongside some of the earliest AIDS patients during a transformative period in medical and social history, while simultaneously grappling with her sister's devastating cancer diagnosis. Through these interwoven [PR.com] ———————————————————————————————————————————————————————————— PCB Technologies Announces Winning of a USD 65 Million Tender for the Supply of Medical PCB Assembly Products in 2027-2028 2026-08-24 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/pcb-technologies-announces-winning-of-a-usd-65-million-tender-for-the-supply-of-medical-pcb-assembly-products-in-2027-2028-302858131.html MIGDAL HAEMEK, Israel, Aug. 24, 2026 /PRNewswire/ -- PCB Technologies (TASE: PCBT), a global leader in advanced electronic and PCB manufacturing solutions, is pleased to announce that on August 23, 2026, it was awarded a tender for the supply of electronic packaging products in 2027-2028... ———————————————————————————————————————————————————————————— Rising Tick-Borne Infections Acceleration in the Global Lyme Disease Market 2026-08-24 · Express Press Release · Healthcare https://express-press-release.net/news/2026/08/24/1769005 Tick-borne infections are no longer restricted to traditional endemics. Driven by shifting climate patterns, expanding vector habitats, and rising public health awareness, the Lyme Disease [read full press release...] ———————————————————————————————————————————————————————————— Girl Power USA Launches Period Power to Address Period Poverty Through Community-Led Solutions 2026-08-24 · PRUnderground · Healthcare, Education https://prunderground.com/girl-power-usa-launches-period-power-to-address-period-poverty-through-community/cmt2wrrxm000004jrj6cps47t Initiative unites menstrual health education, reusable pad production, skills training, and economic opportunity for girls and women in Uganda and Kenya The post Girl Power USA Launches Period Power to Address Period Poverty Through Community-Led Solutions first appeared on ———————————————————————————————————————————————————————————— First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis 2026-08-24 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/24/3349490/0/en/first-patient-treated-in-pioneer-1-registrational-trial-of-privosegtor-for-optic-neuritis.html The PIONEER program marks a key step toward potential first-in-class neuroprotection for optic neuritis and other neurological diseases, supported by positive Acuity Phase 2 data, FDA Breakthrough Therapy and EMA PRIME designations, and recent positive feedback from the FDA Neurology Division. The PIONEER program marks a key step toward potential first-in-class neuroprotection for optic neuritis and other neurological diseases, supported by positive Acuity Phase 2 data, FDA Breakthrough Therapy and EMA PRIME designations, and recent positive feedback from the FDA Neurology Division. ———————————————————————————————————————————————————————————— AI in Cardiology Market: The 31.2% Growth Story Behind the Next Healthcare AI Revolution 2026-08-24 · Express Press Release · AI, Healthcare https://express-press-release.net/news/2026/08/24/1768978 AI in Cardiology Market Size and Growth Forecast The AI in cardiology market reached USD 1.7 billion in 2025 and is estimated to grow to USD 2.2 [read full press release...] ———————————————————————————————————————————————————————————— ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 2026-08-24 · mlpr-businesswire · Finance, Healthcare https://finance.yahoo.com/healthcare/articles/orzeyful-oveporexton-approved-japan-first-063600489.html OSAKA, Japan & CAMBRIDGE, Mass., August 24, 2026--Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine or ———————————————————————————————————————————————————————————— AI In Life Science Analytics Market: How Generative AI Is Changing Pharmaceutical Decision-Making 2026-08-24 · Express Press Release · AI, Healthcare https://express-press-release.net/news/2026/08/24/1768948 The AI in life science analytics market is valued at roughly USD 1.9 billion in 2024 and is projected to reach USD 4.8 billion by 2033, expanding [read full press release...] ———————————————————————————————————————————————————————————— Vicore Pharma to Present at the European Respiratory Society Congress ... 2026-08-24 · PR-Inside · Finance, Healthcare https://pr-inside.com/vicore-pharma-to-present-at-the-european-respiratory-society-congress-r5215433.htm (PR-inside.com) STOCKHOLM, SE / ACCESS Newswire / August 24, 2026 / Vicore Pharma Holding AB (NASDAQ Stockholm:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists, today announced that the company will participate in the European Respiratory Society (ERS) Congress 2026, taking place in Barcelona, Spain and online September 5-9, 2026. Vicore will present new data on the design and baseline characteristics of patients enrolled in the global Phase 2b ASPIRE trial in buloxibutid, the company's lead program in idiopathic pulmonary fibrosis (IPF), along with translational findings on AT2 receptor activation in .. ———————————————————————————————————————————————————————————— TME Pharma fait le point sur ses activités 2026-08-24 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/08/24/3349468/0/fr/tme-pharma-fait-le-point-sur-ses-activit%C3%A9s.html TME Pharma entre en phase finale avec deux partenaires pour la licence du NOX-A12 et le développement de Phase 2 dans le glioblastome. ———————————————————————————————————————————————————————————— TME Pharma provides update on its activities 2026-08-24 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/08/24/3349468/0/en/tme-pharma-provides-update-on-its-activities.html TME Pharma enters final evaluation phase with two potential partners for licensing lead asset NOX-A12 to support Phase 2 glioblastoma development ———————————————————————————————————————————————————————————— Kirkland Minoxidil vs. Rogaine: Consumer Interest in Hair Regrowth ... 2026-08-24 · PR-Inside · Healthcare, Retail https://pr-inside.com/kirkland-minoxidil-vs-rogaine-consumer-interest-in-hair-regrowth-r5215428.htm (PR-inside.com) BURNABY, BC / ACCESS Newswire / August 24, 2026 / As consumer awareness of hair loss treatments continues to grow, interest in over-the-counter hair regrowth solutions has reached new levels across North America. Online search trends indicate that more consumers are actively researching treatment options, comparing brands, and seeking evidence-based information about hair regrowth products. Hair loss affects millions of men and women worldwide, making it one of the most common appearance-related concerns. With greater access to information and e-commerce platforms, consumers are increasingly evaluating treatment options based on clinical research, convenience, product format, and overall value. Among the most frequently compared .. ———————————————————————————————————————————————————————————— Pulnovo Medical Announces First Two U.S. Patients Enrolled in PULSE-LHD IDE Clinical Trial of Pulmonary Artery Denervation in Treating Pulmonary Hypertension Associated with Left Heart Disease 2026-08-24 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/pulnovo-medical-announces-first-two-us-patients-enrolled-in-pulse-lhd-ide-clinical-trial-of-pulmonary-artery-denervation-in-treating-pulmonary-hypertension-associated-with-left-heart-disease-302857962.html NEW YORK, Aug. 23, 2026 /PRNewswire/ -- Pulnovo Medical, a globally recognized pioneer in medical devices for pulmonary hypertension (PH) and heart failure (HF), today announced the enrollment of the first two patients in its PULSE-LHD clinical trial, conducted under a U.S. Food and Drug... ———————————————————————————————————————————————————————————— Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D 2026-08-24 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/antengene-announces-2026-interim-results-achieves-firstever-profitability-and-accelerates-value-creation-through-innovative-rd-302857795.html SHANGHAI and HONG KONG, Aug. 23, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for... ———————————————————————————————————————————————————————————— Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion 2026-08-24 · PR Newswire · Healthcare, Education https://www.prnewswire.com/news-releases/anbogen-therapeutics-and-the-university-of-tokyo-enter-collaborative-research-agreement-to-evaluate-abt-301-across-multiple-tumor-types-targeting-accelerated-human-clinical-indication-expansion-302857360.html TAIPEI, Aug. 23, 2026 /PRNewswire/ -- Anbogen Therapeutics Inc. (TPEx: 7784) ("Anbogen" or the "Company"), a clinical-stage precision oncology company, today announced that it has entered into a Collaborative Research Agreement (CRA) with the Laboratory of Veterinary Surgery, Graduate... ———————————————————————————————————————————————————————————— InterSystems Asia READY 2026 to Showcase AI-Ready Healthcare 2026-08-24 · mlpr-businesswire · AI, Healthcare https://finance.yahoo.com/healthcare/articles/intersystems-asia-ready-2026-showcase-000000243.html BANGKOK, August 24, 2026--InterSystems, a creative data technology provider managing over one billion healthcare records globally, will bring healthcare leaders from across Asia to Bangkok for InterSystems Asia READY 2026, where the focus will be on how trusted data, interoperability, and practical artificial intelligence (AI) can accelerate smarter healthcare delivery and strengthen Thailand's position as a regional medical hub. ———————————————————————————————————————————————————————————— Shape Memory Medical Secures $10 Million Financing Led by August Global Partners to Advance Aortic Clinical Programs 2026-08-24 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/shape-memory-medical-secures-10-000000006.html SAN JOSE, Calif., August 24, 2026--Shape Memory Medical Inc., developer of proprietary shape memory polymer technology for endovascular embolization, today announced the closing of a $10 million convertible note financing led by new investor August Global Partners (AGP), joined by fellow new investor Taiwania Capital. ———————————————————————————————————————————————————————————— Novotech Strengthens Presence in Japan with Opening of Tokyo Office 2026-08-23 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/novotech-strengthens-presence-japan-opening-230100624.html SINGAPORE, August 23, 2026--Novotech, a leading global biotech full service CRO, has strengthened its established presence in Japan with the opening of a new office in Tokyo. ———————————————————————————————————————————————————————————— Pomerantz LLP Announces Class Action Litigation Against Fractyl Health, ... 2026-08-23 · PR-Inside · Finance, Healthcare https://pr-inside.com/pomerantz-llp-announces-class-action-litigation-against-fractyl-health-r5215213.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 23, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Fractyl Health, Inc. ("Fractyl" or the "Company") (NASDAQ:GUTS) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 26-cv-07167, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fractyl securities between January 13, 2025 and January 29, 2026, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations .. ———————————————————————————————————————————————————————————— Pastors worldwide unite for freedom of religion and expression 2026-08-23 · Pressat · Healthcare https://pressat.co.uk/releases/pastors-worldwide-unite-for-freedom-of-religion-and-expression-7aed728a38e23e765b59240241c8000f/ Sunday 23 August, 2026 Seven Christian organisations from South Korea and abroad host the first Joint Assembly of World Pastors, with speakers from Russia and Zambia raising concerns about due process and religious freedom in the Republic of Korea. SEOUL, South Korea, August 13th. Seven Christian organisations from South Korea and abroad, including the Council for Christian Mutual Growth, the Korea Christian Leaders Training Institute, the Pastors Alliance for Life and Human Rights, the Russian Evangelical Alliance and the Thai Evangelical Alliance Association, held the first Joint Assembly of World Pastors. The event brought together an estimated 3,000 pastors from countries around the world, attending in person and online, to discuss the state of religious freedom and the principle of se ———————————————————————————————————————————————————————————— 6 Tips to Practice Yoga in Your Busy Daily Schedule 2026-08-23 · PressReleaseNews · Healthcare https://pressreleasenews.org/pressroom/6-tips-to-practice-yoga-in-your-busy-daily-schedule This press release offers six practical tips for incorporating yoga into a busy daily schedule, emphasizing consistency over duration. Techniques include morning Sun Salutations, quick stretches during work breaks, mindful breathing, short home practices, staying active throughout the day, and winding down with Yoga Nidra. ———————————————————————————————————————————————————————————— Why Patients Are Choosing Surgeon-Led and founder led Dental Implant Care Over Corporate Dentistry 2026-08-23 · PRWeb · Healthcare https://www.prweb.com/releases/why-patients-are-choosing-surgeon-led-and-founder-led-dental-implant-care-over-corporate-dentistry-302857070.html Patient like one on one and personalized care from their doctors. CHICAGO, Aug. 22, 2026 /PRNewswire-PRWeb/ -- When it comes to full mouth dental implants, many patients are looking for more than convenience. They're looking for experience, personalized care, and confidence that they're... ———————————————————————————————————————————————————————————— Lahore Singer Drops Four A Cappella Tracks Born from Hospital Vigil 2026-08-23 · PressReleaseNews · Healthcare, Media https://pressreleasenews.org/pressroom/lahore-singer-drops-four-a-cappella-tracks-born-from-hospital-vigil Lahore artist Omar Rashid (OR) MRX releases four a cappella tracks born from a hospital vigil, now streaming worldwide without autotune or instruments. ———————————————————————————————————————————————————————————— Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate 2026-08-23 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/08/23/3349402/0/en/orum-therapeutics-announces-u-s-fda-clearance-of-an-ind-application-for-orm-1153-a-novel-cd123-gspt1-degrader-antibody-conjugate.html Orum receives FDA clearance for ORM-1153, advancing its novel CD123-GSPT1 degrader-antibody conjugate toward Phase 1 in hematologic malignancies. ———————————————————————————————————————————————————————————— The Games DEA Attorneys Play: What Marijuana Rescheduling Closing Brief ... 2026-08-22 · PR-Inside · Healthcare https://pr-inside.com/the-games-dea-attorneys-play-what-marijuana-rescheduling-closing-brief-r5215035.htm (PR-inside.com) DEA attorneys told the marijuana rescheduling ALJ judge to give the other side's experts "little to no weight." It never told him what its own DEA and FDA two scientists said under oath. WASHINGTON, D.C. / ACCESS Newswire / August 22, 2026 / The post-hearing briefs in DEA's marijuana rescheduling proceeding are now public. MMJ International Holdings, Inc. ("MMJ") read the Government's 50-page closing argument against the seven briefs filed by the opposing parties. The Government attacked nearly every witness the other side called. It said almost nothing about its own. Thirty-one citations and one Dr. Dominic Chiapperino is the FDA official who supervised the .. ———————————————————————————————————————————————————————————— The Games DEA Attorneys Play: What Marijuana Rescheduling Closing Brief Didn't Tell Judge Julius 2026-08-22 · Newswire.com · Healthcare https://www.newswire.com/news/the-games-dea-attorneys-play-what-marijuana-rescheduling-closing-brief-22849278 DEA attorneys told the marijuana rescheduling ALJ judge to give the other side's experts "little to no weight." It never told him what its own DEA and FDA two scientists said under oath.   ———————————————————————————————————————————————————————————— Patient Engagement Solutions Market Growth Supported by Healthcare Digitalization 2026-08-22 · Express Press Release · Healthcare https://express-press-release.net/news/2026/08/22/1768907 The global Patient Engagement Solutions Market was valued at USD 28.0 billion in 2025 and is projected to reach USD 126.2 billion by 2033, expanding at a 20.7% CAGR from 2026 [read full press release...] ———————————————————————————————————————————————————————————— Pomerantz LLP Announces Class Action Lawsuit Filing Against Fractyl ... 2026-08-22 · PR-Inside · Finance, Healthcare https://pr-inside.com/pomerantz-llp-announces-class-action-lawsuit-filing-against-fractyl-r5215032.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 22, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Fractyl Health, Inc. ("Fractyl" or the "Company") (NASDAQ:GUTS) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 26-cv-07167, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fractyl securities between January 13, 2025 and January 29, 2026, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations .. ———————————————————————————————————————————————————————————— Dr. Albert H. Yurvati Reflects on a Lifetime of Service and Resilience in “30 Degrees on Bypass” 2026-08-22 · WebWire · Healthcare, Education https://www.webwire.com/ViewPressRel.asp?aId=359316 Dr. Albert H. Yurvati, a distinguished cardiothoracic surgeon, medical educator, researcher, and Emeritus Professor at the University of North Texas Health Science Center's Texas College of Osteopathic Medicine, reflects on a lifetime dedicated to medicine, education, service, and family in his memoir, “30 Degrees on Bypass.” - - For decades, Albert H. Yurvati, DO, PhD, DSc(hc), DFACOS, FACOS, FICS, FAHA, cared for patients facing critical medical conditions, trained future physicians,... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=359316 ———————————————————————————————————————————————————————————— AANA Launches Anesthesia Answers, a Patient Education Resource Built by CRNAs/Nurse Anesthesiologists 2026-08-22 · PR Newswire · Healthcare, Education https://www.prnewswire.com/news-releases/aana-launches-anesthesia-answers-a-patient-education-resource-built-by-crnasnurse-anesthesiologists-302854979.html ROSEMONT, Ill., Aug. 22, 2026 /PRNewswire/ -- The American Association of Nurse Anesthesiology (AANA) today announced the launch of Anesthesia Answers, a new patient education resource created by Certified Registered Nurse Anesthetists (CRNAs)/nurse anesthesiologists to help patients and... ———————————————————————————————————————————————————————————— Asia Pacific: Fastest-Growing Patient Access Solutions Market 2026-08-22 · Express Press Release · Healthcare https://express-press-release.net/news/2026/08/22/1768866 Healthcare’s “front door” is getting a technology overhaul. Every appointment booked, insurance card scanned, and prior authorization submitted is part of what the industry calls [read full press release...] ———————————————————————————————————————————————————————————— Real World Evidence Solutions Market Size Worth $3.3B in 2026 2026-08-22 · Express Press Release · Healthcare https://express-press-release.net/news/2026/08/22/1768864 Healthcare decision-making is undergoing a quiet but profound shift. Clinical trials alone no longer tell the full story of how a drug or device performs [read full press release...] ———————————————————————————————————————————————————————————— AI in Neurology Market Trends Transforming Brain Disease Diagnosis 2026-08-22 · Express Press Release · AI, Healthcare https://express-press-release.net/news/2026/08/22/1768850 Artificial intelligence is becoming increasingly integrated into neurological care, particularly in medical imaging, clinical decision support, disease monitoring, and precision medicine. The growing prevalence of [read full press release...] ———————————————————————————————————————————————————————————— Healthcare Data Technology Market: Challenges in Privacy and Compliance 2026-08-22 · Express Press Release · Healthcare https://express-press-release.net/news/2026/08/22/1768859 Healthcare organizations are sitting on more data than ever before — electronic health records, connected devices, claims, imaging, and real-world evidence — and the race [read full press release...] ———————————————————————————————————————————————————————————— Edge Computing In Healthcare Market: North America Leads the Way 2026-08-22 · Express Press Release · Healthcare https://express-press-release.net/news/2026/08/22/1768854 Hospitals and clinics generate an enormous, constant stream of patient data — from bedside monitors and imaging scanners to wearables and infusion pumps. Sending all [read full press release...] ———————————————————————————————————————————————————————————— Healthcare Information System Market Trends Shaping Digital Care Delivery 2026-08-22 · Express Press Release · Healthcare https://express-press-release.net/news/2026/08/22/1768844 The global healthcare information system market is entering a period of rapid expansion as healthcare providers accelerate digital transformation, adopt connected care models, and modernize clinical and [read full press release...] ———————————————————————————————————————————————————————————— Benchmark International Successfully Facilitated the Transaction Between National Group Marketing Trust and New Era Life Insurance Companies 2026-08-22 · PR.com · Finance, Healthcare https://www.pr.com/press-release/977002 Benchmark International is pleased to announce the successful completion of the acquisition of the book of business of National Group Marketing Trust (NGM), a Dallas-area insurance marketing organization, by New Era Life Insurance Companies, a Houston-based provider of healthcare and insurance solutions. Founded in 1998, National Group Marketing specializes in health, life, income protection and ancillary insurance [PR.com] ———————————————————————————————————————————————————————————— Cell Culture Vessels Market Trends Supporting Advanced Biomanufacturing 2026-08-22 · Express Press Release · Healthcare https://express-press-release.net/news/2026/08/22/1768838 The global cell culture vessels market is entering a period of strong expansion, supported by rising demand for biologics, growing cell-based research, and increasing clinical development activity. [read full press release...] ———————————————————————————————————————————————————————————— Vanta Announces Closing of First Tranche of Private Placement and Board ... 2026-08-22 · PR-Inside · Healthcare, Retail https://pr-inside.com/vanta-announces-closing-of-first-tranche-of-private-placement-and-board-r5214981.htm (PR-inside.com) VANCOUVER, BC / ACCESS Newswire / August 21, 2026 /Vanta Holdings Inc. (CSE:VNTA)(OTC:VNTXF)(FSE:7BC, WKN:A4205J) ("Vanta" or the "Company"), a consumer health sciences and longevity company focused on preventative wellness and healthspan extension, and parent of the Vanta premium longevity brand, announces that, further to itsnews releasedated May 29, 2026, the Company has closed the first tranche (the "First Tranche") of its previously announced non-brokered private placement (the "Private Placement"), through the issuance of 124,579 units of the Company (each, a "Unit") at a price of $1.00 per Unit, for aggregate gross proceeds of $124,579.42. Each Unit consists of one common .. ———————————————————————————————————————————————————————————— Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 2026-08-21 · mlpr-businesswire · Finance, Healthcare https://finance.yahoo.com/healthcare/articles/zura-bio-reports-inducement-grants-235700984.html HENDERSON, Nev., August 21, 2026--Zura Bio Limited (Nasdaq: ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported that on August 20, 2026, the Company granted inducement awards consisting of options to purchase up to 587,000 Class A Ordinary Shares (the "Options") to thirteen newly hired employees. These a ———————————————————————————————————————————————————————————— Pomerantz Law Firm Announces The Filing of a Class Action Against Fractyl ... 2026-08-21 · PR-Inside · Finance, Healthcare https://pr-inside.com/pomerantz-law-firm-announces-the-filing-of-a-class-action-against-fractyl-r5214950.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 21, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Fractyl Health, Inc. ("Fractyl" or the "Company") (NASDAQ:GUTS) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 26-cv-07167, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fractyl securities between January 13, 2025 and January 29, 2026, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations .. ———————————————————————————————————————————————————————————— Public Healthcare Companies Meet Institutional Investors at the 5th Annual ROTH Healthcare Opportunities Conference 2026-08-21 · NewMediaWire · Healthcare, Retail https://www.newmediawire.com/news/public-healthcare-companies-meet-institutional-investors-at-the-5th-annual-roth-healthcare-opportunities-conference-7088812 A Full Day of 25-Minute 1-on-1 and Small Group Meetings at The Metropolitan Club in New York City on September 29 Executives From Biotech, Life Science Tools and Diagnostics, and MedTech Companies, Alongside Themed Panels and a Keynote on Drug Value, Pricing and Coverage NEW YORK, NY - August 21, 2026 ( NEWMEDIAWIRE ) - B2i Digital, Inc. serves as Marketing Partner for the 5th Annual ROTH Healthcare Opportunities Conference, hosted by ROTH Capital Partners and held at The Metropolitan Club in New York City on Tuesday, September 29, 2026. B2i Digital supports the conference through digital marketing, its media network, social media, and company profiles. The 5th Annual ROTH Healthcare Opportunities Conference is a B2i Digital Featured Conference. ROTH built the program around time with mana ———————————————————————————————————————————————————————————— Regeneron Pharmaceuticals, Inc. Notice of September 14, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP Before Application Deadline 2026-08-21 · mlpr-newsfile · Finance, Healthcare https://www.newsfilecorp.com/release/310894/Regeneron-Pharmaceuticals-Inc.-Notice-of-September-14-2026-Application-Deadline-for-Class-Action-Lawsuit-Contact-Reed-Kathrein-at-Hagens-Berman-Sobol-Shapiro-LLP-Before-Application-Deadline San Francisco, California--(Newsfile Corp. - August 21, 2026) - Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma.The news that the trial failed drove the price of Regeneron shares sharply lower and, along with the severe market reaction ($11 billion market cap wipeout),... ———————————————————————————————————————————————————————————— Kaplan Fox & Kilsheimer LLP Alerts Investors of Hims & Hers Health, Inc. (HIMS) to an Investigation of Potential Securities Law Violations 2026-08-21 · mlpr-newsfile · Finance, Healthcare https://www.newsfilecorp.com/release/310866/Kaplan-Fox-Kilsheimer-LLP-Alerts-Investors-of-Hims-Hers-Health-Inc.-HIMS-to-an-Investigation-of-Potential-Securities-Law-Violations New York, New York--(Newsfile Corp. - August 21, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS).CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATIONIf you are a Hims & Hers investor and have suffered losses, or if you have information that could assist in the Hims & Hers investigation, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing... ———————————————————————————————————————————————————————————— Kairos Pharma Announces 1-for-7 Reverse Stock Split 2026-08-21 · mlpr-businesswire · Finance, Healthcare https://finance.yahoo.com/markets/stocks/articles/kairos-pharma-announces-1-7-203000330.html LOS ANGELES, August 21, 2026--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-7 (the "Reverse Stock Split"). The Reverse Stock Split is expected to become effective on September 1, 2026 at 12:01 a.m. ———————————————————————————————————————————————————————————— Cisneros Brothers Plumbing, Electrical, Heating & Air Responds to Apple Valley Septic Emergency After DIY Repair Goes Wrong 2026-08-21 · PRWeb · Healthcare, Real Estate https://www.prweb.com/releases/cisneros-brothers-plumbing-electrical-heating--air-responds-to-apple-valley-septic-emergency-after-diy-repair-goes-wrong-302856157.html High Desert home services company warns homeowners about the health, property and financial risks of attempting septic repairs without professional help APPLE VALLEY, Calif., Aug. 21, 2026 /PRNewswire-PRWeb/ -- A recent septic emergency in Apple Valley is serving as a warning to... ———————————————————————————————————————————————————————————— Armor Health Deploys ACE Geriatric Model of Care at Franklin County Ohio Correctional Facilities -- Believed to Be a First in Correctional Healthcare 2026-08-21 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/armor-health-deploys-ace-geriatric-model-of-care-at-franklin-county-ohio-correctional-facilities--believed-to-be-a-first-in-correctional-healthcare-302857523.html MIAMI, Aug. 21, 2026 /PRNewswire/ -- Armor Health (ArmorHealthcare.com), a leading national provider of comprehensive correctional healthcare, today announced the deployment of the Acute Care for Elders (ACE) model of care at the Franklin County Correctional Facilities, with plans to... ———————————————————————————————————————————————————————————— FDA Authorizes ZYN ULTRA Nicotine Pouches Following Scientific Review 2026-08-21 · mlpr-businesswire · Finance, Healthcare https://finance.yahoo.com/healthcare/articles/fda-authorizes-zyn-ultra-nicotine-191100420.html STAMFORD, CT, August 21, 2026--Philip Morris International Inc. (NYSE: PM) today announces that the U.S. Food and Drug Administration (FDA) issued Marketing Granted Orders to PMI’s U.S. ———————————————————————————————————————————————————————————— FDA Approves First Therapy for Patients aged 8 years and older with Glycogen Storage Disease Type Ia 2026-08-21 · WebWire · Healthcare https://www.webwire.com/ViewPressRel.asp?aId=359308 The U.S. Food and Drug Administration today issued an accelerated approval for Genglycos (pariglasgene brecaparvovec-opnr) to reduce daily cornstarch intake as an adjunct to nutritional management in adults and pediatric patients 8 years of age and older with glycogen storage disease type Ia (GSDIa), a rare, inherited genetic disorder caused by a deficiency of the enzyme glucose-6-phosphatase, which prevents the body from properly breaking down stored glycogen into glucose. Genglycos is th... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=359308 ———————————————————————————————————————————————————————————— dsm-firmenich initiates patent infringement litigation in China regarding production of Sclareol via biotechnology 2026-08-21 · WebWire · Healthcare https://www.webwire.com/ViewPressRel.asp?aId=359298 dsm-firmenich, innovators in nutrition, health, and beauty, has initiated patent infringement litigation before the Xiong'An New District Court of Hebei Province, China, against multiple Chinese entities, including a sclareol producer and a research institute. The legal petition alleges the unauthorized use of dsm-firmenich's patent for the production of sclareol - a valuable intermediate in the production of amber ingredients such as Ambrox® Super. dsm-firmenich requested that the Court o... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=359298 ———————————————————————————————————————————————————————————— Hundreds of health and nutrition facilities closed as Somalia's child crisis deepens 2026-08-21 · WebWire · Healthcare, Education https://www.webwire.com/ViewPressRel.asp?aId=359289 “In Somalia today, aid cuts are closing doors to healthcare, shutting down nutrition services, and pushing water, education and protection further out of reach. As ever, children are paying the price. - - “On the back of unprecedented cuts in humanitarian aid, 205 health and nutrition facilities have already closed. The impact on children has been immediate: in the first six months of this year, Somalia has seen a 32 per cent increase (from the same period last year) in children being admit... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=359289 ———————————————————————————————————————————————————————————— Memorial Hospital Miramar Earns Level III Maternal Levels of Care Designation from Joint Commission 2026-08-21 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/memorial-hospital-miramar-earns-level-iii-maternal-levels-of-care-designation-from-joint-commission-302857350.html HOLLYWOOD, Fla., Aug. 21, 2026 /PRNewswire/ -- Memorial Hospital Miramar is one of only two hospitals in South Florida that has been verified as a Level III Maternal Levels of Care designation by the Joint Commission, recognizing its ability to provide specialized care for mothers with... ———————————————————————————————————————————————————————————— Joint Statement from the American Society of Health-System Pharmacists (ASHP) and the American Pharmacists Association (APhA) 2026-08-21 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/joint-statement-from-the-american-society-of-health-system-pharmacists-ashp-and-the-american-pharmacists-association-apha-302857449.html BETHESDA, Md., Aug. 21, 2026 /PRNewswire/ -- ASHP and APhA are deeply saddened by the reported harm experienced by Glenda Dorton and by the devastating impact this event has had on her family and loved ones. We also recognize that other patients were reportedly harmed, and our thoughts... ———————————————————————————————————————————————————————————— Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering 2026-08-21 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/21/3349242/0/en/jupiter-neurosciences-announces-pricing-of-2-0-million-registered-direct-offering.html New York, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced it has entered into a securities purchase agreement for the purchase and sale of 307,692 shares of common stock in a registered direct offering. ———————————————————————————————————————————————————————————— DEA Has Published the Evidence Against Marijuana Rescheduling 2026-08-21 · PR-Inside · Healthcare https://pr-inside.com/dea-has-published-the-evidence-against-marijuana-rescheduling-r5214807.htm (PR-inside.com) As Judge Derek Julius prepares his recommendation and Dr. Heidi Overton awaits Senate confirmation, the federal government's own findings expose the contradiction between the AG's rescheduling order, state acceptance and pharmaceutical science. DEA Said Cannabis Labeling Is "Not Controlled and Often Significantly Inaccurate." The Next FDA Commissioner Inherits the Consequences. WASHINGTON, D.C. / ACCESS Newswire / August 21, 2026 / MMJ International Holdings, Inc. ("MMJ") today called on Dr. Heidi Overton, President Trump's nominee to serve as Commissioner of the U.S. Food and Drug Administration, to confront the widening divide between the scientific standards FDA imposes on investigational medicines and those applied .. ———————————————————————————————————————————————————————————— BIX 2026 to Spotlight the Future of Stem Cell and Global Biopharma M&A 2026-08-21 · PR.com · Healthcare https://www.pr.com/press-release/976434 BIX 2026 unveils keynotes on stem cell advances for nervous system diseases and global biopharma M&A trends, bringing together biotech leaders, investors, and researchers to drive collaboration and innovation. [PR.com] ———————————————————————————————————————————————————————————— Coordinated Care Brings Free Health Screenings to Washington Communities with Statewide Vision & Dental Van Tour 2026-08-21 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/coordinated-care-brings-free-health-screenings-to-washington-communities-with-statewide-vision--dental-van-tour-302856982.html Nine-day tour offers free vision and dental screenings to bolster access to critical health services in communities across the state. TACOMA, Wash., Aug. 21, 2026 /PRNewswire/ -- Today, Coordinated Care, Washington's trusted healthcare partner and wholly owned subsidiary of the Centene... ———————————————————————————————————————————————————————————— OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing ... 2026-08-21 · PR-Inside · Finance, Healthcare https://pr-inside.com/osr-health-preparing-our-appeal-advancing-our-catalysts-continuing-r5214803.htm (PR-inside.com) The Company details its Nasdaq hearing request, its $15 million Put Option, and continued development across its subsidiary pipeline BELLEVUE, WA / ACCESS Newswire / August 21, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today released the following letter from its Chief Executive Officer to shareholders. To OSR Health Shareholders: I am aware that many of you are watching closely to see what comes next. I want to address some of your concerns directly and with specificity. OSR Health's stock is showing resilience this morning after a difficult session yesterday. In our opinion, that resilience reflects something real: the conviction of shareholders who understand this .. ———————————————————————————————————————————————————————————— OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission 2026-08-21 · Newswire.com · Finance, Healthcare https://www.newswire.com/news/osr-health-preparing-our-appeal-advancing-our-catalysts-continuing-our-mission The Company details its Nasdaq hearing request, its $15 million Put Option, and continued development across its subsidiary pipeline   ———————————————————————————————————————————————————————————— Zakay Law Group, APLC Files a Class Action Against the Madera Community Hospital, Alleging Failure to Implement and Maintain Appropriate Security Measures, Causing Unauthorized Access to Sensitive Personal Information 2026-08-21 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/zakay-law-group-aplc-files-a-class-action-against-the-madera-community-hospital-alleging-failure-to-implement-and-maintain-appropriate-security-measures-causing-unauthorized-access-to-sensitive-personal-information-302856939.html The lawsuit alleges the Madera Community Hospital failed to implement the enhanced security measures necessary to protect from unauthorized access to personally identifying information and protected health information. MADERA, Calif., Aug. 21, 2026 /PRNewswire/ -- Zakay Law Group, APLC... ———————————————————————————————————————————————————————————— Segal Trials Reinforces Leadership in Acute Schizophrenia Research Following Participation in MapLight Therapeutics’ Phase 2 ZEPHYR Study 2026-08-21 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/segal-trials-reinforces-leadership-acute-153300446.html MIAMI LAKES, Fla., August 21, 2026--Segal Trials today announced its participation in the Phase 2 ZEPHYR clinical trial evaluating MapLight Therapeutics’ investigational muscarinic receptor-targeted therapy, ML-007C-MA, for the treatment of adults experiencing an acute exacerbation of schizophrenia. ———————————————————————————————————————————————————————————— HCN Global Expands Leadership for a Culture of Health Series Through New Partnership 2026-08-21 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/hcn-global-expands-leadership-for-a-culture-of-health-series-through-new-partnership-302857405.html Series Two, developed in partnership with the Society for Health Communication, focuses on preventive care, maternal health and community resilience WASHINGTON, Aug. 21, 2026 /PRNewswire/ -- HCN Global is expanding its Leadership for a Culture of Health webinars with a second series of... ———————————————————————————————————————————————————————————— Allies of Skin Celebrates the Launch of Peptint with an Exclusive Los Angeles Event Featuring Amber Mark 2026-08-21 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/allies-of-skin-celebrates-the-launch-of-peptint-with-an-exclusive-los-angeles-event-featuring-amber-mark-302857397.html The Sound Lounge at Revolve at The Grove Unveiled the Grammy-Nominated Singer-Songwriter as the Face of the Brand's New Peptint Campaign LOS ANGELES, Aug. 21, 2026 /PRNewswire/ -- Allies of Skin, the results-driven skincare brand known for its supercharged clinical formulas, celebrated... ———————————————————————————————————————————————————————————— Cunion Brings Reward-Based Health Engagement to the AI Wearables Market 2026-08-21 · PressReleaseNews · AI, Healthcare https://pressreleasenews.org/pressroom/cunion-brings-reward-based-health-engagement-to-the-ai-wearables-market ———————————————————————————————————————————————————————————— CharmHealth Introduces Ria, AI Solutions Advisor, to Speed Up Health IT Evaluation for Provider Organizations 2026-08-21 · mlpr-businesswire · AI, Healthcare https://finance.yahoo.com/healthcare/articles/charmhealth-introduces-ria-ai-solutions-141200830.html PLEASANTON, Calif., August 21, 2026--CharmHealth website visitors can start a conversation with AI solutions advisor Ria to run product demos, answer pricing, billing & setup questions. ———————————————————————————————————————————————————————————— New Cancer Center at Intermountain Health Park City Hospital Expands Access to World Class Treatment 2026-08-21 · PRUnderground · Healthcare https://prunderground.com/new-cancer-center-at-intermountain-health-park-city-hospital-expands-access-to-w/cmt2ynqfe000004jrjr0gzmtv Intermountain Health Park City Hospital opens new Cancer Center, bringing world-class cancer care to communities throughout the Wasatch Back and beyond The post New Cancer Center at Intermountain Health Park City Hospital Expands Access to World Class Treatment first appeared on ———————————————————————————————————————————————————————————— MDCE Advances StrainScan Pro as Scalable Enterprise Platform for Multi-Billion-Dollar ... 2026-08-21 · PR-Inside · AI, SaaS, Healthcare, Retail, Education https://pr-inside.com/mdce-advances-strainscan-pro-as-scalable-enterprise-platform-for-multi-billion-dollar-r5214755.htm (PR-inside.com) Proprietary AI Vision Software Delivers a Single, Portable Standard for Visual Quality Verification Across Multiple High-Value Industries MESA, AZ / ACCESS Newswire / August 21, 2026 / Medical Care Technologies Inc. (OTCID:MDCE) today reinforced the enterprise positioning of its StrainScan Pro platform, highlighting the proprietary AI vision software as a scalable solution designed to serve multi-location retail and agricultural operators through a single, unified system. Over the course of recent announcements, Medical Care Technologies has outlined how StrainScan Pro supports visual strain and quality verification for licensed retail operators, early detection of pests and crop illness in the field, and freshness tracking .. ———————————————————————————————————————————————————————————— In HelloNation, Expert Optometrist Dr. Harlan Snyder Explains Medical Eye Care vs. Routine Vision Exams 2026-08-21 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/in-hellonation-expert-optometrist-dr-harlan-snyder-explains-medical-eye-care-vs-routine-vision-exams-302857342.html The article explains when patients need routine vision exams or medical eye care to protect long-term eye health. ALHAMBRA, Calif., Aug. 21, 2026 /PRNewswire/ -- What is the difference between medical eye care and routine vision exams? A new HelloNation article provides the answer by... ———————————————————————————————————————————————————————————— TransformativeMed Partners with Red Rover Health to Bring Agentic AI Across Clinical Workflows 2026-08-21 · PR Newswire · AI, Healthcare https://www.prnewswire.com/news-releases/transformativemed-partners-with-red-rover-health-to-bring-agentic-ai-across-clinical-workflows-302857306.html Companies to showcase agentic discharge planning solution at Oracle Health Summit SEATTLE, Aug. 21, 2026 /PRNewswire/ -- TransformativeMed, a 'Best in Klas' Healthcare IT company, today announced a strategic partnership with Red Rover Health to design and deploy agentic AI solutions that... ———————————————————————————————————————————————————————————— Coreline Soft and INFINITT North America Deploy Chest CT-Based AI Reading Workflow at St. Joseph's Health 2026-08-21 · PR Newswire · AI, Healthcare https://www.prnewswire.com/news-releases/coreline-soft-and-infinitt-north-america-deploy-chest-ct-based-ai-reading-workflow-at-st-josephs-health-302851592.html PHILLIPSBURG, N.J. and ATLANTA, Aug. 21, 2026 /PRNewswire/ -- Coreline Soft, a leading medical AI innovator, and INFINITT North America have announced the deployment of a chest CT-based AI reading workflow at St. Joseph's Health in Paterson, New Jersey. This marks the second major North... ———————————————————————————————————————————————————————————— New Book Equips Healthcare Leaders with the Inner and Relational Skills That Clinical Training Never Provided 2026-08-21 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/new-book-equips-healthcare-leaders-with-the-inner-and-relational-skills-that-clinical-training-never-provided-302856947.html Retired Army Colonel, ICU Physician, and Executive Coach Jess Bunin Offers a Practice-Based Framework for Trust, Repair, and Values-Aligned Leadership in Healthcare WASHINGTON, Aug. 21, 2026 /PRNewswire/ -- The American Association for Physician Leadership (AAPL) announces the publication... ———————————————————————————————————————————————————————————— Munley Law Lawyers Named to 2027 Best Lawyers in America® List 2026-08-21 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/munley-law-lawyers-named-to-2027-best-lawyers-in-america-list-302856943.html SCRANTON, Pa., Aug. 21, 2026 /PRNewswire/ -- Munley Law is pleased to announce that 9 of its lawyers have been included in the 2027 Edition of The Best Lawyers in America®. Our personal injury lawyers received recognition in the following practice areas: Marion Munley - Medical... ———————————————————————————————————————————————————————————— Splash Beverage Group to Become Endovia Health Sciences; New NYSE American Ticker “EDVA” Effective Monday 2026-08-21 · GlobeNewswire · Finance, SaaS, Healthcare https://www.globenewswire.com/news-release/2026/08/21/3349067/0/en/splash-beverage-group-to-become-endovia-health-sciences-new-nyse-american-ticker-edva-effective-monday.html New corporate identity and ticker reflect Splash Beverage Group's transformation into a diversified cannabinoid-based health sciences platform. ———————————————————————————————————————————————————————————— RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement 2026-08-21 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/21/3349060/0/en/renovorx-regains-compliance-with-nasdaq-minimum-bid-price-requirement.html MOUNTAIN VIEW, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared drug-delivery device, today announced that it has received written notification from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. ———————————————————————————————————————————————————————————— Black Book Research Announces 2026 Independent Provider Network Orchestration ... 2026-08-21 · PR-Inside · Healthcare https://pr-inside.com/black-book-research-announces-2026-independent-provider-network-orchestration-r5214737.htm (PR-inside.com) National benchmark finds independent provider networks are prioritizing multi-EHR practice activation, accountable workflow execution and referral closure over traditional population-health dashboards. CHICAGO, IL / ACCESS Newswire / August 21, 2026 / Black Book Market Research today announced the publication of its Q3 2026 Independent Provider Network Orchestration Solutions report, an assessment of the technology platforms used to coordinate value-based care across independently governed practices, heterogeneous EHR environments and multiple payer contracts. Based on 402 respondent records representing 316 healthcare organizations, the research examines a critical shift in the value-based care market: provider networks increasingly need technology that can move work to ac ———————————————————————————————————————————————————————————— Black Book Research Announces 2026 Independent Provider Network Orchestration Report; The Garage | Bridge Earns No. 1 Overall Ranking 2026-08-21 · Newswire.com · Healthcare https://www.newswire.com/news/black-book-research-announces-2026-independent-provider-network-22848439 National benchmark finds independent provider networks are prioritizing multi-EHR practice activation, accountable workflow execution and referral closure over traditional population-health dashboards. ———————————————————————————————————————————————————————————— Peripheral Vascular Devices Market Expands With Growing Vascular Disease Burden 2026-08-21 · Express Press Release · Healthcare https://express-press-release.net/news/2026/08/21/1768780 The Peripheral Vascular Devices Market is entering a period of steady expansion as the rising prevalence of peripheral vascular diseases, an aging population, and continued medical device [read full press release...] ———————————————————————————————————————————————————————————— AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline 2026-08-21 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/abbvie-to-present-new-data-at-wclc-2026-showcasing-innovation-across-lung-cancer-pipeline-302856994.html Clinical data from AbbVie's ABBV-1480 (RC148) PD-1/VEGF bispecific antibody in the frontline non-small cell lung cancer (NSCLC) setting will be presented via an oral presentation Additionally, new data and updates from AbbVie's telisotuzumab adizutecan (Temab-A) and ABBV-706 programs... ———————————————————————————————————————————————————————————— Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer 2026-08-21 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/21/3349016/14025/en/arbutus-announces-intent-to-repurchase-up-to-us-230-million-of-its-common-shares-through-modified-dutch-auction-tender-offer.html WARMINSTER, Pa., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced plans to commence a modified “Dutch Auction” tender offer (the “Offer”) to repurchase up to US$230 million of its common shares at a purchase price of not less than US$5.00 per share and not more than US$5.75 per share, in cash, less any applicable withholding taxes and without interest. The Offer is expected to commence on or about August 24, 2026 and, unless extended or terminated by the Company, expire on or about September 29, 2026. The Offer is expected to be funded through the Company’s cash on hand. ———————————————————————————————————————————————————————————— Obesity Action Coalition Calls on Starbucks to Reverse Decision to End GLP-1 Coverage for Obesity 2026-08-21 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/obesity-action-coalition-calls-on-starbucks-to-reverse-decision-to-end-glp-1-coverage-for-obesity-302856908.html TAMPA, Fla., Aug. 21, 2026 /PRNewswire/ -- The Obesity Action Coalition (OAC) is calling on Starbucks to reverse its reported decision to end health plan coverage of GLP-1 medications prescribed for weight loss beginning in October. Business Insider reports that Starbucks health plans... ———————————————————————————————————————————————————————————— How Emerging Markets Are Creating New Opportunities for Oncology Real-World Evidence 2026-08-21 · Express Press Release · Healthcare https://express-press-release.net/news/2026/08/21/1768745 Real-World Evidence Solutions for Oncology: How Patient Data Is Shaping Cancer Research Cancer research is becoming increasingly data-driven as researchers, healthcare providers, and regulators look [read full press release...] ———————————————————————————————————————————————————————————— Population Health Management Market: Data-Driven Care Enters a New Era 2026-08-21 · Express Press Release · Healthcare https://express-press-release.net/news/2026/08/21/1768734 The global population health management (PHM) market was valued at USD 103.6 billion in 2025 and is expected to reach USD 126.2 billion in 2026. By 2033, the market is [read full press release...] ———————————————————————————————————————————————————————————— How AI Is Reshaping the Healthcare Cloud Picture Archiving And Communication System Market 2026-08-21 · Express Press Release · AI, SaaS, Healthcare https://express-press-release.net/news/2026/08/21/1768733 Healthcare Cloud PACS Is Reshaping the Future of Medical Imaging Medical imaging has become one of the most data-intensive areas of modern healthcare. Every day, [read full press release...] ———————————————————————————————————————————————————————————— The Moss Way publishes independent sea moss heavy metal testing results 2026-08-21 · PressReleaseNews · Healthcare https://pressreleasenews.org/pressroom/the-moss-way-publishes-independent-sea-moss-heavy-metal-testing-results The Moss Way releases independent lab results for heavy metals, microbiology, and nutrition in its wild Irish sea moss, providing consumers with transparent data. ———————————————————————————————————————————————————————————— Australians Are Sicker at 45 Than Prior Generations, Testing Reveals Why 2026-08-21 · PressReleaseNews · Healthcare https://pressreleasenews.org/pressroom/australians-are-sicker-at-45-than-prior-generations-testing-reveals-why ———————————————————————————————————————————————————————————— Inner Awakening, Outer Success: Yoga Teacher Training in India Draws Global Attention 2026-08-21 · PressReleaseNews · Healthcare https://pressreleasenews.org/pressroom/inner-awakening-outer-success-yoga-teacher-training-in-india-draws-global-attention A growing number of professionals worldwide are choosing Yoga Teacher Training in India as a career shift and personal transformation. Rishikesh, known as the Yoga Capital of the World, is attracting students seeking to escape burnout and find balance. ———————————————————————————————————————————————————————————— China's Personalized mRNA Cancer Therapy Sector Accelerates: How Far Is It From a "DeepSeek Moment"? 2026-08-21 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/chinas-personalized-mrna-cancer-therapy-sector-accelerates-how-far-is-it-from-a-deepseek-moment-302857240.html BEIJING, Aug. 21, 2026 /PRNewswire/ -- Personalized mRNA cancer therapy has recently reached an important milestone. An international Phase 3 study in high-risk melanoma reported positive results, further supporting the clinical potential of personalized neoantigen therapy and drawing... ———————————————————————————————————————————————————————————— Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) NDA Accepted by NMPA, Poised to Become World's First Approved 4-1BB-Targeting Therapy 2026-08-21 · PR Newswire · Finance, Healthcare https://www.prnewswire.com/news-releases/leads-biolabs-opamtistomig-pd-l14-1bb-bispecific-antibody-nda-accepted-by-nmpa-poised-to-become-worlds-first-approved-4-1bb-targeting-therapy-302857237.html NANJING, China, Aug. 21, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA)... ———————————————————————————————————————————————————————————— Breast Pump Market: How Affordability Could Determine the Next Wave of Global Adoption 2026-08-21 · Express Press Release · Healthcare https://express-press-release.net/news/2026/08/21/1768693 The global breast pump market is valued at approximately USD 1.8 billion in 2026 and is projected to reach USD 2.9 billion by 2033, expanding at a [read full press release...] ———————————————————————————————————————————————————————————— Mary-Beth Newell, RN, MS Named Woman of the Month for August 2026 by P.O.W.E.R. (Professional Organization of Women of Excellence Recognized) 2026-08-21 · PR.com · Healthcare https://www.pr.com/press-release/977004 Mary-Beth Newell, RN, MS of Sarasota, Florida, has been named Woman of the Month for August 2026 by P.O.W.E.R. (Professional Organization of Women of Excellence Recognized). This prestigious distinction acknowledges her outstanding contributions and achievements in healthcare and healthy aging advocacy. About Mary-Beth Newell, RN, MS Mary-Beth Newell, RN, MS, is senior vice president of clinical reimbursement at [PR.com] ———————————————————————————————————————————————————————————— SCU Launches Accelerated Doctor of Physical Therapy Program in Phoenix Metro 2026-08-21 · PR Newswire · Healthcare, Education https://www.prnewswire.com/news-releases/scu-launches-accelerated-doctor-of-physical-therapy-program-in-phoenix-metro-302856896.html Two-year online-hybrid program expands SCU's physical therapy education to Arizona amid growing national demand for practitioners. WHITTIER, Calif., Aug. 21, 2026 /PRNewswire/ -- Southern California University of Health Sciences (SCU) is expanding its Doctor of Physical Therapy (DPT)... ———————————————————————————————————————————————————————————— Implantica publishes Interim Report January - June 2026 (Q2) 2026-08-21 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/implantica-publishes-interim-report-january--june-2026-q2-302857155.html VADUZ, Liechtenstein, Aug. 21, 2026 /PRNewswire/ -- FDA Approval of RefluxStop® - Strategic Preparation Sets the Stage for Success Significant events in the second quarter of 2026 RefluxStop® sales increased by more than 60% compared with the prior-year period, reflecting continued... ———————————————————————————————————————————————————————————— Hofseth BioCare ASA: SECOND QUARTER 2026 FINANCIAL REPORT 2026-08-21 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/08/21/3348894/0/en/hofseth-biocare-asa-second-quarter-2026-financial-report.html HBC recorded total operating revenues of NOK 65.7 million in the second quarter of 2026, compared to NOK 68.4 million in the same period last year. Net operating revenues were NOK 63.1 million, down from NOK 67.8 million in Q2 2025. EBITDA for the quarter was negative NOK 2.7 million, compared to negative NOK 5.4 million in Q2 2025. The Operational EBITDA* amounted to negative NOK 0.6 million (positive NOK 1.3 million in Q2 2025), excluding non-recurring and strategic development costs such as clinical trials and R&D expenses, and Berkåk project costs. The operating result (EBIT) was negative NOK 12.9 (-14.9) in the last quarter. Cash and cash equivalents increased by NOK 59.7 million during the quarter, ending at NOK 108.0 million as of 30 June 2026 (68.0). Including available credit ———————————————————————————————————————————————————————————— Akeso's AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline 2026-08-21 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/akesos-ak157d1-b7-h3-adc-cleared-for-phase-i-trial-in-solid-tumors-adding-a-third-differentiated-adc-to-its-pipeline-302857140.html HONG KONG, Aug. 21, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its investigational next-generation B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received clinical trial clearance from the Center for Drug Evaluation (CDE) of... ———————————————————————————————————————————————————————————— Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline 2026-08-21 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/21/3348882/0/en/ipsen-completes-acquisition-of-kartos-therapeutics-strengthening-late-stage-oncology-pipeline.html PARIS, FRANCE, 21 AUGUST 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today it has completed the acquisition of Kartos Therapeutics, a clinical-stage biopharmaceutical company adding late-stage MDM2 inhibitor navtemadlin in Phase III clinical development in myelofibrosis. ———————————————————————————————————————————————————————————— inFlow Inventory führt die Nachverfolgung von Chargennummern und Verfallsdaten ein 2026-08-21 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/inflow-inventory-fuhrt-die-nachverfolgung-von-chargennummern-und-verfallsdaten-ein-302857078.html Kleinere Hersteller und Händler in der Lebensmittel-, Getränke-, Pharma- und Medizinproduktebranche können nun jede Charge vom Wareneingang bis zum Kunden zurückverfolgen – und das zu einem Bruchteil der Kosten eines Unternehmens-ERP-Systems. TORONTO, 21. August 2026 /PRNewswire/ --... ———————————————————————————————————————————————————————————— Implantica receives FDA approval for RefluxStop® - Opening the U.S. market 2026-08-21 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/implantica-receives-fda-approval-for-refluxstop--opening-the-us-market-302857063.html VADUZ, Liechtenstein, Aug. 21, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, announced today that the U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for RefluxStop®, the... ———————————————————————————————————————————————————————————— NPTA Launches International I.M.P.A.C.T. Awards to Recognize Pharmacy ... 2026-08-21 · PR-Inside · Healthcare, Education https://pr-inside.com/npta-launches-international-i-m-p-a-c-t-awards-to-recognize-pharmacy-r5214608.htm (PR-inside.com) New international awards program honors measurable contributions to medication safety, patient access, innovation, education and operational excellence HOUSTON, TX / ACCESS Newswire / August 20, 2026 / TheNational Pharmacy Technician Association (NPTA)has established the Pharmacy Technician I.M.P.A.C.T. Awards-Inspiring Meaningful Progress And Celebrating Technicians-an international recognition program honoring pharmacy technicians whose measurable contributions are advancing medication safety, patient care and pharmacy practice across all care settings. Pharmacy technicians play an increasingly important role in healthcare delivery, yet many of their most consequential contributions happen behind the scenes. They improve medication-use systems, prevent errors, expand pati ———————————————————————————————————————————————————————————— NPTA Launches International I.M.P.A.C.T. Awards to Recognize Pharmacy Technicians Advancing Patient Care and Pharmacy Practice 2026-08-21 · Newswire.com · Healthcare, Education https://www.newswire.com/news/npta-launches-international-i-m-p-a-c-t-awards-to-recognize-pharmacy New international awards program honors measurable contributions to medication safety, patient access, innovation, education and operational excellence ———————————————————————————————————————————————————————————— Aveanna Announces Pricing of Secondary Offering of Common Stock 2026-08-21 · GlobeNewswire · Finance, SaaS, Healthcare https://www.globenewswire.com/news-release/2026/08/21/3348868/0/en/aveanna-announces-pricing-of-secondary-offering-of-common-stock.html ATLANTA, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, announced today the pricing of the previously announced secondary offering by certain selling stockholders (the “Selling Stockholders”), including affiliates of J.H. Whitney Equity Partners VII, LLC and certain current and former directors and officers of the Company, of 15,000,000 shares of its common stock at a price of $11.75 per share (the “Offering”). Certain affiliates of J.H. Whitney Equity Partners VII, LLC have also granted the underwriter a 30-day option to purchase up to an additional 2,250,000 shares of the Company’s common stock. The Selling Stockholders will receive ———————————————————————————————————————————————————————————— Supplement Brands Chasing Informational Keywords Are Getting Less Traffic, Content Stream Report Finds 2026-08-20 · PRWeb · Healthcare, Media https://www.prweb.com/releases/supplement-brands-chasing-informational-keywords-are-getting-less-traffic-content-stream-report-finds-302854901.html New study of 116 supplement websites finds that sites leaning heavily on informational content earn 2.7x less traffic per keyword than those with a balanced content mix NEW YORK, Aug. 20, 2026 /PRNewswire-PRWeb/ -- Content Stream, an SEO and content agency specializing in health and... ———————————————————————————————————————————————————————————— Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results 2026-08-20 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/brii-biosciences-provides-corporate-updates-and-reports-2026-interim-financial-results-302856508.html Topline Data from Phase 2b Studies Inform HBV Functional Cure Strategy; Additional Data Expected in 2H 2026 Emerging Discovery Programs Build Momentum BRII-5395 mRNA Cancer Vaccine Moving into Clinical Evaluation for HCC Strong Cash Position Supports Continued Strategic Execution... ———————————————————————————————————————————————————————————— Dr. Vinson Eugene Allen Provided Critical Guidance as Actor Ernest ... 2026-08-20 · PR-Inside · Healthcare https://pr-inside.com/dr-vinson-eugene-allen-provided-critical-guidance-as-actor-ernest-r5214560.htm (PR-inside.com) Beloved Actor Ernest Harden Jr. is Grateful, Healthy and Excited to Get Back to Work LOS ANGELES, CA / ACCESS Newswire / August 20, 2026 / Emmy‑nominated actor Ernest Harden Jr., known for his outstanding role in the HBO Max series The Pitt, turned to longtime friend, medical pioneer Dr. Vinson Eugene Allen when a dangerous decline in his health placed him at severe risk. Harden, who later said publicly that Dr. Allen "saved my life," relied on Allen's medical guidance as his condition worsened during preparation for the role that would earn him his first Emmy nomination. Ernest Harden Jr., a .. ———————————————————————————————————————————————————————————— Dr. Vinson Eugene Allen Provided Critical Guidance as Actor Ernest Harden Jr. Faced a Medical Emergency While Filming The Pitt 2026-08-20 · Newswire.com · Healthcare https://www.newswire.com/news/dr-vinson-eugene-allen-provided-critical-guidance-as-actor-ernest-22848673 Beloved Actor Ernest Harden Jr. is Grateful, Healthy and Excited to Get Back to Work ———————————————————————————————————————————————————————————— Noveris Health Sciences Announces Proposed Private Placement of Convertible Debentures for up to $500,000 2026-08-20 · mlpr-newsfile · Healthcare https://www.newsfilecorp.com/release/310680/Noveris-Health-Sciences-Announces-Proposed-Private-Placement-of-Convertible-Debentures-for-up-to-500000 Vancouver, British Columbia--(Newsfile Corp. - August 20, 2026) - Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) (the "Company" or "Noveris") is pleased to announce its intention to complete a non-brokered private placement of convertible debentures of the Company (the "Debentures") in an aggregate principal amount of up to $500,000, issuable in increments of $1,000 principal amount, for aggregate gross proceeds of up to $500,000 (the "Offering"). The Offering is expected... ———————————————————————————————————————————————————————————— Karen Martel Midlife Solutions Expands Access to Personalized Hormone Care for Women in Perimenopause and Menopause 2026-08-20 · PressReleaseNews · Healthcare https://pressreleasenews.org/pressroom/karen-martel-midlife-solutions-expands-access-to-personalized-hormone-care-for-women-in-perimenopause-and-menopause ———————————————————————————————————————————————————————————— FDA Clearance of C2N Diagnostics' PrecivityAD2 Blood Test Advances Precision Medicine for Alzheimer's, Building on Groundwork Laid by Early ADDF Investment 2026-08-20 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/fda-clearance-of-c2n-diagnostics-precivityad2-blood-test-advances-precision-medicine-for-alzheimers-building-on-groundwork-laid-by-early-addf-investment-302856858.html First Alzheimer's blood test cleared for patients as young as 40, advancing the ADDF's long-standing push to close the gap between early pathology and early detection Milestone reflects nearly two decades of sustained ADDF investment, expanding access to scalable blood-based diagnostics... ———————————————————————————————————————————————————————————— Perimeter Announces Preliminary Second Quarter 2026 Financial Results 2026-08-20 · PR Newswire · AI, Healthcare https://www.prnewswire.com/news-releases/perimeter-announces-preliminary-second-quarter-2026-financial-results-302856831.html Results characterized by continued strong commercial momentum and improved operating performance Conference call/webcast today at 5:00 pm ET TORONTO and DALLAS, Aug. 20, 2026 /PRNewswire/ -- Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a... ———————————————————————————————————————————————————————————— In HelloNation, Dental Expert Dr. Paula Joseph Hasson Details What to Expect During a Dental Exam 2026-08-20 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/in-hellonation-dental-expert-dr-paula-joseph-hasson-details-what-to-expect-during-a-dental-exam-302856835.html The article explains how routine exams help identify oral health concerns early while supporting long-term preventive care. NEW CASTLE, Pa., Aug. 20, 2026 /PRNewswire/ -- What happens during a dental exam? A HelloNation article answers that question through insights from Dental Expert Dr.... ———————————————————————————————————————————————————————————— IQVIA's AI-Enabled Clinical Decision Support Tool Wins 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year 2026-08-20 · mlpr-businesswire · Finance, AI, Healthcare https://finance.yahoo.com/healthcare/articles/iqvias-ai-enabled-clinical-decision-201500451.html RESEARCH TRIANGLE PARK, N.C., August 20, 2026--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced that its AI-enabled Clinical Decision Support Tool, developed in collaboration with Breakthrough T1D, has won the 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year. ———————————————————————————————————————————————————————————— Aveanna Announces Launch of Secondary Offering of Common Stock 2026-08-20 · GlobeNewswire · Finance, SaaS, Healthcare https://www.globenewswire.com/news-release/2026/08/20/3348810/0/en/aveanna-announces-launch-of-secondary-offering-of-common-stock.html ATLANTA, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, announced today that certain selling stockholders (the “Selling Stockholders”), including affiliates of J.H. Whitney Equity Partners VII, LLC and certain current and former directors and officers of the Company, have commenced a secondary offering of 15,000,000 shares of its common stock (the “Offering”). Certain affiliates of J.H. Whitney Equity Partners VII, LLC will also grant the underwriter a 30-day option to purchase up to an additional 2,250,000 shares of the Company’s common stock. The Selling Stockholders will receive all of the net proceeds from the Offering. The Company ———————————————————————————————————————————————————————————— Assembly Health Appoints Bracha Eidelman as General Manager, Quality 2026-08-20 · PR Newswire · Finance, Healthcare https://www.prnewswire.com/news-releases/assembly-health-appoints-bracha-eidelman-as-general-manager-quality-302856824.html Experienced operations executive to lead Assembly Health's skilled nursing financial services business CHICAGO, Aug. 20, 2026 /PRNewswire/ -- Assembly Health, a leading provider of tech-enabled revenue cycle management services serving more than 5,000 providers across 59 specialties in 48... ———————————————————————————————————————————————————————————— Cresso Health Announces Partnership with Slate Financial 2026-08-20 · PRWeb · Healthcare https://www.prweb.com/releases/cresso-health-announces-partnership-with-slate-financial-302856814.html Cresso Health announced it has partnered with Slate Financial a Southwest-based distributor of Medicare and health insurance products. NEW YORK, Aug. 20, 2026 /PRNewswire-PRWeb/ -- Cresso Health, a technology-enabled provider of sales and marketing solutions for leading health insurance... ———————————————————————————————————————————————————————————— Quantum BioPharma (QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves 2026-08-20 · NewMediaWire · Healthcare, Retail https://www.newmediawire.com/news/quantum-biopharma-qntm-advances-myelin-protecting-ms-therapy-as-treatment-paradigm-evolves-7088771 MS drug development is increasingly expanding beyond controlling inflammation toward approaches designed to protect the nervous system and address mechanisms underlying progressive disability. Remyelination and protection of existing myelin remain major unmet needs in MS, as no approved therapy has established the ability to restore previously damaged myelin. Quantum BioPharma’s Lucid-MS is a patented new chemical entity designed to inhibit demyelination and protect myelin without suppressing the immune system. The U.S. FDA has cleared Quantum BioPharma to proceed with its planned phase 2 clinical trial of Lucid-MS in people with multiple sclerosis. LOS ANGELES, CA - August 20, 2026 ( NEWMEDIAWIRE ) - Multiple sclerosis (“MS”) treatment has traditionally focused on controlling the immune a ———————————————————————————————————————————————————————————— Your Telehealth Doctor Must Be Licensed in the State You're In, Not the State They're In, Promise Analysis Finds 2026-08-20 · PR Newswire · SaaS, Healthcare https://www.prnewswire.com/news-releases/your-telehealth-doctor-must-be-licensed-in-the-state-youre-in-not-the-state-theyre-in-promise-analysis-finds-302856741.html 3,633 physician licenses were issued in a single month through the Interstate Medical Licensure Compact — American Medical Association, 2026. SCOTTSDALE, Ariz., Aug. 20, 2026 /PRNewswire/ -- Promise, a Scottsdale-based telehealth platform offering doctor-guided consultations for peptide... ———————————————————————————————————————————————————————————— Starlight Children's Foundation Announces 2026 Starlight Awards Honorees 2026-08-20 · PR Newswire · Healthcare, Media https://www.prnewswire.com/news-releases/starlight-childrens-foundation-announces-2026-starlight-awards-honorees-302856737.html Annual awards recognize hospital teams, corporate partners, content creators, and changemakers transforming the pediatric healthcare experience for seriously ill children and their families. LOS ANGELES, Aug. 20, 2026 /PRNewswire/ -- The nonprofit Starlight Children's Foundation today... ———————————————————————————————————————————————————————————— Vascarta Outlines Proposed Mechanistic Link Between VAS-101's (Vasceptor®) Vascular and Red Blood Cell Effects in Sickle Cell Disease 2026-08-20 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/vascarta-outlines-proposed-mechanistic-link-between-vas-101s-vasceptor-vascular-and-red-blood-cell-effects-in-sickle-cell-disease-302856724.html Company connects new preclinical microcirculation findings with prior low-dose sublingual clinical data to propose how Vasceptor® (VAS-101) may improve red blood cell sickling kinetics without requiring direct, high-concentration inhibition of hemoglobin S polymerization SUMMIT, N.J., Aug.... ———————————————————————————————————————————————————————————— Home Healthcare Expert Kellan Roberts Reviews Non-Medical Transportation and Medicaid Waiver Programs for Adults With Disabilities in HelloNation 2026-08-20 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/home-healthcare-expert-kellan-roberts-reviews-non-medical-transportation-and-medicaid-waiver-programs-for-adults-with-disabilities-in-hellonation-302856708.html The article explains how transportation services support community participation, independence skills, and coordinated service planning. CANTON, Ohio, Aug. 20, 2026 /PRNewswire/ -- How can families ensure reliable non-medical transportation for adults with developmental disabilities in... ———————————————————————————————————————————————————————————— Michael Bogdan Scholarship for Healthcare Opens 2027 Application Cycle for Future Medical Professionals 2026-08-20 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/michael-bogdan-scholarship-for-healthcare-opens-2027-application-cycle-for-future-medical-professionals-302856707.html Essay Competition Supports Undergraduate Students Committed to Patient Care, Innovation, and Healthcare Leadership BOCA RATON, Fla., Aug. 20, 2026 /PRNewswire/ -- The Michael Bogdan Scholarship for Healthcare announces the opening of its 2027 application cycle, inviting undergraduate... ———————————————————————————————————————————————————————————— Immunis Chairman Dr. Hans Keirstead Nominated to Speak at SXSW 2027 on Restorative Approaches to Longevity Medicine 2026-08-20 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/immunis-chairman-dr-hans-keirstead-172800003.html IRVINE, Calif., August 20, 2026--Immunis, Inc., a clinical-stage biotechnology company developing off-the-shelf multi-active biologics for muscle health and healthy aging, today announced that its Chairman, Dr. Hans Keirstead, has been nominated as a panelist at SXSW 2027 in a conversation titled "Can We Get Better at Aging?: Hope, Hype, and Hard Science." ———————————————————————————————————————————————————————————— Dr. Wael Sakr Scholarship Opens Applications for Aspiring Medical Students Nationwide 2026-08-20 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/dr-wael-sakr-scholarship-opens-applications-for-aspiring-medical-students-nationwide-302856699.html Scholarship supports undergraduate students pursuing a future career in medicine and encourages a commitment to healthcare, research, and meaningful patient impact DETROIT, Aug. 20, 2026 /PRNewswire/ -- The Dr. Wael Sakr Scholarship for Medical Students announces the opening of... ———————————————————————————————————————————————————————————— PhalloFILL® Highlighted on The Human Upgrade With Dave Asprey 2026-08-20 · PRUnderground · Healthcare https://prunderground.com/phallofill-highlighted-on-the-human-upgrade-with-dave-asprey/cmt1q53rk000k04ibhqk8sund PhalloFILL® medical advisory board member Dr. Alex Tatem joined Dave Asprey's The Human Upgrade to discuss male wellness and hyaluronic acid girth enhancement. The post PhalloFILL® Highlighted on The Human Upgrade With Dave Asprey first appeared on ———————————————————————————————————————————————————————————— New ACCESS Trial Results Widen Donor Pool and Expand Patient Access to Transplant Among Adults with High-Risk Blood Cancers 2026-08-20 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/access-trial-results-widen-donor-164600531.html MINNEAPOLIS, August 20, 2026--ACCESS Trial data published in Blood Advances show young,<7/8 mismatched unrelated donor one-year patient outcomes are similar to fully matched donors ———————————————————————————————————————————————————————————— Living Longer Is Not Enough. California Trim Clinic Says NAD+ Is Making Healthspan the New Obsession 2026-08-20 · PRUnderground · Healthcare https://prunderground.com/living-longer-is-not-enough-california-trim-clinic-says-nad-is-making-healthspan/cmt1ow4in000304ibdmw91r8s Research estimates a nine-year healthspan gap. California Trim Clinic says NAD+ deserves medical review, not anti-aging hype, with direct eligibility screening available. The post Living Longer Is Not Enough. California Trim Clinic Says NAD+ Is Making Healthspan the New Obsession first appeared on ———————————————————————————————————————————————————————————— Doceree Launches Care Sequence, Activating One Clinical Signal Across All Moments of Care, From the Waiting Room to the Pharmacy Counter 2026-08-20 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/doceree-launches-care-sequence-activating-one-clinical-signal-across-all-moments-of-care-from-the-waiting-room-to-the-pharmacy-counter-302856624.html One verified clinical event, three stakeholders reached in order: the patient, the physician, and the pharmacist. SHORT HILLS, N.J., Aug. 20, 2026 /PRNewswire/ -- Doceree today launched Care Sequence, the first point-of-care offering to activate a brand across all moments of a patient... ———————————————————————————————————————————————————————————— 10,000 COREWELL HEALTH EAST NURSES RATIFY FIRST TEAMSTERS CONTRACT 2026-08-20 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/10-000-corewell-health-east-nurses-ratify-first-teamsters-contract-302856621.html RNs at Michigan's Largest Health Care System Win Historic Collective Bargaining Agreement WASHINGTON, Aug. 20, 2026 /PRNewswire/ -- Registered nurses at Corewell Health East, represented by Teamsters Local 2024, have voted to ratify their first union contract after more than 13 months of... ———————————————————————————————————————————————————————————— [Video] [Galaxy Unpacked July 2026] Samsung Health Envisions Simpler, More Connected Care With AI 2026-08-20 · mlpr-samsung · AI, Healthcare, Media https://news.samsung.com/global/video-galaxy-unpacked-july-2026-samsung-health-envisions-simpler-more-connected-care-with-ai Managing health can be complicated. But what if it didn’t have to be? At Galaxy Unpacked July 2026 in London on July 22, Dr. Hon Pak, Senior Vice President and Head of the Digital Health Team, Mobile eXperience (MX) Business at Samsung Electronics, sat down with cognitive neuroscientist and science communicator Dr. Dong-seon Chang to […] ———————————————————————————————————————————————————————————— Avant Interventional Psychiatry Supports Atlanta Families at Back-to-School Health and Wellness Event 2026-08-20 · PRWeb · Healthcare, Education https://www.prweb.com/releases/avant-interventional-psychiatry-supports-atlanta-families-at-back-to-school-health-and-wellness-event-302854925.html Avant Interventional Psychiatry joined Atlanta community partners to support children and families preparing for the new school year while promoting awareness of mental and emotional wellness. ATLANTA, Aug. 20, 2026 /PRNewswire-PRWeb/ -- Avant Interventional Psychiatry recently joined... ———————————————————————————————————————————————————————————— inFlow Inventory launches lot number and expiry date tracking 2026-08-20 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/inflow-inventory-launches-lot-number-and-expiry-date-tracking-302856584.html Small manufacturers and distributors in food, beverage, pharmaceutical and medical device industries can now trace any batch from receipt to customer, at a fraction of the cost of an enterprise ERP. TORONTO, Aug. 20, 2026 /PRNewswire/ -- inFlow Inventory has launched lot number and expiry... ———————————————————————————————————————————————————————————— FDAQRC Strengthens Position as Premier Global Regulatory Compliance Expert with Compliance Architects Acquisition 2026-08-20 · PRWeb · Finance, Healthcare https://www.prweb.com/releases/fdaqrc-strengthens-position-as-premier-global-regulatory-compliance-expert-with-compliance-architects-acquisition-302854917.html FDAQRC has acquired Compliance Architects LLC, adding new depth to its role as a resource for pharmaceutical and medical device companies searching for global regulatory compliance expertise. Completed July 17, 2026, the acquisition combines two established consulting firms under one roof.... ———————————————————————————————————————————————————————————— ILD Day 2026 Spotlights Precision Medicine's Potential to Transform Patient Care 2026-08-20 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/ild-day-2026-spotlights-precision-medicines-potential-to-transform-patient-care-302856583.html Free Sept. 16 webinar will explore how individualized approaches may improve the diagnosis, treatment and management of interstitial lung disease CHICAGO, Aug. 20, 2026 /PRNewswire/ -- The emerging role of precision medicine in diagnosing and treating interstitial lung disease will take... ———————————————————————————————————————————————————————————— Zylox-Tonbridge Delivers Strong First-Half 2026 Results as International Revenue Surges 349% 2026-08-20 · PR Newswire · Finance, Healthcare https://www.prnewswire.com/news-releases/zylox-tonbridge-delivers-strong-first-half-2026-results-as-international-revenue-surges-349-302856580.html Revenue rose 31.1% to RMB 632 million, while net profit increased 47.8% to RMB 179 million HANGZHOU, China, Aug. 20, 2026 /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190, "Zylox-Tonbridge" or the "Company") today announced its interim results for the six months... ———————————————————————————————————————————————————————————— Vadzo Imaging Introduces Armor-1335CRO-FPD3: AR1335 13MP Autofocus FPD-Link III Camera with Optical Image Stabilization and Standard FAKRA Connector for Medical Devices 2026-08-20 · Newswire.com · Healthcare, Media https://www.newswire.com/news/vadzo-imaging-introduces-armor-1335cro-fpd3-ar1335-13mp-autofocus-fpd-22848519 Built for surgical robotics, endoscopy, and portable diagnostic equipment that cannot tolerate a blurred or misaligned frame, this camera pairs the Onsemi AR1335 sensor with optical image stabilization, autofocus, and a standard FAKRA connector over FPD-Link III, giving medical device manufacturers stable, detailed video without a proprietary cable or connector to source and qualify. ———————————————————————————————————————————————————————————— ArchWell Health™ Mid-Campaign Data Shows Over 64% of Senior Women Complete Mammograms in 4th Annual Pink Letter Project 2026-08-20 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/archwell-health-mid-campaign-data-shows-over-64-of-senior-women-complete-mammograms-in-4th-annual-pink-letter-project-302856559.html NASHVILLE, Tenn., Aug. 20, 2026 /PRNewswire/ -- ArchWell Health™, a national healthcare company providing an advanced model of primary care for adults 60+, today released mid-campaign metrics for its fourth annual Pink Letter Project breast cancer awareness campaign. The three-month... ———————————————————————————————————————————————————————————— Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment 2026-08-20 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/20/3348540/0/en/vivos-therapeutics-opens-new-sleep-testing-and-treatment-facility-in-nevada-to-meet-rapidly-growing-patient-demand-for-sleep-apnea-testing-and-treatment.html Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment ———————————————————————————————————————————————————————————— PETVIVO HOLDINGS ANNOUNCES NAME CHANGE OF HUMAN SUBSIDIARY TO SOMATRIX TECHNOLOGIES, INC. AND EXPANDS FOCUS ON HUMAN HEALTH INNOVATION 2026-08-20 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/08/20/3348537/0/en/petvivo-holdings-announces-name-change-of-human-subsidiary-to-somatrix-technologies-inc-and-expands-focus-on-human-health-innovation.html New Human Health Subsidiary to Advance Development of Innovative Biomaterial Technologies and Potential New Products for Human and Animal Health ———————————————————————————————————————————————————————————— NAPA Expands E&O Insurance Program for Life & Health Agencies and Launches New Coverage for IMOs 2026-08-20 · PRWeb · Healthcare https://www.prweb.com/releases/napa-expands-eo-insurance-program-for-life--health-agencies-and-launches-new-coverage-for-imos-302854958.html NAPA, the National Association of Professional Agents, announces enhancements to its Insurance Agency Errors & Omissions (E&O) Insurance program, furthering the availability of its accessible and comprehensive coverage to high-volume Life & Health Agencies. Additionally, these... ———————————————————————————————————————————————————————————— Join Virax's Live Investor Webinar: Advancing Immune Diagnostics, Clinical ... 2026-08-20 · PR-Inside · Finance, Healthcare https://pr-inside.com/join-virax-s-live-investor-webinar-advancing-immune-diagnostics-clinical-r5214385.htm (PR-inside.com) CEO James Foster to discuss the Company's financial and strategic position, commercial strategy for ImmuneSelect and development plans for ViraxImmune™ Webinar to include an overview of recent corporate developments and management's priorities for the coming months and quarters ORLANDO, FL / ACCESS Newswire / August 20, 2026 / RedChip Companies will host an investor webinar on Tuesday, August 25, 2026, at 4:15 p.m. ET with Virax Biolabs Group Limited (Nasdaq:VRAX) ("Virax" or the "Company"). The event will feature Virax Chief Executive Officer James Foster, who will provide an overview of the Company's financial and strategic position following its fiscal 2026 annual report and .. ———————————————————————————————————————————————————————————— Join Virax's Live Investor Webinar: Advancing Immune Diagnostics, Clinical Development and Commercial Execution 2026-08-20 · Newswire.com · Healthcare https://www.newswire.com/news/join-viraxs-live-investor-webinar-advancing-immune-diagnostics-clinical CEO James Foster to discuss the Company's financial and strategic position, commercial strategy for ImmuneSelect and development plans for ViraxImmune ™ Webinar to include an overview of recent corporate developments and management's priorities for the coming months and quarters ———————————————————————————————————————————————————————————— Hemostemix Commercializes Its Vascular Dementia Clinical Trial of VesCell(TM) Under LARTA 2026-08-20 · mlpr-newsfile · Healthcare https://www.newsfilecorp.com/release/310607/Hemostemix-Commercializes-Its-Vascular-Dementia-Clinical-Trial-of-VesCellTM-Under-LARTA Leading cognitive-disorders specialist, Dr. William Shankle, will discuss vascular cognitive impairment, vascular dementia and the proposed clinical trial of VesCell™ (ACP-01) today at 12:00 EST, at https://us06web.zoom.us/webinar/register/WN_nJ8ViLkRSeiU_NXMYJ-jbwCalgary, Alberta--(Newsfile Corp. - August 20, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce > 130 participants have enrolled to hear Dr. William R. Shankle, MS,... ———————————————————————————————————————————————————————————— CEPR and Cohesive Receive Maximo Award for Power Plant Health and Safety Excellence 2026-08-20 · mlpr-businesswire · Healthcare https://finance.yahoo.com/energy/articles/cepr-cohesive-receive-maximo-award-133000813.html NASHVILLE, Tenn., August 20, 2026--(MaximoWorld 2026) – Cirebon Energi Prasarana (CEPR), one of West Java’s leading independent power producers, and Cohesive, part of Bentley Systems, have received a prestigious award recognizing CEPR’s advancement of workplace safety using IBM Maximo. ———————————————————————————————————————————————————————————— Cosmos Health Enters Saudi Arabia Through Exclusive Distribution Agreement With Innova Healthcare; Secures Initial Purchase Order of 126,000 Sky Premium Life Units, With More Than 5 Million Units Expected Over Initial 5-Year Term 2026-08-20 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/20/3348496/0/en/cosmos-health-enters-saudi-arabia-through-exclusive-distribution-agreement-with-innova-healthcare-secures-initial-purchase-order-of-126-000-sky-premium-life-units-with-more-than-5-.html Cosmos Health Enters Saudi Arabia. Signs Exclusive Distribution Agreement With Innova Healthcare; Secures Purchase Order of 126,000 Sky Premium Life Units. ———————————————————————————————————————————————————————————— Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment 2026-08-20 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/20/3348494/0/en/polyrizon-completes-clinical-site-network-for-nasarix-study-and-advances-toward-patient-enrollment.html Polyrizon completes contracting with all five U.S. clinical sites and advances its NASARIX™ study toward enrollment of 120 patients ———————————————————————————————————————————————————————————— Medical Simulation Market Growth Outlook 2026-08-20 · Express Press Release · Healthcare https://express-press-release.net/news/2026/08/20/1768615 The global Medical Simulation Market is entering a high-growth phase as healthcare institutions increasingly prioritize patient safety, clinical competency, and workforce readiness. Valued at USD 1.9 billion in [read full press release...] ———————————————————————————————————————————————————————————— Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning 2026-08-20 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/20/3348448/0/en/creative-medical-technology-holdings-successfully-completes-enrollment-and-treatment-across-entire-fda-cleared-adapt-trial-including-opioid-cohort-advancing-celz-201-olastrocel-tow.html All patients enrolled and treated across original and FDA-cleared expansion cohorts ———————————————————————————————————————————————————————————— StrainScan Pro Enables Farm-to-Plate Freshness and Quality Tracking ... 2026-08-20 · PR-Inside · AI, SaaS, Healthcare, Retail https://pr-inside.com/strainscan-pro-enables-farm-to-plate-freshness-and-quality-tracking-r5214376.htm (PR-inside.com) Proprietary AI Vision Platform Supports Visual Consistency from Harvest Through Distribution and Retail MESA, AZ / ACCESS Newswire / August 20, 2026 / Medical Care Technologies Inc. (OTCID:MDCE) today highlighted the farm-to-plate capabilities of its StrainScan Pro platform, positioning the proprietary AI vision software as a tool for visual freshness and quality tracking across the food supply chain. Maintaining consistency from the field to the final destination remains one of the most persistent challenges in agriculture and food distribution. StrainScan Pro is designed to support that process through rapid, on-device visual analysis that can help operators assess quality indicators at multiple points .. ———————————————————————————————————————————————————————————— Children account for half of suspected mpox cases in Guinea-Bissau 2026-08-20 · WebWire · Healthcare https://www.webwire.com/ViewPressRel.asp?aId=359198 Children under 15 account for half of all 46 suspected mpox cases in Guinea-Bissau. UNICEF is scaling up its support to the Ministry of Public Health in direct response to the country's first-ever mpox outbreak. - - “This is the first time mpox cases have been reported in Guinea-Bissau, making even a small outbreak a major public health event,” said Sandra Martins, UNICEF Deputy Representative in Guinea Bissau. “While the country's surveillance system remains extremely fragile, we face the... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=359198 ———————————————————————————————————————————————————————————— Inovalon, UST, and AXIOM Systems Join 1upHealth's Partner Program 2026-08-20 · PR-Inside · AI, Healthcare https://pr-inside.com/inovalon-ust-and-axiom-systems-join-1uphealth-s-partner-program-r5214374.htm (PR-inside.com) 1upHealth's Growing Partner Ecosystem Gives Health Plans Faster Access to CMS-0057 Compliance Ahead of 2027 Deadline BOSTON, MA / ACCESS Newswire / August 20, 2026 /1upHealth, a leader in health data interoperability, today announced the addition of three new organizations to the 1up Partner Program: Inovalon, a leading provider of data and solutions empowering data-driven healthcare; AXIOM Systems, a privately held IT solutions firm focused exclusively on the healthcare industry; and UST, a leading AI and technology transformation solutions company. Launched in 2025, the 1up Partner Program allows members to extend interoperability and CMS compliance solutions to their payer clients without .. ———————————————————————————————————————————————————————————— Hua Medicine Announces 2026 Interim Results 2026-08-20 · mlpr-acnnewswire · Finance, AI, SaaS, Healthcare, Real Estate, Energy, Education https://www.acnnewswire.com/press-release/english/109284/ -  Sales of HuaTangNing reached 3.055 million packs in the first half of 2026, representing a 73% year-on-year increase; revenue hit RMB378.9 million, up 74% year-on-year. The in-house commercialization drive maintained robust growth with continuously improved operational efficiency. -  Expanded manufacturing scale lifted gross profit margin substantially to 61.8%, a year-on-year rise of 7.6 percentage points. -  Profit generated from commercial operations doubled year-on-year, and loss narrowed markedly to RMB30.2 million after excluding one-off income, demonstrating a clear path to full-scale profitability. -  Selling expense-to-revenue ratio stabilized at 33.5%, reflecting tangible gains from increased marketing efforts and streamlined operations. -  Dorzagliatin secured marketing approvals in both the Hong Kong and Macao Special Administrative Regions of China; demonstrating our innovative business model is showing early success and marking a key milestone for global expansion. -  A five-year patent term extension was granted for dorzagliatin, extending core patent protection to April 2034. The National Reimbursement Drug List price of the product will remain unchanged for 2026 and 2027, reinforcing long-term commercial profitability certainty. -  Topline results from real-world studies further validated the broad applicability, safety and tolerability of dorzagliatin across diverse real-world patient populations. -  Multiple combination therapy studies revealed synergistic metabolic benefits when dorzagliatin is paired with oral small-molecule GLP-1 receptor agonists, THR-β agonists and pan-PPAR agonists, tapping into development therapeutic potential in new disease areas including obesity and MASLD. -  Clinical development of the second-generation GKA in the United States proceeded smoothly. R&D initiatives for new indications including MODY-2, diabetes prevention, neurodegenerative diseases and frailty were accelerated across the board. SHANGHAI, August 20, 2026 - (ACN Newswire) - Hua Medicine (the “Company”, HKEx: 2552) announced the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2026 (the “Reporting Period”), as well as the Company's business progress during the first half of the year and future outlook. During the Reporting Period, HuaTangNing, dorzagliatin tablets), the Company’s core globally first-in-class oral anti-diabetic glucokinase activator (GKA), entered a rapid scale-up phase under proprietary commercialization. Revenue and gross profit both recorded substantial growth with sustained gross margin improvement. The Company achieved critical milestones in global expansion through the commercial launch of dorzagliatin in Hong Kong and Macao SARs. Multiple pivotal clinical datasets were presented at leading international academic conferences, delivering continuous breakthroughs across the full product pipeline. Core operating losses narrowed steadily, while robust cash reserves laid a solid foundation for the Group’s long-term sustainable growth. Dr. Li Chen, Founder and CEO of Hua Medicine, stated: “The first half of 2026 represents a pivotal stage for Hua Medicine as we translate original innovation into marketing value realization. Sales volume and revenue of dorzagliatin grew more than 70% year-on-year, gross margin surpassed 60%, and profit from commercial operations doubled compared with the same period last year. It validates the Company’s successful transition from R&D-innovation-driven growth to rapid commercial development in the chronic disease space. It fully demonstrates that domestically developed first-in-class drugs from China possess strong and sustainable market momentum, backed by national policies that support innovative drugs across the full-value chain. Meanwhile, dorzagliatin was successfully launched in Hong Kong and Macao SARs, officially kicking off our internationalization strategy anchored in Greater China with outreach to Southeast Asian, Spanish-speaking and Portuguese-speaking markets. Chinese original innovative medicines are now deeply participating in the global metabolic disease treatment landscape. Moving forward, rooted in glycemic homeostasis regulation, the Company will advance a new paradigm for diabetes homeostasis-targeted therapy featuring next-generation long-acting GKAs, fixed-dose combinations and combination therapies. We will build a human energy-metabolism health pipeline matrix covering disease prevention, special types of diabetes, fatty liver diseases and steatohepatitis, cognitive impairment and frailty. Leveraging artificial intelligence technologies, the Company will continuously expand the clinical boundaries and application scenarios of its glycemic homeostasis technology platform, and strive to bring China-originated innovative therapies to patients with metabolic diseases at home and abroad.” Business Highlights and Operational Progress 1. Accelerated Proprietary Commercialization with Major Operational Efficiency Improvements - Rapid sales expansion. During the Reporting Period, we sold approximately 3,055,000 packs of HuaTangNing in the first half of 2026, up 73% from 1,764,000 packs sold during the same period in 2025. This rapid sales growth trajectory is further supported by the maintenance of China’s National Reimbursement Drug List (NRDL) price for the 2026 and 2027 calendar years. Regions that already led sales in 2025, coastal areas including Shanghai, Tianjin and Guangdong province and Beijing, continued to deliver strong growth during the reporting period, reflecting the substantial market potential for further market penetration and providing a solid basis for sustained strong growth in the future. - Markedly enhanced profitability driven by scale effects. Relying on expanded production capacity and optimized manufacturing processes, gross margin rose significantly from 54.2% in the first half of 2025 to 61.8%, up 7.6 percentage points; gross profit reached RMB234.3 million, a 99% year-on-year surge. Selling expenses totalled RMB126.9 million, with the ratio of selling expense to revenue standing at 33.5%. Our commercialization efforts achieved profit of approximately RMB107.4 million (as defined by gross profits less selling expenses), doubled from RMB53.7 million in the same period of 2025. as profitability from proprietary commercialization continues to materialize. - Normalized financial performance with healthy cash reserves. Loss before tax stood at approximately RMB30.2 million. Excluding the one-off release of contract liabilities in the corresponding period of 2025 following the termination of the Bayer contract, the loss for the current reporting period is expected to narrow by approximately RMB29.4 million as compared with the adjusted loss of approximately RMB59.6 million for the corresponding period in 2025. Fundamental business operations continued to improve. Cash balances were approximately RMB1,072.9 million as of June 30, 2026 a decrease of RMB19.4 million from bank balances and cash position as of December 31, 2025. Ample liquidity supports domestic market expansion, global clinical R&D, and overseas commercialization in Hong Kong, Macao and Southeast Asia. - Our commercialization team continued to scale. The professional sales team expanded to 187 product representatives, and 75 staff actively engaged in marketing, medical affairs and commercial operation as of June 30, 2026, representing growth of 93% and 79% respectively compared with the same period of 2025. 2. Strengthened Core Intellectual Property Rights and Breakthroughs in Overseas Market Development - Marketing approvals secured and commercialization rolled out in Hong Kong and Macao. Dorzagliatin (brand names: MYHOMSIS(R) was approved for marketing in Hong Kong on February 2026 and in Macao on June 2026. The product has been distributed to hospitals and pharmacies in Hong Kong, with the first prescription issued in August 2026, providing a new treatment option for patients with Type 2 diabetes outside mainland China.  - Patent term extension secured to boost long-term commercial certainty. In February 2026, the China National Intellectual Property Administration granted a five year patent term extension for dorzagliatin, extending core patent protection to April 2034. 3. Real-World Clinical Evidence Reinforces the Product’s Differentiated Value The Group continued advancing post-marketing real-world studies of dorzagliatin to further validate its efficacy and safety profiles in complex patient cohorts. - Topline data released from large-scale multi-centre post-marketing real-world study HMM0601. At the 2026 ADA Scientific Sessions, the Company presented results from HMM0601, a large-scale post-marketing real-world study. Across 80 clinical centres in China, HMM0601 enrolled 2024 patients with Type 2 diabetes with mean disease duration of 7.9 years. Over the 52-week treatment period, no drug-related serious adverse events (SAEs) or episodes of severe hypoglycemia were observed; the incidence of clinically meaningful hypoglycemia was below 1%, and no new safety signals were identified compared with the Phase III clinical trials; HbA1c was significantly reduced from baseline, and the proportion of patients achieving HbA1c<7% increased markedly. This provides robust evidence of dorzagliatin’s strong safety and tolerability profile and consistent glycemic control efficacy. - Interim findings disclosed from prospective real-world observational study HMM0701. This study enrolled 255 patients with Type 2 diabetes, the majority of whom had long disease duration and were already receiving multi-drug regimens including insulin. The 6-month interim results of subgroup analysis indicates that dorzagliatin provides meaningful efficacy in glycemic control. Even in patients with severely compromised baseline TIR, clinically meaningful reductions in HbA1c, improved TIR, enhanced β-cell function, and reduced insulin resistance were observed, collectively indicating the restoration of glucose homeostasis. This study provides a solid rationale for a novel glycemic management option in complex T2D cases. - Preparations remain underway for post-marketing study HMM0602. The study is designed to generate further clinical evidence regarding the role of dorzagliatin in restoring glucose homeostasis and its potential contribution to diabetes remission. Research and Development Pipeline and Future Outlook 1. Multiple R&D Innovation Breakthroughs Usher in New Chapters for First-in-Disease Indications - Dorzagliatin for Patients with GCK-MODY Medical experts in mainland China and Hong Kong have conducted independent clinical and preclinical studies of dorzagliatin for MODY-2 treatment. MODY-2, also called GCK-MODY, is a monogenic disease in which patients have a genetic defect of glucokinase gene (GCK) which results in elevated blood glucose and significant reduction of the second phase release of insulin. The population of GCK-MODY patients is approximately 1.7 million in China. These patients are diagnosed with diabetes at a young age and represent an unmet medical need given currently available medications are not effective. In clinical studies with MODY-2 patients, a single dose of dorzagliatin improved overall glucose sensitivity and second phase insulin secretion significantly in GCK-MODY patients, suggesting a unique mechanism of action of dorzagliatin to regulate glucagon like peptide 1 (GLP-1) secretion. During the Reporting Period, we continued to advance the regulatory development of dorzagliatin for GCK-MODY in China. Following prior communications with the Center for Drug Evaluation of the National Medical Products Administration, we completed the proposed clinical protocol. We plan to submit an IND application for dorzagliatin in GCK-MODY by December 2026. - Dorzagliatin for Diabetes Prevention Prevention of diabetes is an important focus at Hua Medicine. There are approximately 1.12 billion people living with prediabetes worldwide. We have initiated the SENSITIZE 3 clinical study in Hong Kong in pre-diabetic (IGT) subjects and in early diabetes patients under the leadership of Dr Juliana Chan and Dr Elaine Chow of the Chinese University of Hong Kong. These studies represent first-in-disease studies. In this double-blinded placebo-controlled study, we will evaluate the blood glucose management and pancreatic function under intravenous glucose tolerance test and oral glucose tolerance test conditions to better define the clinical treatment baseline and endpoints. We expect to complete this study in 2026 and file IND applications of dorzagliatin for diabetes prevention in China and Asia-Pacific regions thereafter. - Dorzagliatin for Neurodegenerative Diseases MCI shows approximately 15.5% prevalence among elderly people in China and approximately 22% in the United States, and is common in T2D patients with a 45% incidence rate. Development of dorzagliatin for neurodegenerative disease is a new focus in our drug discovery efforts. Through the Genome-Wide Association Study (GWAS) and Mendelian Randomization (MR) study, we have realized the important role of GCK gene activation in prevention of memory loss and cognitive impairment in humans. It has also come to our attention that post-meal glucose excursion is closely related to Alzheimer disease and dementia. Impaired glucose homeostasis and diabetes conditions result in a reduction of glucose transporter expression and insulin receptor expression in the brain, which can be prevented by low dose dorzagliatin. We have realized the potential of dorzagliatin in the treatment of MCI and are initiating these first-in-disease clinical studies. Preparation of the clinical study protocol and clinical development plan has been initiated. We expect to launch pre-IND communications with the relevant regulatory authority in the fourth quarter of 2026. - Dorzagliatin for Frailty Frailty is an age-related geriatric syndrome characterized by reduced tolerance to internal and external stressors. Approximately 17% of American older adults and 11% of Asian older adults suffer from frailty, while pre-frailty affects roughly 50% and 47% of these populations, respectively. It is not a single-organ disease, but the consequence of dysregulated multisystem homeostasis. Genetic evidence has suggested a potential relationship between glucokinase activation and a reduced risk of frailty, supporting further investigation of dorzagliatin in this area. We intend to progress the regulatory preparations for an IND submission in 2026. 2. Robust Pipeline Gains Momentum, AI Powers Collaborative Innovation - Fixed Dose Combination of Dorzagliatin and Metformin We are fast forwarding the development of the FDC of dorzagliatin with metformin. An IND with the NMPA has been filed for our FDC with metformin in China in 2025, with an NDA submission planned for 2027. - The 2nd Generation of GKA under Development in the United States HM1005 is our second-generation GKA program based on a sustained-release formulation of dorzagliatin and is being developed as a once-daily oral therapy. In 2025, we successfully initiated MAD clinical study in T2D patients in the United States. As of the date of this report, five cohorts have been completed as planned in the Phase Ib multiple ascending dose study. HM1005 was generally well tolerated across the completed cohorts. We are conducting a subsequent cohort evaluating two 246 mg tablets in the United States. Topline data are expected to be published in the second half of 2026, and we will pursue partnerships to develop the 2nd generation GKA for global markets. - Development of Combination Therapies for Diabetes and Metabolic Diseases We presented three combination therapy studies in animal models of metabolic disorder at 2026 ADA. The combination of dorzagliatin and orforglipron, an oral small-molecule GLP-1 receptor agonist, demonstrated synergistic glycemic control, significantly enhanced β-cell function, and maintained weight loss and lipid-lowering benefits in diet-induced obese (DIO) mice. Notably, the data revealed a compelling dose-sparing effect which directly reduces the overall side-effect burden – particularly common GLP-1-related gastrointestinal adverse events – thereby meaningfully improving long-term patient adherence. These complementary mechanisms across glycemic control, weight loss, and lipid improvement, position the potential combination as a highly effective, well-tolerated, and differentiated oral option for T2D patients with obesity. In the study combining dorzagliatin with the THR-β agonist resmetirom, the combination synergistically improved systemic metabolism and exerted hepatoprotective effects, optimizing glycemic control, regulating lipids, reducing uric acid, and alleviating hepatic fibrosis. This supports the clinical potential of dorzagliatin for T2D patients with MASLD. Additionally, the combination of dorzagliatin with chiglitazar, a pan-PPAR agonist, improves glucose tolerance, reduces insulin resistance, enhances insulin sensitivity and β-cell function, and elevates high-density lipoprotein cholesterol levels in DIO mice model of MASLD. - Integration of AI, LLMs and Clinical Big Data Alongside the continued development of dorzagliatin in research and clinical practice, the Company has continued to invest in the integration of AI, large language models (LLMs) and clinical big data, and has achieved concrete outcomes. We launched our proprietary GK education platform (GK Charger) in 2025. The platform uses natural language interaction to present complex glucokinase relevant knowledge in evidence-based, clinically relevant format that is easy for both physicians and patients to understand. It enables doctors to obtain up to date diagnostic and treatment information, make accurate clinical decisions, and develop individualized treatment plans for patients. Since the launch of GK Charger, the platform has cumulatively responded to more than 3,700 queries. Financial Summary As of June 30, 2026 - Sales volume of HuaTangNing reached approximately 3.055 million packs, up 73% year-on-year, generating revenue of approximately RMB378.9 million, representing a 74% year-on-year increase. - Gross profit totalled approximately RMB234.3 million, up 99% year-on-year, with gross margin rising to 61.8%. - Loss before tax stood at approximately RMB30.2 million, representing a substantial narrowing compared with adjusted loss recorded in the same period of 2025. - Bank balances and cash position were approximately RMB1,072.9 million, maintaining a healthy liquidity profile. - Total expenditures amounted to approximately RMB265.4 million, including selling expenses of approximately RMB126.9 million and research and development expenses of approximately RMB66.8 million. Forward-Looking Statements This document contains statements regarding Hua Medicine’s future expectations, plans, and prospects for the Company and its products. These forward-looking statements pertain only to events or information as of the date they are made and may change due to future developments. Unless required by law, we are not obligated to update or publicly revise any forward-looking statements or unexpected events after the date of such statements, regardless of new information, future events, or other circumstances. Please read this document carefully and understand that our actual future performance or results may differ materially from expectations due to various risks, uncertainties, or other legal requirements. About Hua Medicine Hua Medicine (the “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Drawing on global resources, Hua Medicine partners with high-calibre talent worldwide to develop breakthrough technologies and products that advance innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets) targets the glucose sensor glucokinase, restores glucose sensitivity in patients with type 2 diabetes (T2D), and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30, 2022. It can be used alone or in combination with metformin for adult patients with T2D. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral glucose-lowering drug that can be used in patients with T2D with renal function impairment. In February 2026, dorzagliatin (brand name: MYHOMSIS(R), was approved for marketing by the Pharmaceutical Service of the Department of Health of the Government of the Hong Kong Special Administrative Region of the People's Republic of China. In June 2026, dorzagliatin (brand name: MYHOMSIS(R), was approved for marketing by the Pharmaceutical Administration Bureau of the Macao Special Administrative Region of the People's Republic of China. Based on the International Diabetes Federation’s 2025 Diabetes Atlas – 11th Edition, there are approximately 148 million diabetic patients in mainland China, 706,000 diabetic patients in Hong Kong SAR, and 52,000 diabetic patients in Macao SAR as of 2024. For more information Website: www.huamedicine.com Investors Email: ir@huamedicine.com Media Email: pr@huamedicine.com Press Disclaimer For accuracy and completeness in context, information related to products marketed in China in this material, especially those identified or required, should comply with documents approved by Chinese regulatory authorities. Additionally, such information should not be interpreted as a recommendation or promotion of any drug or treatment, nor should it replace medical advice from healthcare professionals. For medical-related matters, please consult a healthcare professional. Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com ———————————————————————————————————————————————————————————— AQP One Announces Apple HealthKit and Android Health Connect Integration ... 2026-08-20 · PR-Inside · AI, SaaS, Healthcare https://pr-inside.com/aqp-one-announces-apple-healthkit-and-android-health-connect-integration-r5214368.htm (PR-inside.com) New read/write interoperability expands BioBaseline™ modeling beyond the JBA AICare™ wearable ecosystem GARDEN GROVE, CA / ACCESS Newswire / August 20, 2026 / AQP One, Inc. today announced an expansion of its JBA AI Physiological Intelligence Platform with planned bidirectional connectivity for Apple HealthKit and Android Health Connect. The integration is designed to allow JBA AI, with user permission, to read selected health and wellness information available through these ecosystems and write supported data back to them. The capability supports AQP One's ongoing development of a broader physiological intelligence architecture that is not limited to a single wearable device or application. "The future .. ———————————————————————————————————————————————————————————— AQP One Announces Apple HealthKit and Android Health Connect Integration for JBA AI Platform 2026-08-20 · Newswire.com · AI, SaaS, Healthcare https://www.newswire.com/news/aqp-one-announces-apple-healthkit-and-android-health-connect-22848064 New read/write interoperability expands BioBaseline ™ modeling beyond the JBA AICare ™ wearable ecosystem ———————————————————————————————————————————————————————————— GeoVax Chairman and CEO David Dodd to Participate in 2026 Georgia Life Sciences Summit 2026-08-20 · NewMediaWire · Finance, Healthcare https://www.newmediawire.com/news/geovax-chairman-and-ceo-david-dodd-to-participate-in-2026-georgia-life-sciences-summit-7088738 Former Georgia Life Sciences Chair Selected for CEO Spotlight and Private Global Health Policy Roundtable With U.S. Rep. Rich McCormick ATLANTA, GA - August 20, 2026 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today announced that Chairman, President and Chief Executive Officer David Dodd will participate in two leadership and policy events associated with the 2026 Georgia Life Sciences Summit, August 25–26, at the Performing Arts Center in Sandy Springs, Georgia. Dodd, a former Chair of Georgia Life Sciences, has been selected as one of four biotechnology CEOs participating in “CEO Spotlights: Decisions That Define a Company,” presented by BioSpark Labs, on August 26 ———————————————————————————————————————————————————————————— Maxwell Biosciences' Spinout SHU.ai Announces Closing of $1M Financing Round 2026-08-20 · mlpr-newsfile · AI, Healthcare https://www.newsfilecorp.com/release/310550/Maxwell-Biosciences-Spinout-SHU.ai-Announces-Closing-of-1M-Financing-Round Austin, Texas--(Newsfile Corp. - August 20, 2026) - Maxwell Biosciences, a global health technology company pioneering a new category of immune-inspired small molecules called Claromers®, December 5, 2025 incorporated its first spinout SHU.ai and June 27, 2026 announced the closing of SHU's $1 million Seed round. The round was oversubscribed and fully funded by private angel investors and led by Keiretsu Forum, "The World's Largest Angel Investor Network." The funds will support accelerating... ———————————————————————————————————————————————————————————— Sagility Named a Market Leader in HFS Research Horizons HCP Service Providers 2026 Report 2026-08-20 · PRWeb · AI, Healthcare https://www.prweb.com/releases/sagility-named-a-market-leader-in-hfs-research-horizons-hcp-service-providers-2026-report-302854906.html • Sagility recognized as a Market Leader (Horizon 3), evaluated among 50 healthcare service providers across clinical, operational, and financial dimensions. • Sagility's 25-year history of payer policy intelligence and domain-led AI platforms help healthcare providers reduce clinical... ———————————————————————————————————————————————————————————— India Medical Polymers Market Opportunities in Healthcare Manufacturing 2026-08-20 · Express Press Release · Healthcare https://express-press-release.net/news/2026/08/20/1768611 The Medical Polymers Market was valued at USD 25.1 billion in 2025 and is projected to reach USD 47.1 billion by 2033, expanding at a [read full press release...] ———————————————————————————————————————————————————————————— Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13 2026-08-20 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/20/3348379/0/en/artelo-biosciences-secures-notice-of-allowance-in-japan-for-patent-claims-for-the-intended-commercial-formulation-of-art27-13.html SOLANA BEACH, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”) , a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that the Japanese Patent Office has issued a notification of allowance with a Decision to Grant for the Company’s patent application covering the intended commercial formulation of ART27.13, Artelo’s peripherally selective dual cannabinoid agonist currently being evaluated in two Phase 2 clinical trials. ———————————————————————————————————————————————————————————— Amanda Owens Joins Precision for Medicine To Expand Access to Fit-for-Purpose Biospecimens for Advanced Research 2026-08-20 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/amanda-owens-joins-precision-for-medicine-to-expand-access-to-fit-for-purpose-biospecimens-for-advanced-research-302855905.html Experienced life sciences executive to expand access to high-quality, deeply annotated biospecimens supporting research and development of next-generation therapies BETHESDA, Md., Aug. 20, 2026 /PRNewswire/ -- Precision for Medicine, a global leader in biomarker-driven clinical research... ———————————————————————————————————————————————————————————— Fertility Brand Bird&Be Partners with Mandell's Clinical Pharmacy to Expand Access to Fertility Care Nationwide 2026-08-20 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/fertility-brand-birdbe-partners-with-mandells-clinical-pharmacy-to-expand-access-to-fertility-care-nationwide-302856412.html Filling a critical care gap where fertility care in the U.S. falls short, the partnership puts doctor-recommended, treatment-safe supplements directly in the hands of fertility patients nationwide. TORONTO, Aug. 20, 2026 /PRNewswire/ -- Bird&Be, the fertility and wellness brand making... ———————————————————————————————————————————————————————————— Do alumni relationships between judges and lawyers affect court rulings? 2026-08-20 · WebWire · Healthcare, Education https://www.webwire.com/ViewPressRel.asp?aId=359189 Using Florida medical malpractice cases with randomly assigned judges, investigators found that sharing a law school with the presiding judge boosted a plaintiff's attorney's probability of recovering damages by approximately 2 percentage points. - - The researchers found no comparable effects when judges and lawyers attended different law schools of similar rank or shared the same gender or minority status, suggesting that the result is not driven by school quality or these other observabl... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=359189 ———————————————————————————————————————————————————————————— Protagenic Therapeutics Receives FDA Pre-IND Feedback Supporting New ... 2026-08-20 · PR-Inside · Healthcare https://pr-inside.com/protagenic-therapeutics-receives-fda-pre-ind-feedback-supporting-new-r5214361.htm (PR-inside.com) FDA raises no objection to the Company's planned Phase 1 program design, dose-escalation approach, or CMC and nonclinical packages; IND submission remains on track for the fourth quarter of 2026 NEW YORK, NY / ACCESS Newswire / August 20, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company developing novel peptide-based treatments for stress-related neuropsychiatric disorders, today announced that it has received written responses from the U.S. Food and Drug Administration (FDA) to its Type B pre-Investigational New Drug (pre-IND) meeting request for PT00114, the Company's leading investigational neuropeptide product candidate, for the treatment of generalized anxiety disorder (GAD). In its .. ———————————————————————————————————————————————————————————— Protagenic Therapeutics Receives FDA Pre-IND Feedback Supporting New IND for PT00114 in Generalized Anxiety Disorder 2026-08-20 · Newswire.com · Healthcare https://www.newswire.com/news/protagenic-therapeutics-receives-fda-pre-ind-feedback-supporting-new-ind-for FDA raises no objection to the Company's planned Phase 1 program design, dose-escalation approach, or CMC and nonclinical packages; IND submission remains on track for the fourth quarter of 2026 ———————————————————————————————————————————————————————————— RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment 2026-08-20 · GlobeNewswire · Finance, Healthcare, Real Estate https://www.globenewswire.com/news-release/2026/08/20/3348338/0/en/renovorx-receives-notice-of-allowance-for-new-u-s-patent-covering-renovocath-an-advanced-dual-occlusion-catheter-for-targeted-therapeutic-drug-delivery-for-cancer-treatment.html As Commercial and Clinical Programs Advance, RenovoRx Continues to Strengthen its Global Intellectual Property Portfolio with 20 Issued or Allowed Patents and 13 Pending Patents to Support the Commercialization of RenovoCath As Commercial and Clinical Programs Advance, RenovoRx Continues to Strengthen its Global Intellectual Property Portfolio with 20 Issued or Allowed Patents and 13 Pending Patents to Support the Commercialization of RenovoCath ———————————————————————————————————————————————————————————— Healthcare Analytics Market Innovation: Technologies Shaping the Future of Healthcare 2026-08-20 · Express Press Release · Healthcare https://express-press-release.net/news/2026/08/20/1768606 Healthcare organizations are generating unprecedented amounts of information through electronic health records (EHRs), wearable devices, remote monitoring technologies, insurance claims, clinical research, and other digital [read full press release...] ———————————————————————————————————————————————————————————— BioInvent Announces Publication of Preclinical Manuscript on BI-1808 ... 2026-08-20 · PR-Inside · Finance, Healthcare https://pr-inside.com/bioinvent-announces-publication-of-preclinical-manuscript-on-bi-r5214357.htm (PR-inside.com) Preclinical manuscript that characterizes the mechanism of action, broad antitumor efficacy, and immune-activating properties of BI-1808 and BI-1910 across diverse tumor microenvironments Data demonstrates the ability of the lead anti-TNFR2 antibody BI-1808 to elicit antitumor immunity in CD8+ T cell poorly infiltrated tumors resistant to immune checkpoint blockade BI-1808 is currently being evaluated in ongoing Phase 2a clinical trials with clinical data showing promising activity across both hematologic and solid tumor settings with the potential to become the next standard of care in ovarian cancer LUND, SE / ACCESS Newswire / August 20, 2026 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in .. ———————————————————————————————————————————————————————————— Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement ... 2026-08-20 · PR-Inside · Healthcare https://pr-inside.com/lobe-sciences-ltd-announces-closing-of-non-brokered-private-placement-r5214350.htm (PR-inside.com) NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / August 20, 2026 /Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE), a clinical-stage biopharmaceutical company advancing therapeutic development programs through focused subsidiary companies, is pleased to announce the closing of its previously announced non-brokered private placement offering of 24,705,880 common shares in the capital of the Company ("Common Shares") at a price of $0.085 per Common Share, for aggregate gross proceeds of approximately $2,100,000 (the "Private Placement"). The Company intends to use the proceeds of the Private Placement for working capital and .. ———————————————————————————————————————————————————————————— Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at ... 2026-08-20 · PR-Inside · Finance, Healthcare https://pr-inside.com/ensysce-biosciences-to-showcase-a-new-era-in-pain-therapeutics-at-r5214347.htm (PR-inside.com) ~Major symposium to highlight breakthrough innovations in severe pain and Complex Regional Pain Syndrome (CRPS) ~ ~Discussions to feature a first-in-class approach to neural reset and novel chemical safety switch technology ~ SAN DIEGO, CA / ACCESS Newswire / August 20, 2026 /Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on complex pain, today announced that it will host an educational symposium at PAINWeek 2026, entitled A New Era in Pain Therapeutics. The symposium will present a vision for the future of pain management-one that introduces an entirely .. ———————————————————————————————————————————————————————————— EVERSANA Expands AI-Powered Commercialization Platform with New Capabilities Across Medical Affairs, Market Research and Commercial Operations 2026-08-20 · PR Newswire · AI, SaaS, Healthcare https://www.prnewswire.com/news-releases/eversana-expands-ai-powered-commercialization-platform-with-new-capabilities-across-medical-affairs-market-research-and-commercial-operations-302855424.html Expansion advances Company's vision for an AI-native, connected commercialization ecosystem to help life sciences organizations improve efficiency, accelerate execution and support better patient outcomes CHICAGO, Aug. 20, 2026 /PRNewswire/ -- EVERSANA, a leading provider of global... ———————————————————————————————————————————————————————————— Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Letter of Intent with Darmiyan, Inc. to Explore Use of FDA De Novo Authorized BrainSee(R) AI Platform in Early Alzheimer's Disease Trial Design 2026-08-20 · mlpr-newsfile · AI, SaaS, Healthcare https://www.newsfilecorp.com/release/310598/Rhelion-Life-Sciences-Wholly-Owned-Subsidiary-Filament-Health-Signs-Letter-of-Intent-with-Darmiyan-Inc.-to-Explore-Use-of-FDA-De-Novo-Authorized-BrainSeeR-AI-Platform-in-Early-Alzheimers-Disease-Trial-Design Collaboration looks to explore the use of Darmiyan's FDA De Novo authorized BrainSee® imaging platform, authorized for predicting risk of progression to Alzheimer's disease in patients with amnestic mild cognitive impairment, as well as Darmiyan's core technology, the Virtual Microscope, tailored towards use in pharmaceutical clinical trialsThe goal of the collaboration is to inform the identification, selection and monitoring of the best candidates for clinical trials of PEX010, Rhelion's... ———————————————————————————————————————————————————————————— REDICO and One Orchard launch InfraMed Properties -- a medical outpatient investment platform poised for nationwide growth 2026-08-20 · PR Newswire · SaaS, Healthcare, Real Estate https://www.prnewswire.com/news-releases/redico-and-one-orchard-launch-inframed-properties--a-medical-outpatient-investment-platform-poised-for-nationwide-growth-302855869.html InfraMed is structured to acquire, develop and manage medical outpatient properties across the United States New venture seeded with a 25-asset portfolio across 16 states Formation of InfraMed combines REDICO's 60 years of experience as a commercial real estate investor with One Orchard's... ———————————————————————————————————————————————————————————— Avant Brands Completes EU GMP Audit at Flowr Facility 2026-08-20 · PR-Inside · Healthcare https://pr-inside.com/avant-brands-completes-eu-gmp-audit-at-flowr-facility-r5214333.htm (PR-inside.com) KELOWNA, BC / ACCESS Newswire / August 20, 2026 /Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BU) ("Avant" or the "Company"), is pleased to announce the completion of its European Union Good Manufacturing Practice ("EU GMP") audit at the Company's largest cultivation facility, The Flowr Group Okanagan Inc. ("Flowr"), located in Kelowna, B.C. Completion of the on-site audit represents an important step in Avant's efforts to obtain EU GMP certification at the Flowr facility. If certification is ultimately granted, it could support increased growth of Avant's international medical cannabis markets, providing the Company with greater control over its international supply chain. Norton Singhavon, Founder & CEO .. ———————————————————————————————————————————————————————————— UniDoc Health Signs MOU with Ventripoint Diagnostics to Evaluate Remote ... 2026-08-20 · PR-Inside · AI, SaaS, Healthcare https://pr-inside.com/unidoc-health-signs-mou-with-ventripoint-diagnostics-to-evaluate-remote-r5214332.htm (PR-inside.com) Proposed collaboration would combine UniDoc's connected-care infrastructure with Ventripoint's AI-enabled cardiac imaging platform VANCOUVER, BC / ACCESS Newswire / August 20, 2026 / UniDoc Health Corp. (CSE:UDOC)(FRA:L7T)(OTCQB:UDOCF) ("UniDoc" or the "Company"), a company developing eHealth solutions, is pleased to announce that it has signed a non-exclusive and non-binding memorandum of understanding (the "MOU") with Ventripoint Diagnostics Ltd. (TSXV:VPT) (OTC:VPTDF) ("Ventripoint") to evaluate a potential collaboration focused on remote cardiac assessment and cardiovascular screening. Key Takeaways: The collaboration will assess Ventripoint's VMS+™ platform as an optional cardiac imaging component within selected UniDoc Health Cube configurations and virtual-care deplo ———————————————————————————————————————————————————————————— Evaxion announces business update and second quarter 2026 financial results 2026-08-20 · GlobeNewswire · Finance, AI, SaaS, Healthcare https://www.globenewswire.com/news-release/2026/08/20/3348249/0/en/evaxion-announces-business-update-and-second-quarter-2026-financial-results.html COPENHAGEN, Denmark, August 20, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces second quarter 2026 financial results. ———————————————————————————————————————————————————————————— Keenova Advances Podiatry Pipeline with First Patient Dosed in Phase 3 Trial of XIAFLEX® (collagenase clostridium histolyticum) for Hammer Toe 2026-08-20 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/keenova-advances-podiatry-pipeline-with-first-patient-dosed-in-phase-3-trial-of-xiaflex-collagenase-clostridium-histolyticum-for-hammer-toe-302855400.html First registered, randomized Phase 3 trial evaluating the efficacy, safety, and tolerability of XIAFLEX in adults with hammer toe No FDA-approved nonsurgical therapies currently indicated for the treatment of hammer toe Hammer toe treatment today is limited to mainly orthotics,... ———————————————————————————————————————————————————————————— $CAPR Securities: Capricor Therapeutics Shareholders Who Lost Money ... 2026-08-20 · PR-Inside · Finance, Healthcare https://pr-inside.com/capr-securities-capricor-therapeutics-shareholders-who-lost-money-r5214317.htm (PR-inside.com) Capricor Therapeutics, Inc. has been sued for securities fraud over alleged misstatements about Deramiocel and the integrity of the clinical data supporting its Biologics License Application leading to a 64% stock drop. NEW YORK CITY, NY / ACCESS Newswire / August 20, 2026 / Leading securities law firmBleichmar Fonti & Auld LLPannounces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ:CAPR) and certain of the company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws. If you invested in Capricor Therapeutics securities, you are encouraged to obtain additional .. ———————————————————————————————————————————————————————————— AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 2026-08-20 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/20/3348200/0/en/ac-immune-announces-positive-preliminary-phase-1-data-for-nlrp3-inhibitor-aci-19764.html AC Immune announced positive interim Phase 1 results from a first-in-human clinical study evaluating ACI-19764, an NLRP3 inhibitor targeting inflammation. ———————————————————————————————————————————————————————————— Covalon Announces Conference Call to Discuss Third Quarter Fiscal 2026 Results 2026-08-20 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/covalon-announces-conference-call-discuss-110000139.html MISSISSAUGA, Ontario, August 20, 2026--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, will release its Q3 Fiscal 2026 results on Thursday, August 27, 2026, before markets open. A conference call and webcast to discuss the results will be held on Thursday, August 27, 2026, at 8:30am ET. ———————————————————————————————————————————————————————————— Herantis Pharma releases 1H 2026 report today 2026-08-20 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/08/20/3348198/0/en/herantis-pharma-releases-1h-2026-report-today.html Espoo, Finland, August 20, 2026: Herantis Pharma Plc ("Herantis") a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, releases today the Company’s 1H 2026 report. The full report is attached to this release and is also available on the Company’s website: www.herantis.com . ———————————————————————————————————————————————————————————— Humana Names Dr. Shantanu Nundy as Chief Medical Officer 2026-08-20 · mlpr-businesswire · Finance, Healthcare https://finance.yahoo.com/healthcare/articles/humana-names-dr-shantanu-nundy-110000094.html LOUISVILLE, Ky., August 20, 2026--Humana Inc. (NYSE: HUM) today announced that Shantanu Nundy, M.D., will join the company as Chief Medical Officer, effective August 31. A practicing physician, healthcare executive, and technology leader, Dr. ———————————————————————————————————————————————————————————— Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial 2026-08-20 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/20/3348199/0/en/radiopharm-theranostics-receives-positive-recommendation-from-data-safety-and-monitoring-committee-to-advance-to-cohort-4-in-177lu-rad202-phase-1-heat-clinical-trial.html Advancing RAD202 Phase 1 trial to next dose level of 180mCi in patients with HER2+ advanced solid tumors ———————————————————————————————————————————————————————————— Serif Health Receives Significant Growth Investment From SEVA 2026-08-20 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/serif-health-receives-significant-growth-110000839.html SAN FRANCISCO, August 20, 2026--Serif Health ("Serif" or the "Company"), the leading provider of healthcare price transparency data and intelligence, today announced a significant minority investment from SEVA Growth LP ("SEVA"). ———————————————————————————————————————————————————————————— HealthTab™ Enters Multi-Year Collaboration Agreement with Abbott for Point-of-Care Testing Across the UK 2026-08-20 · GlobeNewswire · SaaS, Healthcare https://www.globenewswire.com/news-release/2026/08/20/3348189/0/en/healthtab-enters-multi-year-collaboration-agreement-with-abbott-for-point-of-care-testing-across-the-uk.html VANCOUVER, British Columbia, Aug. 20, 2026 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) is pleased to announce that its wholly-owned subsidiary, HealthTab Ltd, has entered into a formal collaboration agreement with Abbott, a global healthcare company, to supply and distribute Abbott’s point-of-care testing products through the HealthTab™ platform in the UK. ———————————————————————————————————————————————————————————— UNLOCKD Completes Initial Production Run of Morning Magic Functional Mushroom K-Cups, Targets E-Commerce and Retail Expansion 2026-08-20 · NewMediaWire · Retail, Healthcare https://www.newmediawire.com/news/unlockd-completes-initial-production-run-of-morning-magic-functional-mushroom-k-cups-targets-e-commerce-and-retail-expansion-7088730 Ancient Extracts USA Enters the Multibillion-dollar Single-serve Coffee Market as UNLOCKD Expands Its Consumer Portfolio to 72 SKUs LANCASTER, PA - August 20, 2026 ( NEWMEDIAWIRE ) - BitFrontier Capital Holdings, Inc. (OTCID: BFCH), doing business as UNLOCKD Inc. (“UNLOCKD” or the “Company”), today announced that Ancient Extracts USA has completed the initial production run of Morning Magic functional mushroom coffee in a K-Cup-compatible single-serve format. The Company is now preparing Morning Magic K-Cups for launch on Amazon and its direct-to-consumer website, AncientExtracts.com , while sending samples to prospective retail category buyers as it pursues broader brick-and-mortar distribution opportunities. For UNLOCKD, the significance extends well beyond another product launch. Mornin ———————————————————————————————————————————————————————————— Specialty PACS Market Report: Growth Drivers and Forecasts 2026-08-20 · Express Press Release · Healthcare https://express-press-release.net/news/2026/08/20/1768555 Medical imaging is expanding faster than most hospital IT budgets can comfortably absorb. Every additional MRI, mammogram, or pathology slide adds to a growing pile [read full press release...] ———————————————————————————————————————————————————————————— Dr. Roger Wu, CEO of 20Slash20 Inc, to Present The Eye Drink Company ... 2026-08-20 · PR-Inside · Healthcare, Retail, Education https://pr-inside.com/dr-roger-wu-ceo-of-20slash20-inc-to-present-the-eye-drink-company-r5214293.htm (PR-inside.com) Presentation Scheduled for September 9, 2026, at 9:35 AM in Room 2 SAN DIEGO, CA / ACCESS Newswire / August 20, 2026 /As an incubated client of Fast Moving Consumer Goods (GGII), 20Slash20, Inc., a health and wellness company focused on advancing eye health awareness through innovative consumer products and education, announced today that Dr. Roger Wu, Founder and CEO of 20Slash20, will present the company's vision, growth strategy, and market opportunities at the Moody's Capital 2026 Disruptive Growth and Life Sciences Conference September 9-10. Dr. Wu's presentation is scheduled to begin at 9:35 AM in Room 2 on September 9, 2026, .. ———————————————————————————————————————————————————————————— Strategic Trends Fueling Healthcare Command Center Adoption 2026-08-20 · Express Press Release · Healthcare https://express-press-release.net/news/2026/08/20/1768553 Hospitals today are being asked to do more with less — fewer beds, tighter staffing, and rising patient volumes, all while maintaining safety and quality. [read full press release...] ———————————————————————————————————————————————————————————— Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow‑Up Shows Continued Efficacy Improvement 2026-08-20 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/20/3348153/0/en/leads-biolabs-opamtistomig-pd-l1-4-1bb-bispecific-antibody-abstract-published-by-wclc-extended-follow-up-shows-continued-efficacy-improvement.html NANJING, China, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that the full abstract of the Phase II clinical study evaluating its proprietary drug candidate LBL-024 (Opamtistomig, a PD-L1/4-1BB bispecific antibody) in combination with chemotherapy as a first-line treatment for non-small cell lung cancer (“NSCLC”) has been published on the official website of the World Conference on Lung Cancer (the “WCLC”). Based on data analyzed as of March 6, 2026, LBL-024 in combination with chemotherapy demonstrated an encouraging antitumor activity in the overall population, with robust tumor shrinkage observed in both the squamous and non-squamous NSCLC. The abstract data were based on a median follow‑up of 3 ———————————————————————————————————————————————————————————— BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026 2026-08-20 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/20/3348151/0/en/biontech-highlights-late-stage-lung-cancer-pipeline-momentum-and-first-global-data-for-pumitamig-elfetabart-drozuntecan-novel-novel-combination-at-wclc-2026.html MAINZ, Germany, August 20, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present new clinical data from its diversified development program in lung cancer treatment at the IASLC 2026 World Conference on Lung Cancer (“WCLC”) in Seoul, Republic of Korea, from September 12-15, 2026. ———————————————————————————————————————————————————————————— Study Found Artery Damage in Adults in Their 20s, Highlighting Need for Early Cardiovascular Risk Assessment 2026-08-20 · NewMediaWire · Healthcare, Retail https://www.newmediawire.com/news/study-found-artery-damage-in-adults-in-their-20s-highlighting-need-for-early-cardiovascular-risk-assessment-7088729 Research Highlights : A new study found that nearly 8 out of 10 young adult participants, average age 23 years, had cardiovascular-kidney-metabolic syndrome (CKM syndrome) stages 1 – 3. Participants in higher CKM syndrome stages had early signs of arterial injury. Young adults with more advanced CKM syndrome stages also had lower cardiovascular health scores, as measured by the American Heart Association's Life's Essential 8™ metrics. DALLAS - August 20, 2026 ( NEWMEDIAWIRE ) - A new scientific study found that nearly 8 out of 10 young adult participants, average age 23 years, had cardiovascular-kidney-metabolic syndrome (CKM syndrome), according to new independent research published today in Circulation: Population Health and Outcomes, a peer-reviewed scientific journal of the American He ———————————————————————————————————————————————————————————— London Private GP Launches Next-Generation Longevity and Preventative Medicine Clinic to Combat Chronic Illness 2026-08-20 · Pressat · Healthcare https://pressat.co.uk/releases/london-private-gp-launches-next-generation-longevity-and-preventative-medicine-clinic-to-combat-chronic-illness-26b2834f62cb0e1d030dc75bc82fbe18/ Thursday 20 August, 2026 London-based private GP clinic DrStavy.com has officially launched an advanced suite of longevity and preventative medicine services, designed to shift the healthcare paradigm from reactive treatment to proactive wellness. Founded by experienced general practitioner Dr Stavroula Nikitopoulou, the clinic integrates cutting-edge health screening, functional medicine, and personalized internal medicine to identify and address the root causes of chronic illness before symptoms manifest. As global interest in health optimization and lifespan extension reaches an all-time high, DrStavy.com bridges the gap between traditional family medicine and evidence-based longevity therapies. The clinic’s comprehensive protocols feature advanced diagnostic testing, including tailored ———————————————————————————————————————————————————————————— Rise Nano Optics Joins the Vision Council, a Leading Optical Trade Association, Expanding Access to Key Optical Relationship 2026-08-20 · mlpr-newsfile · Healthcare https://www.newsfilecorp.com/release/310558/Rise-Nano-Optics-Joins-the-Vision-Council-a-Leading-Optical-Trade-Association-Expanding-Access-to-Key-Optical-Relationship Vancouver, British Columbia--(Newsfile Corp. - August 20, 2026) - Rise Nano Optics Ltd. (CSE: EYE) (OTCQB: RNOLF) (FSE: U9Y) ("Rise" or the "Company"), a health technology company advancing vision care through patented nanotechnology lens solutions, is pleased to announce that it has joined The Vision Council, one of the optical industry's leading trade associations representing hundreds of eyewear manufacturers, lens laboratories, retailers, distributors and technology companies across North... ———————————————————————————————————————————————————————————— Akiram Therapeutics and ITM Sign Lutetium-177 Supply Agreement to Support Development of AKIR001 for the Treatment of Solid Tumors 2026-08-20 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/akiram-therapeutics-and-itm-sign-lutetium-177-supply-agreement-to-support-development-of-akir001-for-the-treatment-of-solid-tumors-302856112.html Akiram Therapeutics, a Swedish clinical-stage biotech company specializing in molecular radiotherapy, and ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced a supply agreement for non-carrier-added (n.c.a.) Lutetium-177 (Lu-177 or... ———————————————————————————————————————————————————————————— TLC Healthcare engages Mayo Clinic Global Consulting to advance healthcare excellence 2026-08-20 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/tlc-healthcare-engages-mayo-clinic-060500836.html MELBOURNE, Australia, August 20, 2026--TLC Healthcare (TLC) - a leading healthcare provider of multi-generational healthcare across Victoria, Australia - announced today that it has engaged Mayo Clinic Global Consulting to provide advisory services related to TLC’s integrated care expansion with the launch of its new Hospital Day Surgery in Hallam, Victoria. ———————————————————————————————————————————————————————————— HELP Therapeutics Announces Nature Medicine Has Published HiCM-188 Clinical Trial Data for Advanced Ischemic Heart Failure 2026-08-20 · mlpr-acnnewswire · Healthcare https://www.acnnewswire.com/press-release/english/109269/ NANJING, CHINA, August 20, 2026 - (ACN Newswire) - Aug 19, HELP Therapeutics today announced the Nature Medicine publication of 12-month results from the HEAL-CHF clinical trial evaluating HiCM-188, an investigational allogeneic human iPSC-derived cardiomyocyte (hiPSC-CM) therapy for the treatment of severe ischemic heart failure. The randomized controlled trial enrolled 20 patients, assigned 1:1 to receive either coronary artery bypass grafting (CABG) alone or CABG combined with transepicardial HiCM-188 injection. The study achieved both pre-specified primary safety endpoints, demonstrating no treatment-related tumor formation through 12 months and no sustained ventricular tachycardia through 6 months. At 12 months, 90% of patients receiving transepicardial HiCM-188 injection combined with (CABG improved to NYHA Class II, versus 60% of patients in the CABG-only group.. "HEAL-CHF provides the first clinical evidence that delivering HiCM-188 intraoperatively during CABG may combine the benefits of revascularization with myocardial regeneration," said Professor Dongjin Wang, Lead Author and Director of the Department of Cardiothoracic Surgery at Nanjing Drum Tower Hospital. "Over 12 months, we observed no serious cell-related adverse events alongside encouraging signs of reverse cardiac remodeling. Given the substantial global burden of heart failure and the persistent shortage of donor hearts, regenerative approaches like HiCM-188 have the potential to fill a critical unmet need for patients living with end-stage disease." "The publication of the HEAL-CHF study in Nature Medicine reflects years of dedication to advancing breakthrough stem cell technologies into clinically validated therapies," said Dr. Eugene Jiaxian Wang, Chief Executive Officer of HELP Therapeutics. "With our pivotal Phase III trial now enrolling patients in China and our Phase I program initiating in the U.S., we are eager to maintain this momentum as we work toward bringing a new regenerative medicine breakthrough to heart failure patients worldwide." About HiCM-188 HiCM-188 is an investigational allogeneic human induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) therapy designed as a standardized, off-the-shelf product for scalable manufacturing and distribution. HiCM-188 is the first iPSC-derived cardiomyocyte therapy worldwide to obtain Investigational New Drug (IND) clearances from both the U.S. FDA and China's NMPA. It is currently being evaluated in a multicenter Phase III trial in China led by TEDA International Cardiovascular Hospital, and a Phase I trial in the United States at the Texas Heart Institute. About HELP Therapeutics Founded in 2016, HELP Therapeutics is a global clinical-stage biopharmaceutical company developing iPSC-based cell therapies for cardiovascular and other degenerative diseases. The company leverages proprietary off-the-shelf cell therapy platforms and national iPSC bank infrastructure to ensure scalable clinical and commercial delivery. HELP Therapeutics has established a commercialization partnership with China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (SZSE: 000999) to build out distribution infrastructure in China. For more information, please visit https://en.helptherapeutics.com. Disclosure Notice The information contained in this release is as of August 19, 2026. HiCM-188 is an investigational product and has not been approved for commercial use by the U.S. Food and Drug Administration, China National Medical Products Administration, or any other regulatory authority. This release contains forward-looking statements regarding HiCM-188, including potential clinical benefits and regulatory development timelines, which involve substantial risks and uncertainties that could cause actual results to differ materially. References & Publication Details 1.Journal: Nature Medicine (2026) DOI: 0.1038/s41591-026-04605-1 2.Clinical Trial Registry: ClinicalTrials.gov (NCT03763136) 3.Ethics Approval: Nanjing Drum Tower Hospital IRB (No. SC202000102); National Health Commission of China (MR-32-21-014649) Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com ———————————————————————————————————————————————————————————— Focus on The Path Forward for Orviglance 2026-08-20 · PR-Inside · Healthcare https://pr-inside.com/focus-on-the-path-forward-for-orviglance-r5214284.htm (PR-inside.com) MALMÖ, SE / ACCESS Newswire / August 20, 2026 / Ascelia Pharma (STO:ACE) today published its Half-Year Report for 2026 (January - June), which is now available on the company's website: Financial Reports - ASCELIA KEY EVENTS IN Q2 2026 Ascelia Pharma completed a directed share issue of SEK 20 million before transaction costs Bulletin from the Annual General Meeting in Ascelia Pharma AB on 4 May 2026 Orviglance data presented at the Annual Radiology Congress ESGAR 2026 Orviglance IP Portfolio expanded with new patent filing KEY EVENTS AFTER THE PERIOD Ascelia Pharma receives a Complete Response Letter from the U.S. Food and Drug Administration regarding the .. ———————————————————————————————————————————————————————————— Vistin Pharma ASA: Second quarter and YTD 2026 financial results 2026-08-20 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/08/20/3348089/0/en/vistin-pharma-asa-second-quarter-and-ytd-2026-financial-results.html Oslo, Norway, 20 August 2026 ———————————————————————————————————————————————————————————— Curitics Health Unveils Next-Generation AI Platform to Transform Clinical Workflows 2026-08-20 · PR Newswire · AI, SaaS, Healthcare https://www.prnewswire.com/news-releases/curitics-health-unveils-next-generation-ai-platform-to-transform-clinical-workflows-302855756.html New Curitics Point of Care Solution, Ambient Listening, AI Care Management, and mobile capabilities help reduce administrative burden, strengthen care coordination, and improve patient outcomes. LOS ANGELES, Aug. 20, 2026 /PRNewswire/ -- Curitics Health today announced the expansion of... ———————————————————————————————————————————————————————————— Zelluna ASA: Second Quarter 2026 results 2026-08-20 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/08/20/3348082/0/en/zelluna-asa-second-quarter-2026-results.html Oslo, 20 August 2026 – Zelluna (OSE: ZLNA), a clinical-stage company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today presents its results for the second quarter 2026. ———————————————————————————————————————————————————————————— Hope Services Expands Its Reach With Purchase Of Second Vocational Training Center In Hudson 2026-08-20 · PRLog · Healthcare https://www.prlog.org/13165670-hope-services-expands-its-reach-with-purchase-of-second-vocational-training-center-in-hudson.html New Hudson center will expand access to hands-on vocational training and career opportunities while introducing a basic medical training program. ———————————————————————————————————————————————————————————— Essity acquires feminine care business in Brazil 2026-08-20 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/essity-acquires-feminine-care-business-in-brazil-302855886.html STOCKHOLM, Aug. 20, 2026 /PRNewswire/ -- Hygiene and health company Essity has entered into an agreement to acquire Kenvue's feminine care business in Brazil, including the market-leading brands Carefree, Sempre Livre and o.b. The purchase price amounts to USD 284m (approximately SEK... ———————————————————————————————————————————————————————————— Edesa Biotech Announces Pricing of $25.0 Million Public Offering 2026-08-20 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/20/3348070/0/en/edesa-biotech-announces-pricing-of-25-0-million-public-offering.html TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the pricing of an underwritten public offering consisting of (i) 3,870,500 common shares and accompanying common share warrants to purchase an aggregate of 3,870,500 common shares and (ii) in lieu of common shares to investors who so choose, pre-funded warrants to purchase up to 675,000 common shares and accompanying common share warrants to purchase an aggregate of 675,000 common shares, at an exercise price of $0.0001 per pre-funded warrant. Each common share and pre-funded warrant is being sold in combination with an accompanying common share ———————————————————————————————————————————————————————————— HIMS INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims ... 2026-08-20 · PR-Inside · Finance, Healthcare https://pr-inside.com/hims-investor-alert-kirby-mcinerney-llp-investigates-potential-claims-r5214220.htm (PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 19, 2026 / (ACCESS NEWSWIRE)-The law firm of Kirby McInerney LLP continues its investigation on behalf of Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE:HIMS) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices. [CONTACT THE FIRM IF YOU SUFFERED A LOSS] What Happened? On July 29, 2026, the Federal Trade Commission (the "FTC") filed a lawsuit against Hims, accusing the Company of sharing customers' medical information with third-party advertisers. The FTC complaint accuses the Company of "deceptive and .. ———————————————————————————————————————————————————————————— RMTG Provides Details for First-Ever Investor Call to Answer Shareholder ... 2026-08-19 · PR-Inside · Healthcare https://pr-inside.com/rmtg-provides-details-for-first-ever-investor-call-to-answer-shareholder-r5214175.htm (PR-inside.com) Company Announces Date, Time and Connection Details for Its Inaugural Investor Call Following a Strong First Half of 2026 MIAMI, FL / ACCESS Newswire / August 19, 2026 / Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, today announced the connection details for its first-ever investor call, during which management will present prepared remarks responding to questions submitted by shareholders. The call reflects the Company's strong performance through the first half of 2026 and management's commitment to increased transparency and engagement with its shareholders. As previously .. ———————————————————————————————————————————————————————————— Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates 2026-08-19 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/19/3348052/0/en/ascentage-pharma-reports-2026-interim-unaudited-financial-results-and-provides-business-updates.html Earnings release ———————————————————————————————————————————————————————————— Onco-Innovations Enters into LOI with Ifowonco for Exclusive Option ... 2026-08-19 · PR-Inside · Healthcare https://pr-inside.com/onco-innovations-enters-into-loi-with-ifowonco-for-exclusive-option-r5214164.htm (PR-inside.com) CALGARY, AB / ACCESS Newswire / August 19, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has entered into a non-binding Letter of Intent ("LOI") with Ifowonco Informatics Incorporated ("Ifowonco") as an initial step toward negotiating a definitive agreement that would, if completed, grant Onco an exclusive option relating to Ifowonco's proprietary small-molecule inhibitor program targeting lymphocyte-activation gene 3 ("LAG-3") (the "LAG-3 Program"). The proposed collaboration is intended to combine Ifowonco's novel oral small-molecule immune checkpoint technology with Onco-Innovations' expertise in DNA damage response (DDR) therapeutics, translational oncology and clinical deve ———————————————————————————————————————————————————————————— The Inner Circle acknowledges V. Ray Cordry, Jr., DO as a 2026 Preferred Psychiatrist 2026-08-19 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/the-inner-circle-acknowledges-v-ray-cordry-jr-do-as-a-2026-preferred-psychiatrist-302855657.html HENNESSY, Okla., Aug. 19, 2026 /PRNewswire/ -- Prominently featured in The Inner Circle, V. Ray Cordry, Jr., DO is acknowledged as a 2026 Preferred Psychiatrist for his contributions to Behavioral Health and Psychiatric Care. Dr. V. Ray Cordry, Jr., DO, has built a distinguished career in... ———————————————————————————————————————————————————————————— Gallion Health Announces Yale New Haven Health as Development Partner and Investor to Advance Next-Generation Supply Chain Technology 2026-08-19 · PR.com · Healthcare https://www.pr.com/press-release/976766 Joint Development Partnership provides Gallion Health access to one of the country’s leading academic health systems to further the development of the Company’s products and service offerings. [PR.com] ———————————————————————————————————————————————————————————— Ingenia Therapeutics Nominated for Both the Prix Galien USA and the Inaugural Prix Galien Korea for Best Startup 2026-08-19 · mlpr-businesswire · Healthcare https://finance.yahoo.com/healthcare/articles/ingenia-therapeutics-nominated-both-prix-220000089.html WATERTOWN, Mass., August 19, 2026--Ingenia Therapeutics, a clinical-stage biotechnology company pioneering next-generation vascular-targeted therapies, today announced that it has been nominated for the Prix Galien USA and the inaugural Prix Galien Korea, both in the Best Startup category by The Galien Foundation. The Galien Foundation is the premier global institution recognizing and awarding outstanding achievements of innovators in life sciences. ———————————————————————————————————————————————————————————— Piramal Pharma Limited schließt die Übernahme einer Mehrheitsbeteiligung an Yapan Bio Private Limited ab 2026-08-19 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/piramal-pharma-limited-schlieWt-die-ubernahme-einer-mehrheitsbeteiligung-an-yapan-bio-private-limited-ab-302855718.html Yapan Bio Private Limited ist auf Prozessentwicklung, Charakterisierung sowie GMP-konforme Herstellungsdienstleistungen für klinische Studien der Phasen I und II mit Impfstoffen und Biologika spezialisiert. Piramal hält seit 2021 eine Beteiligung an Yapan Bio und kann dadurch ein breites... ———————————————————————————————————————————————————————————— Picard Medical Reports Second Quarter 2026 Financial Results 2026-08-19 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/19/3348025/0/en/picard-medical-reports-second-quarter-2026-financial-results.html - Revenue Increases 39% and Net Loss Decreases 16%- ———————————————————————————————————————————————————————————— Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa) 2026-08-19 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/08/19/3348019/20739/en/ultragenyx-announces-u-s-fda-approval-of-genglycos-gene-therapy-the-first-ever-fda-approved-treatment-designed-to-treat-the-underlying-cause-of-glycogen-storage-disease-type-ia-gsd.html GENGLYCOS is the first gene therapy approval, and fifth FDA approval overall, for the company ———————————————————————————————————————————————————————————— Centers Health Care Makes History and Sets Guinness World Record™ for Largest Seated Dance Lesson - Multiple Venues 2026-08-19 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/centers-health-care-makes-history-and-sets-guinness-world-record-for-largest-seated-dance-lesson--multiple-venues-302855702.html Achievement Reflects the Power of Healthy Movement and Community BRONX, N.Y., Aug. 19, 2026 /PRNewswire/ -- Centers Health Care, the largest and most complete post-acute health care continuum in the Northeast that touches one million lives each year with 36 skilled nursing and... ———————————————————————————————————————————————————————————— Phibro Animal Health Corporation to Host Webcast and Conference Call on Fourth Quarter and Fiscal Year 2026 Results 2026-08-19 · mlpr-businesswire · Finance, Healthcare https://finance.yahoo.com/healthcare/articles/phibro-animal-health-corporation-host-203000109.html TEANECK, N.J., August 19, 2026--Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its fourth quarter and fiscal year 2026 financial results on Wednesday, August 26, 2026, after the market closes. Phibro management will host a conference call and webcast on Thursday, August 27, 2026, at 9:00 AM Eastern Time. ———————————————————————————————————————————————————————————— SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER 2026-08-19 · PR Newswire · Finance, Healthcare https://www.prnewswire.com/news-releases/sera-prognostics-appoints-scott-gleason-chief-financial-officer-302855636.html SALT LAKE CITY, Aug. 19, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, announced today that Scott Gleason has been... ———————————————————————————————————————————————————————————— Hims & Hers Health (NYSE: HIMS) Stock Plunges 14% Following Major FTC Lawsuit Over Privacy & Billing; Hagens Berman Investigates Corporate Compliance and Investor Ramifications 2026-08-19 · PR Newswire · Finance, Healthcare https://www.prnewswire.com/news-releases/hims--hers-health-nyse-hims-stock-plunges-14-following-major-ftc-lawsuit-over-privacy--billing-hagens-berman-investigates-corporate-compliance-and-investor-ramifications-302855605.html SAN FRANCISCO, Aug. 19, 2026 /PRNewswire/ -- investors in Hims & Hers Health, Inc. (NYSE: HIMS) saw the price of their shares slide about 14% lower on news that the FTC sued the company over alleged improper business practices. The events have prompted national shareholders rights firm... ———————————————————————————————————————————————————————————— Jaguar Health Reports Second Quarter 2026 Financials 2026-08-19 · PR-Inside · Healthcare https://pr-inside.com/jaguar-health-reports-second-quarter-2026-financials-r5214127.htm (PR-inside.com) Company remains sharply focused on its ongoing global development program for crofelemer for rare intestinal failure (IF) diseases; as announced, presentation at ESPGHAN 2026 described additional groundbreaking results of evaluation of crofelemer as adjunctive oral therapy for the treatment of pediatric IF, which demonstrate reduction of parenteral support normalized to body weight of up to 48% in patient with the ultrarare microvillus inclusion disease (MVID); company expects clinical package for NDA for MVID to be ready by end of 2026, allowing submission of NDA in Q2 2027 REMINDER: Jaguar to host investor webcast Wednesday, August 19 at 4:30 p.m. Eastern regarding .. ———————————————————————————————————————————————————————————— OSR Health Receives Nasdaq Staff Delisting Determination and Intends ... 2026-08-19 · PR-Inside · Finance, Healthcare https://pr-inside.com/osr-health-receives-nasdaq-staff-delisting-determination-and-intends-r5214125.htm (PR-inside.com) BELLEVUE, WA / ACCESS Newswire / August 19, 2026 / OSR Health, Inc. (NASDAQ:OSRH) ("OSR Health" or the "Company") today announced that it has received a written Staff Delisting Determination (the "Determination") from the Nasdaq Listing Qualifications Department notifying the Company that its common stock and warrants are subject to delisting from The Nasdaq Capital Market as a result of the Company's failure to regain compliance with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2). Nasdaq Hearing Request The Company intends to request a hearing before the Nasdaq Independent Hearings Panel (the "Panel") to appeal the Staff Determination, pursuant to .. ———————————————————————————————————————————————————————————— OSR Health Receives Nasdaq Staff Delisting Determination and Intends to Request Hearings Panel Appeal 2026-08-19 · Newswire.com · Finance, Healthcare https://www.newswire.com/news/osr-health-receives-nasdaq-staff-delisting-determination-and-intends-to-request ———————————————————————————————————————————————————————————— NAMI Expands Partnership With Dr. John Torous to Advance Safe, Informed Use of AI in Mental Health 2026-08-19 · PR Newswire · AI, Healthcare https://www.prnewswire.com/news-releases/nami-expands-partnership-with-dr-john-torous-to-advance-safe-informed-use-of-ai-in-mental-health-302855639.html Strengthening NAMI's leadership at the intersection of mental health and AI ARLINGTON, Va., Aug. 19, 2026 /PRNewswire/ -- The National Alliance on Mental Illness (NAMI), the nation's largest grassroots mental health organization, announced today that John Torous, M.D., will serve as... ———————————————————————————————————————————————————————————— Recording Available: State Health Leaders Outline Strategies Ahead of Respiratory Virus Season 2026-08-19 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/recording-available-state-health-leaders-outline-strategies-ahead-of-respiratory-virus-season-302855624.html ARLINGTON, Va., Aug. 19, 2026 /PRNewswire/ -- On August 18, the Association of State and Territorial Health Officials (ASTHO), convened state health officials for a deskside briefing focused on preparations for the upcoming respiratory virus season with a specific focus on seasonal flu,...